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Abstract New	 developments	 such	 as	 ‘Precision	 Medicine’	 and	 ‘Digital	 Health’	 are	 emerging	 areas	 in	healthcare	 technology,	 underpinned	 by	 ‘convergent	 technology’	 or	 ‘cross-industry’	 innovation.		However,	 convergence	 results	 in	 greater	 uncertainty	 and	 influence	 from	 new	 knowledge	 and	actors,	including	previously	disparate	technologies	and	capabilities,	bringing	specific	challenges	in	the	development	of	innovations.		Although	the	literature	addresses	the	context	of	technology	convergence,	there	has	been	limited	research	reported	on	the	how	such	innovation	is	effected	in	nascent	ecosystems.		This	qualitative	research	addresses	identified	literature	gaps,	initially	by	using	a	combination	of	ecosystem	actor	interviews	(n=39)	to	understand	the	context,	followed	by	five	longitudinal	in-depth	case	studies	at	innovator	organisations.	Case	evidence	was	obtained	from	a	combination	of	 interviews	 (n=62),	 supplemented	 by	 field	 observations,	 primary	 documents	 and	 evidence	from	 publicly	 available	 sources.	 	 The	 data	 was	 subjected	 to	 multiple	 coding	 methods,	 with	plausible	causal	mechanisms	identified	through	case	and	cross-case	analyses.			The	research	findings	identify	a	set	of	five	interconnected	micro-processes	(early	organisational	routines)	which	 together	 form	a	non-deterministic	activity	system	 that	enables	an	 innovator	 to	
navigate	 (the	 ecosystem),	 negotiate	 (a	 position	 within	 it)	 and	 nurture	 (the	 innovation	 and	ecosystem).	 The	 research	 further	 identifies	 the	 importance	 of	 careful	 balancing	 between	relationally	 focussed	 credibility-seeking	 and	 advantage-seeking	 actions	 as	 the	 main	 driver	‘guiding’	managers	when	developing	the	innovation,	the	associated	business	model(s)	and	value	network	in	the	evolving	ecosystem.				A	 conceptual	 model	 and	 framework	 are	 developed	 to	 show	 the	 interrelationships	 between	organisational	 routines,	 the	 activity	 systems	 and	 the	 ecosystem.	 In	 developing	 organisational	capabilities,	 it	 is	 argued	 that	 convergent	 innovation	 requires	mostly	 incremental	 changes	 (low	depth	of	change)	across	many	organisational	routines	(high	breadth	of	change),	which	reduce	the	uncertainty	of	organizational	change	and	thus	increase	internal	acceptance.			These	 findings	 support	 the	 argument	 that	 innovators	 require	 a	 more	 ‘systemic’	 view	 of	innovation	 and	 governance	 approaches	 contributing	 to	 the	 innovation	 and	 capabilities	literature.	 	 	 From	 a	 practice	 perspective,	 the	 research	 provides	 mechanisms	 for	 building	relational	capabilities	critical	to	innovation	delivery. 
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1 Introduction 
1.1 Background  Healthcare	 systems	 around	 the	 world	 face	 major	 challenges	 to	 meet	 the	 ever-increasing	demands	 on	 services	 and	 to	 control	 costs	 (Abbasi	 et	 al.,	 2013;	Christensen,	 2000;	Herzlinger,	2000,	1978;	Kim	et	al.,	2013).	 	 Increasingly,	health	systems	are	looking	beyond	the	 traditional	industry,	technologies	and	suppliers	for	solutions.	These	new	approaches	have	the	potential	to	change	health	delivery,	and	to	drive	a	greater	 ‘convergence’	of	medical	and	other	technologies	(Burns,	 2012;	 Fish	 and	 White,	 2014;	 Sharp	 et	 al.,	 2011).	 	 These	 ‘cross-industry’	 (Enkel	 and	Gassmann,	 2010)	 or	 ‘convergent’	 (Stieglitz,	 2003)	 technologies,	 including	 nanotechnology,	biotechnology,	 information	 technology,	 electronics	 and	 cognitive	 science	 (Venkatesan,	 2010),	will	 require	diverse	organisations	 to	work	more	closely	 together	 to	deliver	solutions,	at	every	stage	in	the	value	chain	(Eselius	et	al.,	2008).				Future	healthcare	technology	value	chains	therefore	face	greater	uncertainty	and	influence	from	organisations	and	 institutions	not	 traditionally	part	of	 the	value	network	or	 industrial	system	(Rikkiev	and	Mäkinen,	2013).		Understanding	and	addressing	these	challenges	is	potentially	key	to	the	success	of	enterprises	designing,	developing	and	supplying	new	healthcare	systems	and	to	delivering	products	and	services	that	could	transform	patient	outcomes	and	public	health.	The	importance	of	convergent	innovation	in	healthcare	has	been	identified	(Dube	et	al.,	2014),	but	there	is	limited	research	on	how	this	innovation	is	enacted.				
1.2 How might convergence impact healthcare technologies? The	challenges	in	delivering	quality,	affordable	healthcare	have	been	long	debated	(Herzlinger,	1978).	 	 Healthcare	 represents	 a	 significant	 part	 of	 the	 economy	 for	many	 countries,	 typically	between	6	and	17%	of	GDP	(OECD,	2013,	p.	157).		Health	systems	around	the	globe	face	major	challenges	to	meet	the	ever-increasing	care	demands	and	to	control	costs	(Abbasi	et	al.,	2013;	Christensen,	 2000;	 Herzlinger,	 2000,	 1978;	 Kim	 et	 al.,	 2013).	 Consequently,	 most	 major	economies	are	reviewing	and	transforming	their	healthcare	systems	(Abbasi	et	al.,	2013).		Typically,	 healthcare	 systems	 currently	 operate	 using	 a	 ‘fee	 for	 service’	 (FFS)	 model	 where	payment	is	made	for	each	visit	or	the	duration	of	visit	and	services	consumed	(Thomson	et	al.,	2013).	 	 Porter	 (2010a)	 and	 Christensen	 (2009)	 have	 both	 suggested	 that	 alternative	models	with	FFS	being	replaced	by	a	‘fee	for	outcome’	(FFO)	or	a	‘fee	for	membership’	(FFM)	depending	on	the	treatment	or	care	need.		These	types	of	solution	have	the	potential	to	change	healthcare	delivery	models,	 and	 one	 underlying	 feature	 is	 that	 they	 rely	 on	 innovation	 from	 outside	 the	
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traditional	healthcare	sector	(Thakur	et	al.,	2012).	 	 	This	will	drive	a	 ‘convergence’	 (Enkel	and	Gassmann,	2010;	Hacklin	and	Wallin,	2013;	Stieglitz,	2003)	of	medical	and	other	 technologies,	from	 other	 industries,	 such	 as	 computing	 and	digital,	 electronics	 and	novel	materials	 (Burns,	2012;	 Fish	 and	White,	 2014;	 Sharp	 et	 al.,	 2011).	 	 This	may	 not	 just	 occur	 in	 the	 technology	development	but	will	likely	happen	at	every	stage	in	the	value	chain	(Eselius	et	al.,	2008).			The	magnitude	of	the	potential	changes	is	significant;	McKinsey	(Abbasi	et	al.,	2013)	have	estimated	the	value	of	the	‘shift	in	system’	and	potential	savings,	at	$300-400	billion.				
	The	changes	identified	have	a	consequential	impact	on	the	healthcare	value	chain	actors:		
• An	 increasing	move	 towards	 payment	 for	 outcomes,	 as	 opposed	 payment	 for	 product	 or	service	(Christensen	et	al.,	2009;	Porter,	2010b)	
• A	move	 to	more	 patient	 centric	 treatment	 and	 care	 delivery	 services	 requiring	 increased	personalisation	and	precision	(Herzlinger,	2001;	Shaller,	2007)	
• Convergence	of	medical	 technologies	to	create	value	adding	new	products,	 to	simplify	and	reduce	cost	in	the	healthcare	providers’	delivery	value	chain	(Burns,	2012;	Downey,	2008;	Eselius	et	al.,	2008;	Fish	and	White,	2014).		
	Sabatier	et	al.	(2012)	identified	a	number	of	‘new	healthcare	philosophies’	including	personalized	medicine,	 nanobiotechnology,	 and	 systems	 biology,	 all	 involving	 convergent	 technologies	 and	‘incumbents	 from	 other	 sectors’.	 Burns	 also	 identified	 that	 to	 deliver	 next	 generation	 of	healthcare	products,	there	is	 ‘a	need	for	technological	convergence	across	sectors’	(Burns,	2012,	p.	539).		The	technological	changes	have	been	described	as	the	‘Third	Revolution’	(Sharp	et	al.,	2011)	 and	 have	 the	 potential	 to	 produce	 highly	 disruptive	 innovations.	 Convergence	 in	healthcare	 technologies	will	also	 impact	healthcare	provider	businesses	(e.g.,	hospitals)	which	are	 currently	 fragmented,	 and	new	 initiatives	 like	 ‘precision	medicine’	will	 change	 actors	 and	business	models	(Bojovic	et	al.,	2015;	Fish	and	White,	2014;	Mason	et	al.,	2013).						The	importance	and	relevance	of	‘convergence’	or	‘cross	industry’	(Enkel	and	Gassmann,	2010)	innovation	 in	 healthcare	 is	 illustrated	 by	 the	 extent	 to	 which	 the	 major	 government	 health	initiatives:	 for	 example,	 precision	medicine,	 regenerative	medicine,	 bioelectronics	 and	 digital	health	(Committee	on	a	Framework	for	Development	a	New	Taxonomy	of	Disease	and	National	Research	Council,	2011;	Office	for	Life	Sciences	and	Monitor	Deloitte,	2015)	are	all	underpinned	by	‘convergence’.		This	is		depicted	in	Figure	1-1,	which	is	derived	from	Shmulewitz	et	al	(2006),	Bernabo	et	al	(2009a)	and	Kim	et	al	(2012).		This	phenomenon	has	also	been	discussed	recently	by	scholars	(Dube	et	al.,	2014),	considering	it	as	a	‘meta-innovation’	that	also	innovates	the	way	innovation	is	conducted.	This	need,	to	consider	different	ways	to	innovate,	is	one	driver	for	this	research.	
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Figure	 1-1	 Importance	 of	 convergence	 in	 delivering	 new	 healthcare	 technologies	
(developed	from	Bernabo,	Kim	and	Shmulewitz)		There	 is	 already	 evidence	of	 cross	 sector	 engagement	 (Mack,	 2017),	which	 includes:	 alphabet	(formerly	 Google)	 and	 Apple	 migrating	 towards	 healthcare.	 	 Recently,	 alphabet	 announced	collaborations,	via	their	Verily	division,	with	Novartis	on	lens	technology	(Novartis,	2014)	and	with	 GlaxoSmithKline	 on	 bioelectronics	 (GlaxoSmithKline,	 2016).	 Apple	 updated	 their	 iOS	operating	 system	 to	 provide	 a	 personalized	 healthcare	 application	 (Apple,	 2014),	 and	 their	platform	 is	now	widely	 used	 by	 healthcare	 providers	with	 over	 75%	 of	mobile	 digital	 health	applications	being	on	the	iOS	and	Android	platforms	(Research2Guidance,	2016).			Healthcare	 technologies	 including	 pharmaceuticals,	 medical	 devices	 and	 diagnostics	 typically	have	 long	 and	 complex	 supply	 chains	 that	are	 typically	not	well	managed,	 compared	 to	other	industries	 (Christensen	 et	 al.,	 2009).	 Like	 other	 industries,	 there	 is	 a	 trend	 towards	fragmentation	(disaggregation)	of	existing	product	value	chains	(Srai	and	Alinaghian,	2013),	but	at	 the	 customer-facing	 end	 of	 the	 value	 chain,	 there	 is	 a	 potential	 for	 integration	 or	 re-integration	via	new	end-service	provision	 and	new	business	models	 (Kim	et	 al.,	 2013;	Porter,	2010a;	Porter	and	Lee,	2013).		However,	healthcare	technology	companies	have	not	historically	been	good	collaborators	and	have	limited	expertise	in	customer	facing	ventures	or	in	high	value	service	provision	(Burns,	2012,	2002),	and	so	may	find	convergence	and	new	ways	to	innovate	a	significant	challenge.		
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The	ecosystem	 is	made	more	complex	as	new	collaborators	and	alliance	partners	are	 likely	to	have	divergent	cultures,	capabilities	and	perceptions,	in	terms	of	time,	risk,	investment,	cost,	and	regulation	 (Mason	 et	 al.,	 2013;	 Rikkiev	 and	 Mäkinen,	 2013).	 	 This	 presents	 challenges	 in	developing	 not	 only	 the	 innovation,	 but	 also	 the	 required	 business	model	 (Baden-Fuller	 and	Mangematin,	2013;	Zott	et	al.,	2011)	and	value	network	(Srai	et	al.,	2014;	Sturgeon,	2001;	Tsai	and	Ghoshal,	1998).				Given	 these	 multiple	 practice	 challenges	 and	 the	 limited	 previous	 research,	 the	 resulting	challenge	 is	 in	 understanding	 how	 organisations	 innovate	 in	 this	 environment.	 	 Are	 existing	innovation	 approaches	 using,	 for	 example,	 stage	 gates	 (Cooper,	 1990)	 or	 open	 innovation	 (H.	Chesbrough,	 2006;	 Chesbrough,	 2003)	 or	 disruptive	 innovation	 (Christensen	 et	 al.,	 2015;	Danneels,	2004)	practices	satisfactory	or	do	firms	need	to	develop	new	capabilities?			If	so,	how	do	they	develop	these	capabilities?	Do	they	employ	dynamic	capabilities		(Teece	et	al.,	1997)	as	has	 been	 widely	 accepted?	 Or,	 do	 they	 already	 need	 the	 required	 capability	 through	organisational	ambidexterity	(Jansen	et	al.,	2008;	Raisch	and	Birkinshaw,	2008)?		Convergent	innovation,	with	its	potential	to	be	disruptive,	not	only	impacts	existing	innovation	approaches,	 value	 chains	 and	 existing	 business	 models	 	 but	 also	 impacts	 the	 downstream	healthcare	pathways;	 it	potentially	changes	the	way	healthcare	 is	delivered.	 In	this	sense,	 it	 is	‘systemic’	 (Midgley	 and	 Lindhult,	 2017),	 suggesting	 that	 innovators	 and	 researchers	 need	 to	take	a	wider	‘systems’	perspective	to	both	the	innovation	and	the	innovation	approach.				
1.3 Motivation for this Research The	practice	challenges	stem	from	the	rapidly	changing	environment	with	the	formation	of	new	‘ecosystems’,	 and	 the	 ability	 of	 healthcare	 technology	 ‘producers’	 to	 succeed	 by	 identifying,	creating,	 delivering	 and	 capturing	 ‘value’	 in	 the	 new	 and	 complex	 environment.	 	 Given	 the	importance	 of	 healthcare	 systems	 and	 healthcare	 technologies	 to	 society,	 and	 the	 potential	impact	 of	 ‘convergence’	 and	nascent	 innovation	 ecosystems,	 this	 research	 is	 of	 relevance,	 and	importance,	in	helping	identify	approaches	for	future	healthcare	innovation.		
	
1.4 Research Objectives and Contributions The	research	aims	to	better	understand	how	organisations	innovate	in	healthcare	technologies	where	the	underpinning	context	is	the	convergence	of	technologies,	across	industries	to	create	nascent	ecosystems.			
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It	is	first	proposed	to	develop	an	improved	understanding	of	the	ecosystem	‘,	as	a	systems-based	form	of	organising,	providing	a	context	for	later	research.	This	involves	Identifying	the	system	(and	 boundaries)	 from	 different	 perspectives,	 identifying	 key	 actors	 (or	 agents	 and	stakeholders),	 their	 inter-relationships	 and	 their	 influence	 on	 activities,	 and	 identifying	 the	dynamics	and	co-evolution	through	key	trends,	issues	and	opportunities		The	main	research	objective	 is	 identifying	how	firms	develop	convergent	 innovations	 in	 these	nascent	 ecosystems,	 with	 an	 emphasis	 on	 the	 value	 creation	 and	 capture	 activities,	 and	capabilities	 required.	 This	 will	 involve	 exploring	 stakeholder	 requirements	 and	 analysing	approaches	 to	 defining	 ‘value	 sources’,	 understanding	 how	 those	 ‘value’	 requirements	 are	translated	via	development	of	the	innovation,	business	models	and	value	networks	into	required	capabilities	 and	 investment	 decisions.	 The	 aim	 is	 to	 develop	 frameworks	 that	 enable	 some	linkage	 between	 the	 ecosystem,	 innovation	 processes,	 value	 network	 formation	 and	organisation	capabilities	to	be	identified.		Finally,	as	well	as	contributing	to	the	innovation	and	convergent	innovation	fields,	the	research	will	contribute	towards	the	development	of	a	more	integrated	or	systemic	approach	and	provide	insights	for	practice.	 	Given	the	importance	of	sustainable	healthcare	systems	to	us	all,	and	the	potential	 that	 new	 technologies	may	 bring	 to	 achieving	 that;	 another	 aim	 is	 to	 contribute	 to	healthcare	 ‘producers’	 to	 improve	 their	 innovation	 approaches	 as	 a	 step	 to	 realising	 that	potential.					
1.5 Research Approach The	 research	 predominantly	 focusses	 on	 ‘how’	 organizations	 act,	 structure	 and	 organize	 for	innovation,	and	secondly,	to	understand	‘why’	they	adopted	those	approaches.	Given	the	nature	of	 the	 enquiry	 and	 the	 evolving	 nature	 of	 setting,	 a	 longitudinal	 qualitative	 approach	 was	adopted	(Anteby	et	al.,	2014;	Garud	et	al.,	2013).			This	research	uses	a	longitudinal	case	study	approach	to	explore	these	challenges	by	considering	two	 aspects:	 an	 analysis	 of	 the	 innovation	 ecosystem	 (Adner	 and	 Kapoor,	 2008;	 Autio	 and	Thomas,	2014)	itself:	to	assess	the	context,	including	the	diversity	of	participants,	the	dynamics,	and	complexity	of	 the	emergent	environment,	by	drawing	on	stakeholder	 theory	and	complex	systems	theory,	and	an	organisation	and	innovation	capabilities	approach,	to	address	value	creation	and	capture	in	a	nascent	ecosystem	via	a	value	network.					As	‘systems’	are	being	investigated,	a	holistic	multi-method	approach	is	adopted	(Midgley,	2011;	Mingers,	2006),	initially	looking	at	system	as	whole,	then	focussing	in	on	areas	and	activities	that	
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appear	to	have	the	greatest	impact	on	overall	behaviour	and	performance	(see	Figure	1-2).		This	approach	provides	context	 to	enlighten	the	case	observations	(Garud	et	al.,	2013;	Pawson	and	Tilley,	1997).		
	
Figure	1-2	Overall	research	approach	
1.6 Scope This	thesis	will	focus	on	the	development	of	innovative	technologies,	products	and	services	for	healthcare	(for	example	new	diagnostic,	treatment	or	patient	management	technologies),	with	a	specific	focus	on	‘convergent’	medical	products,	which	are	defined	here	as	those	that	bring	two	or	more	technologies	from	different	industries	(Enkel	and	Gassmann,	2010;	Hacklin	and	Wallin,	2013;	Stieglitz,	2003).		Whilst	it	is	intended	that	the	frameworks	and	models	developed	will	be	relevant	 across	 healthcare,	 they	 will	 focus	 on	 using	 data	 and	 information	 from	 research	primarily	conducted	in	the	UK.		
1.7 Structure of this Thesis Following	this	introductory	chapter,	Chapter	2	contains	the	main	literature	review	covering	the	underpinning	 theory	 related	 to	 this	 research.	 	 Chapter	 3	 identifies	 the	 underpinning	 practice	problems,	the	research	challenges	and	gaps	identified	in	the	literature,	to	develop	the	emerging	research	 questions.	 	 Chapter	 4	 describes	 the	 development	 of	 the	 research	 methodology	 and	approach.			Chapter	5	presents	the	preliminary	research	and	the	development	of	an	exploratory	
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framework,	 for	use	 in	 the	 in-depth	 case	studies.	 Chapter	6	presents	 the	 case	 studies	 and	 case	findings.		Chapter	7	provides	cross-case	analyses	to	identify	patterns	and	differences.		Chapter	8	discusses	the	proposed	models	in	the	context	of	existing	literature.	 	Chapter	9	summarises	the	key	findings	and	the	contributions	of	this	research.		Chapter	10	contains	the	References.			Appendices	are	 included,	 containing	 supplementary	 information	on	 the	preliminary	 interview	and	case	study	protocols,	the	research	sources	and	data,	and	key	research	analyses. 		
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2 Literature Review  
2.1 Introduction The	 literature	 review	 starts	 by	 highlighting	 the	 practice	 challenges	 and	 then	 describes	 the	underpinning	theory	relating	to	these	challenges.	The	approach	proposed	provides	a	variety	of	perspectives,	 to	 enable	 a	 ‘systemic	 view’	 of	 innovation	 management,	 thereby	 building	 upon	Malerba’s	 (2002)	multidimensional,	 integrated	and	dynamic	view	concept,	and	addressing	 the	call	for	multi-level,	 longitudinal	perspectives	and	context	to	be	better	recognized	in	innovation	research	(Garud	et	al.,	2013).		The	 literature	 covers	 three	 main	 areas	 (see	 Figure	 2-1).	 	 The	 first	 explores	 the	 context,	 the	
underlying	phenomena	and	dynamics	of	convergent	innovation	and	innovation	ecosystems,	 a	 key	focus	being	the	implications,	opportunities	and	challenges	for	innovators.			The	second	takes	an	organizational	perspective,	 to	 consider	 innovation	management	and	organizational	capabilities	required	and	how	these	are	developed.	The	third	area	considers	the	requirements	for	taking	a	‘systemic	view’,	using	systems	theory	and	thinking	and	how	this	can	be	applied	 to	the	research	methodology.		This	is	separately	covered	in	the	Methodology	(Chapter	4).				
	
Figure	2-1	Scope	of	literature	review	
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2.2 Industry Evolution and Convergence 
2.2.1 Evolution and change New	 industries	 are	 catalysed	 by	 technological	 change	 and	 characterised	 by	 high	 uncertainty	(Benner	and	Tripsas,	2012).		These	changes	are	rooted	in	industrial	evolution,	a	combination	of	incremental	 change	 (Marshall,	 1921)	 punctuated	 with	 waves	 of	 ‘creative	 destruction’	(Schumpeter,	 1947,	1939,	1928).	Building	on	Alchian’s	 (1950)	 initial	 concepts,	Winter	 (1960)	proposed	 and	 subsequently	 developed	an	 evolutionary	 approach	 to	 economics	 (Nelson	 et	 al.,	1976;	 Nelson	 and	Winter,	 2002,	 1974,	Winter,	 1984,	 1964),	 explaining	 evolution	 in	 terms	 of	variation,	 selection,	 and	 retention.	 	 	 The	 concept	 of	 ‘punctuated	 equilibrium’	 (Nelson,	 1994;	Romanelli	 and	 Tushman,	 1994),	 also	 drawn	 from	 biology	 (Eldredge	 and	 Gould,	 1972;	 Gould,	1980)	describes	an	alternative	approach	to	gradual	change.	Nelson	(2002)	extended	the	earlier	evolutionary	 concept	 (Nelson	 and	 Winter,	 1982)	 to	 address	 the	 co-evolution	 of	 technology,	firms,	 institutions	 and	 industry.	 	 This	 concept	 of	 the	 co-evolution	 of	 technology,	 firms	 and	institutions	has	more	recently	been	developed	by	Geels	(2014,	2005,	2002),	considering	these	as	
multi-level	reconfigurations	using	the	concept	of	a	‘triple-embeddedness	framework’,	providing	a	perspective,	 addressing	 technological,	 economic	 and	 socio-political	 contexts,	 that	 is	 more	‘systemic’	(Senge	et	al.,	2007).	These	evolutionary	concepts	are,	however,	rooted	in	an	industry	perspective.		A	 more	 recently	 studied	 phenomenon	 that	 impacts	 this	 evolution	 and	 firms’	 capabilities	 is	‘convergence’	 (Hacklin,	 2005;	 Stieglitz,	 2003)	 or	 ‘cross-industry’	 innovation	 (Enkel	 and	Gassmann,	 2010;	 Gassmann	 et	 al.,	 2010b),	which	may	 disrupt	 existing	 technologies,	 business	models,	 industries	and	markets.	 	The	concept	of	disruptive	 innovations	was	re-popularised	by	Christensen	 (1997),	 exploring	 the	 impact	 of	 sustaining	 and	 disruptive	 change.	 	 Disruptive	innovations	tend	to	come	from	small	entrepreneurial	firms	(Christensen,	1997)	or	involve	new	actors	 (Raynor	 and	 Christensen,	 2002)	 and	 so	 to	 survive	 in	 the	 evolving	 environment	 larger	incumbent	firms	need	to	adapt	(Anderson	and	Tushman,	1990;	Winter	et	al.,	2000).	 	However,	the	power	of	organizations	to	manage	their	routines	may	result	in	 ‘rigidities’	(Leonard-Barton,	1992)	 and	 interfere	 with	 their	 ability	 to	 cope	with	 the	 unexpected	 (Anderson	 and	 Tushman,	2001).	 	 Therefore	 survival	 is	 often	 linked	 to	 agility	 and	 the	 concepts	 such	 as	 “dynamic	
capabilities”	(Easterby-Smith	et	al.,	2009;	Eisenhardt	and	Martin,	2000;	Teece,	2007;	Teece	et	al.,	1997)	 that	 enable	 firms	 to	 create	 new	 capabilities.	 	 Rikkiev	 and	 Mäkinen	 (2013)	 identified	convergence	as	a	‘complex’	phenomenon;	they	identified	common	themes	in	literature	clustered	around	 company	 strategy,	 management,	 process,	 people	 and	 offering;	 concluding	 that	convergence	reshapes	existing	industry	value	networks	and,	“by	using	innovative	business	models	
and	alliances,	companies	can	find	profitable	positions	or	niche	in	new	industry	value	chain”	(2013,	p.	10).		So,	convergent	innovation	has	the	potential	to	be	disruptive	(Christensen,	2006),	not	only	
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to	 change	 technology	 and	 products,	 but	 also	 create	 new	 industries	 (Stieglitz,	 2003)	 or	‘ecosystems’	 (Moore,	 1993),	 new	 business	models	 (Enkel	 and	 Gassmann,	 2010)	 and	markets,	and	thus	requiring	new	capabilities	(Barney,	1991;	Leonard-Barton,	1992;	Penrose,	1996).	The	following	sections	will	explore	each	of	these	aspects.			
2.2.2  Convergence as a phenomenon As	 previously	 identified,	 there	 is	 evidence	 that	 healthcare	 products	 and	 systems	 will	 see	 a	‘convergence’	of	technologies	(Dube	et	al.,	2014).		In	the	literature	the	terms	‘convergence’	(Choi	and	Valikangas,	2001;	Gauch	and	Blind,	2014;	Hacklin,	2005;	Hacklin	and	Wallin,	2013;	Stieglitz,	2003),	 ‘fusion’	(Kodama,	1992;	Rao	et	al.,	2006)	or	 ‘cross-industry	innovation’	(Enkel	and	Heil,	2014a;	 Gassmann	 et	 al.,	 2010b;	 Heil	 and	 Enkel,	 2015)	 are	 fields	 which	 exhibit	 similar	phenomena.	 These	 phenomena	 include:	 working	 with	 knowledge	 and	 actors	 from	 different	fields	 or	 industries	 (Enkel	 and	 Gassmann,	 2010;	 Gassmann	 et	 al.,	 2011;	 Hacklin	 and	Wallin,	2013),	 the	 need	 to	 search	 for	 more	 distant	 knowledge	 and	 partners	 to	 build	 new	 networks	(Enkel	and	Heil,	2014a;	Rikkiev	and	Mäkinen,	2013),	the	need	to	adapt	innovation	approaches	(Enkel	and	Heil,	2014b;	Heil	and	Enkel,	2015;	Rikkiev	and	Mäkinen,	2013),	and	integration	risks	(Hacklin	and	Wallin,	2013;	Rikkiev	and	Mäkinen,	2013).				‘Convergence’	in	relation	to	industries	and	technologies	has	been	used	for	four	decades	(Hacklin	and	Wallin,	 2013;	 Stieglitz,	 2003),	 but	multiple	 definitions	 exist	 for	 it	 (Rikkiev	 and	Mäkinen,	2013).	 For	 the	 purposes	 of	 this	 research,	 the	 following	 definition	 will	 be	 adopted:	 using	
analogous	knowledge	with	high	cognitive	distance	or	 technologies	of	organisations	outside	 their	
own	 value	 chain	 to	 develop	 innovative	 products	 and	processes	 or	 business	models	 (Brunswicker	and	Hutschek,	2010;	Enkel	and	Heil,	2014a;	Gassmann	et	al.,	2010a,	2010b).		Much	prior	 research	 is	 in	 semiconductors,	 computing	 and	 communications	 technology,	which	saw	waves	of	convergence	in	the	1990s	and	early	2000s	(Bernabo	et	al.,	2009b;	Hacklin,	2005;	Hacklin	and	Wallin,	2013;	Stieglitz,	2003).		There	are	limited	studies	in	automotive	(Bernabo	et	al.,	2009a;	Gassmann	et	al.,	2010b)	and	biotechnology	(Bernabo	et	al.,	2009a;	Eselius	et	al.,	2008;	Shmulewitz	et	al.,	2006),	which	largely	address	the	trends	and	industrial	implications,	and	there	are	 a	 small	 number	 of	 papers	 exploring	 early	 research	 challenges	 (Roco,	 2003;	 Sharp	 et	 al.,	2011;	 Venkatesan,	 2010)	 in	 the	 field.	 	 But	 in	 healthcare	 technologies,	 despite	 several	practitioner	articles	(Eselius	et	al.,	2008;	Gupta	et	al.,	2013;	Mason	et	al.,	2013;	Rajan	and	Frost	&	Sulivan,	 2014),	 there	 is	 limited	academic	 literature	 (Bernabo	 et	 al.,	 2009a;	 Dube	 et	 al.,	 2014;	Ramachandran	et	 al.,	 2011;	Shmulewitz	 et	al.,	 2006)	and	 little	 evidence	of	 empirical	 research.	However,	there	are	a	few	studies	examining	the	implications	for	technological	or	business	model	
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discontinuities	 (Bojovic	 et	 al.,	 2015;	 Sabatier	 et	 al.,	 2012)	 and	 more	 broadly	 health	 systems	convergence	 (for	 example	 Kim	 et	 al.,	 2013;	 Porter,	 2010a;	 Porter	 and	 Lee,	 2013),	 which	 is	outside	the	scope	of	this	research.		
	Convergence	has	been	 classified	 as	 either	 ‘substitution’	 or	 ‘complementarity’	 and	 to	be	 either	technology	or	product	focused	(Stieglitz,	2003),	resulting	in	four	convergence	types	(Table	2-1).		
Table	2-1	Types	of	industry	convergence	(from	Stieglitz,	2003)	
	 Substitution	 Complementarity	
Technology-based	convergence	 Technology	substitution	 Technology	integration	
Product-based	convergence	 Product	substitution	 Product	complementarity		Following	 this	 reasoning,	 the	 convergent	 technologies	 in	 the	 healthcare	 ecosystem	 can	 be	classified	 as	 largely	 	 ‘technology-based	convergence’	and	 therefore	 likely	 to	 lead	 to	 ‘technology	substitution’	or	‘technology	integration’	paradigms;	“combining	of	new	or	existing	technologies	previously	 associated	 with	 different	 established	 industries	 into	 a	 new	 product,	 process	 or	service”	(Rikkiev	and	Mäkinen,	2013).		Here,	making	correct	choices	amongst	many	technologies	is	 considered	 important,	 together	with	a	 strong	 ability	 to	 integrate	 those	 technologies	 (Iansiti	and	West,	1997).		The	innovation	does	not	need	to	be	‘radical’	(Partanen	et	al.,	2014;	Sainio	et	al.,	2012;	 Slater	 et	 al.,	 2014)	 as	 incremental	 innovations	 in	 one	 industry,	 that	 cross	 industry	boundaries,	 can	create	disruptive	 innovations	 in	others	(Hacklin,	2005)	through	 four	 life-cycle	stages:	 (1)	 ‘knowledge	 convergence’,	 (2)	 ‘technological	 convergence’,	 (3)	 ‘applicational	convergence’,	 and	 (4)	 ‘industrial	 convergence’	 (2010).	 	 Given	 the	 nascence	 of	 convergence	 in	healthcare	technologies	(Dube	et	al.,	2014),	 the	expectation	 is	 that	knowledge,	 technology	and	early	application	convergence	will	constitute	much	of	the	current	field.			
2.2.3  Technology evolution and the impact of convergence The	role	of	technological	innovation	has	been	the	source	of	much	research	(Devezas,	2005;	Dosi,	1997,	1982;	Malerba	et	al.,	1999;	Nelson,	1994;	Romer,	1990;	Tushman	and	Anderson,	1986).	Tushman	and	Anderson	(1986),	concluded	that	breakthroughs,	or	technological	discontinuities,	significantly	 increase	 environmental	 uncertainty.	 	 Dosi	 (1997,	 1982),	 borrowing	 from	 Kuhn’s	earlier	 work	 on	 scientific	 advances,	 proposed	 ‘technological	 paradigms’	 or	 ‘technological	
trajectories’,	 with	 relatively	 minor	 technological	 developments	 along	 a	 pattern,	 set	 by	 a	paradigm.	 	 This	 concept	 results	 in	 path	 dependence,	 with	 new	 designs	 building	 upon	 the	previous	 (Page,	 2006;	 Vergne	 and	 Durand,	 2011).	 A	 related	 concept,	 the	 ‘dominant	 design’,	further	 argues	 the	 importance	 of	 the	 technological	 evolution	 on	 an	 industry	 (Abernathy	 and	Utterback,	 1978;	 Murmann	 and	 Frenken,	 2006;	 Suarez	 and	 Utterback,	 1995;	 Utterback	 and	
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Suarez,	1993;	Utterback	and	Abernathy,	1975).		There	is	an	expectation	of	a	high	degree	of	path	dependence:	"As	a	first	approximation,	…	,	firms	may	be	expected	to	behave	in	the	future	according	
to	the	routines	they	have	employed	in	the	past"	(Nelson	and	Winter,	1982,	p.	134);	routines	form	the	basis	of	organizational	learning	and	capabilities.	However	as	the	technology	matures,	firms	may	also	look	downstream	to	diversify,	but	alternatively,	it	may	result	in	a	re-direction	of	effort	(Fai	and	von	Tunzelmann,	2001).			But	 with	 convergence,	 firms	 look	 outside	 their	 industry,	 thus	 breaking	 the	 path	 dependent	trajectory	 (Dosi,	 1982;	 Karim	 and	Mitchell,	 2000),	 and	 this	 results	 in	 emergence	 (Adner	 and	Levinthal,	2002;	Probert	et	al.,	2013).	Consequently,	new	learning	must	be	acquired.	Technology	convergence	 is	 only	 part	 of	 the	 challenge,	 	 intercompany	 collaboration	 is	 one	 of	 the	 primary	strategies	in	convergence	(Bores	et	al.,	2003;	Lee	et	al.,	2012)	with	most	innovation	happening	at	 the	boundaries	between	disciplines	 (Hacklin	 and	Wallin,	2013).	 	Rim	et	al	 (2009)	 explored	convergence	 between	media	 and	 telecommunications,	 which	 resulted	 in	 ‘rebundling’	 of	 value	chains	to	create	a	 ‘composite	business	model’.	 	As	Choi	(2001)	suggests,	 	convergence	results	in	“blurred	 boundaries	 between	 industries	 by	 converging	 value	 propositions,	 technologies	 and	
markets”.	 	 The	 phenomena	 are	 complex,	 potentially	 requiring	 a	 multi-faceted	 approach	 to	explore	 them	 (Anteby	 et	 al.,	 2014).	 So,	 as	 a	 conclusion,	 an	 industry	perspective	 is	 considered	inappropriate	as	 convergence	 invariably	 involves	multiple	 industries,	 and	 the	 creation	of	new	ecosystems.	 	 This	 suggests	 an	 ecosystem	 perspective	 as	 potentially	 more	 fruitful	 to	 study	convergent	technology	innovation.		
	
2.3 Business and Innovation Ecosystems  Following	its	initial	appearance	in	practitioner	outlets	(e.g.	Moore,	1993;	Iansiti	&	Levien,	2004),	the	 ecosystem	 concept	 has	 featured	 increasingly	 in	 leading	 management	 and	 organization	studies	journals,	including	the	Academy	of	Management	Review	(e.g.	Alexy	et	al.,	2013;	Priem	et	al.,	2013);	Organization	Science	(e.g.	Jacobides	&	Tae,	2015;	Wareham	et	al.,	2014)	and	Strategic	
Management	 Journal	 (e.g.	 Ansari	 et	 al.,	 2016;	 Kapoor	&	 Furr,	 2015;	 Pierce,	 2009).	 Ecosystem	research	 has	 highlighted	 the	 managerial	 relevance	 of	 viewing	 organizations	 and	 their	environments	as	systems,	characterised	by	interdependence,	co-evolution,	non-linear	behaviour	and	scalable,	system-level	opportunities	and	challenges	(e.g.	Adner,	2012;	Moore,	1993;	Priem	et	al.,	 2013).	 In	 contrast	 to	 the	 classical	 ‘market	 focus’,	 ecosystem	 studies	 have	 explored	 users,	complementors	 and	producers	 in	network	markets	 (Frels	 et	 al.,	 2003),	 identifying	 the	 role	of	‘platforms’	 in	creating	connectivity	between	actors	(Gawer	and	Cusumano,	2013;	Wareham	et	al.,	2014)	and	examining	their	emergence	and	evolution	(Ansari	et	al.,	2016).		The	concept	of	an	‘innovation	ecosystem’	 (Adner	and	Kapoor,	2010;	Autio	and	Thomas,	2014)	 ,	would	appear	to	
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provide	 a	 relevant	 context	 for	 this	 research.	 A	 review	 of	 recent	 ecosystem	 literature	 (for	exmaple,	Adner	and	Kapoor,	2016;	Kapoor	and	Lee,	2013;	Rong	et	al.,	2015;	Rong	and	Shi,	2015;	Shang	et	al.,	2014)	identify	that	it	focuses	largely	on	what	an	ecosystem	is,	and	what	it	is	for,	with	
limited	focus	on	how	they	are	designed	or	created,	and	the	processes	operating	within	them.		Importantly,	ecosystem	research	expands	the	boundaries	of	organizational	research	to	achieve	a	more	 holistic	 view	 (Autio	 and	 Thomas,	 2014),	 but	 the	 field	 arguably	 lacks	 a	 more	 coherent	methodology	 to	 support	 its	 further	development.	To	 illustrate	 this	deficit,	 the	 seminal	papers	(top	20	cited	business	or	innovation	ecosystem	in	the	ISI	Web	of	Science),	including	for	example	Moore	 (1993)	 and	 Iansiti	 and	 Levien	 (2004),	 rarely	 elaborate	 explicit	 systems	 thinking	 or	systems	 approaches.	 Recent	 reflective	 critiques	 and	 reviews	 (Badinelli	 et	 al.,	 2012;	 Oh	 et	 al.,	2016)	have	noted	the	same	issues.	Badinelli	et	al.	noted	that	“much	of	the	use	of	the	word	‘system’	
in	literature	merely	describe	interconnectedness	of	entities,	but	do	not	adhere	to	systems	thinking	
principles,	which	often	disrupt	the	traditional	thinking”	(2012,	p.	499).	In	their	recent	overview,	Autio	 and	 Thomas	 (2014)	 found	 that	 while	 many	 systems-related	 concepts	 were	 used	 in	ecosystem	research,	there	was	no	explicit	reference	to		systems	thinking	or	methods.			Although	 a	 number	 of	 approaches	 have	 been	 proposed	 to	 the	 study	 of	 ecosystems,	 including	prior	research	on	networks	(Lin	et	al.,	2009;	Rong	et	al.,	2015)	or	on	institutionalization	(Vargo	et	al.,	2015),	 there	 is	no	strong	or	prevailing	 theoretical	and	methodological	approach.	Where	systems-like	 approaches	 are	 used,	 they	 have	 tended	 to	 focus	 on	 structure	 and	 specific	phenomena	 (Anggraeni	 et	 al.,	 2007).	 This	may	 in	 part	 be	 due	 to	 early	 research	 that	 focused	predominantly	on	 the	structure	of	ecosystems	and	 identification	of	key	actors	and	their	roles.	Some	 notable	 exceptions	who	 take	 a	 systems	perspective	 include	 those	 approaching	 them	 as	technical	systems	(Adner	&	Kapoor,	 2010;	Baldwin	&	Clark,	2000;	Gawer	&	Cusumano,	 2013;	Kapoor	 &	 Furr,	 2015)	 or	 as	 economic	 systems	 (Jacobides	 and	 Tae,	 2015).	 Some	 studies,	including	Peltoniemi	(2006)	and	Váncza	et	al.	(2011),	have	adopted	a	broader,	complex	systems	approach,	but	these	remain	a	minority	within	the	larger	body	of	ecosystem	studies.			Among	the	multiple	ways	of	exploring	such	phenomena	as	business	or	innovation	ecosystems,	a	narrow	approach	may	be	more	 appropriate	 in	addressing	 theoretical	and	empirical	 questions	such	as	how	ecosystem	actors	and	their	linkages	are	structured	(Basole	et	al.,	2016;	Still	et	al.,	2014),	or	how	a	hub	firm	manages	governance	tensions	inherent	in	the	system	(Wareham	et	al.,	2014).	However,	 ‘‘the	smaller	the	unit	of	analysis,	the	more	one	loses	of	the	connectedness	that	is	
the	 very	 essence	 of	 the	 network’’	 (Easton,	 1995,	 p.	 417).	 	 There	 is	 currently	 no	 ‘meta-level’	methodological	 approach	 to	 systems-based	 forms	 of	 organizing	 to	 match	 the	 theoretically	ambitions	of	ecosystem	scholars,	 such	as	co-evolution	(Adner	and	Kapoor,	2010)	or	collective	
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institutional	 logic	 formation	 (Vargo	 et	 al.,	 2015).	 Among	 the	 perceived	 shortcomings	 of	narrower	approaches,	the	multitude	of	different	studies	in	the	current	literature	differ	in	their	focus	and	level	of	analysis—an	effect	that	is	especially	visible	in	the	recent	ecosystems	literature	(e.g.	 Oh	 et	 al.,	 2016).	 This	 diversity	 makes	 synthesis	 and	 cross-study	 inferences	 more	problematic	(Ritala	and	Almpanopoulou,	2017),	inhibiting	the	development	of	a	solid	theoretical	and	methodological	base	and	potentially	slowing	the	progress	of	scholarly	knowledge.			This	presents	two	challenges:	firstly	methodological,	given	the	identified	need	in	this	research	to	understand	the	innovation	ecosystem,	as	the	context	influencing	the	innovators.	 	Secondly,	the	lack	of	an	accepted	approach	to	their	study	means	that	innovator	firms	are	unlikely	to	have	well	developed	approaches	to	understand	their	ecosystem.		This	presents	a	both	method	and	practice	gap,	which	will	be	further	addressed	in	Chapters	3	and	4.		The	need	to	understand	the	ecosystem	and	 the	 actors	 within	 it	 point	 to	 two	 related	 fields	 of	 literature,	 a	 ‘social’	 perspective	(Cropanzano	and	Mitchell,	 2005;	 Liebeskind	 et	al.,	 1996;	 Luhmann,	1984;	Parsons,	 1951;	Tsai	and	Ghoshal,	1998)	and	a	‘stakeholder’	perspective	(Freeman,	1984),	which	collectively	support	a	more	‘systemic’	approach	(Midgley	and	Lindhult,	2017).		Taking	 a	 ‘social’	 perspective,	 an	 organisation’s	 human	 and	 financial	 capital,	 the	 impact	 of	entrepreneurship,	 the	 network	 patterns	 and	 configuration	 can	 all	 have	 an	 impact	 on	convergence	 (Phillips	 and	 Su,	 2009).	 	 Lee	 et	 al.	 (2010)	 exploring	 convergence	 from	multiple	perspectives	 (or	 levels)	 identified	 not	 just	 products	 and	 technologies	 but	 also	 organizational	innovation	 and	 infrastructure	 changes,	 therefore	 requiring	 new	 alliances.	 	 Different	 alliances	need	different	 capabilities	as	different	 types	of	 partners	 connect	 (Rikkiev	and	Mäkinen,	2013;	Rothaermel	and	Deeds,	2006),	the	size	and	capability	of	partners	(such	as	SMEs)	in	any	alliance	is	 another	 potential	 factor	 (Dickson	 et	 al.,	 2006).	 	 Hacklin	 et	 al.	 (2013),	 identified	 the	‘disciplinary’	distance	between	a	firm’s	own	knowledge	and	other	integration	knowledge	as	key,	although	other	studies	(Enkel	and	Gassmann,	2010)	question	this.	The	integration	challenge	lies	mainly	 in	 individual	 or	 group-level	 learning	 (Rikkiev	 and	Mäkinen,	 2013),	 as	 actors	 seek	 to	understand	 and	 assimilate	 diverse	 knowledge,	 via	 their	 absorptive	 capacity	 (Cohen	 and	Levinthal,	 1990;	 Enkel	 and	 Heil,	 2014b).	 The	 cultural	 challenges	 in	 convergent	 innovation	(Dingler	and	Enkel,	2016)	point	to	the	need	to	develop	social	integration	approaches,	as	well	as	addressing	the	technology.	But	not	all	interactions	need	to	result	in	integration,	many	are	simply	about	understanding	 the	position	of	 others,	 as	 stakeholders	 (Freeman,	1984).	The	 cumulative	implications	of	these	‘social’	challenges	suggests	the	need	to	take	a	more	relational	perspective	(Dyer	and	Kale,	2007).		
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Stakeholder	management	is	not	a	new	field	of	inquiry,	with	origins	traced	to	 ‘systems’	work	at	SRI	 in	 the	early	1960s	(Freeman,	1984).	However	the	application	can	be	 identified	as	early	as	the	1930s	through	the	work	of	Professor	E	M	Dodd	with	executives	at	General	Electric	(Preston	and	 Sapienza,	 1990,	 p.	 362).	 Stakeholder	 theory	 is	 rooted	 in	 systems	 theory	 (Ackoff,	 1974;	Freeman	and	McVea,	 2001).	 Freeman’s	seminal	work	 (1984)	 and	 later	works	 (Freeman	et	al.,	2010;	Freeman	and	McVea,	2001)	provide	a	broad	description	of	the	theory,	its	implications	and	applications.	 	Stakeholders	are	often	defined	as	 ‘primary’	(including	the	immediate	value	chain	of	 suppliers,	 employees	 and	 customers)	 and	 ‘secondary’	 (which	 includes	 government,	competitors,	 media	 and	 interest	 groups)	 (Freeman,	 1984,	 p.	 25).	 	 Mitchell	 and	 workers	summarise	 the	main	 formative	 literature	and	definitions	of	stakeholders	(Mitchell	et	al.,	1997,	pp.	860–862),	with	a	generally	accepted	definition	as:	“an	individual	or	group	who	can	affect	or	is	
affected	by	the	achievement	of	the	organization’s	objectives”	(Freeman,	1984).	 	 	Mitchell	 further	proposes	a	typology	or	scoring	system	to	categorise	stakeholders	based	upon	three	attributes:	‘power’,	 ‘legitimacy’	 and	 ‘urgency’	 (1997,	 pp.	 874–879).	 	 Much	 stakeholder	 literature	distinguishes	 between	 those	 who	 affect	 and	 who	 are	 affected	 by	 a	 decision	 or	 action.	 This	concept	 is	 summarised	 in	 the	 power	 (influence)	 and	 interest	 model	 (Ackermann	 and	 Eden,	2011,	p.	183)	now	commonly	used	to	segment	stakeholder	groups	(Mainardes	et	al.,	2012;	Reed	et	al.,	2009).	So,	understanding	these	would	appear	 to	be	an	 important	step	 in	 the	 innovation	approach.			The	nature	of	 interdependence	 influences	 the	stakeholders’	 strategies	 (Frooman,	2002),	being	determined	by	whether	the	network	is	unfamiliar	or	stable.		Rowley	(1997)	considers	the	nature	(density)	 of	 the	 network	 and	 the	 position	 of	 the	 focal	 firm	 (centrality)	 as	 influencing	 factors.		Ackermann	mapped	interactions,	a	‘stakeholder	management	web’	(2011,	p.	189),	to	understand	the	needs	of	stakeholders	and	how	these	were	met	at	three	levels:	rational	(whole	organization),	process,	and	transactional.	 	Much	stakeholder	analysis	is	static,	but	in	reality	evolves	(Rowley,	1997).		Prior	literature	suggests	that	stakeholder	interests	need	to	be	balanced	over	time,	“it	is	
more	important	to	invest	in	long-term	interactions,	than	to	rely	on	a	series	of	potentially	unrelated,	
one-time	 exchanges”	 (Zinkhan,	 2002,	 p.	 5).	 But	 in	 nascent	 or	 emergent	 ecosystems	 key	stakeholders	 may	 not	 be	 immediate	 (Maignan	 et	 al.,	 2005).	 	 More	 recent	 approaches	 to	stakeholder	 theory	 focus	 on	 the	 ‘jointness’	 of	 stakeholder	 interests	 rather	 than	 trade-offs	(Freeman	 et	 al.,	 2010).	 Stakeholders	 themselves	 collaborate,	 leading	 to	 additional	 complexity	(Savage	et	al.,	2010).	However,	insights	from	complexity	theory	suggest	that	the	most	connected	agents	are	often	not	the	most	influential	(Quax	et	al.,	2013),	which	may	appear	counterintuitive,	and	that	a	key	determinant	of	influence	was	more	about	the	susceptibility	and	structure	of	the	influence	 network	 (Watts	 and	 Dodds,	 2007).	 	 This	 would	 suggest	 that	 the	 quality	 of	 the	
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interactions	 is	 more	 potentially	 important	 than	 the	 quantity	 of	 interactions,	 reinforcing	 the	argument	for	the	importance	of	a	relational	perspective.		Interestingly,	 whilst	 relationships	 and	 stakeholders	 are	 often	 mentioned	 in	 value	 chain	 and	business	model	literature,	analysis	rarely	goes	beyond	acknowledging	they	exist	(for	examples,	see	 Baden-Fuller	 and	Morgan,	 2010;	 Fine	 and	 Simchi-Levi,	 2010;	 Gardner	 and	 Cooper,	 2003;	Gereffi,	 2011;	 Srai,	 2007;	 Zott	 and	 Amit,	 2010)	 and,	 as	 such,	 has	 not	 formed	 a	 significant	component	 of	 recent	 business	 model	 or	 value	 network	 analysis.	 	 There	 has	 been	 some	assessment	of	stakeholders,	 to	 the	 level	of	classification	into	 ‘primary’	and	 ‘secondary’,	but	no	further	(Harrington	and	Srai,	n.d.;	Kumar	et	al.,	2013).		This	represents	a	gap	in	the	literature	for	both	value	networks	and	ecosystems.				A	conclusion	is	that	a	better	articulation	of	the	‘how’,	i.e.	the	processes	and	the	relationships	or	stakeholder	influences,	and	explicitly	defining	and	mapping	these	may	provide	a	more	coherent	link	to	the	wider	ecosystem	and	aid	understanding	of	causality	in	convergent	innovation.		
2.4 Developing Organisational Capabilities The	success	of	organisations	is	based	upon	understanding	factors	external	to	the	company	(e.g.	the	 environment	or	 ecosystem)	and	 the	 internal	 factors	or	 organizational	 capabilities	 (Porter,	1998).	 	 Considering	 the	 previously	 discussed	 challenges	 three	 aspects	 of	 capabilities	 appear	relevant,	 namely:	 innovation	 capabilities,	 the	 formation	 of	 value	 networks,	 and	 the	 broader	organisational	capabilities	needed	to	address	the	changes	required	for	convergent	innovation.			Traditional,	neoclassical,	economic	theories	draw	upon	transaction	cost	economics	to	determine	firm	 boundaries	 (Williamson,	 1985),	 but	 convergence	 requires	 not	 only	 efficiency	 and	transaction	 cost	 considerations,	 it	 also	 impacts	 complementary	 assets	 to	 advance	 and	commercialise	 new	 technologies	 (Rikkiev	 and	 Mäkinen,	 2013).	 	 A	 resource	 based	 approach	(Barney,	 1991;	 Grant,	 1996;	 Penrose,	 1996;	 Prahalad	 and	 Hamel,	 1990;	 Teece	 et	 al.,	 1997),	building	on	a	knowledge	and	capability	perspective,	identifies	collaboration	as	essential	to	gain	access	to	external	resources,	and	as	such,	may	provide	a	stronger	basis	to	consider	convergence.		The	 success	 of	 each	 actor	 or	 member	 is	 “influenced	 by	 the	 ….	 ecosystem”,	 as	 “a	 holistic,	
intertwined	entity	that	is	in	continuous	evolution”	(Iansiti	and	Levien,	2004).		Thus,	reinforcing	a	need	 to	 address	 the	 ecosystem,	 the	 business	 models	 and	 the	 value	 networks,	 in	 order	 to	understand	the	implications	for	decisions	and	organisation	capabilities.		
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The	 resource	 based	 view	 (Barney,	 1991,	 2001,	 1999;	 Collis,	 1994;	 Grant,	 1991;	 Wernerfelt,	1984)	holds	 that	 the	key	 to	a	 firm’s	competitive	advantage	 is	 the	possession	of	valuable,	 rare,	inimitable,	 and	 non-substitutable	 (VRIN)	 capabilities	 (Barney,	 1991;	 Eisenhardt	 and	 Martin,	2000)	 and	 confer	 competitive	 advantage	 to	 firms	 either	 through	 superior	 product	 or	 service	offerings	(Porter,	1996)	or	via	production	performance		or	efficiency	(Womack	et	al.,	1990).		The	concept	of	‘core	competencies’	(Hamel	et	al.,	1989;	Prahalad	and	Hamel,	1990),	a	revisiting	of	the	resource	 based	 view,	 popularised	 such	 concepts	 within	 management,	 perceived	 easier	 for	executives	 to	 consider,	 being	 controllable,	 unlike	 the	 external	 environment	 (Eisenhardt	 and	Martin,	2000).		The	creation	of	‘core	capabilities’,	through	path-dependent	learning	can	however	become	 a	 ‘rigidity’	 (Leonard-Barton,	 1992).	 It	 is	 argued	 that	 these	 can	 be	 overcome	 by	possessing	 ‘dynamic	 capabilities’	 (Teece	 et	 al.,	 1997).	 	 These	 contrast	 with	 ordinary	 or	‘operational’	 capabilities	 (Winter,	 2003),	 and	 are	 employed	 by	 the	 firm	 to	 create	 new	capabilities.		Teece,	Pisano	and	Shuen	(1997)	identified	dynamic	capabilities	as	“the	firm’s	ability	
to	integrate,	build,	and	reconfigure	internal	and	external	competences	to	address	rapidly	changing	
environments”	 (1997,	 p.	 516).	 Subsequent	 authors	 (for	 example,	 Easterby-Smith	 et	 al.,	 2009;	Eisenhardt	and	Martin,	2000;	Helfat	and	Peteraf,	2003;	Pandza	and	Thorpe,	2009;	Teece,	2007;	Winter,	2003;	Zollo	and	Winter,	2002)	have	addressed	questions	such	as:	what	constitutes	such	abilities,	their	attributes	and	where	they	come	from?			The	dynamic	capability	perspective	suggests	that	existent	organisational	routines	for	innovation	could	be	deployed	to	create	something	radically	new	(di	Stefano	et	al.,	2014;	Teece,	2012).	 In	this	case,	an	incumbent	firm	requires	ambidextrous	structures	(Gupta	et	al.,	2007;	Tushman	and	Reilly,	1996)	and	appropriate	social	practices	to	balance	exploitative	and	exploratory	innovation	(Fagiolo	 and	 Dosi,	 2003).	 If	 exploratory	 new	 product	 development	 capabilities	 (Brown	 and	Eisenhardt,	1997)	are	embedded	in	processes	of	experiential	learning	(Zollo	and	Winter,	2002)	within	 an	 incumbent	 firm,	 then	 it	 is	 possible	 to	 argue	 that	 it	 could	 develop	 a	 disruptive	convergent	 technology	 without	 changes	 in	 organizational	 capabilities.	 An	 incumbent	 must	confront	 technological	 and	market	 uncertainties,	 but	 would	 unambiguously	 know	 how	 to	 act	when	developing	the	innovation.			An	 alternative	 argument	 however,	 suggests	 that	 advances	 in	 technology	 almost	 inevitably	trigger	requirements	for	incumbents	not	only	to	innovate	their	products,	but	to	change	how	they	organize	for	innovation	(Dougherty,	1992;	Dougherty	and	Dunne,	2011;	Greve	and	Taylor,	2000;	Yoo,	2013).	Moreover,	scholars	assert	that	existing	organizational	capabilities	more	likely	act	as	core	 rigidities	 (Leonard-Barton,	 1992)	 by	 supporting	 cognitive	 inertia	 of	 relevant	 decision	makers	(Bettis	and	Prahalad,	1995;	Danneels,	2011;	Tripsas	and	Gavetti,	2000).	This	potentially	obstructs	 internal	acceptance	of	potentially	disruptive	convergent	 innovation	at	an	 incumbent	
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firm.	 	 This	 line	 of	 argument	 therefore	 suggests	 it	 is	 highly	 unlikely	 for	 an	 incumbent	 firm	 to	develop	 a	 convergent	 and	potentially	disruptive	 technology	without	 changes	 in	 its	 underlying	organizational	routines	and	capability	for	innovation.				This	sharp	dichotomy	between	sustaining	existing	organizational	routines	for	innovation	versus	developing	 entirely	 new	 ones	 leads	 to	 two	 sharply	 different	 implications	 for	 managers	 at	incumbent	 companies.	 They	 should	 either	 replicate	 (Szulanski,	 1996;	 Winter	 and	 Szulanski,	2001)	 existing	 organizational	 routines	 and	 learn	 ‘as	 they	 go’,	 or	 radically	 depart	 from	 the	existing	ways	of	how	they	innovate.	So,	a	more	nuanced	and	subtle	understanding	of	change	in	organizational	capability	for	convergent	and	potentially	disruptive	innovation	would	be	relevant	for	 both	 innovation	 theory	 and	 practice.	 	 	 An	 implication	 of	 this	 is	 that	 understanding	 ‘why’	processes	are	employed	 is	as	 important,	and	relevant,	as	understanding	 ‘which’	processes	are	employed,	and	‘how’.			
2.5 Innovation Management Innovation	has	been	the	focus	of	extensive	research	(Fagerberg	et	al.,	2012)	with	much	of	that	focus	being	on	the	innovation	system	or	on	organizing	innovation.		Smith	et	al.	(2008)	conducted	a	systematic	literature	review	of	innovation	identifying	nine	important	factors	that	impact	on	an	organisation’s	ability	to	manage	innovation,	and	concluded	that	the	 innovation	process	 is	a	key	factor	 to	which	all	other	 factors	impact.	 	A	 further	systematic	review	by	Crossan	and	Apaydin	(2010)	developed	a	 framework	 to	delineate	 the	 ‘determinants	of	 innovation’	 (e.g.,	 leadership,	organisation	and	business	processes)	 from	the	 ‘dimensions	of	 innovation’	 (e.g.	 innovation	as	a	process	 and	 as	 an	 outcome),	 concluding	 that	 innovation	 as	 a	 process	 (i.e.,	 how?)	 is	 under-developed	 in	 the	 literature.	 Montoya-Weiss	 (1994)	 and	 Holahan	 (2014)	 identified	 ‘best	practices’,	with	 the	emphasis	being	 in	organising	 innovation.	However,	much	of	 this	 literature	has	focused	on	innovation	by	incumbents	in	existing	industries.				Innovation	 and	 new	product	development	processes	 are	 often	 considered	 as	 sequential,	with	‘stage-gates’	 (Cooper,	 1990)	 reinforcing	 linearity,	 but	 in	 reality	 they	 are	 ‘messy’,	 ‘improvised’	and	 experimental	 (Garud	 et	 al.,	 2013,	 p.	 787),	 especially	 at	 the	 early	 stages	 (and	 as	 later	acknowledged	by	Cooper	(2008)).	New	product	development	(NPD)	and	 innovation	processes	may	be	considered	as	complex	adaptive	systems	(Frenken,	2000;	McCarthy	et	al.,	2006).		This	is	echoed	 by	 Anderson	 and	 Joglekar	 	 (2012)	 who	 describes	 a	 systems	 approach	 to	 managing	innovation.	More	recent	work	on	 ‘open	innovation’	(Chesbrough,	2003;	Chesbrough	and	Teece,	1996;	Gassmann	et	al.,	2010a)	further	increases	system	complexity	as	the	number	of	agents	and	interdependencies	increase.	However,	it	appears	that	many	firms	still	operate	‘linear’	processes	
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(Browning	and	Ramasesh,	2009;	Sommer	et	al.,	2014,	p.	980).		Within	health	care	this	perceived	linearity	is	further	reinforced	by	regulation	(FDA,	2014a,	2014b;	Food	and	Drug	Administration,	2013;	Medicines	and	Healthcare	Products	Regulatory	Agency,	2003).				This	 would	 suggest	 that	 incumbent	 firms	 will	 need	 to	 break	 with	 traditional	 innovation	approaches	 and	 develop	 new	 organisational	 capabilities.	 The	 specific	 implications	 for	 the		innovation	processes	will	be	addressed	later	in	this	chapter.	
2.5.1 Cognitive capabilities Whilst	 innovations	are	often	 likely	 to	be	 technology	driven,	 the	 assessment	of	 them	 is	not	an	‘objective’	 phenomenon,	 but	 a	 socio-cognitive	 process	 (Garud	 and	 Ahlstrom,	 1997)	 with	“differences	in	foci	and	sense	making	approaches,	differences	in	epistemologies,	and	differences	in	
criteria	 for	 evaluation”,	 which	 innovating	 firms	 need	 to	 address	 in	 their	 interactions	 with	stakeholders	and	potential	customers	(this	point	is	further	discussed	in	the	section	on	business	models	 and	 value).	 	 Taking	 the	 subject	 of	 stakeholder	 and	 customer	 interaction	 further,	 Von	Hippel	 (von	Hippel,	 2009,	 1988)	 and	 Awa	 (2012,	2010)	 both	 call	 for	 a	 ‘democratizing’	 of	 the	innovation	process,	with	greater	customer	co-development	and	links	to	‘user	groups’	for	testing	and	feedback.	Aligned	with	this,	there	is	a	trade-off	between	enhancing	trust	(in	the	user	group)	versus	 reducing	 risk	 (of	 not	meeting	 expected	performance)	when	developing	 a	new	product	(Nienaber	and	Schewe,	2014),	calling	for	greater	contact	intensity	and	relationship	commitment.		The	influence	of	strategic	partners	(as	part	of	the	emerging	value	network)	on	innovation,	has	also	 been	 shown	 to	 be	 an	 important	 factor	 (Bröring	 and	 Leker,	 2007).	 	 In	 conditions	 of	convergence	those	partners	are	likely	to	be	harder	to	find	and	have	different	norms	in	terms	of	capabilities	and	culture	(Dingler	and	Enkel,	2016).		In	 convergence,	 knowledge	 distance	 between	 partners	 is	 implicit.	 Knowledge	management	 is	considered	 an	 important	 antecedent	 to	 innovation	 (Moos	 et	 al.,	 2013).	 Fundamental	 to	knowledge	 management	 is	 a	 firm’s	 absorptive	 capacity	 (Cohen	 and	 Levinthal,	 1990).	 The	innovation	literature	identifies	strong	links	between	knowledge	management	and	the	need	for	absorptive	capacity	(Cohen	and	Levinthal,	1990;	Enkel	and	Heil,	2014b;	Gauch	and	Blind,	2014;	Moos	et	al.,	2013).			But	given	the	implied	knowledge	distance	there	is	also	a	need	to	exchange	that	knowledge	between	groups	and	individuals	with	different	knowledge	bases,	suggesting	that	any	such	exchange	will	require	the	use	of	 ‘boundary	objects’	(Leigh	Star	and	Griesemer,	1989)	and	 a	means	 to	 either	 ‘transfer,	 translate	 or	 transform’	 (Carlile,	 2004,	 2002)	 that	 knowledge.		Investigating	knowledge	transfer	effectiveness,	Argote	and	Ingram	(2000)	identified	that	to	be	effective,	 information	 needs	 to	 be	 well	 codified	 and	 that	 a	 large	 number	 of	 weak	 ties	(Grannovetter,	1973;	Granovetter,	1983)	are	important	to	provide	the	ability	to	search,	identify	and	acquire	knowledge.	However,	where	knowledge	may	be	poorly	codified,	as	in	convergence,	
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then	 strong	 ties	 and	 repeated	 interaction	 may	 be	 equally	 important.	 	 This	 suggests	 that	 the	nature	of	the	relationships	and	information	exchanges	within	the	innovators	network	could	be	highly	influential.		
2.5.2 Innovation processes As	 previously	 identified,	 the	 innovation	 processes	 have	 had	 limited	 research	 (Crossan	 and	Apaydin,	2010;	Garud	et	al.,	2013).		In	part	this	may	be	due	to	difficulty	in	studying	innovation	processes	in	action,	as	much	research	captures	data	after	the	event.	Furthermore,	complexities	in	studying	them	also	arise,	as	Garud	et	al.	 (2013)	point	out:	 innovation	processes	are:	(a)	co-evolutionary,	as	they	simultaneously	implicate	multiple	levels	of	analyses	(Murmann,	2003);	(b)	relational,	as	they	involve	a	diverse	set	of	social	actors	(Bijker	et	al.,	1987);	(c)	inter-temporal,	as	temporal	events	and	sequences	are	experienced	 in	multiple	ways	(Garud	and	Gehman,	2012);	and	(d)	cultural	(Dooley	and	Van	de	Ven,	1999),	as	they	unfold	within	different	contexts.	Where	processes	 have	 been	 reviewed	 (Browning	 and	 Ramasesh,	 2009;	 Cooper,	 2008;	 Cooper	 and	Kleinschmidt,	1995),	they	identified	various	process	model	‘types’	used,	variously	described	as:	linear;	“spiral”;	concurrent;	networked	and	”vee”.	Many	prior	reviews	focus	on	‘actions’	rather	than	‘interactions’	(Browning	and	Ramasesh,	2009),	further	suggesting	that	prior	research	has	underplayed	the	more	contextual	and	relational	elements	involved	in	innovation.			Convergent	innovations,	whilst	incremental	in	one	industry,	may	be	disruptive	in	others	(Enkel	and	Gassmann,	2010).	Veryzer	(1998)	identified	that	disruptive	innovations	were	less	reliant	on	a	formal	process.		Similarly,	Bessant	et	al.	(2005)	exploring	differences	in	innovation	capabilities	and	approaches	for	‘steady-state’	versus	‘discontinuous’	innovations	identified	that:	there	are	no	clear	rules	by	which	actors	play;	 there	needs	 to	be	a	high	 tolerance	 for	ambiguity;	 there	 is	no	clear	 trajectory;	 that	 routines	 are	 open	 ended,	 based	 around	 managing	 emergence.	 They	concluded	by	suggesting	that	developing	 ‘fuzzy	 front	end’	type	approaches	(Koen	et	al.,	2001)	may	be	beneficial.			Koen,	in	a	number	of	studies	(Koen	et	al.,	2014,	2001,	1996)	identified	several	approaches	to	the	‘fuzzy	front	end’,	or	‘front	end	innovation’.		These	were	seen	to	differ	from	traditional	innovation	perspectives	(e.g.,	Cooper,	1990),	with	opportunity	identification	and	analysis,	idea	genesis	and	selection	 and,	 the	 concept	 and	 technology	 development	 being	 core	 to	 innovation	 capability.		More	importantly	the	‘fuzziness’	implied	is	considered	inappropriate,	being	better	described	as	‘front	end	innovation’.		It	also	suggests	that	processes	are	likely	to	be	context	specific.	Koen	et	al	also	 identify	 key	 capabilities	 for	 organisations	 focussed	 on	 senior	management	 commitment,	
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vision	and	strategy	and	culture,	rather	than	processes	(Koen	et	al.,	2014).	This	role	in	providing	governance	and	in	making	strategic	decisions	is	now	considered.			
2.6 Governance and investment decisions The	 influence	 of	 senior	management	 on	 new	 innovation	 processes	 is	 important,	 primarily	 as	‘gate-keepers’	 (Cooper,	 2008,	 1990;	 Cooper	 and	Kleinschmidt,	 1995)	 	 but	 also	 in	 other	ways,	such	as	learning	and	knowledge	management	(Gomes	et	al.,	2001).	The	success	of	the	venture	depends	upon	sponsorship	of	top	management	and	developing	a	supportive	internal	‘ecosystem’	(Girotra	and	Netessine,	2014).			Investment	decisions	in	situations	with	high	uncertainty	and	risk	carry	an	increased	risk	of	bias	(and	 potential	 failure)	 as	 a	 consequence	 of	 representativeness	 (misconceptions,	 particularly	where	 relationships	 are	 non-linear),	 availability	 (impacted	 by	 the	 ease	 of	 retrievability,	 and	illusory	 correlations)	 and	 adjustment	 and	 anchoring,	 as	 a	 result	 of	 insufficient	 analysis	 and	objectivity	 (Kahneman	and	Tversky,	 2007;	Kahnemann	et	al.,	 1982).	 Convergent	 innovation	 is	characterised	by	higher	uncertainty	(absence	of	knowledge)	and	higher	equivocality	(multiple,	ambiguous	and	sometimes	conflicting	sources	of	knowledge)	(Daft	and	Lengel,	1986),	so,	the	use	of	multiple	and	alternative	perspectives,	and	building	pluralism	in	the	decision	making	is	likely	to	be	important	(Allen,	2001).			Considering	 other	 types	 of	 innovation,	 ‘open	 innovation’	 (H.	 Chesbrough,	 2006;	 Faems,	 2008)	decision	gates	 require	modified	 criteria	 (Gronlund	et	 al.,	 2010)	 to	 ensure	 external	 know-how,	paths	and	capabilities	are	continually	assessed.		Convergent	innovation	could	be	considered	an	extension	of	the	open	innovation	concept,	but	spanning	industry	and	technology	boundaries.		A	similar	 concept	 is	 ‘co-innovation’	 (Lee	 et	 al.,	 2012)	 which	 is	 built	 upon	 ‘	 …	 principles	 of	
convergence	of	ideas,	collaborative	arrangement,	and	co-creation	of	experience	with	stakeholders’	(Lee	et	al.,	2012).	Both	suggest	the	increased	importance	of	external	know-how,	pluralism	and	stakeholder	 input.	 	 A	 further	 challenge	 is	 that	 the	 innovation	 is	 not	 autonomous	 (Dosi	 et	 al.,	1998;	Nelson,	1998),	in	healthcare	there	may	be	wider	effects,	particularly	in	downstream	care	pathways.	 This	 suggest	 a	 more	 systemic	 approach	 to	 innovation	 (Teece,	 1996)	 is	 needed	 for	integration	 of	 the	 innovation	 into	 the	 adoption	 chain	 (Adner,	 2012,	 2006).	 	 This	 systemic	intervention	 (Midgley,	 2014,	 2006)	 or	 systemic	 innovation	 (Midgley	 and	 Lindhult,	 2017)	suggests	 that	 innovators	 need	 to	 pay	 attention	 to	 both	 the	 upstream	 and	 downstream	stakeholders	and	value	chains	and	develop	approaches	 to	utilize	systems	thinking	 to	embrace	complexity	(Garud	et	al.,	2013).			
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Convergent	 innovation	 also	 requires	 integration	 (Rikkiev	 and	Mäkinen,	 2013),	 but	 integrated	product	 development	 (Gerwin	 and	 Barrowman,	 2002),	 managing	 the	 overlapping,	 parallel	execution	and	concurrent	workflow	of	activities	(Gerwin	and	Barrowman,	2002)	brings	further	challenges	 for	 governance	 and	 senior	 management	 (Sommer	 et	 al.,	 2014),	 driven	 by	 the	increased	 complexity	 and	 ambiguity.	 	 The	 risks	 include	 technical,	 management	 and	 market	elements	 (Zhang	and	Yongbo,	 2011),	 determined	by	 innovative	and	 technological	 uncertainty,	resource	uncertainty,	and	consumer	and	competitive	uncertainty	(Moenaert	and	Souder,	1990).			In	 convergent	 innovation	 additional	 risks	 may	 exist	 in	 integrating	 across	 alliance	 partners	(Rikkiev	 and	Mäkinen,	 2013).	 	 	 The	 ability	 to	manage	 across	 these	different	 risk	 types	would	therefore	 be	 expected	 to	 be	 a	 key	 capability	 in	 firms	 developing	 convergent	 healthcare	technology	innovations.				
2.7 Developing Alliances and Value Networks  Developing	 innovation,	 especially	under	 conditions	of	 convergence,	with	diverse	 technologies,	requires	 the	 formation	of	 alliances	 (Doz,	 1996;	 Li	 et	 al.,	 2008);	 defined	here,	 as	by	Kale	 et	 al.	(2002,	p.	748)	as	‘any	independently	initiated	inter-firm	link	that	involves	co-development,	sharing	
or	 exchanges’.	 The	 alliances	 provide	 the	 basis	 for	 resource	 heterogeneity	 (Penrose,	 1959;	Wernerfelt,	1984)	with	the	unique	combination	providing	the	possibility	to	create	and	capture	value.	They	could	be	considered	as	enabling	an	extended	enterprise	model	 (Gulati	et	al.,	2012)	where	 a	 focal	 firm	 (or	 group	 of	 firms)	 contracts	 with	 upstream,	 downstream,	 or	 horizontal	partners	 that	 possess	 complementary	 assets	 (Rothaermel,	 2001)	 to	 enhance	 their	 own	technology,	capabilities,	or	market	reach.	Specifically,	Sebastio	and	Golicic	(2008)	argue	the	case	that	the	successful	emergence	of	a	new	market,	based	on	a	 ‘radical	technological’	 intervention,	depends	 largely	 on	 the	 parallel	 development	 of	 a	 new	 value	 network	 to	 support	commercialization	 activities.	 Adner	 (2012)	 extends	 these	 requirements	 beyond	 the	 value	network	itself	to	consider	the	wider	‘adoption	chain’	necessary	to	commercialize	the	innovation	and,	 hence,	 capture	 value.	 	 These	 activities	 can	 be	 considered	 as	 market	 creating,	 using	 a	
constructionist	approach	(Jaworski	et	al.,	2000)	as	partners	seek	to	complement	knowledge	and	capabilities	to	create	value	(Lepak	et	al.,	2007).		It	is	not	sufficient	to	just	innovate	a	product	or	develop	 a	 value	 network,	 it	 is	 also	 necessary	 to	 construct	 markets	 and	 navigate	 institutions,	which	 requires	 collective	 entrepreneurial	 action	 (Santos	 and	 Eisenhardt,	 2004,	 2009)	 and,	 a	process	of	exploration	to	effect	a	transformation,	or	 ‘effectuation’	(Sarasvathy	and	Dew,	2005)	amongst	multiple	alliances.			
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In	order	to	profit	from	such	cross-industry	collaborations,	innovators	must	be	able	to	find,	and	then	 transfer	 knowledge	 with	 their	 cross-industry	 partners	 (Gilsing	 and	 Nooteboom,	 2006;	Zahra	 and	 George,	 2002)	 and	 then	 create	 new	 organizational	 boundaries	 (Santos	 and	Eisenhardt,	 2005)	 as	 they	 form	 value	 networks	 to	 deliver	 the	 innovations	 to	 customers	(Harrington	 &	 Srai	 2016).	 Firms	 create	 alliances	 to	 address	 strategic	 needs	 and	 social	opportunities	 (Eisenhardt	 and	 Schoonhoven,	 1996),	 but	 despite	 their	 attractiveness	 alliances	can	 have	 high	 transaction	 costs	 (Williamson,	 1999),	 may	 present	 routes	 for	 ‘leakage’	 of	 core	competencies	(Hamel	et	al.,	1989)	and	may	reduce	profit	or	revenue	streams	(Eisenhardt	and	Schoonhoven,	1996).		Alliances	can	fail	due	to	poor	partner	selection	(Hitt	et	al.,	2000)	or	poor	management	(Ireland,	2002).				An	 organisations	 structure,	 as	 previously	 noted,	 is	 also	 impacted	 by	 product	 modularity	(Baldwin	and	Clark,	1997).	One	can	distinguish	between	decoupled,	loosely	coupled	and	tightly	coupled	 systems	 (Brusoni	 et	 al.,	 2001).	 	 Modularization	 reduces	 uncertainty	 and	 complexity	helping	to	identify	problem	and	solution	paths,	enhancing	learning	processes	(Tyre	and	Hippel,	1997)	and	 improving	knowledge	predictability	 (Chesbrough	and	Teece,	1996;	Sanchez,	2002).	Product	 modularization	 shapes	 the	 vertical	 division	 of	 labour,	 which	 favours	 knowledge	specialization	and	creates	boundaries	(Baldwin	and	Clark,	2000;	Langlois	and	Roberston,	1992;	Sanchez	 and	 Mahoney,	 1996;	 Schilling,	 2000).	 	 Consequently,	 firms	 often	 align	 knowledge	boundaries	with	production	boundaries	(Dibiaggio,	2007).	Value	chains	fragment	at	those	points	where	 knowledge	 is	most	 explicit	 and	 codified,	 which	 also	 determines	 the	 form	 of	 economic	governance	(Gereffi	et	al.,	2005).	Although	activities	can	be	divided	between	specialist	firms,	in	convergence	 ‘systems	 integrators’	 must	 develop	 knowledge	 outside	 the	 scope	 of	 their	‘productive	activities’	 (Patel	and	Pavitt,	1994)	and	integrate	knowledge	 from	different	sources	(Brusoni	et	al.,	2001;	Hobday	et	al.,	2005).			The	 concept	 of	 value	 network	 integration	 or	 re-integration	 has	 been	 less	 explored;	 but	Cacciatori	(2005)	noted	that	reintegration	may	occur	when	the	limitations	of	specialization	are	reached	 and	 new	 customers	 services	 are	 demanded.	 Funk	 (2012)	 explored	 the	 relationship	between	 vertical	 disintegration	 and	 entrepreneurial	 opportunities,	 identifying	 that	 those	opportunities	 arose	 at	 the	 ‘interstices’,	 challenging	 conventional	 wisdom	 about	 ‘dominant	
designs’,	 identifying	 that	 niche	 opportunities,	 like	 those	 offered	 by	 open	 interface	 standards,	enabling	late	entrants	to	‘win’.		Davies	(2005;	2004)	examined	integration	to	provide	high-value	services	 to	 address	 customer-centric	 solutions,	 as	 may	 be	 required	 in	 health	 care.	 	 	 But	 by	definition,	 in	 convergent	 innovation	 and	 a	 nascent	 or	 emerging	 innovation	 ecosystem,	 no	dominant	design	exists.		So,	innovators	have	many	options,	paths	and	investment	challenges	and	much	 of	 the	 extant	 literature	 on	 value	 network	 formation	 is	 rooted	 in	 incumbent	 firms	 and	
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established	industries	(for	examples,	see	Eisenhardt	and	Schoonhoven,	1996;	Gulati,	1999;	Lavie	and	Rosenkopf,	2006).		As	 convergence	 requires	 new	 capabilities	 (Enkel	 and	 Heil,	 2014b)	 the	 organization	 has	 a	number	of	options	for	acquiring	or	accessing	these	(Barney,	1999;	Gulati	et	al.,	2012).	Given	the	challenges	 in	 internal	 development	 or	 in	 outright	 acquisition,	 alliance	 formation	 and	 alliance	management	 (Schreiner	 et	 al.,	 2009)	 under	 conditions	 of	 high	 uncertainty,	 would	 therefore	appear	 to	 be	 a	 critical	 capability	 in	 the	 development	 of	 ‘nascent	 value	 networks’.	 In	organizational	 terms,	 this	 may	 be	 considered	 as	 the	 ‘conception	 and	 development’	 stage	(Kazanjian	 and	 Drazin,	 1990),	 either	 as	 a	 new	 venture	 (start-up)	 or	 as	 a	 new	 business	 unit	within	an	incumbent	firm.		Harrington	and	Srai	(2016)	describe	the	stages	of	emergence	of	value	networks	 and	 their	 characteristics,	 the	 network	 stages	 and	 transitions	 from	 ‘embryonic’	 to	‘fragmented’	 to	 ‘formation’	being	the	most	relevant	 to	the	study	of	nascent	value	networks.	 	A	factor	influencing	the	formation	is	the	extent	to	which	the	networks	or	alliances	are	formed	as	a	result	of	an	emergent	process	or	engineered,	via	a	dominant	player	(Doz	et	al.,	2000).			Kale	 and	 Singh	 (2007)	 identified	 that	 an	 alliance	 learning	 process	 involving	 articulation,	codification,	sharing,	and	internalization	(Cohen	and	Levinthal,	1990;	Zahra	and	George,	2002)	of	alliance	management	know-how	is	positively	related	to	a	firm’s	overall	alliance	success,	these	alliance	 capabilities	 being	 described	 as	 ‘higher-order	 dynamic	 capabilities’.	 That	 research	however,	focused	solely	on	large	established	companies	in	existing	industries.		In	the	context	of	the	 formation	 of	 value	 networks	 in	 nascent	 ecosystems,	 they	 can	 also	 be	 considered	 as	 the	quadrant	 of	 ‘pre-formation	 value	 creation’	 (Wang	 and	 Rajagopalan,	 2015)	 and	 that	 a	competence	 based	 approach	 (considering	 information	 search,	 codified	 routines	 and	 partner	evaluation)	 may	 be	 appropriate.	 Draulans	 et	 al.	 (2003)	 recognizing	 that	 most	 alliances	 fail,	looked	 at	 capabilities	 for	 alliance	 success	 in	 inexperienced	 and	 established	 firms,	 concluding	that	learning	processes	are	important,	but	only	up	to	a	point,	and	that	inexperienced	companies	can	benefit	from	training	or	the	use	of	alliance	experts	and	that	the	type	of	alliances	and	their	diversity	 can	 also	 influence	 outcomes.	 	 This	would	 suggest	 that	 context,	 i.e.	 the	 nature	 of	 the	ecosystem	 is	 an	 important	 consideration.	 	 	 However,	 as	 identified	 by	 Stuart	 and	 Sorenson	(2007),	 extant	 research	 focuses	 disproportionately	 on	 the	 consequence	 of	 the	 network	 (or	ecosystem),	rather	than	its	origins	(i.e.	how	they	built	it).		The	 crucial	 role	 of	 relational	 capabilities	 in	 developing	 and	 managing	 alliances	 has	 been	demonstrated	in	the	literature	(Ireland	et	al.,	2002).		For	example,	prior	research	suggests	that	a	firms	negotiating	capability	(Simonin,	1997)	and	its	governance	capability	(Aggarwal	and	Hsu,	2009)	are	strong	determinants	of	alliance	success.	Similarly,	Arikan	(2009)	identifies	a	number	
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of	 failure	 modes	 for	 knowledge	 exchange,	 largely	 driven	 by	 the	 firm’s	 capability	 and	 the	opportunities	 (in	 terms	 of	number	 and	 quality)	 for	 knowledge	 exchange.	 	 Taking	 a	 relational	perspective,	 the	 role	 of	 relationship	 specific	 investments,	 knowledge-sharing,	 complementary	capabilities	and	effective	governance	(Dyer	and	Singh,	1998)	are	seen	as	determinants	of	inter-organizational	competitive	advantage	 in	 the	context	of	an	evolving	network	(or	ecosystem).	A	relational	 view	 of	 governance	 is	 typically	 underpinned	 by	 social	 exchange	 theory	 (e.g.	 Blau	1964),	highlighting	the	role	of	relational	norms,	trust	and	control	in	social	exchange.			Knowing	 the	 key	 stakeholders	 within	 an	 emerging	 ecosystem,	 and	 conversely	 being	 known	within	 it,	 is	 critical	 in	 order	 to	 foster	 effective	 cooperation	 across	 the	 entire	 value	 network	(Harrington	 &	 Srai	 2016).	 Classical	 stakeholder	 management	 (Freeman,	 1984)	 would	 stress	identifying	all	the	stakeholders	as	a	first	step	and	then	addressing	issues	of	power	and	influence.	However	 stakeholder	 salience	 is	 highly	 dependent	 on	 the	 innovators	 position	 within	 the	ecosystem	 (Frow	 and	 Payne,	 2011).	 	 In	 emergent	 ecosystems,	 key	 stakeholders	 may	 not	 be	immediate	(Maignan	et	al.,	2005),	and	so	identification	needs	to	be	a	continual	exploration,	with	iteration	and	refinement.		Making	connections	and	then	making	sense	of	these	connections	and	their	potential	contribution	(Sutcliffe	et	al.,	2005;	Weick	et	al.,	2012)	points	to	heuristics,	with	experimentation	and	learning	(Bingham	and	Eisenhardt,	2011).		A	major	issue,	yet	to	be	explored,	is	how	firms	can	build	these	capabilities	and	ensure	they	are	developed	in	a	complex	evolving	environment	(Donada	et	al.,	2016;	Dyer	and	Kale,	2007).	Much	of	 the	extant	value	network	 literature	 focuses	on	existing	and	established	value	networks	(for	examples,	 see	Choi	&	Hong	2002;	 Srai	&	Gregory	2008),	 identifying	ways	 to	optimize,	 control	(Lee,	2002)	or	govern	these	(Gereffi	et	al.,	2005).			There	is	limited	literature	on	the	formation	of	nascent	and	emerging	value	networks	(Sebastiao	and	Golicic,	2008).	Recent	research	points	to	
relational	 capabilities	 being	more	 important	 than	 internally	 focused	 capabilities	 (Brinckmann	and	 Hoegl,	 2011)	 as	 these	 are	 key	 to	 enabling	 the	 innovator	 to	 access	 wider	 resources	 and	capabilities.	 Furthermore,	 the	 capabilities	 required	 to	 co-create	 with	 multiple	 stakeholders,	implicit	in	this	type	of	innovation,	have	also	had	limited	study	(Kazadi	et	al.,	2016).				In	 summary,	 what	 is	 not	 clear	 are	 the	 key	 relational	 capabilities	 and	 underpinning	 routines	needed	to	successfully	effect	the	development	of	the	innovation,	to	form	the	required	alliances	(with	multiple	co-creators)	and	value	network	in	a	nascent	ecosystem.	A	further	compounding	issue	is	that	such	capabilities	may	be	influenced	by	external	and/or	internal	factors	(Doz	et	al.,	2000),	which	has	not	been	addressed	explicitly	in	empirical	research	(Eriksson,	2014).			
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2.8 Business Modelling A	general	problem	with	any	‘capabilities	approach’,	as	noted	by	Bowman	and	Ambrosini	(2000),	is	that	‘neo-classical’	resource	based	approaches	do	not	explain	value	creation	and	capture	and	this	represents	theoretical	gap.			This	was	later	reiterated	by	Priem	(2007)	who	did	not	consider	any	 of	 the	 firm	 positioning	 (Porter,	 1980),	 transaction	 cost	 (Williamson,	 1998)	 or	 resource	based	views	(Barney,	1991)	as	adequately	capturing	the	demand	needs	and	value	capture,	but	instead	 focuses	on	 ‘how	a	 focal	 firm	as	a	member	of	 a	 value	 system	can	 increase	 its	 share	of	consumer	 payments	 to	 that	 system,	 at	 the	 expense	 of	 other	 members,	 in	 a	 zero	 sum	 game’.		Markides	(2006)	identifies	distinct	differences	between	technology,	product	and	business	model	innovation,	but	notes	that	recent	literature	have	tended	to	treat	this	as	one.		Consistent	with	this	view,	the	implications	of	business	models	and	business	model	innovation	are	now	considered.		In	 the	past	 fifteen	years,	 there	has	been	growing	 interest	 in	 the	 ‘business	model’	 concept	 (Al-Debei	 and	Avison,	 2010).	 	 Interest	 accelerated	with	 the	 advent	 of	 e-business,	which	 required	models	 that	 could	 not	 adequately	 be	 expressed	 by	 classical	 strategy	 and	 value	 chain	models	(Amit	 and	 Zott,	 2001).	 Early	 research	 was	 in	 e-business	 (Zott	 et	 al.,	 2011),	 however,	 the	approaches	 are	now	more	broadly	 accepted	(DaSilva	and	Trkman,	2013;	 Johnson	et	al.,	 2008;	Osterwalder	and	Pigneur,	2013;	Shafer	et	al.,	2005;	Zott	and	Amit,	2013).			Definitions	 of	 business	 models	 are	 ambiguous	 (DaSilva	 and	 Trkman,	 2013),	 lacking	‘paradigmatic	neatness’	(Smart	et	al.,	2016),	but	in	most	studies	they	are	seen	as	an	attempt	to	address	 the	 gap	 between	 strategy	 and	 execution,	 by	 recognising	 that	 conventional	 resource	based	views	do	not	explicitly	explain	value	creation	and	capture	(Baden-Fuller,	2014).		Business	models	have	been	seen:	as	a	means	to	ensure	sustainability	and	performance	(Afuah	and	Tucci,	2000;	 Bocken	 et	 al.,	 2014;	 Funk,	 2003);	 to	 define	 the	 important	 linkages	 between	 critical	capabilities	and	business	components;	to	ensure	balanced	resources	(Achtenhagen	et	al.,	2013);	to	describe	“as	a	system”	how	a	business	fits	together	(Magretta,	2002);	and	to	identify	the	need	for	firms	to	have	knowledge	beyond	their	boundaries	and	current	product	offering	(Brusoni	et	al.,	2001).			Essentially,	business	model	literature	is	split	between	seeing	business	models	as	descriptors	of	a	business	and	its	strategy,	those	who	see	business	models	as	a	model	of	the	business	and	those	who	see	business	models	as	mediating	devices.	Consequently,	 there	 is	no	agreed	 taxonomy	for	business	models	(Baden-Fuller	and	Mangematin,	2015a).	 	However,	they	provide	the	potential	to	link	the	innovation,	the	ecosystem	and	the	value	network	capabilities,	and	thus	are	potentially	important	to	this	research.			
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	A	 significant	 body	 of	 the	 literature	 treats	 business	 models	 as	 ‘descriptors’	 with	 the	 terms	‘business	model’	 and	 ‘strategy’	 often	used	 interchangeably.	 	 	Others	 attempt	 to	 encompass	all	business	 activities	 into	 a	 single	 ‘model’	 (H.	 W.	 Chesbrough,	 2006;	 Johnson	 et	 al.,	 2008;	Osterwalder	et	al.,	2010;	Petrovic	et	al.,	2001;	Rajala	and	Westerlund,	2007).			Chesbrough	(2010;	2002)	identifies	six	functions	in	a	business	model:	the	value	proposition,	the	target	market	segment,	revenue	sources,	the	value	chain	and	complementary	assets,	the	position	of	 the	 firm	 in	 the	 value	 network,	 the	 cost	 structure	 and	 profit	 potential.	 Presented	 as	‘descriptions	 of	 the	 logic	 of	 the	 business	 system’,	 Petrovic	 et	 al	 (2001)	 divides	 a	 business	 into	seven	sub-elements,	thereby	attempting	to	encompass	all	of	the	business	into	a	single	 ‘model’.	Johnson	 and	 Christensen	 (2008)	 take	 a	 simpler	 approach,	 defining	 the	 business	 model	 as:	customer	value	proposition,	a	profit	 formula,	 the	key	resources	and	key	processes,	but	extend	the	concept	to	describe	supply	chain	and	value	chain	activities.	Osterwalder	and	Pigneur	(2010)	developed	a	design	 framework	 that	 is	much	used	 in	practice,	and	can	be	viewed	as	a	series	of	nine	 elements:	 value	 proposition,	 client	 relationships,	 client	 segments,	 distribution	 channels,	partner	 network,	 key	 activities,	 key	 resources,	 and	 finally,	 cost	 structure	 and	 revenue	 flows.				However,	the	framework	infers	design	is	possible,	which	may	not	be	the	case	if	the	information	is	diffuse	and	outcome	ambiguous.	It	has	also	been	identified	as	a	static	tool	and	not	addressing	the	 dynamics	 of	 business	model	 innovation	 or	 evolution	 (Eurich	 et	 al.,	 2014).	 	More	 recently	approaches	 have	 been	 developed	 to	 visualise	 each	 ‘design’	 snapshot	 as	 part	 of	 an	 evolution	(Fritscher	and	Pigneur,	2014).			Baden-Fuller	and	Morgan	(2010),	identify	a	business	model	as	a	‘model’,	and	provide	a	summary	of	different	models,	arguing	that	the	explicit	 link	with	technological	innovation	as	providing	‘a	
more	holistic	view	of	a	business	model’	that	is	seen	as	a	‘system’	that	defines	customers,	engaging	with	their	needs,	delivering	satisfaction	and	monetizing	value.	 	In	essence,	the	model	defines	a	cause	 and	 effect	 relationship	 (Baden-Fuller	 and	 Haefliger,	 2013).	 Business	 models	 maybe	‘conceptual’	rather	than	‘financial’	(David	J.	Teece,	2010),	but	they	create	value,	entice	payments	and	convert	payment	to	profits,	by	identifying	choices.			Much	of	the	extant	literature	takes	an	essentialist	view	of	the	business	model	as	a	description	or	representation.	A	business	model	 can	 also	be	 considered	as	 a	 cognitive	 agenda	 (Baden-Fuller	and	Mangematin,	2013)	by	treating	them	as	categorical	models	built	upon	causal	models,	using	a	typology	 of:	 customers,	 customer	 engagement,	 monetization	 and	 value	 chain	 and	 linking	mechanisms.	 	 In	so	doing,	 	 “business	models	are	‘manipulable	instruments’	which	can	be	used	to	
explore	 cause	 and	 effect	 and	 understand	 the	 world	 of	 business	 better”	 (Baden-Fuller	 and	Mangematin,	2013,	p.	424).	 	In	a	similar	vein	a	business	model	can	be	considered	as	a	 ‘market	
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device’	(Doganova	and	Eyquem-Renault,	2009).			Some	authors	(Eppler	et	al.,	2011;	Velu,	2015)	have	conceptualised	them	as	‘boundary	objects’	(Carlile,	2002;	Leigh	Star	and	Griesemer,	1989)	enabling	interchange	between	stakeholders.	As	a	market	device,	Margetta	(2002)	identifies	two	key	 components	 for	 a	 business	model:	 the	 narrative	 (the	 story	 or	 value	 proposition)	 and	 the	numbers	(the	economics).	A	market	device	infers	that	business	models	are	developed	through	a	trial	and	error	process	 (Sosna	et	al.,	2010),	 rather	 than	designed.	 	This	approach	 is	consistent	with	McGrath’s	view	(2010)	 that	the	creation	of	a	business	model	requires	an	 ‘outside	 in’	and	experimental	discovery	approach.	
2.8.1 Business models as systems Zott	and	Amit	have	undertaken	considerable	research	on	business	models	(Amit	and	Zott,	2012,	2001;	Zott	et	al.,	2011;	Zott	and	Amit,	2013,	2010,	2008,	2007),	describing	recent	developments	as	a	“holistic-system	level	approach”	that	is	now	theoretically	anchored	and	address	the	challenge	of	unresolved	overlaps	with	other	theories,	which	can	be	used	as	a	unit	of	analysis.			Their	model	is	described	as	an	“activity	system”	 (Siggelkow	and	Porter,	2008)	with	a	set	of	 interdependent	organizational	 activities	 centred	 on	 the	 focal	 firm,	 using	 four	 ‘design	 themes’	 to	 create	 value:	novelty,	lock-in,	complementarities	and	efficiency,	and	recognise	that	more	than	one	theme	can	exist	within	a	firm’s	model.		Richardson	(2008)	also	takes	an	integrative	approach	using	a	wide	range	 of	 literature	 to	 derive	 common	 elements	 that	 “can	 be	 seen	 as	 the	 conceptual	 and	
architectural	implementation	of	a	business	strategy	and	as	the	foundation	for	the	implementation	
of	 business	 processes”.	 Using	 marketing-like	 approaches	 (Kapferer,	 2004;	 Kotler,	 2003)	 the	model,	aiming	for	“a	simplified	logical	structure”,	is	defined	by:	the	value	proposition,	how	value	is	 created	 and	 then	 captured.	 	 These	 core	 elements	 are	 common	 themes,	 however	 various	authors	elaborate	adding	elements,	extending	into	capabilities	or	the	value	chain	(Figure	2-2).				
	
Figure	2-2	Business	model	concept	(derived	from	Richardson,	2008)	
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	The	notion	of	a	business	model	 is	 that	 it	 represents	 ‘an	extension	of	the	value	chain	idea’	 (Zott	and	 Amit,	 2013).	 	 It	 can	 therefore	 be	 consistent	 with	 the	 resource	 based	 view	 and	 value	networks	from	a	philosophical	perspective.	 	It	has	also	been	argued	that	a	business	model	 is	a	standalone	concept	because	it	is	a	‘model’	(Baden-Fuller	and	Haefliger,	2013)	and	the	extent	and	complexity	of	that	‘model’	is	a	major	strand	of	recent	research	(Andersson	et	al.,	2006;	Zott	et	al.,	2011).	 	 	 	Business	models	are	not	static,	but	evolve	(Demil	and	Lecocq,	2010).	However,	Sosna	(2010)	 identified	 that	 there	 is	 limited	 literature	 on	 their	 evolution,	 representing	 another	literature	gap.		
2.8.2 Value, Creation and Capture In	the	analysis	of	business	models,	the	concept	of	 ‘value’,	 its	creation	and	capture	are	constant	themes.	 	 Until	 recently	 there	 has	 been	 little	 agreement	 about	 what	 is	 ‘value’	 (Bowman	 and	Ambrosini,	2010,	2000;	Lepak	et	al.,	2007;	Makadok	and	Coff,	2002;	Priem,	2007).	Bowman	and	Ambrosini	 (2010)	 suggested	 that	 a	 prime	 cause	 was	 that	 ‘value’	 means	 different	 things	 to	different	people.		To	resolve	this,	‘value’	has	been	defined	(Bowman	and	Ambrosini,	2000;	Lepak	et	al.,	2007)	 in	 terms	of	 ‘value	creation’	and	 ‘value	capture’	and	between	 ‘use	value’	 (UV)	and	‘exchange	 value’	 (EV).	 	 The	 ‘use	 value’	 can	 be	 considered	 akin	 to	 marketing’s	 ‘customer-perceived	 value’	 	 (Kotler,	 2003,	 pp.	 418–426),	which	 results	 from	 the	 prospective	 customer’s	evaluation	of	all	benefits	and	costs	of	the	offering	or	alternatives	(Treacy	and	Wiersema,	1997).	Lepak	(2007)	 introduced	 the	concept	of	 ‘value	slippage’,	 the	difference	between	a	 firm’s	value	creation	and	what	it	receives	in	capture.		The	‘slippage’	being	ascribed	to	the	combined	effect	of	competition	 and	 the	 countering	 ‘isolating	mechanism’,	 which	 provides	 knowledge,	 physical	 or	legal	 barriers	 to	 prevent	 replication	 of	 the	 product	 or	 service.	 	 	 Priem	 (2007)	 identifies	 the	concept	 of	 ‘consumer	 benefit	 experienced’,	 as	 alternative	 viewpoint	 on	 value,	 such	 that	 value	creation	 is	 only	 a	pre-condition	 for	 value	 capture.	 	 	 	 Importantly	Lepak	(2007)	 identifies	 that	value	creation	and	capture	can	occur	and	transfer	across	the	hierarchy	of	society,	organisation	and	individual,	so	it	has	multi-level	properties	and	potential	utility	in	healthcare	settings	where	benefits	may	be	ascribed	at	different	levels	(Di	Gregorio,	2013).			The	concept	of	using	integrated	models	that	address	the	value	build	up,	dynamics	and	exchange	were	proposed	by	Khalifa	(2004).	Allee	(2008,	2000)	used	a	value	‘network	analysis’	to	address	intangible	assets,	identifying	that	they	may	be	converted	to	monetary	value	or	a	negotiable	form	of	value.		During	the	development	of	a	product,	the	asset	is	often	intangible	(Teece,	2010),	until	it	can	be	‘converted’	or	‘enhanced’	to	‘recipient	perceived	value’	or	its	wider	‘societal	value’.	This	suggests	an	evolutionary	or	lifecycle	approach,	with	the	potential	value	proposition	as	a	device	to	link	to	key	stakeholders	in	the	ecosystem,	and	to	the	ultimate	customers	and	consumers.		
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	Returning	 to	 the	 challenge	 of	 the	 innovation,	 Rogers	 (Rogers,	 2003)	 suggests	 a	 model	 of	innovation	diffusion.		This	model	of	diffusion	has	five	significant	elements:	an	innovation,	which	is	communicated	through	certain	channels	over	time	by	members	of	a	social	system	(emphasis	in	original).	 So,	 rather	 than	 a	 description,	 design	 or	 model,	 the	 concept	 of	 business	 model	evolution,	 or	 ‘business	modelling’,	 especially	 in	 a	 nascent	 ecosystem	 represents	 a	 potentially	important	concept.		Considering	the	act	of	business	modelling,	as	a	dynamic	process,	rather	than	a	design	or	one-off	event,	is	considered	next.		
2.8.3 Business modelling (as an activity or process) Baden-Fuller	 and	 Mangematin	 (2015a)	 took	 a	 process	 perspective	 identify	 a	 consider	strategizing,	 modelling	 and	 enacting	 business	 models.	 Fundamental	 to	 the	 business	 model	concept	 is	 a	 resolution	of	 the	questions	 “Who	 is	 the	 customer?”,	 “What	 value	 is	 created?”	and	“How	 is	 that	 monetized?”	 (Teece,	 2010).	 	 As	 identified	 early,	 during	 the	 early	 phases	 of	 the	innovation,	the	asset	may	be	intangible,	but	also	the	actual	customers	and	how	it	is	monetized	may	also	be	opaque,	resulting	in	challenges	due	to	uncertainty,	ambiguity,	lack	of	knowledge	and	skills	(Cavalcante	et	al.,	2011;	Chesbrough,	2010;	Doganova	and	Eyquem-Renault,	2009).			This	may	 be	 addressed	 by	 a	 trial	 and	 error	 process	 	 (Sosna	 et	 al.,	 2010),	 but	 to	 do	 this	 requires	innovators	 to	 conduct	 an	 ‘experiment’	 and	 obtain	 data.	 	 This	 may	 be	 achieved	 through	 an	information	 pooling	 process	 (Eppler	 et	 al.,	 2011),	 enabling	 knowledge	 to	 cross	 epistemic	
boundaries	 (Gavetti	 and	 Levinthal,	 2000).	 Taking	 the	 business	 model	 as	 ‘boundary	 object’	(Eppler	 et	 al.,	 2011)	provides	 a	mechanism	 to	 engage	others	 and	 conduct	 the	 experiments.	A	boundary	object	 (Carlile,	2004,	2002;	Leigh	Star,	2010;	Leigh	Star	and	Griesemer,	1989)	allow	different	groups	to	attribute	different	meanings	(particular	to	their	needs)	to	the	same	material	or	artefact.	Leigh	Star	(1989)	conceived	four	types	of	boundary	object:	repositories,	 ideal	type,	coincidence	boundaries	and	standardized	 forms.	 	Carlile	 (2004)	considered	 their	management	as	 a	 process	 involving	 transferring	 (syntactic),	 translating	 (semantic)	 and	 transforming	(pragmatic).	 	Here	it	 is	argued	that	counter	to	Eppler	et	al	(2011)	the	business	model	per	se	 is	not	 a	 suitable	 ‘boundary	object’	 for	business	modelling,	 however,	 components	of	 it	 are;	 these	being	 the	 potential	 value	 proposition	 (pVP)	 and	 the	 corresponding	 potential	 exchange	 value	(pEV),	and	that	these	represent	‘ideal	type’	boundary	objects	(Leigh	Star	and	Griesemer,	1989)	and	therefore	suitable	and	adaptable	for	the	interchange	of	ideas	and	concepts,	and	of	economic	valuation.		The	value	exchange	process,	especially	in	convergence,	requires	boundary	crossing	(Akkerman	and	Bakker,	2011)	and	polycontextuality	(Engeström	et	al.,	1995),	and	therefore	tends	towards	
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the	 need	 for	 pragmatic	 transformation	 in	 Carlile’s	 	 (2004)	 model.	 In	 a	 different	 sense	 it	represents	 the	 mechanism	 for	 co-creation	 (Nenonen	 and	 Storbacka,	 2010)	 of	 the	 business	model.	 	 In	 the	 transaction	 between	 these	 actors,	 the	 ‘value	 exchange’,	 provides	 a	 linking	mechanism.	 	 Traditionally,	 this	 ‘value	 exchange’	 has	 been	 seen	 as	 a	 dyadic	 relationship	(Jacobides	et	al.,	2006).		In	health	care,	economic	evaluations	are	a	common	precursor	to	market	access	(Kobelt,	2013)	and	involve	an	analysis	of	outputs	(benefits	to	patients	and	society)	and	inputs	(costs	and	resource	usage).	In	healthcare	a	triadic	approach,	or	more,	may	be	necessary	to	 explain	 the	 complex	 nature	 of	 the	 value	 exchange	 between	 a	 producer,	 and	 the	 patient,	practitioner,	provider	and	payer.	 	In	business	model	terms	this	could	be	described	as	a	 ‘multi-sided	model’	(Baden-Fuller	and	Mangematin,	2013),	requiring	different	cognitive	capacity	from	traditional	 customer	 relationship	models.	 	More	 importantly	 in	business	modelling	 terms	 this	appears	 to	 require	 approaches	 to	 embrace	 the	 complexity	of	multi-sidedness.	 	 	However	 it	 is	noted	that	the	study	of	business	modelling,	with	the	fairly	recent	field	of	business	models,	has	received	limited	attention	(Baden-Fuller	and	Mangematin,	2015a,	2015b).		
2.9 Emerging questions and conclusions The	literature	review	suggests	that	the	nature	of	convergent	innovation	requires	that	multiple	research	 perspectives	 are	 taken.	 	 The	 literature	 has	 considered	 both	 the	 context	 (convergent	technologies	 and	nascent	 ecosystems)	 and	 innovation	 approaches	 (capabilities	and	processes,	value	 networks	 and	 business	 modelling).	 	 Several	 potential	 gaps	 in	 the	 literature	 have	 been	identified	which	will	 be	 further	 addressed	 in	Chapter	3,	 to	help	define	 the	 research	 aims	 and	objectives.			As	previously	noted,	the	empirical	study	of	convergent	innovation	in	healthcare	technologies	has	received	little	attention	to	date.		Given	the	importance	of	this	field,	this	is	surprising..		This	leads	to	several	method	related	questions:		As	noted	by	Garud	et	al	(2013),	despite	the	plethora	of	research	on	‘innovation’	there	has	been	very	limited	research	of	the	process	and	on	understanding	the	context	of	agency,	which	talks	to	considering	 more	 fundamentally:	 “How	 to	 study	 innovation	 processes?”.	 The	 literature	suggests	taking	a	more	contemporaneous	approach,	with	longitudinal	studies	and	engagement	with	actors	to	better	understand	nuances	and	reasoning.	This	suggests	in-depth	case	studies	as	the	most	appropriate	approach,	which	will	be	discussed	in	the	methodology	chapter.			All	ecosystems	are	dynamic	and	evolve.			In	convergence	that	evolution	is	likely	to	be	more	rapid	and	 dynamic,	 resulting	 in	 highly	 dynamic	 ecosystems.	 	 Consequently,	 the	 context	 for	 any	research	is	likely	to	change	as	the	research	is	undertaken.	Addressing	this	is	therefore	important	
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to	increase	confidence	in	any	findings	and	infers	a	need	to	address:	“How	to	study	innovation	
in	the	context	of	a	nascent	and	evolving	ecosystem?”.		Furthermore,	there	are	acknowledged	challenges	in	studying	ecosystems	in	general	(Oh	et	al.,	2016;	Ritala	and	Almpanopoulou,	2017),	which	will	be	addressed	in	the	methodology	chapter.	
	Thirdly,	the	research	aims	to	better	understand	how	organisations	undertake	innovation	in	this	more	 complex	 and	 dynamic	 environment.	 	 The	 literature	 points	 to	 several	 areas	 where	‘innovation	practices’	may	be	apparent.		It	is	not	just	the	‘innovation’	that	is	being	developed,	but	also	 the	 associated	 value	 network	 and	 the	 business	 model	 required	 and	 in	 doing	 so	 the	organisation	 may	 need	 to	 develop	 its	 own	 organisational	 routines.	 So,	 a	 question	 of	 scope	emerges:	“What	aspects	of	innovation	to	study?”		A	classical	approach,	would	suggest	focussing	on	one	aspect,	for	example	the	formation	of	value	networks,	 but	 adopting	 this	 approach	 runs	 the	 risk	 of	 narrowing	 the	 potential	 sources	 of	causality	too	much	and	missing	important	factors.		Equally	attempting	an	all	embracing,	holistic	approach	is	too	ambitious	and	risks	over	generalisation.	It	therefore	requires	an	approach	is	to	consider	 the	 wider	 implications	 of	 innovation,	 but	 also	 to	 address	 a	 range	 of	 specific	 sub-questions	 relevant	 to	 the	 field.	 	 For	 example,	 “How	 are	 nascent	 ecosystems	 developed?”,	“How	are	 value	 networks	 formed?”,	and	“How	are	 business	models	 developed?”.	 	Whilst	these	questions	point	to	different	aspects	of	the	literature	they	are	linked	in	terms	of	innovation	approaches,	and	so	may	be	linked	in	terms	of	underlying	causality,	and	so	this	identifies	a	need	to	address:	“Are	there	links	between	the	development	of	the	innovation,	the	value	network	
and	the	business	model?”	and,	“Are	there	common	sources	of	causality?”.			As	convergence	implies	working	with	actors	from	different	fields	and	the	potential	formation	of	new	ecosystems,	the	question	of:	“How	organisations	manage	their	relationships?”,	emerges	as	potentially	 important	as	 this	may	 influence	 their	connections,	and	access	to	knowledge	and	capabilities.			Innovations	 require	 organisations	 to	 make	 investments	 in	 the	 innovation	 itself	 and	 in	supporting	 capabilities.	 Given	 the	 inherent	 risks	 associated	with	 convergence,	 it	would	 imply	that	investment	decisions	may	be	regarded	as	more	risky	or	difficult	than	for	other	innovation,	and	 so:	 “Do	 innovators	 need	 to	 change	 their	 risk	 and	 investment	 management	
approaches?”	 If	 they	 do	 change,	 how	 are	 these	 managed?	 And	 do	 they	 present	 additional	challenges?			
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Finally,	 the	 question	 of	 “How	 are	 these	 brought	 together?”,	 emerges	 as	 a	 final	 ‘integrating’	question.		The	complex	nature	of	the	emerging	ecosystems,	converging	technologies	and	issues	around	 concurrently	 developing	 the	 innovation,	 business	 models,	 value	 networks	 and	capabilities	result	in	a	diverse	set	of	challenges,	for	the	innovator	and	the	researcher;	as	well	as	being	nascent,	they	are	dynamic	in	that	knowledge	and	actors,	and	institutional	frameworks	are	also	changing.									  
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3 Research Aims and Objectives  
3.1 Research Challenges and Emerging Gaps  This	 research	 aims	 to	 better	 understand	 the	 challenges	 of	 convergence	 in	 healthcare	technologies	and	to	identify	how	organisations	innovate	in	the	resulting	nascent	ecosystem.	In	so	doing,	 this	addresses	 identified	gaps	 in	 the	 innovation	 literature	(for	exmaple,	Garud	et	al.,	2013)	and	provides	empirical	evidence	in	a	field	of	increasing	importance	in	practice.					This	 leads	 to	 the	 primary	 research	 question:	 “How	 do	 organisations	 innovate	 in	 complex,	
highly	dynamic	convergent	and	emergent	healthcare	ecosystems?”.		Approaches	to	understanding	convergence	and	ecosystems	(Hacklin	and	Wallin,	2013;	Rikkiev	and	Mäkinen,	2013)	have	been	considered	in	terms	of	identifying	product	and	technology	trends	(e.g.	via	road	mapping)	and	identifying	infrastructure	and	policy	development	influences	(Geum	et	 al.,	 2015).	 Recent	 ecosystem	 mapping	 has	 made	 progress	 in	 identifying	 stakeholders	(Harrington	 and	 Srai,	 2012;	 Srai	 et	 al.,	 2014),	 but	 does	 not	 explicitly	address	 the	 impacts	 of	dynamics,	 relationships	 and	 influence.	 Taking	 a	 stakeholder	 view,	 mapping	 linkages	 and	influence-interest	 (Ackermann	 and	 Eden,	 2011),	 together	 with	 roadmaps	 and	 other	mapping	approaches	should	substantially	address	this	gap.			Attempts	to	use	systems	or	complex	systems	approaches	 for	 investigation	 in	 this	 field	to	date	are	limited	(Sull	and	Eisenhardt,	2012;	Zahn,	1999),	with	a	few	notable	exceptions	(Choi	et	al.,	2001;	 Choi	 and	 Dooley,	 2009;	 Frenken,	 2006;	 McKelvey,	 1999),	 whilst	 of	 potential	 benefit,	 a	complex	systems	approach	has	not	been	widely	adopted	 in	the	development	of	approaches	 to	address	ecosystem	(Oh	et	al.,	2016;	Ritala	and	Almpanopoulou,	2017).		In	order	to	do	this	it	will	be	necessary	to	develop	a	systems-consistent	methodology	for	the	study	of	the	wider	ecosystem.		For	healthcare	technologies,	the	convergence	taking	place	is	largely	‘complementarity’	in	nature	(Rikkiev	 and	 Mäkinen,	 2013).	 The	 integration	 of	 technologies	 from	 other	 industries	 has	 the	potential	 to	 deliver	 disruptive	 change	 (Hacklin	 et	 al.,	 2010).	 	 Convergence	 creates	 challenges	akin	to	those	in	front	end	innovation,	discontinuous	and	disruptive	innovation	where	knowledge	is	dispersed,	poorly	codified,	needs	to	be	translated	or	transformed.	Given	the	nascent	nature	of	the	ecosystems	being	studied	and	the	field	in	general,	an	exploratory	approach	that	enables	an	understanding	 of	 how,	 and	 why,	 organisations	 undertake	 innovation	 activities	 is	 appropriate	(Garud	 et	 al.,	 2013).	 Furthermore,	 innovation,	 as	 a	 process,	 has	 been	 the	 subject	 of	 limited	empirical	 studies.	 	 In	studying	 such	 innovation	processes,	 the	 literature	 identifies	 the	need	 to	
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adopt	 an	 in-depth,	 longitudinal	 approach	and	 to	understand	both	 context	 and	agency.	 	Again,	there	has	been	limited	empirical	research	adopting	this	approach.			The	value	chain	or	value	network	approach	might	offer	some	insights,	but	there	has	been	little	research	on	early,	or	nascent,	value	networks	(Harrington	and	Srai,	2016).			Furthermore,	value	network	approaches	do	not	explicitly	address	the	issues	of	value	creation	or	capture	(Bowman	and	Ambrosini,	2000;	Zott	et	al.,	2011;	Zott	and	Amit,	2013,	2008),	and	so,	provide	only	a	partial	answer.				Finally,	 innovation	 is	 essentially	 about	 creating	 and	 capturing	 value,	 and	 so	 by	 considering	
business	 modelling	 approaches	 a	 means	 to	 help	 integrate	 the	 innovation,	 value	 network	 and	capabilities	may	be	possible,	 thus	addressing	a	gap	 in	 the	 literature	and	help	move	 towards	a	more	integrated	or	systemic	approach.			Organisational	capabilities,	including	those	for	innovation	will	likely	change	under	conditions	of	convergence.	 	 The	 existing	 capabilities	 literature	 does	 not	 satisfactorily	 address	 the	 apparent	dichotomy	between	path	dependent,	dynamic	capability	and	ambidexterity	arguments	for	how	these	capabilities	are	changed.	 	As	part	of	the	organisational	capability,	there	 is	also	a	need	to	create	 value	 networks	 in	 a	 rapidly	 evolving	 ecosystem,	 the	 creation	 of	 these	 nascent	 value	networks	has	had	limited	empirical	study	to	date.		Therefore,	understanding	how	and	why	they	develop	their	capabilities.		The	final	challenge,	as	previously	identified,	is	in	identifying	how	to	integrate	these,	to	provide	a	more	holistic	perspective.		Here	again,	taking	a	more	systemic	view	of	innovation	provides	some	promising	solutions.			
3.2 Research Question Taking	account	of	 the	challenges	 in	 the	ecosystem,	 the	specific	challenges	of	convergence	and	requirements	for	new	product	development,	the	main	research	question	is:		
RQ:	How	do	organisations	innovate	in	complex,	highly	dynamic	convergent	and	emergent	
healthcare	ecosystems?	
	Drawing	on	 the	 emerging	questions	 and	 conclusions	 from	 the	 literature	 review,	 this	 research	question	 can	 be	 further	 decomposed	 or	 complemented	 by	 several	 supplementary	 questions,	considering	specific	aspects	of	the	innovation	activities,	which	this	research	will	aim	to	address:	
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SRQ1:	How	do	they	manage	relations	in	the	ecosystem?	
SRQ2:	How	do	they	identify	partners	and	form	value	networks?			
SRQ3:	How	do	they	decide	and	manage	investments?			
SRQ4:	How	do	they	develop	their	innovations?		
SRQ5:	Why	do	they	adopt	these	approaches?		In	attempting	to	address	this	combination	of	questions,	a	more	holistic	and	potentially	systemic	perspective	on	innovation	may	be	elucidated.				 	
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Kierkegaard once noted that life is most clearly understood backwards,  
but it must be lived forwards. 
4 Research Methodology 
4.1 Introduction In	 this	 chapter,	 the	 research	 approach	 is	 described	 in	 terms	 of	 the	 overall	 design,	 the	philosophical	 positioning,	 the	 type	 of	 research	 questions	 being	 addressed	 together	 with	 the	methods	and	analysis	employed.			The	 fundamental	 nature	 of	 this	 research	 is	 to	 understand	 how	 organisations	 innovate	 in	conditions	of	convergence	and	in	doing	so,	identify	what	agency,	processes	and	capabilities	are	needed.	Given	the	evolving	nature	of	the	observed	innovation	initiatives	and	the	need	to	explore	organizational	capabilities	and	managerial	agency	at	a	 level	of	detail	and	nuance,	a	qualitative	approach	was	deemed	the	most	appropriate	(Meredith,	1998;	Yin,	2014).			Understanding	innovation	in	nascent	and	convergent	ecosystems,	addresses	an	established	gap	in	the	literature	(Enkel	and	Gassmann,	2010;	Forbes	and	Kirsch,	2011;	Harrington	et	al.,	2012).		Furthermore	 approaches	 to	 studying	 such	 ecosystems,	 which	 are	 nascent,	 yet	 complex	 and	dynamic,	 are	 not	 well	 established	 (Oh	 et	 al.,	 2016;	 Ritala	 and	 Almpanopoulou,	 2017;	 Rong,	2011),	 so	 as	 part	 of	 this	 research	 an	 approach	 to	 studying	 these	 is	 developed,	which	 aims	 to	contribute	to	the	methodology	literature.				Many	previous	studies	in	innovation	and	new	ventures	rely	on	retrospective	accounts,	long	after	the	events	(see	for	example,	Jones	&	Holt,	2008).	However	the	perspective	taken	here	is	that	the	actions	of	innovators	is	largely	as	a	result	of	‘path	creation’	and	in	line	with	Garud	et	al.	(2010,	p.	770),	“it	is	important	for	a	researcher	to	study	processes	in	‘real	time’,	i.e.	place	oneself	at	the	time	
that	 events	 occurred”.	 So,	 accordingly	 the	 approach	 taken	 here	 diverges	 from	 typical	retrospective	 approaches	 by	 using	 contemporaneous	 accounts	 and	 evidence,	 using	 a	combination	 of	 interviews,	 documents	 and	 observation,	 and	 by	 making	 refinements	 to	 the	research	 process	 as	 new	 evidence	 and	 phenomena	 are	 uncovered.	 	 By	 taking	 this	 approach,	small	 details,	 that	 maybe	 impactful,	 are	 less	 likely	 to	 get	 lost	 in	 “the	 passage	 of	 time”.	 The	approach	is	designed	to	address	calls	by	innovation	scholars,	notably	Garud	et	al	(2013)	to	take	a	multi-level,	 longitudinal	 perspective,	 and	 to	 follow	 events	 implicating	 actors,	 artefacts,	 and	institutions	over	time	and,	in	addition	to	paying	attention	to	the	context,	to	understand	the	sub-text	of	agency.		
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4.2 Philosophical Approach 
4.2.1 Philosophical Positioning The	 main	 approaches	 in	 terms	 of	 research	 philosophy	 for	 business	 and	 social	 sciences	 are	described	(Saunders	et	al.,	2012)	as:	
• Positivism,	assumes	a	rational	world,	which	can	be	measured	objectively	and	thus	favours	quantitative,	and	a	‘scientific’	reductionist	approach	
• Realism,	 assumes	 that	 reality,	 or	 some	 aspect	 of	 it,	 is	 ontologically	 independent	 of	 our	perceptions,	but	that	our	beliefs	are	only	an	approximation	of	reality	
• Interpretivism,	or	relativism,	assumes	the	‘facts’	are	socially	constructed	(constructivism)	and	subjective	(subjectivism),	and	that	 the	researcher	or	observer	 influences	 the	observed	phenomena.			A	summary	of	different	philosophies	and	associated	research	approaches	and	methodologies	are	depicted	 in	 Figure	 4-1	 which	 has	 been	 adapted	 from	 Saunders	 et	 al.,	 (2012).	 Traditionally	operational	 research	 and	 management	 sciences	 were	 rooted	 in	 positivism	 (Meredith	 1998),	although	 it	 is	 argued	 that	 despite	 the	 ‘positivist’	 claims	 many	 methodologies	 are	 either	 not	stated	 or	 are	 actually	 a	 mix	 of	 methodologies,	 drawing	 on	 different	 philosophical	 stances	(Mingers,	2003).						
	
Figure	4-1	Summary	of	research	philosophies	and	methodologies	The	 nature	 of	 this	 research	 is	 exploratory	 and	 investigative,	 to	 identify	 impactful	 or	 causal	factors,	therefore	a	high	degree	of	interaction	with	study	subjects	is	anticipated.		However,	many	of	the	issues	and	challenges	(such	as	how	networks	are	formed)	are	not	measurable	per	se;	this	would	 suggest	 a	 qualitative	 interpretive	 or	 realist	 approach	 is	 more	 appropriate.	 Boulding	
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(1987),	analysing	the	epistemology	of	complex	systems,	identifies	that	the	methods	need	to	be	appropriate	 to	 the	 system	 and	 that	different	methods	may	 be	 required	 for	 different	 systems,	thereby	advocating	a	multi-methodology.			
4.2.2 Critical Realism  The	European	perspective	on	critical	 realism	(CR)	in	social	sciences	 is	 traditionally	associated	with	 Bhaskar	 (2011,	 2008,	 1998,	 1989,	 1986)	 who	makes	 an	 important	 distinction	 between	
ontology	 (what	 exists)	 and	 epistemology	 (knowledge	 of	 what	 exists).	 	 At	 its	 simplest,	 critical	realism	 combines	 a	 realist	 ontology	 (the	 belief	 that	 there	 is	 a	 real	 world	 that	 exists	independently	of	our	beliefs)	and	a	constructivist	epistemology	(that	our	knowledge	of	the	world	is	inevitably	our	own	construction,	from	a	specific	vantage	point	or	perspective).		Many	authors	build	upon	 the	 foundations	of	Bhaskar,	 including	Archer	 (1995),	 Campbell	 (1988),	 Cartwright	(1999),	Tsoukas	 (1989),	 Pawson	and	Tilley	 (1997),	 and	Miles	 and	Huberman	 (2014).	Thus,	 a	range	of	methodologies	are	available	to	address	issues	of	causation	in	complex	social	systems.			
Causation	and	mechanisms	The	identification	of	underlying	causal	mechanisms	(i.e.	 innovation	actions	and	routines)	are	a	key	component	of	this	research.	CR	has	the	potential	to	address	this,	as:	“the	fundamental	tenet	
of	 critical	 realism	 is	 that	 we	 can	 use	 causal	 language	 to	 describe	 the	 world”	 (Easton,	 2010).			Bhaskar	(2008)	defines	an	‘event’	as	a	specific	happening	or	action	resulting	from	the	enactment	of	one	or	more	‘mechanisms’.	But	whilst	mechanisms	may	be	activated,	it	is	also	possible	that	no	change	occurs	because	of	the	counteracting	effects	of	one	or	more	other	mechanisms	(Tsoukas,	1989).		Further,	in	the	context	of	this	research,	causation	is	agential	(Howe,	2012)	and	therefore	intentional,	 determined	 by	 a	 combination	 of	 ‘objects’	 (processes	 or	 structures)	 having	 ‘causal	powers	or	liabilities’	that	are	triggered	in	some	‘context	or	condition’	to	create	an	‘event’	(Figure	4-2).		
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Figure	4-2	Causation	as	viewed	by	critical	realism		For	 Bhaskar	 (2008)	 causal	mechanisms	 sit	 primarily	within	 the	 structural	 component,	 in	 the	powers	and	resources	of	institutions	and	organisations.		Others,	including	Pawson	(see	Pawson,	2013;	Pawson	and	Tilley,	1997),	take	the	view	that	mechanisms	reside	within	the	reasoning	of	actors	and	contend	that	data	construction	should	be	 theory	driven	–	 “the	researchers	theory	is	
the	subject	matter	of	the	interview,	and	the	subject	(stakeholder)	is	there	to	confirm,	to	falsify	and	
above	all	to	refine	that	theory”	(Pawson	and	Tilley,	1997,	p.	155).			This	however,	presumes	that	theory	 is	 already	 established,	 which	 may	 be	 problematic	 in	 studying	 nascent	 systems,	 with	limited	prior	research.	Mechanisms	can	therefore	have	different	meanings	depending	on	context	and	intended	explanations.					To	 address	 this	 the	 initial	 phase	 of	 the	 research	 specifically	 considers	 context,	 aiming	 to	understand	the	nascent	ecosystem	and	the	implications	in	terms	of	conditions	or	limitations	this	poses	 to	organisations	to	either	mediate	or	moderate	 their	actions	(Chen,	2005,	nn.	240-241).	Bhaskar	(1989)	developed	an	approach,	the	‘Transformational	Model	of	Social	Activity’	(TMSA)	to	link	observations	to	underlying	causal	mechanisms,	but	this	is	considered	problematic	to	use.	Archer’s	 (1995)	 	 morphogenic	 approach,	 therefore	 builds	 on	 Bhaskar’s	 TMSA	 through	 three	stages:	conditioning,	 interaction,	and	elaboration.		 	More	importantly,	“the	relationship	between	
causal	powers	or	mechanisms	and	their	effects	is	therefore	not	fixed,	but	contingent”	(Sayer,	1992,	p.	 102);	 	 that	 contingency	 depends	 on	 the	 context,	 or	 local	 conditions,	 which	 in	 a	 nascent	ecosystem,	 may	 change	 during	 the	 research.	 The	 approach	 adopted	 therefore	 must	 address	ways	in	which	structures	of	necessarily	related	entities	cause	events	to	occur	(Sayer,	1992)	and	take	account	of	temporal	effects.	
Inference	Within	qualitative	 research	 there	 are	 a	 range	of	 options	 for	 inference	 -	 the	basis	 for	 reaching	conclusions.		A	comparison	of	the	four	main	modes	of	inference	in	qualitative	research,	namely:	
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deduction,	induction,	abduction	and	retroduction,	is	summarised	in	Table	4-1,	which	is	derived	from	 Danermark	 et	 al.	 (2002,	 p.	 80).	 	 No	 single	 approach	 would	 appear	 appropriate	 to	 this	research.		The	intent	to	understand	the	wider	ecosystem,	would	suggest	an	inductive	approach	initially,	 thereby	 ensuring	 the	 context	 is	 expressed	 as	 closely	 as	 possible	 in	 the	 terms	 of	 the	actors	(Gioia	et	al.,	2012).	Then	the	output	may	guide	the	development	of	later	research,	which	would	 suggest	 combining	 the	 empirical	 output	and	 relevant	 theory	 (or	 literature)	 sources	 via	abduction.		For	the	case	research	induction,	abduction	or	retroduction	may	be	appropriate,	but	given	 the	 context	 sensitive	 and	 changing	 nature	 of	 events,	 a	 retroduction	 approach	 would	appear	 the	 more	 relevant.	 Unique	 to	 CR,	 retroduction	 (Bhaskar,	 2008;	 Easton,	 2010)	 is	 a	‘backwards’	process,	essentially	addressing	the	question:	what	must	be	true	to	make	this	event	possible?	"Retroduction	is	a	meta-process	the	outcome	of	which	is	the	identification	of	mechanisms	
that	 explain	 what	 caused	 particular	 events	 to	 occur.	 Its	 adoption	 does	 not	 imply	 that	 the	
mechanisms	are	postulated	then	data	collected	or	that	they	are	“induced”	from	the	event	data.	In	
practice	the	process	is	likely	to	be	an	iterative	one"	(Easton,	2010,	op.	124).				
Implications	for	methodology	Maxwell	 (2012)	 and	 Danermark	 et	 al.	 (2002)	 identify	 several	 CR-based	 approaches	 in	qualitative	 research,	 the	 fundamental	 principles	 of	 which	 are	 used	 here	 to	 guide	 the	development	 of	 the	 case	 methodology.	 	 Pawson	 and	 Tilley	 (1997)	 developed	 a	 widely	 used	approach	 to	 link	 context	 to	 mechanism	 to	 outcome	 (CMO)	 and	 argue	 that,	 to	 improve	 rigor,	observations	should	be	based	upon	multi-methodology.	Bhaskar	(2008)	building	on	the	concept	of	retroduction,	developed	a	method	known	as	DREI:	describe	the	events	of	interest;	retroduce	explanatory	 mechanisms;	 eliminate	 false	 hypotheses;	 identify	 the	 correct	 mechanisms.	 This	approach	aims	to	explain	events	by	identifying	and	verifying	the	existence	of	mechanisms	which	are	theorised	to	have	produced	them.	Others	including	Archer	(1995)	and	Easton	(2010)	have	built	 upon	 this	 approach,	 providing	 practical	 methodologies.	 Sayer	 (1992)	 also	 developed	Bhaskar’s	original	‘DREI’	approach,	providing	a	clearer	means	for	inference.	A	modified	version	of	 this	 is	 proposed	 (Figure	 4-3),	 which	 recognises	 that	 the	 context	 and	 conditions	 may	 be	independent	of	the	objects	and	causal	powers.					
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Table	4-1	Modes	of	inference	in	qualitative	research	
	 Deduction	 Induction	 Abduction	 Retroduction	(CR)	
Fundamental	
Structure	and	
thought	
operations	
To	derive	logically	valid	
conclusions	from	given	premises.	To	derive	knowledge	of	individual	phenomena	from	universal	laws	
From	several	observations	to	draw	
universally	valid	conclusions	about	the	whole	population.		To	see	similarities	in	a	number	of	observations		
To	interpret	and	recontextualize	individual	phenomena	within	a	conceptual	framework.	To	
understand	something	by	
observing	and	interpreting	in	a	
new	conceptual	framework.	
From	a	description	and	analysis	of	phenomena	to	reconstruct	the	basic	
conditions	for	these	phenomena	to	be	
what	they	are.	Using	thought	operations	and	counterfactual	thinking	to	argue	towards	transfactual	conditions		
Central	Issue(s)	 What	are	the	logical	conclusions	of	
the	premises?	
What	is	the	common	element	for	a	
number	of	observed	entitles?	Is	it	
true	of	the	wider	population?	
What	meaning	is	given	to	
something	interpreted	within	a	
particular	framework?	
	
What	must	exist	for	something	to	be	
possible?	
Strength	 Provides	rules	and	guidance,	logically	valid	 Provides	guidance		 Provides	guidance	for	interpretative	processes	to	enable	meaning	to	be	ascribed		
Provides	knowledge	of	transfactual	conditions,	structures	and	mechanisms	that	cannot	be	directly	observed	
Limitations	 Deduction	does	not	say	anything	new	about	reality,	beyond	existing	premises.		It	is	strictly	analytical.	
Inductive	inference	can	never	be	either	analytically	or	empirically	certain.	Restricted	to	conclusions	at	the	empirical	level			
There	are	no	fixed	criteria	to	assess	the	validity	of	an	abductive	conclusion	
There	are	no	fixed	criteria	to	assess	the	validity	of	a	retroductive	conclusion	
Required	
research	
approach	
Logical	reasoning	ability	 Statistical	analysis	Pattern	analysis	 Creativity	and	imagination	 Ability	to	abstract	
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Figure	4-3	Causation	mechanism	developed	for	this	research		In	a	further	development,	Danermark	et	al.	combined	Bhaskar’s,	Easton’s	and	other	CR	approaches	into	their	six	step	Explanatory	Model	(Danermark	et	al.,	2002),	although	this	has	not	been	widely	used	(Raduescu	and	Vessey,	2008)	it,	along	with	the	Easton	method,	offer	 some	 avenues	 for	 method	 development	 for	 this	 research.	 	 	 Taking	 the	 six-step	process	 as	 a	 starting	 point	 and	 combining	 with	 the	 causation	 mechanism,	 the	application	of	this	approach	to	this	research	is	summarised	in	Table	4-2.			For	 this	 research	 a	 combination	 of	 induction,	 abduction	 and	 retroduction	 would	therefore	appear	to	be	most	relevant.	 	However,	unlike	other	 forms	of	research,	 in	CR	the	analysis	is	not	carried	out	in	the	last	phase	of	the	research,	but	data	gathering	and	analysis	take	place	in	parallel	–	so	there	is	a	need	for	reflection	as	the	research	proceeds	(Easton,	2010;	Sayer,	1992),	including	cross-case	analyses.			In	essence,	there	is	a	need	to	 ‘make	 sense	 of	 the	 interpretations	 of	 others’,	 by	 segmenting	 data,	 categorising,	 and	comparing.	 	 So,	 for	 example,	 using	 comparative	methods	 in	 coding	 to	 find	 similarities	and	then	refine	categories	(coding)	that	grow	out	of	the	data	(Saldaña,	2013).		From	a	CR	perspective,	an	explanation	of	a	causal	mechanism	requires	a	 theoretically	guided	 analysis	 of	 the	 relationships	 between	 generative	 processes	 (by	which	 entities	with	 causal	 powers	 or	 liabilities,	 cause	 events),	 conditions	 (which	 may	 mediate	 or	moderate	 causal	 tendencies)	 and	 outcomes	 (the	 observable	 events)	 (Ackroyd,	 2009;	Edwards	et	al.,	2014;	Sayer,	1992).	Since	causal	factors	may	not	operate	in	the	same	way	
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for	 all	 cases,	 this	 study	 seeks	 to	 explain	 the	 relationship	 between	 the	 phenomena	 of	interest	by	factoring	in	the	combination	of	conditions	found	in	each	case.			
Table	4-2	Six	step	method	of	Danermark	and	its	application	
CR	Method	-	Danermark	et	al	(2002)	 Interpretation	 and	 Application	 to	 this	
Research		Description	of	phenomena:	
Context,	activities	and	events	
Description	of	phenomena:	
Healthcare,	convergence	and	innovation	activities	
Ecosystem	‘building’	Resolution	(and	focus):	
Identify	components	to	be	studied	
Resolution	(and	focus):	
‘Convergent’	 Innovation	 processes	 and	
Capabilities	Abduction	(theoretical	description):	
As	 an	 exploratory	 framework	 based	 on	
literature	and	empirical	evidence	
Abduction	(theoretical	description):	
Develop	 an	 Exploratory	 Framework	 for	
‘convergent	 innovation’	 using	 preliminary	
ecosystem	findings	Retroduction	(causal	mechanisms):	
From	 events,	 context/conditions,	 causal	
tendencies/liabilities,	 to	 generative	
mechanisms	and	structures	
Retroduction	(causal	mechanisms);	
Conceptualized	 processes	 that	 might	 underpin	
observed	activities	in	cases	and	resolve	to	a	model			Comparison	 with	 alternative	 theories	 /	abstractions:	
Assess	 relative	 explanatory	 power	 vs	
alternatives	(i.e,	elimination	in	Bhaskar)	
Comparison	 with	 alternative	 theories	 /	abstractions:	
Assess	relative	explanatory	power	of	the	proposed	
model	vs	alternatives			Concretization	and	contextualization:	
How	structures	and	mechanisms	manifest	
in	concrete	situations	(via	Cases)	
Concretization	and	contextualization:	
Evidence	 from	 case	 events/observations	 with	
conditions/context,	 and	 tendencies/liabilities,	 to	
define	 objects	 (processes	 and	 capabilities)	 to	
provide	direct	‘evidence’	to	support	explanations			With	 a	 small	 number	of	 cases,	 even	with	 case	diversity,	 there	 are	 likely	 to	be	 limited	number	 of	 generative	 mechanisms.	 	 This	 study	 is,	 thus,	 characterised	 as	 intensive	
multiple	 case	 studies	 (Ackroyd,	 2009;	 Ackroyd	 and	 Fleetwood,	 2000)	 allowing	 the	understanding	 of	 interacting	 causal	mechanisms	 in	 various	 contexts	 (see	 Figure	 4-4).	However,	sampling	is	strategic,	and	not	statistically	representative	(Sayer,	1992).		
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Figure	4-4	Case	study	typology	in	critical	realism	(from	Ackroyd	and	Fleetwood,	
2000)	
	
Verification	and	falsification	As	mechanisms	in	complex	systems	that	result	in	an	identified	action	or	event	cannot	be	directly	 observed	a	 key	 requirement	 to	 improve	methodological	 rigor	 is	 the	 ability	 to	verify	 or	 falsify	 alternative	 explanations.	 	 This	 presents	 problems	 where	 direct	observation	is	not	possible,	as	classic	 techniques	like	 triangulation	(Yin,	2014)	are	not	viable.	 	 Instead	Sayer	(1992)	 and	Collier	 (1994)	provide	CR–consistent	approaches	 to	help	verify	or	show	falsification	of	causal	mechanisms,	by	considering	multiple	plausible	explanations	and	seeking	to	eliminate	the	least	plausible.		Multiple	sources	provide	one	such	 avenue,	 for	 example	 conducting	 interviews	 with	 multiple	 knowledgeable	 but	diverse	 sources,	 combining	 interviews	 with	 other	 data	 sources	 (Dubois	 and	 Gadde,	2002).	 	 In	 terms	 of	 this	 research,	 using	 multiple	 interviewees,	 multiple	 sources	 and	multiple	cases	provides	an	opportunity	 to	seek	corroboration	 to	support	explanations	(Easton,	2000).					
Conclusions	To	conclude,	as	seen	from	critical	realist	perspective	this	research	would	be	considered	as:	 an	 intensive,	 passive	 multi-case	 study	 to	 identify	 context-mechanism	 interactions.			However,	 recognising	 the	research	 is	 taking	place	 in	 the	context	of	 complex	system,	a	nascent	and	emerging	innovation	ecosystem,	there	is	also	a	need	to	address	ecosystem	study	 more	 robustly,	 to	 provide	 good	 context	 and	 ‘condition’	 evidence	 (from	 Figure	5.3.5)	for	the	determination	of	causal	mechanisms.		Research	recommendations	by	both	
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Midgley	 and	 Mingers	 would	 suggest	 a	 pluralist	 approach,	 mixing	 methodologies	 to	enable	alternative	perspectives	to	inform	the	research	(Midgley,	2008,	2003a;	Mingers,	2006).	 	 This	 would	 imply	 employing	 critical	 realism	 but	 recognising	 the	 need	 for	systems	thinking	to	understand	the	context,	and	thus	using	mixed	methodologies.						
4.3 Overall Research Approach Having	 identified	 an	 overall	 philosophy	 and	 its	 implications	 for	 the	methodology,	 the	actual	research	approach	is	now	considered.	 	As	previously	identified	one	challenge	in	this	research	is	that	the	innovations	and	the	cases	are	taking	place	within	a	nascent	and	highly	dynamic	ecosystem.	 	 	Whilst	aiming	to	understand	how	organisations	 innovate,	the	 ‘diffusion	 of	 (their)	 innovation’	 (Rogers,	 2003),	 requires	 that	 the	 innovation	must	meet	 a	 customers	 perceived	 need,	 or	 needs,	 and	 also	 be	 compatible	with	 their	 other	important	 beliefs	 and	 practices	 (Maxwell,	 2012).	 	 	 Thus,	 taking	 a	 more	 holistic	 or	systemic	view	(Midgley,	2003b)	of	innovation	would	appear	to	be	an	important	step	in	understanding	how	organisations	innovate	in	these	complex	ecosystems.		Therefore,	to	provide	context	and	the	‘conditions’	to	assess	causal	mechanisms,	the	first	step	(phase	1)	is	to	understand	the	wider	innovation	ecosystem	and	then	those	specific	to	each	case.		Initially,	to	accurately	capture	the	input	of	individual	actors’	perspectives	on	 the	ecosystem,	an	 inductive	approach	 is	suggested.	The	output	of	phase	1	 together	with	a	review	of	the	relevant	literature,	using	abduction,	is	used	to	build	an	exploratory	framework	for	phase	2.				Having	addressed	the	context,	next	a	series	of	longitudinal	in-depth	case	studies	(phase	2)	each	 investigating	a	 firm	and	 its	evolving	 innovation	are	used	 to	 identify	processes	and	 routines	 for	 innovating	 in	nascent	 ecosystems.	 Adopting	 such	 an	 approach	 infers	different	modes	of	 inference,	at	different	phases.	 	 	The	 inference	 for	 the	case	research	uses	retroduction	to	elucidate	plausible	mechanisms	and	models.		The	overall	research	approach	is	depicted	in	Figure	4-5.						
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Figure	4-5	Overall	research	scheme		
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4.4 Studying Ecosystems – development of an approach As	previously	identified	in	section	2.3,	there	are	challenges	in	studying	business	and	innovation	ecosystems.	 From	 a	 methodological	 perspective,	 business	 ecosystems	 present	 an	 interesting	challenge	as	research	approaches	have	varied	from	an	exploration	of	a	key	actor’s	role	(Ritala	et	al.,	2013),	inter-firm	relationships	and	networks	(Basole	et	al.,	2015),	industry	analysis	(Ansari	et	al.,	2016)	or	more	holistic	ecosystem	phenomena.		However,	much	of	the	research	appears	to	use	‘ecosystem’	primarily	as	an	analogy	or	inspiration	given	the	methodological	challenges	(see	also	 Oh	 et	 al.,	 2016).	 As	 identified	 earlier,	 what	 is	 lacking	 is	 a	 ‘meta-level’	 methodological	approach	 to	 systems-based	 forms	 of	 organizing	 which	 would	 address	 the	 perceived	shortcomings	of	 various,	 narrower	 approaches	 and	match	 the	 theoretically	 ambitious	 aims	of	ecosystem	scholars,	 such	 as	 co-evolution	 (Adner	 and	Kapoor,	 2010)	or	 collective	 institutional	logic	formation	(Vargo	et	al.,	2015).	The	challenge	in	the	current	literature	lies	in	the	multitude	of	 different	 studies	 with	 different	 foci,	 which	 is	 especially	 visible	 in	 the	 recent	 ecosystems	literature	 (see	 e.g.,	 Oh	 et	 al.,	 2016).	 This	 diversity	 of	 approaches	makes	 synthesis	 and	 cross-study	inferences	more	problematic,	which	in	turn	inhibits	the	development	of	a	solid	theoretical	and	methodological	base,	and	potentially	slows	down	the	progression	of	scholarly	knowledge	on	this	 important	 topic.	 This	 is	 an	 important	 research	 gap	 (Oh	 et	 al.,	 2016;	 Ritala	 and	Almpanopoulou,	2017).			To	address	 this,	 it	 is	proposed	to	develop	a	complex	adaptive	systems	research	approach	and	related	methodological	 framework	 to	provide	a	better	means	to	examine	 these	systems-based	phenomena.	Developed	from	the	ideas	of	Cabrera	(2008),	the	approach	envisages	three	specific	dimensions	 in	 this	 regard,	 namely;	 conceptual,	 physical	and	 temporal.	 These	 dimensions	 have	been	 addressed	 within	 systems	 sciences	 and	 related	 fields	 (Anderson,	 1999;	 Cilliers,	 2001;	Holland,	1995;	von	Bertalanffy,	1968),	but	they	are	not	explicitly	or	exhaustively	addressed	 in	the	research	approaches	in	studying	ecosystems.			The	 key	 elements	 of	 the	 research	 framework	 have	 been	 developed	 by	 taking	 a	 systemic	approach	 to	 understanding	 ecosystems	 (Phillips,	 2015).	 	 This	 has	 been	 further	 developed	 to	“PBSRDC”	 (perspectives,	 boundaries,	 structure,	 relationships,	 dynamics	 and	 co-evolution),	summarised	 in	Table	4-3	with	 the	 example	 activities	 for	 each	of	 the	 conceptual,	 physical	 and	temporal	dimensions	are	depicted	in	Figure	4-6,	Figure	4-7	and	Figure	4-8.								
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Table	4-3	Conceptual,	physical	and	temporal	dimensions	and	their	implications		 Conceptual	 Physical	 Temporal		 How	we	think		
about	the	system..?	
What	we	know		
about	the	system..?	
How	systems	change	
over	time..?	
Systems-
theoretic	
definition	
The	epistemology	and	theoretical	considerations	and	their	implications	for	the	ecosystem	research	scope	and	design.		
The	ecosystem	components	and	the	relationships	between	them	that	impact	‘structure’	and	processes.	
The	temporal	considerations	impacting	the	dynamics	and	evolution	of	the	ecosystem.	
Key	focus	
of	
systems-
based	
inquiry	
Perspectives:	how	to	address	the	differing	perspectives	of	actors,	the	ecosystem,	and	its	environment	
	
	
Boundaries:	determining	the	type	and	scope	of	ecosystem	being	considered	(e.g.	business,	knowledge,	innovation)		
Structure:	the	components	(actors)	in	the	ecosystem	study,	which	may	include	sub-systems	and	individuals	
	
Relationships:	the	links	(and	their	nature)	between	components	(actors),	driven	by	actors	processes	(schema)	
Dynamics:	the	changes	in	the	ecosystem,	actors,	relationships	and	boundaries	over	time			
	
Co-evolution:	the	interdependent	evolution	within	the	ecosystem	and	with	its	environment		
Key	
research	
design	
questions	
	
What	is	the	focal	issue?	
	
What	philosophical	and	
theoretical	positioning	is	
appropriate?	
	
What	are	the	
implications	for	the	
scope	and	determining	
the	boundary?	
What	structures,	
processes	and	
relationships	should	be	
considered?				
	
How	might	these	be	
mapped	and	studied?			
	
What	is/are	level(s)	of	
analysis?	
What	are	the	
underpinning	dynamics	
(of	the	environment,	
ecosystem	and	its	
components)?			
	
What	time	frame	and	
approach	is	appropriate?		
	
How	might	time	impact	
the	conceptual	and	
physical	considerations?	
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Figure	4-6	Methodological	framework	to	identify	boundaries,	perspectives	and	objectives					
	
Figure	4-7	Methodological	framework	to	address	system	structure	and	relationships		
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Figure	4-8	Methodological	framework	to	address	system	dynamics	and	co-evolution		Developing	 this	 approach	 was	 considered	 a	 necessary	 precursor	 for	 undertaking	 the	 key	research	 objective,	 as	 such	 it	 is	 a	 further	 objective	 of	 this	 research,	 but	 not	 its	 focus.	Consequently,	 in	the	interests	of	brevity,	there	is	limited	discussion	on	the	development	of	the	approach	 here,	 but	 the	 early	 development	 is	 summarised	 in	 Phillips	 (2015).	 This	 approach	contributes	to	the	field	of	organizational	research	by	moving	forward	from	using	“ecosystems”	as	an	analogy,	towards	studying	ecosystems	as	a	systems-consistent	methodological	approach,	thus	 addressing	 identified	 gaps	 (Oh	 et	 al.,	 2016;	 Ritala	 and	 Almpanopoulou,	 2017)	 in	 the	ecosystem	literature.		
4.5 Data Collection and Analysis In	this	section,	the	general	approach	to	data	collection	and	analysis	will	be	discussed.	Discussion	on	specific	methods	employed	during	the	case	studies	will	be	covered	in	later	sections.			All	data	collected	was	stored	on	a	secure,	password-protected	cloud-based	server.	 	 	Data	was	imported	into	a	CADQAS	software	package	(NVivo	10	and	later	NVivo	11)1	to	enable	coding	and	analysis.			Much	of	the	data	collected	remains	subject	to	non-disclosure	and	confidentiality	agreements	as	the	data	pertains	to	ongoing	innovation	projects.		However,	data	and	key	analysis	is	presented	in	an	anonymised	form	in	this	thesis.	
																																																													1	NVivo	is	a	trademark	of	QSR	International	Pty	Ltd,	Australia		
	52	 	
4.5.1 Units and Levels of Analysis As	 identified	earlier,	units	and	 levels	of	analysis	present	challenges	 in	studying	ecosystems,	as	multiple	 units	 and	 levels	 exist.	 	 To	 understand	 causality	 an	 investigation	 of	 each	 may	 be	required.	 	 The	 first	 part	 of	 this	 research,	 to	understand	the	 emergent	healthcare	 technologies	ecosystem	requires	a	‘system	view’,	with	the	unit	of	analysis	as	the	wider	health	care	innovation	
ecosystem	 itself.	 	 	 	 For	 the	 subsequent	 case	 research,	 the	 unit	 of	 analysis	 moves	 to	 the	 firm	specific	innovation	ecosystem	and	specifically	the	innovation	project	or	venture	undertaken.			The	 second	 phase	 of	 the	 research	 considers	 the	 routines	 and	 actions	 required	 to	 create	 and	deliver	 innovation.	 	 This	 could	 be	 undertaken	 at	 a	 focal	 firm	 level,	 although	 where	 multiple	organisations	 are	 involved	 this	may	be	 limiting.	 	 There	 are	 also	 arguments	 for	using	multiple	‘units	of	analysis’	(Mingers	and	Brocklesby,	1997),	but	given	the	nature	of	convergence	it	makes	more	sense	to	explore	each	innovation	case	from	the	perspective	of	each	venture	or	innovation.		This	 would	 include	 the	 orchestrator	 or	 lead	 firm	 and	 other	 key	 collaborators	 and	 their	
stakeholders	 in	 the	 research	 case.	 By	 considering	 the	 different	 stakeholders,	 different	perspectives	on	how	that	project	or	product	is	valued	and	the	capabilities	needed	by	different	value	network	partners	can	be	assessed.			In	addition	 to	 the	 innovator	cases,	an	on-going	study	of	 the	wider	ecosystem,	 through	 further	interviews	was	continued	(extending	the	earlier	preliminary	research),	thus	enabling	an	up	 to	date	 context	 to	 be	 provided.	 	 	 The	 on-going	 study	 of	 the	 ecosystem,	 as	 with	 the	 preliminary	research	phase,	used	the	ecosystem	itself	as	the	unit	of	analysis.			So,	in	essence	this	research	is	multi-level	(Klein	and	Kozlowski,	2000;	Kozlowski	et	al.,	2013;	S.	W.	 J.	Kozlowski	 and	Klein,	 2000),	 considering	 the	wider	 ecosystem,	 the	 immediate	 innovation	ecosystem	and	key	firms’	ventures.		 	Levels	of	analysis	have	typically	received	less	attention	in	the	 research	 literature	 (Tight,	 2012),	 but	 are	 key	 in	 complex	 systems,	where	 emergence,	 and	lower	level	dynamics,	result	in	phenomena	elsewhere	in	ecosystem.		
4.5.2 Interview Data 
Preliminary	Ecosystem	Interviews		The	initial	phase	of	the	research	started	by	identifying	an	‘expert	group’,	with	knowledge	of	the	field,	 and	 using	 them	 to	 identify	 initial	 interviewees.	 	 Starting	 from	 these	 interviewees	snowballing	 (Goodman,	1961)	was	used	 to	access	other	 actors	 and	knowledge.	 	 The	 research	process	at	this	stage	was	essentially	inductive,	the	objective	being	to	identify	what	stakeholders	believed	were	the	key	issues	and	what	constituted	the	ecosystem	boundary.		The	approach	used	semi-structured	 interviews	 with	 senior	 leaders	 in	 innovator	 companies,	 venture	 funds,	
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customers,	 regulators	 and	 academics	 (see	 Appendix	 A1	 for	 ecosystem	 interview	 protocol).			Where	 possible	 interviews	 were	 recorded,	 but	 in	 many	 instances	 this	 was	 not	 possible,	 so	contemporaneous	 notes	 were	 always	 made	 and	 these	 were	 written	 up	 promptly	 and	 coded.		Along	with	the	interview	notes,	a	‘map’	of	the	ecosystem	actors	identified	during	the	interview	was	also	made.		Interviews	were	coded	and	at	first	this	was	achieved	using	Excel	spreadsheets,	but	later	CADQAS	software	(QSR’s	NVivo)	was	used	to	improve	methodological	trustworthiness	(Healy	and	Perry,	2000)	 and	 coding	 efficiency	 (Bazeley	 and	 Jackson,	 2013;	 QSR	 International,	 2014).	 	 The	 key	issues	and	identified	ecosystem	actors	were	tracked	as	interviews	progressed.			After	around	20	interviews	it	was	evident	that	little	‘new’	information	was	emerging	from	these	interviews.		So,	it	was	 decided	 to	 complete	 this	 phase,	 however	 three	 more	 preliminary	 interviews	 were	completed	 as	 the	 interviews	 had	 already	 been	 scheduled,	 giving	 in	 total	 23	 preliminary	interviews.	 	 	 These	 additional	 interviews,	 as	 expected,	 revealed	 little	 new	 information,	 thus	increasing	confidence	that	the	key	issues	had	been	identified.		
	
Confirmatory	Ecosystem	Interviews		Following	 the	 initial	 analyses	 to	 identify	 the	 key	 ‘dimensions’	 and	 development	 of	 an	 initial	ecosystem	 ‘map’,	 four	 further	 interviews	 were	 conducted,	 again	 using	 senior	 leaders,	 but	selected	 to	 be	 from	 diverse	 parts	 of	 the	mapped	 ecosystem.	 	 These	 interviews	 were	 used	 to	confirm	or	verify	initial	findings	in	terms	of	ecosystem	actors	and	boundaries	and	the	key	issues,	thus	supporting	construct	validity	(Gibbert	et	al.,	2008).					The	analysis	in	Phase	1	followed	the	methodology	of	Gioia	et	al.	(2012),	which	 is	discussed	 in	more	detail	 in	 Section	4.5.6.	 	 These	verified	 ‘dimensions’	 then	 formed	 the	 starting	process	 for	abduction,	 which	 together	 with	 relevant	 literature	 were	 used	 to	 refine	 the	 ‘dimensions’	 to	develop	an	Exploratory	Framework	(the	analysis	and	development	of	this	is	discussed	in	Section	5.1).			
	
	
Case	Interviews	The	Exploratory	Framework	was	used	as	an	interview	guide,	but	was	not	prescriptive.		Instead	it	identified	broad	themes	and	areas	to	explore	as	part	of	the	case	study.	Case	interviews	were	also	semi-structured,	enabling	interviewees	to	explain,	in	depth,	from	their	own	perspective	(Gioia	et	al.,	2012).	 	 	For	each	case	the	interviewees	were	key	managers	in	the	innovator	firm,	or	senior	
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leaders	 in	 their	 alliance	 partners,	 as	 such,	 the	 interviewees	 were	 considered	 to	 be	knowledgeable	and	credible	sources.					
4.5.3 Interview conduct and processes Interview	protocols	were	used	for	the	preliminary,	confirmatory	and	case	interviews;	these	are	included	 in	 Appendices	 A1	 and	 A2.	 Where	 permitted,	 interviews	 were	 recorded.			Contemporaneous	 interview	 notes	were	made	 at	 every	 interview.	 But	 as	 all	 the	 case	 studies	involved	 confidential	 projects	which	 are	 still	 ongoing	 (at	 time	 of	writing),	 all	were	 subject	 to	non-disclosure	 agreements	 and	 so,	 reporting	 is	 anonymous.	 The	 interview	methodology	 used	follows	 Halcomb	 (2006),	 with	 minor	 modifications	 to	 account	 for	 there	 being	 only	 one	researcher	 being	 involved.	 	 	 This	 process	 is	 summarised	 in	 Table	 4-4	 and	was	 used	 for	 the	preliminary	and	case	interviews.			To	build	confidence	in	the	interview	process	initial	experiments	used	field	notes	alone	(knowing	that	some	interviews	could	not	be	recorded)	and	then	used	notes	with	an	audio	recording	and	a	full	transcription.		Finding	that	full	transcriptions	offered	limited	additional	information	to	that	captured	in	the	notes,	other	than	useful	verbatim	quotes,	transcriptions	were	used	to	check	key	points.		So,	note	taking	was	refined	to	identify	key	issues,	that	could	then	be	verified	by	listening	to	 the	 recording	 or	 identify	 quotes	 to	 transcribe.	 	 As	 this	 research	 was	 not	 an	 in-depth	ethnographic	study	aiming	to	identify	subtle	nuances,	but	is	more	about	identifying	key	actions	and	the	underlying	mechanisms,	this	approach	was	considered	acceptable.			Details	 of	 the	 interviews,	 including	 information	 on	 interviewees	 are	 provided	 in	 the	 relevant	sections	on	the	preliminary	research,	ecosystem	study,	and	each	case	report	and	in	Appendix	A4.		
4.5.4 Observations During	 the	 case	 studies,	 direct	 observation	was	 also	 undertaken	 (e.g.	 at	workshops,	 planning	meetings	or	project	reviews).			Evidence	was	captured	in	the	form	of	field	notes	and	photographs	(e.g.,	of	workshop	outputs	or	events)	and	where	permitted	in	the	official	meeting	minutes.		This	provided	an	opportunity	to	obtain	contemporaneous	and	unfiltered	evidence	to	supplement	that	obtained	from	interviews.	 	However,	 it	 is	noted	that	there	are	limitations,	as	identified	by	Dosi	(1997),	 as	 agents	 have	 an	 imperfect	 understanding	 of	 the	 environment,	 and	 even	more	 so	 of	what	the	future	will	deliver,	hence	‘bounded	rationality’	was	assumed	and	attempts	were	made	to	corroborate	any	observation	with	further	interview	or	documentary	evidence.	Details	of	the	observations	are	provided	in	the	relevant	sections	on	the	ecosystem	study	and	for	each	case.		
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Table	4-4	Interview	Process	(based	on	Halcomb,	2006)	
Step	 Process	Description	 Method	Comments	1	 Explain	interview	objectives	Take	field	notes,	i.e.	record	observations	and	interviewees	explanations		Make	audio	recordings	(where	permitted)	
Explain	Background	to	research	and	interviewee	background	for	context		Extensive	handwritten	notes	taken	during	interview,	with	key	sections	for	audio	checking	highlighted.	2	 Write	up	journal	notes.	Immediate	reflection	on	issues	identified.	 Notes	were	written	up	within	24	hours	and	then	reflected	upon	for	key	issues,	highlighting	these	for	subsequent	coding.	3	 Use	audio	playback	to	check	notes	and	refine	interview	records,	especially	for	key	issues.	Transcribe	key	quotes	from	audio	into	notes.		
Used	audio	recordings	where	permitted	Used	recording	to	check	key	issues	and	obtain	verbatim	quotes.	Notes	typed	up	in	MS	Word,	then	added	to	CADQAS	database	for	logging	and	coding.	4	 Conduct	primary	context	analysis	and	coding	(1st	coding)	 Identified	areas	to	follow	up	in	subsequent	interviews	5	 Further	thematic	coding	and	analysis	 A	range	of	different	coding	and	analysis	approaches	were	used	depending	on	whether	they	were	ecosystem	level	or	individual	case	interviews				
4.5.5 Documentation A	further	source	of	data,	for	the	wider	ecosystem	and	each	case	study	was	documentation.			This	included	 both	 company	 confidential	 information,	 obtained	 under	 non-disclosure	 agreements,	such	 as	 project	 proposals,	 board	 papers,	 project	 reviews,	 and	 internal	 reports.	 Use	 was	 also	made	 of	 public	 documents	 via	 news	 reports,	 press	 releases	 or	 websites	 as	 supplementary	evidence.	 The	 main	 use	 of	 this	 documentation	 was	 to	 help	 corroborate	 interview	 and	 other	evidence.	 	Details	of	the	key	company	and	public	documents	used	are	provided	in	the	relevant	sections	on	the	ecosystem	and	each	case.		
4.5.6 Data Coding and Analysis 
Preliminary	Ecosystem	interview	coding	The	interviews	were	analysed	using	a	process	based	upon	the	Gioia	(2012)	method.	First	order	coding	was	 generally	 holistic	 and	 in	 vivo,	 using	 the	 sources	 own	words	 and	 short	phrases	 to	guide	coding	(Saldana,	2013,	p.	91	and	142),	thus	avoiding	early	influence	or	bias	in	the	analysis.			Second	order	 coding	 largely	 followed	a	pattern	matching	 approach	 (Saldaña,	2013,	 p.	 209)	 to	identify	emerging	themes.		The	final	stage	was	to	use	axial	and	focussed	coding	(Saldaña,	2013,	p.	 213)	 to	 aggregate	 these	 into	 ‘dimensions’	 that	 summarised	 the	 key	 issues	 within	 the	ecosystem.				An	illustration	of	the	process	used	for	these	coding	cycles,	reproduced	from	Gioia	et	al.	(2012,	p.	21)	is	provided	in	Figure	4-9.		
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Figure	4-9	Illustration	of	preliminary	research	analysis		
(reproduced	from	Gioia	et	al.,	2012)	Coding	and	Analysis	were	completed	 for	all	23	preliminary	ecosystem	 interviews,	 resulting	 in	over	800	coding	references.		 	The	aggregate	number	of	coding	references	for	each	coding	node	and	the	number	of	interviews	where	that	code	was	identified	are	summarised	in	Table	4-5.		The	‘challenges’	and	‘opportunities’	are	in	direct	response	to	interview	questions;	the	other	themes	arose	from	in	vivo	coding.			As	the	ecosystem	was	nascent,	and	complex,	adopting	this	approach	provided	an	initial	‘holistic’	view	to	identify	and	understand	key	issues	from	the	perspectives	of	the	stakeholders	or	actors,	before	refining	the	research	focus.		The	 output	 of	 this	 analysis	 was	 used	 as	 the	 basis	 for	 the	 development	 of	 the	 Exploratory	Framework	 (see	Chapter	5	 for	details),	which	was	 then	used	 to	 inform	and	guide	Case	 Study	research.	
	
Case	Study	data	coding	Following	 the	development	of	 the	Exploratory	Framework	described	 in	section	6,	 case	 coding	followed	 approaches	 recommended	 by	 Saldaña	 (2013)	 and	 by	 Miles	 and	 Huberman	 (2014).		Case	 coding	 involved	 coding	 of	 interviews,	 observational	 data	 and	 documentation	 and	 is	discussed	 in	more	 detail	 in	 section	 0.	 	 	 Coding	was	 conducted	during	 the	 research,	 to	 enable	ongoing	 reflection,	 consistent	 with	 realist	 approaches	 (Easton,	 2010;	 Sayer,	 1992).	 	 It	 was	designed	 to	 address	 determination	 of	 causality	 (as	 shown	 in	 Figure	 4-3)	 and	 is	 discussed	 in	more	detail	in	the	case	study	section.		
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Table	4-5	Summary	coding	of	initial	ecosystem	interviews	
Initial Coding Nodes (aggregate level)	 Aggregate number of 
coding references	 Aggregate number of interviews where coded	
Business Model and value creation	 97	 18	
Challenges	 128	 23	
Customers - Stakeholders	 138	 22	
Ecosystem understanding	 122	 21	
Funding and investment	 50	 18	
Innovation Processes and capabilities	 201	 23	
Opportunities	 61	 20	
Regulation-Policy	 21	 9	
Value Network	 81	 20		
4.6 Case Study Methodology The	 following	 section	 discusses	 case	 selection	 (including	 criteria),	 case	 methodology,	 data	collection	and	coding,	and	case	data	analysis.	
4.6.1 Case Selection Criteria Miles	 and	Huberman	 (2002;	 2014)	 recommend	 using	 selective	 sampling	 to	 improve	 research	efficiency.		As	the	research	seeks	to	identify	how	convergent	innovations	are	developed,	the	case	studies	draw	from	across	 the	wider	ecosystem	and	from	different	domains	of	 ‘convergence’,	to	get	perspectives	of	different	 types	of	 ‘producers’,	with	different	 ‘customers’	and	 ‘stakeholders’.		To	supplement	these	studies	and	to	provide	an	alternative	perspective,	an	‘incubator’	as	a	Case	Study	 was	 included.	 	 This	 case	 developed	 their	 strategy	 to	 support	 convergence	 and	 an	‘ecosystem’	of	small	entrepreneurial	firms,	which	may	provide	additional	case	study	options	and	different	perspectives	on	‘value’,	‘capabilities’	and	institutional	gaps.			
	Several	criteria	were	identified	to	help	select	cases.	As	the	research	was	exploring	innovation	in	the	context	of	convergent	or	cross-industry	innovation	(Enkel	and	Gassmann,	2010;	Rikkiev	and	Mäkinen,	2013;	Stieglitz,	2003),	cases	needs	to	be	drawn	that	were	clearly	crossing	traditional	domains.	The	domains	of	interest	in	this	research	are	biomedical	sciences	(B),	novel	materials	and	 nano	 sciences	 (N)	 and	 information	 or	digital	 science’s	 (I),	 as	 described	 by	 Bernabo	 et	 al.	(Bernabo	et	al.,	2009a)	and	Shmulewitz	et	al.	(2006).	An	object	was	to	obtain	cases	that	spanned	these	 domains	 (e.g.	 BNI,	 BN	 and	 BI),	 see	 Figure	 4-10.	 	 Additional	 criteria	 were	 to	 consider	organisational	 variety	 with	 small	 or	 start-up	 organisations,	 and	 in	 large	 or	 multi-national	
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companies	 and	 also	 the	 type	 of	 innovation	 with	 diversity	 in	 product/service	 (Hacklin	 and	Wallin,	 2013)	 or	 platform	 or	 infrastructure	 (Gawer	 and	 Cusumano,	 2013;	Walsh	 and	 Linton,	2000).	 	 	 Given	 that	 the	 intention	 was	 to	 study	 innovation	 practices	 contemporaneously,	 a	conclusion,	 such	 as	 a	 successful	 launch,	 might	 not	 be	 observed,	 so	 surrogate	 indicators	 of	‘success’	 were	 required,	 such	 as	 the	 study	 period	 including	 an	 important	 inflection	 point	 or	transition	(e.g.,	major	 investment,	new	organisation	 formed,	 regulatory	 submission).	The	 final	consideration	 was	 theoretical	 sampling	 (Eisenhardt	 and	 Graebner,	 2007),	 and	 access	 to	 the	value	network,	alliance	partners	and	stakeholders,	and	data.			No	clear	guidance	for	the	number	of	 interviews	and	 interviewees	 that	might	be	 acceptable	was	 identified	 in	 the	 literature,	 for	 a	realist	 and	 in-depth	 study	 it	 has	 been	 argued	 that	 the	 sample	 size	 can	 be	 small	 (Crouch	 and	McKenzie,	2006).		Crouch	and	McKenzie	further	suggest:	“The	work	of	linking	interview	account–	
continually	analysed	–	and	conceptual	frameworks	–	under	construction	throughout	the	research	–	
clearly	requires	small	sample	sizes	so	that	all	the	emerging	material	can	be	kept	in	the	researcher’s	
mind	as	a	 totality	under	 investigation	at	all	 stages	 of	 the	research”	 (2006,	 p.	 495).	 As	 a	 result,	criteria	of	at	 least	10	 interviews	and	access	 to	at	 least	5	different	actors	was	used	as	a	guide.	These	criteria	are	summarised	in	Table	4-6.		
	
Figure	4-10	Distribution	of	case	studies	in	BNI	convergence	domains	
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Table	4-6	Case	selection	criteria	
Case	Criteria	 Rationale	for	criterion	Conducting	convergent	innovation	 Core	to	the	research	question	Spans	 BNI,	 BN	 or	 BI	 domains	 (see	Figure	4-10)	 Cases	are	diverse	and	cover	a	range	of	domains	Mix	of	Large	 (or	MNC)	and	Small	 (or	start-up)	firms		 To	obtain	diversity	in	case	firms	(and	initial	capabilities)	and	help	assess	whether	 convergent	 innovation	practices	vary	 in	different	types	of	organisation	Type	of	innovation	–	product/service,	platform	or	infrastructure	 To	 obtain	 diversity	 in	 innovation	 type	 and	 help	 assess	 whether	innovation	practices	vary	in	different	types	of	innovation	Major	 Inflection	 point	 likely	 to	 occur	during	research	period	 Used	as	surrogate	for	‘success’,	a	major	investment	or	organisation	formation	 is	 an	 indicator	of	 internal	 commitment	and	 continued	progress	Access	to	data	and	key	individuals	for	a	longitudinal	study	 Access	for	at	least	12-18	months	necessary	to	obtain	research	data	and	 to	 observe	patterns	and	dynamics,	 (preferably	 the	ability	 to	conduct	at	least	10	interviews	and	with	5	different	actors)		
4.6.2 Selected Case Studies Case	 identification	 used	 a	 combination	 of	 knowledge	 and	 contacts	 from	 the	 preliminary	interviews,	 and	 contacts	 made	 at	 subsequent	 ecosystem	 events.	 	 In	 total,	 thirteen	 different	organisations	were	approached.			For	several	reasons,	such	as	confidentiality	concerns	or	access	to	 key	 individuals,	 many	 cases	 were	 rejected	 or	 did	 not	 progress.	 However,	 five	 cases	 that	appeared	to	meet	the	criteria	were	identified,	these	are	summarised	in	Table	4-7.				An	original	intent	was	to	complete	ecosystem	interviews	before	starting	case	studies,	but	during	the	research	the	process	was	refined.		These	interviews	were	continued	(beyond	the	initial	27)	as	it	became	evident	that	the	evolving	wider	ecosystem	may	meditate	or	mitigate	potential	case	actions,	 so	 a	 mechanism	 to	 capture	 system	 wide	 data	 and	 cross-analyse	 or	 triangulate	 with	individual	 case	 studies	 was	 potentially	 useful.	 	 	 Thus,	 the	 wider	 ecosystem	 was	 effectively	considered	as	a	case	too,	and	further	interviews,	beyond	the	‘preliminary	research’	phase	were	continued.								
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Table	4-7	Case	studies	selected	
	 “Case	0”	-	
Ecosystem	
Case	1	 Case	2	 Case	3	 Case	4	 Case	5	
Case	ID	 ECO	 CMTI	 NMD	 DH1	 MLD	 DH2	
Unit	of	Analysis	 Overall	
Ecosystem	
Incubator	Ecosystem	 Firm	Innovation	Ecosystem	 Firm	Innovation	Ecosystem	 Firm	Innovation	Ecosystem	 Firm	Innovation	Ecosystem	
Convergence	
Domain	(B	/	N	/	I)	 BNI	 BNI	 BNI	 BI	 BI	 BI	
Diversity	in	Scale?:		
Large	organisation:	
LC,	or	small	
organisation:	SME		
and	start-up	(SU)	
versus	incumbent	(IN)	
n/a	 SME	(IN)	 LC	(IN)	 LC	(IN)	 SME	(SU)	 SME	(SU)	
Diversity	in	
Innovation?:		
Product	(P)	or	
Platform	(T)	or	
Infrastructure	(I)	
n/a	 I	 P/T	 P	 P/T	 P	
Likely	‘inflection	
points’	during	
research	period?	
n/a	 Y	 Y	 Y	 Y	 Y	
Access	to	data,	
actors	and	
stakeholders?	–	
(ideally	at	least	10	
interviews	across	5	
different	actors)	
Y	 Y	 Y	 Y	 Y	 Y	(but	case	terminated	early)	
	
4.6.3 Case Method Overview To	understand	firms’	activities	and	motivations	in-depth	research	is	required.	Case	studies	can	accommodate	 a	 rich	 variety	 of	 data	 sources,	 including	 interviews,	 archival	 data,	 survey	 data,	ethnographies,	and	observations	(Eisenhardt,	1989;	Eisenhardt	and	Graebner,	2007;	Yin,	2014).			Each	case	 itself	can	be	considered	a	 ‘bounded	system’	(Simons,	2009,	p.	29),	a	meaningful	but	complex	configuration	of	events	and	structures	(Byrne	and	Ragin,	2009).	 	It	 is	argued	that	the	use	of	multiple	case	studies	can	provide	a	stronger	basis	for	theory	building	(Eisenhardt,	1989;	Yin,	2014,	2003),	however	this	presupposes	that	causal	mechanisms	are	identified	and	that	any	cross	case	comparison	is	not	superficial	(Easton,	2000).			This	 research	 is	 essentially	 about	 understanding	 processes,	 routines	 and	 capabilities.	 	 A	recognised	method	 for	process	 focussed	 case	based	 research,	 is	 to	use	 longitudinal	 studies	of	intra	organizational	phenomena	(Helfat	et	al.,	2007,	p.	36),		therefore	this	research	is	based	upon	longitudinal	 case	 studies	 	 (Blazejewski,	 2011).	 	 However,	 the	 key	 reference	 on	 case	 study	research,	Yin	(2014)	makes	only	passing	reference	(on	pages	51	and	53)	to	longitudinal	studies.		Furthermore,	longitudinal	studies	are	not	really	not	addressed	in	any	depth	by	other	prominent	case	authors	such	as	Eisenhardt	(for	example,	see	Eisenhardt,	1989;	Eisenhardt	and	Graebner,	2007).	 	 Yet,	 case	 studies	 need	 to	 be	 dynamic	 and	 be	 concerned	 with	 time	 if	 they	 are	 to	 be	
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explanatory	 in	 both	 Yin’s	 (1994,	 2014)	 and	 in	 the	 realist	 sense;	 there	 is	 a	 need	 to	 uncover	temporal	patterns	(Blazejewski,	2011),	particularly	in	innovation	(Garud	et	al.,	2013).		Given	 the	 emergent	 nature	 of	 the	 innovation	 ecosystems	 and	 ventures,	 sources	 such	documentation	and	archival	records	would	be	limited.		Interviews	and	observations	provide	the	most	obvious	sources,	but	have	potential	drawbacks.	 	Direct	observations	are	 time	consuming	and,	 interviews	 risk	bias	 (due	 to	poorly	worded	questioning,	 response	bias	or	 reflexivity)	 and	inaccuracies	 due	 to	 poor	 recall	 or	 records.	 The	 aim	 therefore	 is	 to	 collect	 data	 as	contemporaneously	as	practicable	to	avoid	the	risks	of	interviewing	that	result	from	the	impact	of	 time	 and	 other	 influences	 (Alvesson,	 2003).	 	 However,	 in	 the	 case	 of	 convergence,	 the	approach	also	needs	to	extend	beyond	the	firm	to	consider	wider	ecosystem	perspectives.			The	case	 study	methodology	 largely	 used	 recognised	 approaches	 as	 recommended	 by	 Yin	 (1994,	2014),	 and	 Eisenhardt	 (1989),	 but	 recognising	 the	 complex	 context	 and	 consistent	 with	 a	systems	 and	 critical	 realist	 approach,	 some	 variations	 are	 required.	 	 Taking	 critical	 realists	approach	 to	 Case	 Studies	 (Easton,	 2010;	 Morais,	 2011;	 Sayer,	 1992)	 involves	 developing	mechanism-centred	theorizing	to	seek	causal	mechanisms.	The	implications	of	taking	a	critical	realist	approach	to	case	studies	is	summarized	in	Table	4-8	below,	with	is	adapted	from	Welch	et	 al	 (2011,	 p.	 745).	 	 An	 implication	 of	 this	 is	 that	 the	 findings	 from	 the	 cases	 studies	 are	contingent	(on	context)	and	have	limited	generalizability.			The	 Exploratory	 Framework	 formed	 the	 basis	 for	 the	 case	 studies	 and	 case	 interviews.	 	 	 But	additionally,	each	case	ecosystem	was	mapped	several	times	during	the	longitudinal	studies	and	stakeholder	analysis	was	undertaken	to	better	understand	relationships	within	the	ecosystem.		A	 simple	 timeline	was	 also	 constructed	 to	 describe	 the	 dynamics.	 	 The	 previously	 developed	PBSRDC	 systems	 framework	was	used	 to	 establish	 an	understanding	of	 context	 for	 each	 case,	this	context	then	formed	an	input	to	the	causal	mechanism	approach	developed	early.												
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Table	4-8	Implications	of	CR	approach	to	case	studies	(adapted	from	Welch,	2011)	
Philosophical	
orientation	
Positivist	 Relativist		 Realist	 Critical	Realist	
Key	
Proponent(s)	
Eisenhardt	 Yin	 Pawson	&	Tilley	 Bhaskar	&	Sayer	
Basis	 Empiricist	 Falsification	 Plausibility	 Plausibility	
Exemplified	by:	 “Truth	is	
absolute”	
“Truth	is	relative”	 “Truth	exists	but	…”	 “Truth	exists	but…”	
Nature	of	
research	
Objective	approach	to	generalisation	
Objective	approach	to	identifying	causation	
Subjective	approach	to	identifying	causation	
Mixed	methods	approach	to	identifying	causation	
Research	
Approach	
Inductive	 Internal	validity	 Identify	context-mechanism-outcome	(CMO)	
Mixes	induction	and	deduction,	and	retroduction	via	DREI	methods	
Nature	of	
causality	
Proposes	associations	between	events	
Specifies	cause-effect	relationships	
Identifies	context-	mechanism-outcome	CMO	causality	
Identifies	causality	via	‘object,	causal	tendencies	/	liabilities,	context	and	outcomes’		
Case	outcome	 Explanation	as	testable	propositions	
	 Explanation	in	the	form	of	causal	mechanisms	
Explanation	in	the	form	of	causal	mechanisms	
Applicability	to	
complex	systems	
Limited	by	positivist	intent,	and	desire	to	define	cause-effect	
Limited	by	positivist	intent,	and	desire	to	define	specific	cause-effect	
Partially	aligned,	but	requires	each	CMO	to	be	embedded	in	layers		
Aligned	via	multi-methodological	and	agnostic	approach		
Generalisation	 Generalisable	to	populations	 Generalisation	to	theory	 Contingent	and	limited	generalisation	
Contingent	and	limited	generalisation		
4.6.4 Case Study Protocol Case	studies	were	conducted	using	a	case	study	protocol,	which	is	included	in	Appendix	A2.			The	protocol	was	developed	 from	a	combination	of	 the	PBSRDC	ecosystem	research	approach	and	the	Exploratory	Framework.			
4.6.5 Case Evidence   The	aim	 in	 each	 case	was	 to	use	 the	Exploratory	Framework	 to	provide	 the	basis	 for	a	broad	exploration	 of	 innovation	 processes	 and	 approaches	 used.	 As	 well	 as	 semi-structured	
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interviews,	 evidence	 was	 gathered	 in	 the	 form	 of	 observation	 (of	 meetings	 and	 events)	 and	relevant	documents	which	were	either	publically	available	or	obtained	under	a	confidentiality	agreement	with	each	organisation.		An	overview	of	all	the	case	evidence	collected	is	summarised	in	Table	4-9.	Case	evidence	was	collected	on	a	dedicated	and	secure	case-study	database	(using	Dropbox	and	uploaded	to	the	NVivo	database)	to	heighten	reliability	(Yin,	2014).	An	example	of	the	folder	structure	for	case	data	collection	and	tools	is	shown	in	Figure	4-11.					
	
Figure	4-11	Example	of	data	collection,	storage	and	tool	folders	
	64	 	
Table	4-9	Summary	of	case	evidence	and	sources	
Case		 Organisation	and	Innovation	
Description	
CMT	
Domains	
Interviews	-	with	example	
interviewees	and		
(N=)	number	
Number	of	Observations	(O=)	and	
private/	public	documents	(D=)	
Summary	of	Case	Key	Activities	and	Status	
NMD	 New	Innovation	Unit	in	major	pharma/med	tech	company	developing	an	novel	implantable	medical	device	
BNI	 R&D	Head,	Scientific	Director,	Head	of	Venture	Fund,	Business	Dev	Director,	Alliance	Partner	(N=15)	
External	workshops	(O=1)		Business	Plan,	Board	papers,	White	paper	(D=31)	
Internal	venture	in	incumbent	organisation.	Major	funding	in	place,	with	new	governance	board,	alliance	project	underway	and	venture	fund	in	place.		Formed	JV	with	major	technology	company.	Established	leadership	position	in	field.	MLD	 Start-up,	developing	AI/machine	learning	as	a	basis	for	screening,	diagnosis	and	monitoring	
BI	 CEO,	CTO,	Medical	Director,	Investor,	and	Suppliers	(N=15)	
Board	meetings,	Technical	meetings,	Meetings	with	investors	(O=16)		Business	Plan,	Development	Plan	and	Technical	documents	(D=25)	
Start-up.		In	early	development.	Initial	grants	won	and	pilot	trials	completed.	Development	trials	underway.		First	major	investor	in	place	and	follow-up	funding	in	late	negotiation.	On	track	to	launch.	
DH1	 Innovation	Unit	in	large	healthcare	provider	developing	mobile	and	digital	health	applications	for	a	range	of	medical	conditions	
BI	 Managing	Director,	Project	manager,	Board	members	and	senior	managers	of	their	Suppliers	(N=15)	
Team	meetings,	Customer	meetings,	Project	kick-off	and	review	meetings	(O=8)		Business	plan	and	Project	review	reports	(D=26)	
Internal	venture	in	incumbent	organisation	(regional).	Business	plan	for	new	venture	in	place,	run	as	wholly	owned	subsidiary.		Early	projects	delivered	and	launched.	Increasing	influence	at	national	level.	
DH2	 Start-up	developing	wearable	and	digital	health	solutions	 BI	 Chairman,	CEO,	CTO	(N=6)	 None	(O=0)		Business	plan,	investment	options	(D=9)	
Start-up,	attracted	limited	initial	funding	(grants).		In	process	of	identifying	investors.	Unable	to	find	in	sufficient	time	and	terminated.	CMTI	 Incubator	developing	infrastructure	and	support	for	convergent	medical	technologies	
BNI	 CEO,	Business	Development	Manager,	Board	Members		(N=10)		
Company	workshops,	Company	conferences,	Internal	review	meetings	(O=6)	Board	paper,	Internal	review	papers	(D=11)	
New	venture	in	incumbent	organisation.	Board	approval	to	develop	full	plans,	with	funding	in	place.	Complementary	investments	in	place.	Range	of	ecosystem	building	activities	underway.		
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4.6.6 Case Data Analysis  Case	studies	are	individually	reported	in	Chapter	6	and	cross-case	analyses	(see	Chapter	7)	were	used	 to	 identify	 wider	 themes,	 divergences	 and	 framework	 concepts.	 	 	 Although	 the	 data	analysis	did	not	occur	in	a	linear	fashion,	it	can	be	roughly	divided	into	the	following	stages:		
• Coding	of	evidence	using	the	Exploratory	Framework	as	starting	point	
• Developing	coding	breadth	and	depth	as	events	are	observed	
• Seeking	 patterns	 within	 each	 case	 and	 developing	 potential	 explanations	 which	 are	explored	via	additional	coding		
• Development	of	tentative	models	and	frameworks	for	testing	via	interviews	and	further	coding		Analysis	 of	 the	 Case	 Study	 evidence	 was	 undertaken	 using	 methods	 described	 by	 Miles,	Huberman	and	Saldaña	(2014)	and	for	each	case,	initial	coding	approaches	described	by	Saldaña	(2013)	were	employed.		Initial	coding	or	provisional	coding	(Saldaña,	2013,	p.	144),	used	factors	from	the	exploratory	framework	as	a	starting	point.	At	this	stage	simultaneous	coding	(Saldaña,	2013,	p.	80)	using	both	descriptive	coding	(Saldaña,	2013,	p.	87)	and	structural	coding	(Saldaña,	2013,	 p.	 84)	 was	 used,	 as	 evidence	 could	 be	 construed	 in	 several	 ways.	 	 In	 order	 better	understand	 the	nuances	 in	 the	 evidence	 sub-coding	 (Saldaña,	 2013,	 p.	 77)	was	used	 to	break	down	the	factors	to	consider	detail	(for	example	ecosystem	related	codes	were	sub-divided	into	more	discrete	codes	covering	understanding,	dynamics,	policy	and	institutions	and,	supporting	and	 investing).	 As	 the	 research	 evolved	 some	 initial	 patterns	 and	 themes	 emerged.	 	 So,	categories	 were	 developed	 (for	 example	 ‘creating	 credibility’,	 ‘cooperating	 and	 integrating’)	using	 pattern	 coding	 (Saldaña,	 2013,	 p.	 209).	 	 These	 were	 then	 developed	 into	 themes	 and	concepts	 (for	 example	 ‘knowledge	 sharing’,	 ‘providing	 effective	 governance’)	 typically	 using	
causation	 coding	 (Saldaña,	 2013,	 p.	 163).	 	 Finally,	 models	 were	 developed	 (for	 example	‘searching’,	‘sense-making’,	‘selecting’,	‘shaping’	and	‘sustaining’).			As	the	analysis	evolved,	later	coding	 increasingly	 used	 gerunds	 (e.g.,	 searching,	 selecting,	 managing	 etc.)	 or	 process	 coding	(Saldaña,	2013,	p.	96)	as	this	permitted	“a	strong	sense	of	action	and	sequence”	(Charmaz,	2014,	p.	 120)	 to	 address	 the	 question	 of	 how	 organisations	 innovate.	 An	 example	 of	 the	 coding	evolution	is	provided	in		Figure	4-14,	Figure	4-15	and	Figure	4-16.			Case	 data	 was	 analysed	 (coded	 and	 re-coded)	 on	 ongoing	 basis.	 	 As	 new	 themes	 emerged,	explored,	 further	 literature	 reviews	 were	 undertaken	 to	 assist	 in	 pattern	 identification.				Concepts	 were	 tested,	 including	 direct	 questioning	 of	 interviewees	 (for	 example,	 the	 lack	 of	evidence	for	internal	resistance	in	one	case	was	addressed	by	asking	the	respondent	if	this	was	
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actually	so,	and	if	so,	why?).	 	This	permitted	more	nuanced	and	in	depth	understanding	of	not	only	 ‘how’	 but	 ‘why’	 events	 occurred,	 thereby	 strengthening	 the	 arguments	 for	 the	 proposed	causal	mechanisms.			As	well	as	coding,	analyses	were	undertaken	to	create	a	practical	embodiment	of	Figure	4-3	and	the	‘working	backwards	process’	of	retroduction.	 	 	Starting	from	described	or	observed	events	‘E’,	the	relevant	context	‘C’,	the	likely	drivers	or	powers	‘P’	to	infer	the	causal	activity	or	process	or	object	‘O’.	Summarised	as	ECPO,	the	process	used	is	schematically	depicted	in	Figure	4-12.		
	
Figure	4-12	ECPO	analysis	process	schematic		This	 analysis	 was	 conducted	 using	 an	 Excel	 spreadsheet.	 	 Relevant	 case	 events	 (e)	 were	identified	 from	 the	 investigational	 framework,	 interviews,	 observations	 and	 documentation.	Conditions	or	context	(c)	that	might	limitations	or	enablers	to	those	events	were	identified	from	the	prior	ecosystem	analysis	(see	later)	and	local	conditions.		Likely	causal	powers	and	liabilities	for	 the	 organisation	 (p)	 were	 developed	 (i.e.,	 what	 would	 the	 organisation	 be	 expecting	 to	achieve	or	prevent?)	and	 from	these,	 likely	mechanisms	were	postulated	(x),	which	were	 then	subject	 to	 analysis	 to	 ascertain	 if	 they	 were	 plausible	 and	 whether	 there	 was	 a	 supporting	theoretical	basis.			The	most	plausible	mechanisms	were	identified	(o)	and	finally	confirmed	by	identifying	 ‘concretisation’	 or	 ‘contextualisation’	 evidence	 in	 the	 form	 of	 a	 quote	 that	directly	supported	the	proposed	mechanisms.			The	Excel	spreadsheet	template	used	for	this	process	is	shown	in	Figure	4-13.			As	the	analysis	proceeded	the	initial	codes	were	grouped	into	patterns	that	aimed	to	describe	either	a	structure,	process	or	intent	(see	Figure	4-14).		The	codes	either	built	upon	early	coding	or	were	newly	created	as	concepts	emerged.		Further	coding	aimed	to	establish	evidence	for	specific	themes	from	the	literature,	for	example	the	drivers	for	alliance	formation	(see	Figure	4-15).				
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Figure	4-13	Excel	template	for	ECPO	analysis	to	identify	causal	mechanisms		
	
Figure	4-14	Example	of	development	of	pattern	coding	in	NVivo		
	
Figure	4-15	Example	of	development	of	thematic	coding		As	 potential	 causal	 mechanisms	were	 identified	 and	 developed	 in	 the	 ECPO	 spreadsheets	 by	combining	 the	 context	 and	 potential	 objects	 (Vincent	 and	Wapshott,	 2014),	 these	 were	 also	coded.	 These	 are	 examples	 of	 coding	 with	 gerunds	 which	 enabled	 a	 more	 action	 or	 activity	orientated	perspective	 (Charmaz,	 2014),	 and	are	depicted	 in	Figure	4-16.	Causal	analysis	was	further	supported	by	multiple	sources	(Maxwell,	2012,	1992;	Wynn	Jr.	and	Williams,	2012;	Yin,	2014)	where	a	variety	of	data	types	and	sources	and	analytical	approaches	are	used.		First,	the	data	were	collected	from	varying	sources	(i.e.,	semi-	structured	interviews,	documentation	and	observation).	 Secondly,	 multiple	 data	 points	 within	 each	 source	 of	 evidence	 (e.g.,	 multiple	respondents	with	different	roles	or	skills)	were	used,	where	the	activation	and	operation	of	the	causal	 mechanisms	 were	 derived	 from	 the	 perspective	 of	 multiple	 participants	 involved	 in	certain	innovation	events.		
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	As	 potential	 causal	mechanisms	were	 developed,	 so	were	 alternative	 explanations,	which	 are	discussed	with	each	case	in	Chapter	6.		
	
Figure	4-16	Example	of	development	of	gerund-based	model	coding		
4.7 Methodological Rigour Considerations Drawing	 on	 a	 set	 of	 criteria	 for	 evaluating	 methodological	 rigour	 suggested	 by	 qualitative	research	scholars	in	general	(Guba	and	Lincoln,	1994)	and	critical	realism	scholars	in	particular	(Healy	 and	 Perry,	 2000),	 this	 section	 seeks	 to	 set	 out	 the	 strategies	 developed	 and	 used	throughout	the	study	to	maximise	its	quality	and	rigour.			Healy	 (2000)	 identifies	 methods	 to	 judge	 validity	 and	 reliability	 in	 a	 realist	 paradigm.	 	 “Six	
comprehensive	 and	 explicit	 criteria	 for	 judging	 realism	 research	 are	 developed,	 drawing	 on	 the	
three	elements	of	a	scientific	paradigm	of	ontology,	epistemology	and	methodology.	The	 first	two	
criteria	 concern	ontology,	 that	 is,	 ontological	 appropriateness	 and	 contingent	 validity.	 The	 third	
criterion	concerns	epistemology:	multiple	perceptions	of	participants	and	of	peer	researchers.	The	
final	three	criteria	concern	methodology:	methodological	trustworthiness,	analytic	generalisation	
and	construct	validity.”		Yin	(2014)	similarly	identifies	a	number	of	criteria	for	case	research	validity,	which	have	been	derived	and	summarised	as	Table	4-10.		In	this	study,	the	factual	accuracy	of	the	accounts	(e.g.,	description	of	events)	 is	achieved	by	a	combination	of	 the	 interviewees	accounts,	or	multiple-interviewees	accounts,	combined	with	documentation	and	observation	evidence.		Furthermore,	the	 participants’	 exact	 words	 are	 provided	 in	 direct	 quotations	 throughout	 the	 study	 where	required.	Additionally,	to	ensure	that	case	interviewees	viewpoints	and	evidence	are	accurately	interpreted	 (interpretive	 validity),	 the	 key	 case	 findings	 have,	 in	 part,	 been	 shared	 with	 key	participants	to	review	and	provide	feedback.		
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Table	4-10	Case	validity	tests	
Tests	 Definition	 Case	Study	Tactic	
Construct	
Validity	
To	identify	operational	measures	for	the	concepts	studied	 Use	multiple	sources	of	evidence,	establish	chain	of	evidence.	Have	key	informants	review	draft	case	study	report	or	extracts	
Internal	
Validity	
Seeking	to	establish	a	causal	relationship,	whereby	certain	conditions	are	believed	to	lead	to	other	conditions,	as	distinguished	from	spurious	relationships	
Through	pattern	matching,	explanation	building,	addressing	rival	explanations,	and	using	logic	models.	
External	
Validity	
Defining	the	domain	to	which	a	study's	findings	can	be	generalised	 Use	replication	logic	in	multiple	case	studies,	with	relevant	context.	Define	context	for	each	case.		
Reliability	 Demonstrating	that	the	operations	of	a	study	can	be	repeated	with	the	same	results	 Develop	case	study	process	and	database	using	tools	such	as	NVivo	database.			The	criteria	suggested	by	Yin	have	been	expanded	using	criteria	for	CR	studies	(Healy	and	Perry,	2000)	 to	 address	 the	ontology	 (i.e.	 recognising	 the	 research	 as	 ‘’world	 three’	 (Magee,	 1985)),	contingent	validity	(i.e.	that	causal	mechanisms	influenced	by	context	(Pawson	and	Tilley,	1997),	multiple	perspectives	are	applied	(Danermark	et	al.,	2002),	methodological	trustworthiness	(i.e.,	using	a	database	and	NVivo),	analytic	generalisation	(Yin,	2014)	and	construct	validity	(Gibbert	et	al.,	2008;	Yin,	2014).		The	case	write	up	also	include	examples	of	screens	and	evidence	from	the	NVivo	analysis	to	improve	transparency	(Bringer	et	al.,	2004).			The	approach	is	designed	to	address	calls	by	innovation	scholars,	notably	Garud	et	al	(2013)	to	take	 a	multi-level,	 longitudinal	 perspective,	 and	 to	 follow	 events	 implicating	 actors,	 artefacts,	and	institutions	over	time	and,	in	addition	to	paying	attention	to	the	context,	to	understand	the	sub-text	of	agency.								
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5 Preliminary Research Findings 
5.1 Preliminary Ecosystem Investigation and Framework Development The	aim	of	the	preliminary	research	was	to	better	understand	the	wider	ecosystem	and	use	this	context	to	develop	a	framework	for	the	case	study	investigation.	To	achieve	this	ecosystem	wide	interviews	were	undertaken	 to	help	define	 the	boundary	 and	the	key	 issues	 that	may	 impact	innovation	activities	and	practices.			Following	 initial	 interviews	 with	 a	 small	 expert	 group	 (known	 to	 the	 researcher	 as	knowledgeable	 and	 interested	 in	 this	 field),	 snowballing	 was	 used	 to	 extend	 the	 search	 for	participants.	Interview	data	were	continually	mapped	until,	after	23	interviews,	it	was	clear	that	only	limited	new	information	was	emerging.	By	mapping	the	ecosystem	actors	identified	in	each	interview,	an	initial	map	was	constructed	of	the	ecosystem.			The	ecosystem	map,	boundary	and	summary	of	 key	 issues	were	 then	presented	 to	 four	 further	 interviewees,	 to	help	 validate	 the	boundary	and	preliminary	findings.				The	interviewee	data	for	this	phase	is	summarised	in		
	Table	5-1.		The	 interview	 data	 was	 analysed	 using	 the	 Gioia	 method	 (Gioia	 et	 al.,	 2012),	 via	 an	 Excel	spreadsheet	 to	 sort	 and	 cluster	 data.	 	 First	 order	 coding	was	 largely	 in	 vivo	 using	 ‘concepts’	identified	by	interview	participants.			These	were	then	grouped	and	developed	into	second	order	themes;	 these	 themes	were	 then	 further	aggregated	 into	broader	 ‘dimensions’.	 	An	example	of	this	analysis	for	one	dimension	is	provided	in	Figure	5-1.			This	approach	was	completed	for	all	coding	references.			The	emerging	dimensions	were	 then	considered	 in	 the	 light	of	the	 implications	 for	 innovators	and	 their	capabilities	 (Table	5-2)	which	 then	provided	a	starting	point	 for	development	of	the	exploratory	framework.			The	 identified	 themes	 from	 the	 ecosystem	 interviews,	 via	 a	 process	 of	 abduction	 –	 inference	derived	 from	 the	 induced	 findings	(themes)	 and	a	 review	of	 relevant	 literature,	were	used	 to	generate	a	list	of	expected	capabilities	and	processes,	for	convergent	innovation.			This	analysis	is	 summarised	 in	Table	5-3.	 	 From	 this	 analysis,	 the	 resulting	Exploratory	Framework	 (Table	5-4)	was	developed	and	used	 to	 identify	 topics	 for	 investigation	 in	 the	 case	 studies,	 clustered	into	thematic	areas	or	‘factors’.		
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A	final	step	was	undertaken	to	check	for	alignment	of	this	framework	with	key	issues	identified	in	the	interviews	to	ensure	that	nothing	had	been	‘lost’	or	filtered	in	the	analysis.		
	
Table	5-1	Preliminary	ecosystem	interviews	
ID	#	 Interviewee	Role	 Organisation	Type	 Date	 Approx.	Interview	
Duration	(mins)	
ECO01	 Senior	Managers	and	Directors	(4	people)	 Incubator	 03/02/2014	 75	ECO02	 Vice	President	 Major	Healthcare	Consultancy	 10/02/2014	 60	ECO03	 Director	 NHS	Trust	 12/02/2014	 45	ECO04	 Senior	Executive	 Major	Diagnostic	Company	 18/03/2014	 45	ECO05	 Angel	Investor	and	CEO	 Angel	Investor	 17/04/2014	 75	ECO06	 Chairman	 Private	Equity	 07/04/2014	 60	ECO07	 Partner	 Investment	Fund	 07/04/2014	 75	ECO08	 Project	Director	 Academic	Medical	Research	-	University	 07/04/2014	 60	ECO09	 CEO	 Biotech	 22/04/2014	 45	ECO10	 Vice	President	 Major	Pharmaceutical	Company	 24/04/2014	 75	ECO11	 Non-Exec	Director	 Biotech	 22/04/2014	 60	ECO12	 Senior	Manager	 AHSN	-	NHS	 28/04/2014	 60	ECO13	 Partner	 Health	Media	 08/05/2014	 75	ECO14	 CEO	 Charity	/	Patient	Group	 13/05/2014	 75	ECO15	 CEO	 Incubator	 12/05/2014	 90	ECO16	 CEO	 Biotech	start-up	 15/05/2014	 60	ECO17	 Head	of	Research		 Health	Economics		 16/05/2014	 45	ECO18	 Technology	Leader	 Innovate	UK	 08/09/2014	 30	ECO19	 Partner	 Corp	Venture	Capital	 03/06/2014	 60	ECO20	 Senior	Executive	 MNC	Pharmaceuticals	 19/06/2014	 60	ECO21	 Senior	Executive	 MNC	Pharmacy	 14/07/2014	 45	ECO22	 CEO	 Med	Tech	 21/07/2014	 60	ECO23	 Director	 NHS	Trust	 29/07/2014	 60	
Confirmatory	Interviews	ECO24	 CEO	 Academic	Innovation	Unit	 17/09/2014	 60	ECO25	 CEO	 Biotech	 23/09/2014	 60	ECO26	 Senior	Manager	 Regulator	MHRA	 23/10/2014	 60	ECO27	 Director	 Med	Tech	Incubator	 10/11/2014	 60	
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Figure	5-1	Example	of	1st	and	2nd	order	analysis	leading	to	aggregate	dimensions	following	the	Gioia	method		
1st	Order	Concepts 2nd	Order	Themes Aggregate	Dimensions
11 Convergence	seen	as	a	threat
25 Apple,	Google	entry	may	open	up	options
40 Very	diverse	groups	-	challenge	getting	them	together
55 Cross	industry	collaboration	-	Philips	and	Intel,	MS
56 Challenges	from	Apple,	Google	other	'tech'
59 Key	influencers	not	yet	clear
86 Public	Health	agenda	not	well	represented
91 Navigating	different	stakeholder	agendas
95 CCGs	have	ability	to	use	service	providers	outside	NHS.
99
BUPA,	Axa	might	take	on	new	roles	-	payers	and	
integrators	like	KP	in	USA
106 Community	Pharmacy	to	provide	more	services?
136 CCGs	can	look	outside	Trusts
150 Are	pharma	best	positioned	to	deliver	'health	care'?
2 Industry	rate	change	is	slow
9 Risk	aversion	in	NHS
15 NHS	adoption-	fragmented
103 Markets	all	different,	no	pattern
121
UK	NHS	opportunity,	but	highly	politicised,	fragmented	
and	bureaucratic
50 Big	differences	in	how	assessed,	valued	across	markets
85 Some	markets	(Germany)	no	reimbursement
103 Markets	all	different,	no	pattern
133 Markets	are	heterogeneous,	so	need	different	models
27 Need	wider	engagement,	cross	sector
34
Lots	of	poor	value	tech	being	developed,	due	lack	of	
understanding
40 Very	diverse	groups	-	challenge	getting	them	together
42 Getting	Public	funding	interested	in	CMT
44 Need	better	influencing	network
47 Need	to	create	an	ecosystem	to	support
53 Need	for	hub	or	ecosystem
82 R&D	lots	of	duplication	and	reinvention
91 Navigating	different	stakeholder	agendas
138 Make	better	use	of	AHSNs
Evolving,	heterogeneous	system	-	several	'not	obvious'	
entrants	possible	
Industry	is	generally	risk	averse,	with	fragmented	markets	
and	low	adoption	rates	
Customer	models	are	different	across	countries
Understanding	across	industrial	ecosystem	is	generally	poor,	
resulting	in	missed	opportunities
The	emerging	ecosystem	is	not	well	understood,	new	agile	entrants	and	
new	models	are	meeting	risk	averse	and	fragmented	stakeholders
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Table	5-2	Emerging	‘dimensions’	from	preliminary	ecosystem	interviews	
Emerging	‘dimensions’	from		
ecosystem	interviews	
Potential	Implications	for		
innovators’	capabilities	Knowledge	and	capabilities	are	diffuse	(and	spread	widely).			Diverse	approaches	and	duplication	of	effort	are	evident.											
Search	approaches	may	need	to	be	different,	and	direct	comparisons	of	capabilities	may	be	difficult.	
The	emerging	ecosystem	is	not	well	understood,	new	agile	entrants	and	new	models	are	meeting	risk	averse	and	fragmented	stakeholders	
Significant	knowledge	management	and	learning	are	required	upfront	of	any	investment	or	development	decision	The	emerging	ecosystem	contains	organizations	with	wide	variations	in	Culture	and	Capabilities	 As	well	as	technological	and	capability	differences,	the	value	network	partners	are	likely	to	have	different	cultural	attitudes	and	norms	There	is,	typically,	a	lack	of	Customer	Engagement	and	understanding	of	future	Business	Models		 Given	the	lack	of	clarity	in	potential	business	models,	developing	long	term	alliances	with	clear	value	capture	mechanisms	may	be	challenging	New	assets	carry	higher	risk	and	have	less	understood	investment	decision	criteria	 Governance	and	decision	criteria	need	to	reflect	the	uncertainty	and	inferred	risks	Public	R&D	Funding	and	venture	capital	investment	are	not	well	developed	for	the	ecosystem,	and	these	funders	perceive	new	risks	
The	lack	of	public	funding	may	result	in	‘holes’	within	the	‘ecosystem’	knowledge	base	
The	Value	Networks	and	Supply	Chains	will	require	new	alliances	and	new	models					 Existing	and	established	decision	models	and	approaches	may	need	to	be	modified.		Regulation,	Legal	and	IP	issues	are	more	ambiguous	in	the	emerging	ecosystem	 This	adds	different	risks	to	the	innovation	and	value	network	There	is	a	lack	of	Infrastructure	and	support	organizations	 Which	may	result	in	a	lack	of	certain	specific	capabilities	and	capacities	within	the	ecosystem			 	
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Table	5-3	Abduction	to	translate	ecosystem	themes	into	Exploratory	Framework	
Factor	 Ecosystem	themes	
(from	Table	5-2)	 Literature	Sources	Abduction	 Example	 Response	 in	 terms	 of	capabilities	and	processes	
Ecosystem	and	
Market	
understanding	
Knowledge	 and	 capabilities	 are	diffuse	 (spread	 widely).			Diverse	 approaches	 and	duplication	of	effort	are	evident.						The	 emerging	 ecosystem	 is	 not	well	 understood,	 new	 agile	entrants	 and	 new	 models	 are	meeting	 risk	 averse	 and	fragmented	stakeholders					
(Hacklin,	2005;	Hacklin	and	Wallin,	2013;	Phaal	et	al.,	2011;	Rikkiev	and	Mäkinen,	2013;	Stieglitz,	2003)	
Firm	undertakes	activities	to	map	and	understand	the	ecosystem	to	keep	pace	with	its	evolution.			
Stakeholder	
Management	
There	 is	 a	 lack	 of	 Customer	Engagement	 and	 understanding	of	 future	 Business	 Models.	 The	emerging	 ecosystem	 contains	organizations	 with	 wide	variations	 in	 Culture	 and	Capabilities	
(Ackermann	and	Eden,	2011;	Donaldson	and	Preston,	1995;	Rowley,	1997)	
Map	 and	 engage	 stakeholders	 through	 the	life-cycle	 of	 the	 development	 process	 to	facilitate	 progress,	 and	 evolve	 relationships	over	time.	
Governance	 New	assets	carry	higher	risk	and	less	understood	decision	criteria	 (Cooper,	2008,	1990;	Rikkiev	and	Mäkinen,	2013;	Salomo	et	al.,	2010)	
Active	 senior	 management	 support	 and	engagement	 in	 investment	 decisions.	Adequate	 knowledge	 for	 project	 selection	and	 progression	 through	 objective	 decision	gates.			
Gate	Criteria	 Regulation,	 Legal	 and	 IP	 issues	are	 more	 ambiguous	 in	 the	emerging	ecosystem	
(Cooper,	2008,	1990;	Gronlund	et	al.,	2010)	 Objective	 Go	 /	 no	 go	 decision	 criteria	 to	determine	 progressing	 to	 next	 phase,	 that	consider	external	capabilities	and	paths.	
Process	 No	direct	evidence	 (Holahan	et	al.,	2014)	 A	 process	 or	 methodology	 exists	 to	 guide	process	 development	 and	 quality	management	
Risk	
Management	
Public	 R&D	 Funding	 and	 VC	Investment	 are	 not	 well	developed	 for	 the	 ecosystem,	and	funders	perceive	new	risks	
(Hulbert	et	al.,	2008;	Kayis	et	al.,	2007;	McNeil	et	al.,	2010;	Rikkiev	and	Mäkinen,	2013;	Zhang	and	Yongbo,	2011)	
Risk	 management	 processes	 are	 in	 place	 to	address	patient	and	user	safety	risks,	and	the	combination	 of	 technological	 risks,	 product	integrations	 risks	 and	 business	 and	commercial	risks	
Project	Team		 No	direct	evidence	 (Meyer,	1993;	Patanakul	et	al.,	2012;	Sivasubramaniam	et	al.,	2012)	
The	 core	 team	has	 leadership,	 expertise	 and	experience,	 and	 balances	 autonomy,	accountability	 and	 empowerment	within	 the	governance	framework	
Alliance	
Partners	
The	 Value	 Networks	 /	 Supply	Chains	 will	 require	 new	alliances	and	new	models					
(Dickson	et	al.,	2006;	Hacklin	and	Wallin,	2013;	Ireland	et	al.,	2002;	Lewrick	et	al.,	2012;	Rothaermel	and	Deeds,	2006;	Soda,	2011)	
Inter-organizational	 co-operation	 via	 clarity	in	 objectives	 and	 scope.	 Accessing	capabilities	 through	 alliance	 partners,	adopting	 different	 alliance	 management	approaches	to	different	partners.		
Support	
infrastructure	
The	is	a	lack	of	Infrastructure	and	Support	organizations	 (Moore,	2005;	Peltoniemi	and	Vuori,	2004;	Rikkiev	and	Mäkinen,	2013)		
Firm	builds	and	makes	use	of	ecosystem	and	infrastructure	to	complement	capabilities	and	support	development	culture	
	
Table	5-4	Exploratory	Framework	for	investigation	of	convergent	innovation	
	 Factor	 Example	
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Ecosystem	Factors	
F1	 Ecosystem	and	
Market	
understanding	
Firm	undertakes	activities	to	map	and	understand	the	ecosystem	to	keep	pace	with	its	evolution	and	develop	it.		
F2	 Stakeholder	
Management	
Map	and	engage	stakeholders	through	the	life-cycle	of	the	development	process	to	facilitate	progress,	and	evolve	relationships	over	time.		
Business	Model	Factors	
F3	 Customer	
Engagement	
Routines	 and	 capabilities	 to	 engage	 early	 in	 the	 development	 process	 with	customers	 to	 inform	 product/service	 design	 and	 the	 potential	 business	 model	options	
F4	 Business	Model	
development	
Map	 and	 understand	 the	 links	 between	 the	 business	 model	 and	 the	 required	activities	and	capabilities.	
F5	 Value	Attributes	 Map	 and	 understand	 key	 value	 creation	 and	 capture	 steps	 (linked	 to	 business	model)	
Execution	Factors		
F6	 Governance	 Active	senior	management	support	and	engagement	in	investment	decisions.		Adequate	knowledge	for	project	selection	and	progression	through	objective	decision	gates.			
F7	 Gate	Criteria	 Objective	Go	/	no	go	decision	criteria	to	determine	progressing	to	next	phase,	that	consider	external	capabilities	and	paths.	
F8	 Process	 A	 process	 or	 methodology	 exists	 to	 guide	 process	 development	 and	 quality	management	
F9	 Risk	Management	 Risk	management	processes	are	 in	place	 to	 address	patient	 and	user	 safety	risks,	and	the	combination	of	technological	risks,	product	integrations	risks	and	business	and	commercial	risks	
Value	Network	Factors	
F10	 Alliance	Partners	 Inter-organizational	 co-operation	 via	 clarity	 in	 objectives	 and	 scope.	 Accessing	capabilities	 through	 alliance	 partners,	 adopting	 different	 alliance	 management	approaches	to	different	partners.		
F11	 Project	Team		 The	core	team	has	leadership,	expertise	and	experience,	and	balances	autonomy,	accountability	and	empowerment	within	the	governance	framework	
F12	 Support	
infrastructure	
Firm	builds	and	makes	use	of	ecosystem	and	infrastructure	to	complement	own	capabilities	and	to	support	development	of	innovation	culture					 	
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5.2 Ecosystem Understanding During	 the	 preliminary	 ecosystem	 interviews	 analyses	were	 undertaken	 using	 the	 previously	developed		PBSRDC	method	to	understand	the	ecosystem	boundaries,	structures	and	dynamics.	The	 boundary	 determination	 used	 the	 method	 depicted	 in	 Figure	 4-6,	 as	 the	 first	 step	 in	understanding	the	nascent	ecosystem.		The	approach	to	identifying	the	structures	and	dynamics	were	as	depicted	in	Figure	4-7	and	Figure	4-8	
5.2.1 System Mapping and Determination of System Boundaries  The	 methodology	 followed	 that	 summarised	 in	 Chapter	 4.	 During	 each	 interview	 data	 was	captured	based	upon	actors	and	key	issues	identified,	and	translated	into	a	 ‘map’.	 	An	example	from	 one	 such	 interview	 (ECO12)	 is	 shown	 in	 Figure	 5-2.	 	 As	 actors	 were	 identified	 by	 the	respondent	 they	were	drawn	on	or	highlighted,	as	were	any	key	challenges,	 relationships	and	opportunities.	These	along	with	interview	notes	were	captured	for	all	preliminary	interviews.			
	
Figure	5-2	Example	of	evidence	capture	from	ecosystem	interviews		The	frequency	of	identification	(by	interviewees	and	stakeholders)	and	perceived	‘interest	and	influence’	was	used	as	a	guide	inclusion	(or	exclusion)	 in	 the	ecosystem	boundary	(see	Figure	5-3).			
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Figure	5-3	Analysis	of	ecosystem	boundary	–	using	frequency,	interest	and	influence	
identified	during	interviews			
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The	decision	to	include	or	not	include	is	still	subject	to	researcher	subjectivity,	but	the	process	allows	 a	 degree	 of	 objectivity	 and	 data	 to	 support	 the	 decision.	 	 On	 completion	 of	 the	preliminary	 interviews,	 a	 different	 group	 of	 stakeholders	 was	 used	 to	 confirm	 the	 proposed	ecosystem	boundary	(together	with	a	minor	refinements).			As	part	of	the	process	a	preliminary	map	was	developed	(Figure	5-4),	which	evolved	during	the	interviews.				
5.3 Exploratory Framework Testing via Pilot Cases Before	 starting	 the	 actual	 Case	 Studies,	 two	 preliminary	 cases,	 based	 upon	 literature	 and	desktop	analysis,	were	used	to	review	the	Investigational	Framework,	and	to	assess	whether	it	was	appropriate	and	complete.				Two	pilot	 case	 studies	were	 run,	 both	P1	 and	P2	used	 information	 from	 recent	projects	with	reasonable	access	to	information.		This	enables	the	Exploratory	Framework	to	be	reviewed	in	a	more	realistic	setting	and	aimed	to	address	two	questions:			
• Does	the	framework	help	identify	relevant	issues?			
• Are	there	relevant	issues	outside	the	framework?			These	two	pilot	cases	used	are	summarised	in	Table	5-5.							
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Figure	5-4	Example	of	partial	ecosystem	mapping	(and	tentative	boundaries)			
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Table	5-5	Summary	of	pilot	cases	P1	and	P2	
	 Case	P1	 Case	P2	
‘Case’	firm	 Novartis	 GSK	
Scale:	MNC	or	SME	 MNC	 MNC	
Product	(P)	or	Platform	(T)	
based	or	infrastructure	(I)	
P	 P	
Therapeutic	 Y	 N	
Med	Tech	/	Diagnostic	 Y	 Y	
Health	ICT	 Y	 Y	
Access	to	value	network	and	
stakeholders	
Web,	Literature	based	 Web,	Literature	based	
Issues	identified	with	
Exploratory	Framework	
Minor	changes	to	wording	
of	Factors	
Minor	changes	to	wording	of	Factors.			
	Re-clustering	of	Factors	to	a	more	
logical	structure.		
5.3.1 Case P1 (Pharmaceutical MNC plus Device and Telemedicine) 
Case:	Complementary	Technologies	to	support	a	new	respiratory	product	
• Description	–	A	desktop	/	literature	study	of	the	development	of	delivery	device	and	digital	health	 solutions	 and	 services	 to	 complement	 a	 new	 pharmaceutical	 product	 and	 support	patients	to	improve	health	outcomes.		
• Process	and	Risk	Management-	there	was	insufficient	information	or	evidence	to	draw	any	significant	conclusions.	
• Governance	–	there	was	insufficient	information	or	evidence	to	draw	any	conclusions.		
• Stakeholder	Engagement	 –there	was	limited	information	that	indicates	that	the	lead	firm	were	 addressing	 stakeholder	 engagement	 widely.	 	 A	 field	 study	 acknowledged	 the	challenges	in	stakeholders	perceptions	(García	Lizana,	2013)	but	there	are	no	details	on	how	this	was	being	addressed.	
• Business	Model	 –There	 is	 clear	 evidence	 from	an	 interim	 report	 on	a	 field	 study	 (García	Lizana,	 2013)	 that	business	models	were	 a	 challenge,	 in	 fact	 one	 aim	of	 the	 study	was	 to	investigate	ways	to	address	this.			The	 case	observations	 versus	 the	 exploratory	 framework	are	 summarised	 in	Table	5-6.	There	was	insufficient	information	in	the	public	domain	to	complete	this	Case	Study	to	my	satisfaction,	but	it	did	however	highlight	issues	in	several	areas	including	the	business	model,	the	challenging	perceptions	of	different	stakeholders	and	the	diversity	of	ecosystem	partners.		
5.3.2 Case P2 (Pharmaceutical MNC developing complementary diagnostic) 
Case:	Complementary	Diagnostic	Product	
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• Description	-	Development	of	a	new	diagnostic	product	by	a	MNC	pharmaceutical	company,	with	alliance	partners,	which	complements	the	company’s	existing	therapeutic	products	and	franchises.	
• Process	and	Risk	Management	-	The	firm	had	well-established	NPD	processes	but	needed	to	develop	a	‘modified	NPD	process’	to	manage	the	project.		There	was	recognition	that	the	design	 process	 and	 regulation	 was	 different,	 which	 resulted	 in	 some	 changes	 in	 risk	management	approach.	 	Although	existing	process	provided	an	acceptable	 framework,	 the	differences	 in	 regulation,	 technology	 and	 supply	 chain	 meant	 specific	 processes	 were	inappropriate	in	some	areas	and	therefore	revised.		
• Governance	 -	 The	 existing	 high-level	 governance	 processes	 were	 used.	 	 	 But	 due	 to	 the	faster	nature	of	 the	project	 timelines,	mechanisms	were	needed	to	address	response	 time.		Ad	hoc	reviews	were	used,	which	resulted	in	 ‘less	complete	governance’	and	special	teams	needed	to	be	formed	to	undertake	technical	governance.	
• Stakeholder	Engagement	 -	Was	sporadic	and	usually	for	specific	interventions.		Generally	successful	 in	identifying	 the	need	to	operate	different	processes	for:	 regulation,	CRM,	pack	artwork,	logistics/supply	chain	and	servicing.			Engagement	was	generally	later	than	ideal.	
• Business	Model	-	The	business	model	was	understood	to	be	different.		A	separate	business	unit	was	formed	to	address	this.			The	overview	of	the	business	and	commercial	model	were	completed,	 but	 in	 depth	 analysis	 of	 the	 actual	 business	 model	 and	 how	 and	 when	 value	would	be	 captured	were	only	addressed	 late	 in	 the	project.	 	 This	 resulted	 in	 fundamental	errors	in	the	revenue	model	and	in	a	major	lack	of	confidence	(by	the	governance	review)	in	the	commercial	model;	a	key	contributor	to	the	decision	to	terminate.		The	case	observations	versus	the	exploratory	framework	are	summarised	in	Table	5-7.		This	Case	Study	highlighted	issues	with	the	business	model	challenges	and	the	need	to	modify	processes	 and	governance	 to	manage	 the	different	 technologies.	 	 	 	 The	 study	 also	points	 to	 a	need	 for	 senior	 sponsorship	 and	 governance	 support	 within	 the	 organisation.
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Table	5-6	Case	Study	P1	-	Observations	on	the	framework	factors	
	 Factor	 Observations.		 Conclusion	
F1	 Ecosystem	 and	
Market	
understanding	
Novartis	appear	to	be	particularly	active	in	this	area	with	a	number	of	deals	and	announcements	that	indicate	 intent	 to	 engage	 in	 the	wider	ecosystem.	 	 	Recent	 announcements	with	Proteus	(Proteus,	2014,	2010)	and	Google	(Novartis,	2014).		The	 study	 itself	 is	 addressing	 key	 ecosystem	 challenges.	 	 	 Lack	 of	 interoperability,	 different	perceptions	of	HCPs	and	patients.		
There	is	evidence	to	support	the	existence	of	this	Factor	
F2	 Stakeholder	
Management	
Key	stakeholders	in	individual	markets	are	engaged	(as	markets	are	heterogeneous).	Evidence	of	similar	programmes	across	Europe	in	Scandinavia,	Ireland	as	well	as	Spain.	 Some	evidence	of	this	being	put	in	place.	But	insufficient	to	draw	conclusions	
F3	 Customer	
Engagement	
Some	evidence	based	upon	on-going	EU	study.		 Implicitly	 addressed	 in	 the	 EU	 study	 (see	below).		
F4	 Business	 Model	
development	
Potentially	requires	a	new	Business	Model.		Novartis	sponsoring,	funding	several	studies	to	address	BM	challenges	ongoing,	due	to	read	out	late	2014	(Fundacio	Ticsalut,	2012;	García	Lizana,	2013).		
Implicitly	acknowledged	in	the	EU	study	(see	below).	 They	 have	 identified	 a	 clear	challenge	here,	but	do	not	yet	have	solutions.	
F5	 Value	Attributes	 This	 is	 identified	as	a	challenge,	EU	study	 is	addressing	this.	 	 	These	are	reported	 in	the	European	Innovation	Partnership	site	(García	Lizana,	2013)		
• 	
Evidence	 this	 is	 recognised	 and	 being	addressed,	but	is	not	yet	in	place.	
F6	 Governance	 No	direct	information	on	governance	of	project.		Formally	managed	through	EU	funding.	 Insufficient	evidence	to	draw	conclusions	
F7	 Gate	Criteria	 No	data	 Insufficient	evidence	to	draw	conclusions	
F8	 Process	 No	data	 Insufficient	evidence	to	draw	conclusions	
F9	 Risk	Management	 No	data	 Insufficient	evidence	to	draw	conclusions	
F10	 Alliance	Partners	 Novartis	plays	active	role	in	funding,	sponsorship	and	but	researchers	are	independent.	Key	partners:	Novartis	(Switzerland),	Sosei	(Japan),	Vectura	(UK)	Alliance	partners	in	UK	(device),	UK	(telemedicine	software),	Spain	(field	studies)	
There	is	evidence	this	is	occurring.			Novartis	are	using	a	variety	of	different	approaches	to	manage	partners	and	studies.			
F11	 Project	Team		 No	data	 Insufficient	evidence	to	draw	conclusions	
F12	 Support	
infrastructure	
No	data	 Some	evidence	of	this	being	put	in	place.			
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Table	5-7	Case	Study	P2	-	Observations	on	the	framework	factors	
	 Factor	 Responses	 Conclusion	
F1	 Ecosystem	 and	
Market	
understanding	
Source:		Competitor	landscape	mapping	Regular	updates	on	competitive	landscape	were	undertaken	(roughly	every	6	months)	as	the	field	was	changing	fairly	 rapidly.	 	 	 	 Customers	 (Lab	 directors)	 and	 external	 experts	 were	 regularly	 engaged	 in	 the	 technical	requirements.	 	Regulatory	 landscape	was	well	mapped.	As	was	emerging	regulation.	 	 	Good	understanding	of	overall	market,	key	customers	etc	from	database/market	research.	
Evidence	that	this	was	partially	 in	place.		Good	knowledge	of	 competitors	but	 less	so	for	other	stakeholders	
F2	 Stakeholder	
Management	
Engagement	 with	 several	 key	 stakeholders	 (notified	 Bodies,	 labs,	 LIS	 vendors,	 logistics	 providers)	 and	consultants.			But	not	directly	with	regulators.	(MHRA	/	FDA).	 Some	evidence	of	this	being	put	in	place.	
F3	 Customer	
Engagement	
Source:			User	Needs	document	Input	to	technical	and	functional	requirements	was	in	place.	Initial	engagement	with	potential	users	in	labs	to	define	technical	and	operational	requirements.	Follow	up	meetings	with	users	to	define	specific	supply	chain	and	service	requirements	to	enable	value	creation	to	be	confirmed.		Meetings	with	LIS	system	vendors	to	define	interface	requirements.	Value	 capture	activities	 conducted	very	 late,	 resulting	 in	 change	 in	 commercial	model.	 	 	Target	markets	 and	pricing	changed	late	in	project.	
Some	 evidence	 of	 this	 being	 in	 place.		Developed	 for	 product	 design,	 technical	and	 to	 get	 logistics	 input.	 	 Less	 so	 for	commercial	model.	
F4	 Business	 Model	
development	
Known	to	require	a	new	Business	Model.				 Evidence	need	 for	new	model	 exists	but	not	fully	in	place.		
F5	 Value	Attributes	 Value	capture	via	 ‘reagent	rental’	business	proposed,	but	this	changed	later	as	changes	 in	accounting	practice	made	some	aspects	unacceptable.				Model	still	ultimately	relied	on	main	revenue	generation	via	consumable	sales.			To	achieve	sales	each	customer	(Trust)	required	to	do	own	evaluation,	resulting	in	significantly	delayed	commercial	revenue	stream,	changing	commercial	plans.			It	was	clear	(in	hindsight)	that	the	explicit	revenue		/	capture	process	was	not	understood	in	the	launch	markets.	
Confirmed	as	 ‘absent’.	Failure	to	manage	this	 is	 seen	 as	 major	 contributor	 to	failure.	
F6	 Governance	 There	were	changes	to	governance.			Initial	plan	was	to	use	existing	governance,	but	it	became	apparent	this	was	not	going	to	work	(lack	of	expertise,	and	frequency	of	reviews).		An	alternative	review	mechanism	was	put	in	place,	that	permitted	a	more	dynamic	approach,	but	was	less	rigorous.	
Evidence	 this	 was	 in	 place.	 	 But	 need	some	 refinement	 to	 address	 project	 	 /	technology	needs.		
F7	 Gate	Criteria	 Established	criteria	used	for	major	review	gates.			 Evidence	this	was	in	place.	
F8	 Process	 Used	existing	NPS	process	as	overarching	process,	then	developed	more	customised	process	to	address	specific	 Evidence	this	was	in	place.		
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	 Factor	 Responses	 Conclusion	needs	of	Med	Tech.		
F9	 Risk	
Management	
Source:	Project	reviews	Technical	risks	were	tightly	managed	with	milestone	payments	to	alliance	partners	linked	to	discharge	of	risks.				 Confirmed.	 In	 place	 for	 technical	 and	integration.			Failure	to	manage	business	model	risk	is	seen	as	major	contributor	
F10	 Alliance	Partners	 Source:			Contract	Agreements	Main	Alliance	partner	managed	via	a	detailed	contract.		Contract	needed	updating	due	to	financial	concerns	at	partner.			Main	instrument	supplier	managed	closely	as	technical	risks	high.	Cartridge	manufacturer	relied	on	relationship	with	senior	leader	as	product	represented	small	revenue	stream	(supplier	mainly	in	Consumer	Electronics)	Sample	device	was	 ‘off	 shelf’	 item	with	minor	customisation,	not	 closely	managed	but	 resulted	 in	contractual	issues.	 	 Examples	 of	 different	 approaches	 being	 used.	 Alliance	 partners	 in	 UK	 (device),	 UK	 (telemedicine	software),	Spain	(field	studies)	
Evidence	 of	 this	 being	 put	 in	 place.	 	 	 A	range	of	different	approaches	was	used.			The	main	Alliance	partner	was	seen	as	a	significant	 risk	 and	 the	 management	evolved	to	take	account	of	those	risks.			
F11	 Project	Team		 Experienced	team	drawn	from	across	R&D,	manufacturing	and	commercial.		Some	team	members	from	outside	normal	R&D	(eg	bioinformatics,	physics).	Team	supplemented	with	external	consultants.	Expertise	also	brought	in	from	Consumer	(who	has	CE	marking	knowledge).	
Evidence	 team	had	wide	experience	and	expertise	 and	 was	 supplemented	 where	necessary.	
F12	 Support	
infrastructure	
No	external	infrastructure	used.		Business	Unit	joined	BIVDA	(trade	association)	but	relied	on	Alliance	partners	for	their	network.		Started	to	develop	own	 ‘ecosystem’	from	Alliance	partners,	potential	partners	and	experts.		Internal	 ecosystem	 developed	 from	 staff	 with	 expertise	 in	 specialist	 technologies	 and	 from	 staff	 with	 Med	Tech/CE	marked	product	regulation.				Focussed	input	from	external	experts.	Used	recognised	TRO/	(P)	to	help	technical	integration,	but	no	partnerships	in	commercial	environment.				Used	 range	of	business	 leaders	with	 similar	new	business,	 ‘intrapreneurial’,	 convergent	challenges	 to	 identify	ideas	and	challenges.		But	not	all	were	acted	upon.	
Some	 evidence	 this	 was	 being	 put	 in	place.		
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5.3.3 Conclusions The	 analysis	 in	 Table	 5-6	 and	 Table	 5-7	 indicate	 that	 the	 proposed	 framework	 has	 utility	 in	investigating	convergent	innovation	cases.	During	the	pilot	studies,	only	small	refinements	made	to	framework	wording,	but	not	the	overall	structure	or	factors	developed	during	abduction	were	essentially	 unchanged.	 	 The	 pilot	 cases	 therefore	 confirmed	 the	 usability	 of	 the	 exploratory	framework.	 	 The	 revised	 version	 of	 the	 Exploratory	 Framework,	 used	 for	 case	 studies,	 	 is	included	in	the	Case	Protocol	in	the	Appendices,	Appendix	A2	–	Case	Study	Protocol	(extract).					 	
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6 Case Studies 
6.1 Introduction  The	 Phase	 2	 research	 consisted	 of	 five	 in-depth	 and	 longitudinal	 case	 studies	 together	 with	continued	 data	 collection	 in	 the	 emerging	 ecosystem.	 	 The	 findings	 from	 each	 of	 these	 are	discussed	in	the	following	sections.			
Case	 Context	 –	 Emerging	 Ecosystem	 -	 ongoing	 ecosystem	 review	 to	 understand	context.			
Case	 1	 -	 CMTI	 –	 medium	 sized	 incumbent,	 an	 incubator	 organisation	 providing	‘ecosystem’	for	innovators	and	looking	to	move	into	convergent	medical	technologies		
Case	2	-	NMD	–	a	novel	R&D	unit	within	a	major	pharmaceutical	company.		Developing	a	new	 class	 of	 therapeutics	 based	 upon	 convergence,	 by	 combining	 opto-micro-electromechanical	systems	(O-MEMS)	and	digital	technology	with	therapeutics.		
Case	3	-	DH1	–	an	innovation	unit	within	the	NHS	developing	digital	health	solutions	for	patients	and	providers.		
Case	4	-	MLD	–	a	start-up	developing	a	novel	diagnostic,	based	upon	machine	learning		
Case	5	-	DH2	-	a	start-up	developing	a	novel	medical	device	and	digital	health	tools.	
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6.2 Case Context – Innovation Ecosystem 
6.2.1 Introduction The	 ecosystem	 was	 nascent	 and	 evolving,	 but,	 as	 previously	 identified,	 provides	 important	ongoing	context	for	the	cases	studies.			As	a	result,	ecosystem	interviews	and	analysis	continued	to	 ensure	 that	 contemporaneous	 information	 was	 available	 during	 the	 case	 period.	 	 The	evidence	 consists	 of	 the	 27	 preliminary	 ecosystem	 interviews	 (described	 in	 Chapter	 5	 and	summarised	 in	 Table	 6-1)	 and	 a	 further	 twelve	 ecosystem	 interviews,	 together	 with	observations	 (at	 meetings	 and	 events)	 and	 documents.	 	 Details	 of	 further	 interviewees	 are	provided	in	Appendix	A4.			
Table	6-1	Innovation	ecosystem	data	sources	
Data	Sources		 Details		Preliminary	Ecosystem	Interviews		 27	interviews	of	senior	managers	and	business	leaders		Further	Ecosystem	Interviews	 12	interviews	of	11	senior	managers	and	business	leaders	(see	appendix	A4)	Observations		 11	Conferences,	Meetings	and	Workshops	Academic,	Business	Press	and	Industry	documents		 28	Public	documents	and	papers		
6.2.2 Findings  The	 interviews	 focussed	mainly	on	 institutional	 actors,	 as	 the	preliminary	 research	 identified	institutional	and	infrastructure	gaps.		During	the	case	research	the	top-level	ecosystem	did	not	evolve	 significantly,	 but	 there	 was	 developing	 understanding	 of	 the	 sub-systems,	 which	 are	addressed	in	the	following	sections.			
System	Structure	and	Relationships	The	top-level	map	(Figure	6-1)	was	then	developed	using	a	combination	of	interview	data	and	public	sources,	to	produce	maps	of	sub-systems.	The	structured	was	developed,	and	extended,	from	similar	value	chain	mapping	by	Srai	(Kumar	et	al.,	2013;	Srai	and	Alinaghian,	2013;	Srai	and	 Christodoulou,	 2012),	 but	 with	 actors	 clustered	 by	 type.	 These	 provide	more	 detail	 and	enable	the	identification	of	some	processes,	causal	links	and	relationships.	Where	possible	they	were	 discussed	 and	 verified	 with	 interviewees.	 	 Example	 sub-system	 maps	 are	 provided	 in	Figure	 6-2	 to	 Figure	 6-7.	 One	 identified	 feature	 is	 that	many	 relationships	 are	more	 complex	than	 any	 high-level	 mapping	 would	 suggest.	 	 This	 finding	 reinforces	 the	 view	 that	 better	understanding	of	relationships	is	key	in	understanding	the	ecosystem	and	innovation	options.					
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Figure	6-1	High-level	innovation	ecosystem				
	
Figure	6-2	Knowledge	creation	and	transfer	ecosystem		
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Figure	6-3	Incubators	and	accelerators	ecosystem			
	
Figure	6-4	Investment	and	development	funding	ecosystem			
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Figure	6-5	Policy	and	regulation	ecosystem			
	
Figure	6-6	Health	and	care	delivery	ecosystem			
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Figure	6-7	Digital	and	mobile	health	ecosystem	
	
	
Ecosystem	Dynamics	and	Co-evolution	A	 combination	 of	 interviews	 and	 literature	 sources	 were	 also	 used	 to	 identify	 ecosystem	dynamics	and	evolution.	 	Technology	roadmaps	(Phaal	et	al.,	2011;	Probert	et	al.,	2003)	were	used	to	help	articulate	the	key	trends	and	patterns	in	the	ecosystem	(See	Figure	6-8).	The	source	references	 for	 these	 diagrams	 are	 included	 in	 Error!	 Reference	 source	 not	 found..	 	 The	roadmaps	take	PESTLE	analysis,	using	political	 (P),	economic	(E),	 social	 (S),	 technological	 (T),	legal	 (L),	 and	 environmental	 (E)	 considerations,	 as	 a	 starting	 point.	 	 The	 likely	 products	 and	services,	and	the	underpinning	technology	convergence	required	to	support	these	products	are	then	added.		The	main	themes	identified	from	this	analysis	(the	headline	themes	from	the	roadmap	in	Figure	6-8)	were	as	follows:	
• From	PESTLE	analysis:	
o Growing	and	Ageing	Population	
o Increase	in	Chronic	diseases	(e.g.	diabetes,	respiratory,	cardiac	and	cancer)	
o Healthcare	Policy	evolution		
o Regulatory	reforms	and	evolving	standards	
o Intellectual	Property	and	Tax	incentive	changes	
o Access	to	Seed	and	early	development	funding		
o Access	to	Venture	Funding		
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• Resulting	in	Product	and	Services:	
o New	Integrated	Healthcare	and	Service	providers	
o Convergence	 enables	 new	 products	 and	 services	 in	 fields	 such	 as:	 diagnostics,	precision	medicine,	regenerative	medicine,	digital	health	and	‘cyber’	health	
• Underpinned	by	the	following	technologies:	
o Digital	technologies,	engaging	and	enabling	communities	
o “Big	 Data’,	 artificial	 intelligence	 and	 machine	 learning	 and	 analytics,	 to	 identify	patterns	in	complex	data	
o High	precision	3D	imaging,	to	improve	understanding		
o Sequencing	(DNA)	and	new	biomarkers,	enhancing	disease	understanding	
o Nanotechnology	and	new	materials,	enabling	new	sensor	and	implant	devices	
o Additive	manufacturing,	enables	personalisation	
o Synthetic	biology	toolkits,	create	new	disease	modulation	possibilities	
o Cell-based	technologies,	as	a	step	towards	cures	
o Greater	precision	drugs,	improve	efficacy,	at	reduced	risk			
Issues	Identified	in	the	evolving	Innovation	Ecosystem	Initial	 issues	and	challenges	in	the	ecosystem	were	 identified	in	the	preliminary	research	(see	Chapter	5).		The	follow-on	interviews,	observation	and	documents,	and	subsequent	mapping	and	trend	 analysis	 identified	 several	 additional	 context	 considerations,	 which	 are	 summarised	 in	Table	 6-2.	 Of	 these	 new	 emerging	 ‘implications’	 only	 the	 ambiguity	 around	 regulation	 and	assessment	 of	 digital	 and	 mobile	 technologies	 appeared	 to	 have	 direct	 influence	 on	 cases.		BREXIT	 emerged	 relatively	 late	 in	 the	 research	 period	 and	 raised	 issues	 for	 one	 innovator	around	access	to	funding,	but	had	little	or	no	immediate	apparent	impact	on	other	cases.						
Table	6-2	Emerging	‘dimensions’	from	further	ecosystem	interviews	
Emerging	‘dimensions’	from	ecosystem		 Potential	Implications	for	innovators’		Creation	of	Precision	Medicine	(PM)	Catapult	by	Innovate	UK	to	support	innovation	in	this	field	 Provides	single	focus	point	and	mapping	of	PM	ecosystem.	Investment	funding	remains	a	challenge,	but	a	few	new	funds	are	emerging	 Innovators	may	need	to	look	outside	UK	for	follow	on	funding	NHS	stopped	their	App	assessment	process	and	are	replacing	via	new	scheme	(going	live	April	 Uncertainty	over	digital	health	solutions	and	how	assessed,	but	new	process	provides	
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2017)	 greater	clarity	NICE	and	MHRA	providing	joint	reviews	for	novel	technologies	and	innovations,	where	existing	guidance	is	limited	
Opportunity	to	engage	and	identify	technical	and	economic	expectations.	
Accelerated	Access	Review	for	NHS	 Aims	to	provide	more	‘joined-up’	approach	and	adoption	opportunities	for	innovators.		Delays	in	adoption	of	new	EU	medical	device	regulations	 Increased	uncertainty	but	proposed	regulations	bring	requirements	close	to	US	FDA,	so	simplify	in	long	term.	Unclear	how	some	technologies	such	as	3D	additive	manufacturing	of	prosthetics	and	regenerative	medicine	might	be	regulated	in	future	(FDA	looking	to	‘validate’	the	design	process)	
Implications	for	how	design	is	conducted.		As	interim	measure	innovators	should	engage	FDA	Division	developing	draft	guidance.	
Greater	clarity	of	what	EU	/	FDA	accept	as	an	’App’	and	what	constitutes	a	medical	device.	Software	as	a	Medical	Device	(SaMD)	now	accepted.		
Increasing	regulation,	but	greater	clarity	on	requirements	
BREXIT	referendum	makes	investment	and	regulatory	picture	less	certain	 Need	to	consider	contingencies	in	both	funding	and	regulatory	requirements				
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Figure	6-8	Trends	and	evolution	within	healthcare	innovation	ecosystem	
Shift in PE/VC dev Funding from Pharma/Biotech to Med Tech and Digital 
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6.3 Case 1 – CMTI 
6.3.1 History and Background The	 venture	 is	 an	 incumbent	 innovation	 incubator	 working	 with	 ‘start-ups’	 in	 biomedical	sciences,	typically	with	biotech	and	medical	device	companies.			The	focus	of	CMTI	is	to	provide	an	 ecosystem	 to	 support	 innovators,	with	 a	 combination	 of	 facilities,	 expertise,	 investors	 and	value	network	partners.		Their	aim	was	to	‘catalyse’	convergent	medical	technologies.			The	 venture	 started	 in	 January	 2014,	 with	 a	 proposal	 to	 develop	 a	 ‘convergence’	 capability,	during	one	of	their	Open	Innovation	Summits.	By	May	2014,	the	start	of	the	case	research,	CMTI	had	begun	the	process	of	trying	to	understand	the	ecosystem	and	potential	partners.	Firstly,	the	proposed	venture	did	not	fit	their	existing	technology	structure	and	network.		The	venture	was	aiming	 to	 support	 convergent	 technologies	 with	 a	 major	 investment	 program	 for	 which	 the	incumbent	 organisation	 and	 current	 partners	 had	 little	 expertise.	 There	 was	 limited	understanding	of	the	potential	business	models	and	value.		It	therefore	required	CMTI	to	work	with	a	diverse	range	of	stakeholders,	many	of	whom	were	unknown	at	the	outset	of	the	venture.		During	 the	 case	period,	 the	CMTI	 venture	progressed	 from	an	 idea,	 and	via	 exploration	 to	 an	outline	 concept,	 which	 was	 then	 focussed	 and	 developed,	 in	 the	 process	 they	 built	 a	 new	network	 and	 nascent	 ecosystem	 and,	 via	 external	 funding,	 obtained	 commitment	 for	 a	major	investment	in	convergent	medical	innovations.				The	research	 followed	the	venture	 for	two	years	(until	 June	2016),	so	provides	evidence	 from	close	 to	 its	 inception	 through	 early	 development	 and	 a	major	milestones	whereby	 significant	investment	and	commitment	was	made.	A	summary	timeline,	highlighting	key	events	in	the	case	history	is	provided	in	Table	6-3.											
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Table	6-3	Case	CMTI	study	key	events	
Date	 Event	Jan	2014		 Announce	interest	in	‘convergence’	at	their	open	innovation	(OI)	summit		Mar	2014	 Univ.	College	London	(UCL)	move	into	facility	May	2014		 Case	started.	Initial	discussions	with	Sagentia	to	review	recent	developments	in	convergence	(have	documents)	Jun2014	 Hold	workshop	with	some	board	members	and	interested	parties	(attended	and	observed).	Q3	2014		 Conduct	exploratory	searches	in	the	field	–	what	is	going	on,	who	is	working	in	it.			Aim	for	top	level	understanding	and	whether	opportunity	exists.	Aug	2014		 Internal	 Convergence	 team	 meeting	 with	 some	 external	 input	 (attended	 and	 observed).		Agree	to	follow	up	searches	and	exploration.		Aim	is	to	provide	input	to	a	Phase	2	Strategy,	but	timing	not	finalised.	Jan	2015		 Chair	(and	one	of	convergence	‘visionaries’	steps	down	due	to	ill	health.		Open	 Innovation	 summit	 conference	 –	 also	 discussed	 ‘convergence	 and	 CMTI	 role	 or	potential	roles,	engaging	with	diverse	audience.		Q2	2015	 Some	delays	in	pulling	next	phase	team	together.	Other	priorities.		Jul	2015	 Hold	 meeting	 at	 CMTI	 with	 diverse	 stakeholders	 to	 discuss	 options	 and	 CMTI	 potential	engagement	(attended	and	observed)	Q3	2015		 Start	 process	 to	 gather	 and	 codify	 data	 on	 convergence	 areas.	 	 Focussed	 on	 Precision	Medicine,	Nano	Technology,	Digital,	Big	Data	Analytics,	Cell	Therapy	/	Regen	Medicine	(have	documents)	Aug	2015		 Summarise	 review	 of	 convergence	 as	 input	 to	 Board	 paper	 –	 review	 covers	 science,	companies,	academia,	 institutes,	 research	councils	and	 investors.	Output	 for	 draft	 Phase	 2	Board	paper	(documents	obtained).	Engaged	in	negotiations	for	regen	therapy	capability	at	CMTI	Sep	2015		 New	Chairman	appointed.	 	Plan	for	 ‘convergence’	updated.	 	 	Focus	on	Regen,	Bioelectronic	and	 Precision	 Med,	 plus	 facility	 design	 options.	 Pitched	 to	 Wellcome	 Trust	 as	 potential	investors	and	Board	members.		Oct	2015	 Contribute	to	‘Castell’	article	on	Precision	Medicine	Nov	2015	 Construction	of	regen	therapy	facility	started.		Q1	2016	 Conduct	 more	 systematic	 review	 and	 study	 via	 interviews	 –	 formally	 reported	 monthly.		Exploring	wider	stakeholders	and	opportunity	area.		Apr	2016		 Phase	2	Board	Paper	developed.	[XXX]	Technology	moves	to	Facility.	May	2016		 Formal	decision	at	Board	 to	commit	 to	Phase	2	–	with	 focus	on	Regen	Medicine,	Precision	Medicine	and	Bioelectronics,	in	addition	to	existing	biotech	capabilities.		Dec	2016	 Begin	progress	of	convergent	(Future	Healthcare’	capabilities	at	CMTI.			
6.3.2 Case Evidence  Case	Research	 followed	the	methodology	developed	 in	Section	4.	 	 	During	the	case	study,	data	was	 collected	 from	 interviews,	 observations	 and,	 from	 public	 and	 company	 documents	(obtained	under	a	confidentiality	agreement).	A	summary	of	the	interviewees,	observations	and	documents	accessed	 is	provided	in	Table	6-4	and	 the	 interviewees	sources	are	summarised	 in	Appendix	 A4.	 Direct	 observation	 at	 meetings	 and	 workshops	 with	 innovators,	 investors	 and	other	 key	 stakeholders	 also	 provided	 evidence	 of	 practices	 and	 capabilities.	 All	 data	 was	securely	 stored	on	 a	 confidential	 cloud	 server	 and	uploaded	 into	NVivo	CADQAS	 software	 for	analysis.		
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Table	6-4	Case	CMTI	study	data	sources	
Data	Sources		 Details		 Aspects	studied		Case	Interviews		 10	interviews	of	8	senior	managers	and	business	leaders	over	the	case	period,	totalling	over	11	hours	(ranging	from	30	mins	to	90	mins).	
Identification	of	patterns	in	capability	change;	manifestations	of	skilful	agency	and	existing	innovation	capabilities		Internal	strategic	documents		 11	Business	Plans,	internal	Board	and	governance	reports,	and	project	status	reports	
Identification	of	patterns	in	broader	capability	change;	and	engagement	with	ecosystem	Observations		 6	Workshops,	project	meetings,	and	internal	team	meetings	 Observation	of	innovation	practices	and	working	with	partners	Company	Website	 News	updates,	thought-pieces	and	open	calls	for	input	from	2014	to	2016.	 Public	information	on	the	new	ventures	and	engagement	Academic,	Business	Press	and	Industry	documents		
2	Public	documents	including	Reports	and	papers	CMTI	contributed	too,	other	documents	on	initiatives	related	to	ecosystem			
Examples	of	engagement	with	others,	and	driving	forces	elsewhere	in	ecosystem		
	
6.3.3 Analysis  Coding	 followed	 the	 process	 described	 in	 Section	 4.	 	 Initial	 coding	 was	 based	 upon	 the	exploratory	framework.	The	main	events	identified	in	the	exploratory	framework	under	factors	F1	 to	F12	were	 summarised	 and	used	as	 input	 to	subsequent	 coding,	 and	 then	 subject	 to	 the	ECPO	analysis	 to	 identify	plausible	mechanisms.	 	 	The	ECPO	analysis	 for	 this	 first	 case	(Table	6-5)	is	included	below	but	for	subsequent	cases	(and	clarity)	these	analyses	are	included	in	the	Appendices.		
	During	 the	 case,	 simple	 ecosystem	maps	were	also	developed	based	upon	 interview	evidence	and	interviewee	input.							
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Table	6-5	ECPO	Analysis	for	Case	CMTI		 ECPO Analysis Case: 
CMTI 
 	 	 	 	 	 	 	 	 	
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
e1 Use of OI Events 
and seminars 
c1 Poor 
understanding 
of opportunity 
and ecosystem 
p1 Ensure CMTI 
had access 
wider 
ecosystem 
actors 
x1.1 Crowdsourcing 
for inputs and 
solutions 
Chesbrough - 
open 
innovation 
Yes - well 
established 
mechanism 
o1, 
o6 
Strategic Search via 
multiple engagements, 
meetings to build 
relations.   Creating 
Visibility and Legitimacy 
in field 
Multiple evidence at CMTI events and website 
(observed at events on 01/1214, 02/12/14, 06/01/15, 
28/02/15, 21/10/15, 11/01/16) 
            x1.2 Events as 
'showcase' 
Kotter, Eisend? 
publicity v 
marketing 
No, clear 
intent in 
agenda and 
approach to 
engage and 
seek input, 
not self-
advertise  
      
e2 Workshops and 
Meetings with 
innovators, 
developers, 
funders and 
charities 
c1 Poor 
understanding 
of opportunity 
and ecosystem 
p2 Need to 
identify 
collaborators, 
sources of 
knowledge to 
ensure 
solutions were 
appropriate 
and 
acceptable.  
x2.1 Systematic 
search  
Garud, Pandza 
- strategic 
search 
Yes - there is 
a need to 
identify 
where 
knowledge 
resides, it is 
new to the 
organization 
o1, 
o2, 
o6 
Strategic Search (both 
local and distant - using 
structured and snowball 
approaches) 
11/11/15 CMTI-2: "We’ve run events like the Cell 
Therapy and Regen Med event, which involved 2 
tenants and the rest were a national audience, maybe 
70 people. Then we’ve run convergence events and 
summits, so it's in 100s. Tomorrow we have a cell 
therapy investors event." 
c2 Ecosystem of 
potential 
parters did not 
exist at the 
outset.  
Increase 
network 
awareness 
across 
ecosystem 
x2.2 Use network to 
extend search 
(snowball) 
Goodman - 
snowballing 
Rosenkopf / 
Nerkar- distant 
knowledge 
Yes - it is a 
novel area, so 
need 
approach to 
scan 'distant' 
knowledge 
and sources 
o1, 
o2, 
o6 
Strategic Search (both 
local and distant - using 
structured and snowball 
approaches) 
11/11/15 CMTI-2: "Tomorrow I’m at the 3rd Annual 
EU Advanced Therapies Investor Day in London. It 
involves GE, CTC, BIA, Lonza, Panmuir Gordon 
(solicitors), its invite only at RIBA. It will open up a 
new network for us." 
20/05/15 CMTI-3: "I think one of the things that has 
come out of today is the need to get that better 
clarity. So we are going to probably do some more 
research. We are thinking of engaging even more 
widely. " 
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	 ECPO Analysis Case: 
CMTI 
 	 	 	 	 	 	 	 	 	
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
c3 Specific 
knowledge and 
technology 
gaps across 
ecosystem  
x2.3 Interchange of 
idea and 
challenges - 
sense-making 
Gioia, Weick, 
Daft and Lengel 
- sense-making 
Yes - as 
knowledge is 
new, there is 
a need to 
exchange and 
challenge to 
build 
understandin
g 
o2, 
o6 
Sense-making via 
diverse stakeholder 
interactions and an 
integrating role 
11/11/15 CMTI-2: "We recently attended a 
bioelectronics meeting with Wellcome Trust, that [...] 
organised. It involved GSK, Wellcome, EPSRC. One 
interesting things was that in UK, there was no one, in 
academia, that saw themselves with a bioelectronics’ 
label, but when you got underneath and found out 
what they were doing, they were doing BE related 
work. So the labelling and branding are important, 
and affect communication and understanding."  
x2.4 Events as 
'showcase' 
Kotter, Eisend? 
P publicity v 
marketing 
No, clear 
intent in 
agenda and 
approach to 
engage, not 
self-advertise  
      
e3 Open innovation 
and 
'crowdsourcing' 
projects 
c3 Specific 
knowledge and 
technology 
gaps across 
ecosystem  
p3 Need to 
engage users in 
identify (real) 
problems and 
potential 
solutions 
x3.1 Interchange of 
ideas and 
challenges - to 
create known/ 
unknown 
knowledge 
domains 
Gioia, Weick, 
Daft and Lengel 
- sense-making 
Yes - as 
knowledge is 
new, there is 
a need to 
exchange and 
challenge to 
build 
understandin
g 
o2, 
o6 
Sense-making via 
diverse stakeholder 
interactions and an 
integrating role 
"We also plan to have another Summit in April 2016, 
on Open Innovation and convergence." 
c1 Poor 
understanding 
of opportunity 
and ecosystem 
11/11/15 CMTI-2: "But we see it as natural extension 
of our OI agenda, so we don’t differentiate. " 
e4 Mapping 
stakeholders and 
understanding 
the emerging 
ecosystem 
c1 Nascent 
ecosystem, key 
actors not 
established, 
knowledge 
gaps in 
ecosystem 
p4 Need to 
develop wider 
understanding 
and stronger 
ecosystem 
links to support 
decision 
making and 
identify long 
term partners 
x4.1 identifying 
potential 
partners, future 
value network 
and blocks to 
progress 
Gioia, Weick, 
Daft and Lengel 
- sense-making 
Yes - as 
knowledge is 
new, there is 
a need to 
exchange and 
challenge to 
build 
understandin
g 
o2, 
o9 
Sense-making via 
diverse stakeholder 
interactions and an 
integrating role 
CMTI Database: (via GoogleDrive - access provided) 
contains summary of key organisations, convergence 
interest, contacts  and links to further information 
11/11/15 CMTI-2: [referring to above database] "Each 
of us, adds to it as we come across academics, tech 
companies etc. We’ve been working on it for 8-9 
months. [CMTI-5] often adds to it. It gives us a sense 
of who the players are and what’s going on. Its not 
just UK though. " 
05/10/15 CMTI-3: "It’s fairly structured.    We started 
with people we know.   But are now expanding the 
interviews, talking to their suggested contacts....  We 
want to extend our search beyond the usual suspects.   
We want some diversity.   We also want to complete 
it by the end of the year so we can focus in 2016." 
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	 ECPO Analysis Case: 
CMTI 
 	 	 	 	 	 	 	 	 	
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
17/11/15 CMTI-6: "It's fairly informal, understanding 
the issues and challenges, across clinical, regulatory, 
supply china, financing, technology. We want to 
understand where [CMTI] can help overcome 
problems. With at UK level or with [CMTI] facilities." 
e5 Business model 
mapping 
exercises 
c4 Business 
models in 
ecosystem not 
generally 
established 
p5 Identify viable 
and 
sustainable 
model to 
deliver value 
and meet 
vision -  
x5.1 Need to develop 
a viable model 
for the venture, 
sources of 
funding / income 
not clear 
Gioia, Weick, 
Daft and Lengel 
- sense-making 
Yes, evidence 
that diversity 
of 
stakeholders 
and broader 
legal, IP 
issues make 
the decision 
challenging.   
o4, 
o7 
Sustain- identify 
solutions that ensure 
venture is viable 
17/11/15 CMTI-6 "Its more about understanding the 
landscape. Trying to identify who, where, what and 
importantly what the potential value is. We are still in 
the storming phase organisationally. We want to 
understand the value of being linked to [CMTI], from 
their perspective. We also know that this is 
potentially an area where first followers will get the 
real benefit, particularly in things like regulatory. 
Whoever goes first will have challenges." 
e6 Mapping value 
from different 
stakeholder 
perspectives - 
'persona' 
c5 Lack of 
understanding 
of 'value' for 
new 
technologies 
and 
'convergence' 
p6 Desire to add 
value and 
contribute to 
outcomes 
x6.1 Want to ensure 
solutions are 
valuable to 
others  
Sarasvathy, 
Garud, Sydow - 
shape 
Yes - 
examples, of 
seeking to 
create value 
from several 
perspectives 
and where 
they can 
create future 
value 
o2, 
o4, 
o7 
Understanding and then 
trying to Shape - a 
viable model and 
advantage 
11/11/15 CMTI-2: "… recently asked to speak at 
Wellcome Trust. We positioned it as ‘Future of 
Healthcare’ rather than ’convergence’. We’ve also 
positioned convergence as a natural extension of 
what we are doing on open innovation." 
x6.2 Want to ensure 
value is 
understood in 
nascent 
ecosystem 
Yes - 
evidence of 
desire 
explore value 
widely 
17/11/15 CMTI-6: "The other issue of course is EU 
versus USA. They are different from a regulatory view 
and a market. So what may work in one might not 
work in the other. That changes the value. 
Particularly things like the reimbursement model. Its 
not clear how it will be funded. That’s not just for 
things like Apps, but all technologies where there 
isn’t a clear product exchange and selling model." 
e7 Development of 
own view of 
'convergence' and 
implications 
c2 Lack of 
understanding 
across 
stakeholders 
p7 Need to create 
common 
understanding 
to move 
investment and 
partnerships 
forward 
x7.1 Need for clarity 
in vision  
Gioia, Weick, 
Daft and Lengel 
- sense-making 
Yes, seeking 
to position 
role in 
emerging 
ecosystem - 
as 
connectors, 
integrators 
o2, 
o7 
  11/11/15 CMTI-1: "As you know I see the Future 
Healthcare agenda as about convergence. We’ve 
been working on it for 18 months or so. Its about 
bringing IT, electronics, engineering to the 
biosciences to deliver ne solutions to biological 
problems. If you think traditionally its about bringing 
the pill, the diagnostics, the data and devices all 
together. " 
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	 ECPO Analysis Case: 
CMTI 
 	 	 	 	 	 	 	 	 	
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
e8 Building 
governance and 
oversight on 
existing 
approaches  
c6 There are some 
established 
processes, and 
criteria. 
p8 Make minor 
modifications 
to suit contact 
and increase 
objectivity in 
decision 
making 
x8.1 Need to engage 
and bring 'on 
board' key 
stakeholders 
Ries - efficiency 
/ lean  
Yes - partial o8, 
o10 
  11/11/15 CMTI-1: "To develop our thoughts, we have 
been bringing, as you know, experts, panels together, 
running workshops. As we are asking the Board for 
£50M (...) we need evidence, its not just us saying this 
and we are not trying to create ‘just another science 
park’, we want to drive an Open Innovation agenda. 
Thankfully our Board agree. " 
e9 Refining internal 
processes to 
address 
'convergence' - 
use small teams, 
external support, 
mini-conferences, 
conduct different 
searches 
 
 
 
 
 
 
 
 
 
 
 
c7 The 
established 
processes or 
criteria are not 
always suitable 
p8 Need to 
maintain 
momentum to 
secure funding, 
but also be 
agile and 
efficient 
x9.1 Need agile 
process to 
deliver 
recommendatio
ns in an efficient 
way and address 
key risks 
Shape - 
Sarasvathy, 
Garud, Sydow 
Yes, moved 
to frequent 
meetings 
with 
ecosystem 
actors, and 
monthly 
updates to 
accelerate 
knowledge 
and option 
generation 
o8, 
o10 
Shape - legitimacy-
seeking 
Evidence	in	'Convergence'	Monthly	Reports	2016	(accessed)	-	CMTI	has	moved	to	more	regular	meetings	with,	for	exmaple:	MRC,	NIHR,	Genomics	England,	Illumina,	Medtronic,	IBM,	Boston	Scientific,	Roche.			Then	conducts	internal	review	on	feedback.	 
Selection - 
experiential 
learning 
Yes - needed 
to refine and 
focus 
decision 
criteria 
o3, 
o10 
Selection, experiential 
x9.2 Need to improve 
processes 
Dynamic 
capability - 
Teece et al 
Partial?  - 
some 
experiential 
learning, but 
no evidence 
of systematic 
SST.  
o9 Evidence of range of 
small changes, across 
several processes.  
More driven by 'design' 
of management, who 
are clear a different way 
is needed 
Observations 
Ambidexterity - 
Birkinshaw et 
al 
Partial - no 
evidence of 
significant 
range of 
capabilities 
across 
organisation 
o9 
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	 ECPO Analysis Case: 
CMTI 
 	 	 	 	 	 	 	 	 	
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
x9.3 Desire to be 
creative and 
develop 'own' 
solutions 
Amabile - 
Creativity 
No, whilst 
evidence 
looking for 
creative 
solutions, 
they appear 
happy to use 
existing tools 
where they 
work 
      
e10 Internal Business 
Plan regularly 
refined 
c4 Business 
models in 
ecosystem not 
generally 
established 
p5 Identify viable 
and 
sustainable 
model to 
deliver value 
and meet 
vision  
x10.1 Business Model 
is to engage, 
identify 
problems and 
solutions, create 
IP and develop 
offerings that 
can then be 
delivered by 
others (for 
royalty) or 
license to other 
providers 
Selection Yes, partial - 
the key 
elements of 
required 
model are 
understood 
o3, 
o10 
Selection,  Sustain 12/05/14 CMTI-1 "Probably a bigger concern is focus. 
Given the complexity and lack of understanding, it 
would be easy to step in and step into the wrong 
place. Equally you cannot cover it all. So we will need 
to think about how we focus. [CMTI] is interested. 
But initially the play is probably building on existing 
strengths in neurodegeneration, cell therapy, maybe 
bioelectronics .... But with others on board that may 
change." 
p9 Initial models 
too ambitious, 
defined as 
more 
information 
obtained 
x10.2 Unsure as to 
what is best 
option, diverged 
at first, but then 
refined, as 
engaged to build 
understanding 
Wieck - sense 
making 
Yes,  o2, 
o8, 
o10 
Sense-making - 
experiential learning 
process 
17/1/15 CMTI-6: " … so we wanted to understand 
their position and plans so we can look to build 
synergies or help plug the gaps. Add value and avoid 
reinvention." 
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Figure	6-9	Case	CMTI	ecosystem	evolution	over	case	period		
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6.3.4 Findings 
Ecosystem	evolution	The	evolution	of	 the	ecosystem,	over	approximately	24-month	period,	 is	shown	 in	Figure	6-9.	CMTIs	ecosystem	was	already	developed	with	biotech	start-ups,	pharmaceutical	companies	and	academia.		To	support	convergence	required	new	interactions	with	technology	companies.	CMTI	focussed	developing	a	new	network	and	partnerships.	In	addition	to	technology	companies,	they	engaged	funding	bodies,	charities	and	other	investors:	to	attract	funding	for	the	facility	and,	to	ensure	convergent	 technology	partners	could	secure	 future	 funding.	 	From	CMTI’s	perspective	this	was	an	 important	step;	 for	 the	venture	 to	succeed	 there	needed	to	be	confidence	of	 ‘deal	flow’.				During	much	of	the	case	CMTI	were	exploratory	as	they	sought	to	identify	the	most	appropriate	solution	 and	 partners.	 There	was	 divergence	 as	 they	 reached	 out	 to	 actors.	 As	 their	 strategy	developed	they	focussed	on	diagnostics,	technology	and	data	analytics.	 	 	They	set	up	a	venture	fund	 and	 ran	 open	 innovation	 challenges	 to	 address	 known	 issues	 and	 attract	 new	 partners.	They	 won	 a	 big	 for	 a	 new	 pilot	 manufacturing	 facility	 to	 complement	 their	 capabilities.	 This	combination	of	partners	and	the	emerging	ecosystem	enabled	them	to	support	developments	in	new	 ‘convergent’	 areas,	 including:	 advanced	 diagnostics,	 precision	 medicine,	 regenerative	medicine	and	bioelectronics.	Ultimately,	they	decided	on	a	strategy	that	was	more	evolutionary.		The	 resulting,	 but	 still	 evolving,	 ecosystem	 is	 shown	 in	 Figure	 6-10.	 	 	 The	 emphasis	 remains	clearly	on	early	innovation	stages.			
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Figure	6-10	Case	CMTI	overall	innovation	ecosystem		
	
Building	external	credibility	and	legitimacy	CMTI	already	had	credibility	in	the	UK	biotech	ecosystem.		They	moved	to	position	themselves	in	 ‘convergence’	 through	 a	 series	 of	 interactions	 with	 diverse	 stakeholders.	 This	 was	supplemented	by	online	 research	via	 relevant	public	documents	 (see	Figure	6-11).	 	 They	 also	developed	a	database	of	potential	collaborators	and	partners	(see	Figure	6-12)	in	relevant	fields.			As	well	as	developing	their	knowledge	and	network	they	held	several	‘summits’	and	workshops	on	 ‘convergence’,	 increasing	 their	 visibility	 in	 the	 field.	 	 These	 did	 not	 always	 result	 in	 the	desired	 outcomes	 and	 often	 required	 further	 engagement,	 as	 identified	 by	 CMTI3	 after	 one	workshop:	 “’I	 think	 one	 of	 the	 things	 that	 has	 come	 out	 of	 today	 is	 the	 need	 to	 get	 that	 better	
clarity.	 So,	we	are	 going	 to	 probably	 do	 some	more	 research.	We	are	 thinking	of	 engaging	 even	
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Figure	6-11	Case	CMTI	example	of	their	background	research	spreadsheet	
	
	
Figure	6-12	Case	CMTI	example	of	their	‘database’	of	ecosystem	actors		These	 challenges	 were	 addressed	 by	 conducting	 further	 interviews	 and	 holding	 follow-up	workshops	 with	 other	 stakeholders.	 	 They	 also	 engaged	 potential	 investors	 and	 key	 opinion	leaders,	positioning	themselves	as	a	home	for	 ‘Future	Healthcare’,	as	they	branded	convergent	
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medical	technologies.	 	These	steps	can	be	considered	as	building	a	 legitimacy	or	credibility	 in	the	emerging	 ‘convergent	medical	 technologies’	 field,	which	 they	 then	planned	to	use	 to	build	value	creating	relationships.	
	
Value	Network	Development	As	highlighted	above,	much	of	the	search	and	exploratory	activity	was	based	upon	networking	and	building	relationships	through	meetings,	conferences	and	workshops.	The	basis	for	working	together	was	more	than	just	a	connection,	there	needed	to	be	alignment	and	confidence	that	the	outcome	could	result	in	investment	and	deal	flow.			
	Their	search	and	network	building	approach	was	exploratory	and	evolutionary,	developing	as	their	connections	and	relationships	grew	and	as	new	information	and	needs	arose.		Much	of	this	activity	was	conducted	by	a	dedicated	team	consisting	of	a	few	CMTI	leaders,	insightful	external	experts	 and	 resources.	 	 This	 appeared	 to	 achieve	 two	 things	 –	 one	 to	minimise	 the	 internal	resource	usage	and	disruption,	and	secondly	to	ensure	they	had	diverse	inputs.			
Developing	a	business	model	and	advantageous-position	Considerable	 time	 was	 spent	 developing	 a	 viable	 business	 plan	 and	 model,	 as	 described	 by	CMTI8:	 “What	 we	 are	 trying	 to	 do	 is	 understand	 where	 [CMTI]	 could	 add	 value.	 The	 current	
research	 is	 short	 term,	as	 input	 to	 the	…	Board	meeting.	But	what	we	want	 to	do	 is	provide	 the	
Board	 with	 some	 proposals	 for	 who	 to	 target	 as	 potential	 Supply	 Chain	 partners,	 Technology	
partners	and	Digital	partners.”		This	was	not	a	simple	process,	and	required	exploration	to	gain	understanding,	 followed	by	a	decision	on	where	 to	 focus,	CMTI1:	 “Probably	a	bigger	concern	is	
focus.	Given	the	complexity	and	lack	of	understanding,	it	would	be	easy	to	step	in	and	step	into	the	
wrong	place.	Equally	you	cannot	cover	it	all.	So,	we	will	need	to	think	about	how	we	focus.”			Towards	the	end	of	the	case	period,	CMTI	had	Board	agreement	and	investment,	as	explained	by	CMTI1:	 “To	develop	our	 thoughts,	we	have	been	bringing,	as	you	know,	experts,	panels	 together,	
running	workshops.	As	we	are	asking	the	Board	for	£50M	…	we	need	evidence,	it’s	not	just	us	saying	
this	 and	 we	 are	 not	 trying	 to	 create	 ‘just	 another	 science	 park’,	 we	 want	 to	 drive	 an	 Open	
Innovation	 agenda.	 	 Thankfully,	 our	 Board	 agree…	 I	 think	 the	 big	 trick,	 and	we	 have	 [CMTI6’s]	
enlightened	 vision	 to	 thank	 for	 this,	 was	 to	 position	 convergence	 as	 just	 an	 extension	 of	 Open	
Innovation.”						
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Management	and	Capability	Development	CMTI	 already	 had	 a	 well-developed	 suite	 of	 processes	 to	 engage	 potential	 partners	 and	stakeholders.	 	They	also	had	established	support	and	governance	processes.	To	progress	 their	convergence	program,	 the	 leadership	 and	 team	 in	CMTI	 largely	developed	existing	processes.		But	rather	than	use	the	wider	organisation	and	established	management	team,	they	engaged	a	new	 smaller	 team	 consisting	 of	 CMTI	 leaders	 and	 outsiders	 to	 develop	 the	 proposition	 and	capability.		They	did	not	appear	to	make	major	changes	to	their	processes	but	adjusted	them	as	needs	arose.	The	main	changes	were	in	their	approach	to	search	and	gaining	insights	from	the	emerging	ecosystem.				Importantly,	 to	 gain	 Board	 acceptance	 they	 positioned	 the	 move	 into	 convergence	 as	 an	extension	 of	 their	 existing	 capability,	 thereby	 reducing	 the	 perceived	 risk.	 CMTI	 therefore	appear	to	have	developed	via	relatively	minor	modifications	to	a	suite	of	existing	processes,	to	create	a	new	capability.						 	
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6.4 Case 2 – NMD 
6.4.1 History and Background The	innovation	organisation	is	a	new	R&D	unit	(NMD)	within	a	major	pharmaceutical	company.	The	 company	 had	 historically	 focussed	 on	 the	 development	 of	 new	 treatments,	 but	 has	 been	involved	 in	 the	 development	 of	 diagnostic	 products	 and	 digital	 services	 to	 support	 its	 main	pharmaceutical	business.		The	focus	of	NMD	is	to	develop	novel	implantable	medical	devices	to	modulate	 chronic	 diseases	 in	 organs.	 	 	 The	 innovations	 are	 convergent,	 involving	 bioscience,	novel	 materials,	 electronics	 and	 digital	 (e.g.,	 BNI),	 requiring	 an	 understanding	 of	 clinical	mechanisms,	 miniature	 opto-electronic	 devices	 and	 digital	 systems	 to	 interpret	 signals	 and	control	the	devices.			The	 NMD	 innovation	 was	 conceived	 in	 an	 internal	 ‘White	 Paper’	 in	 late	 2011	 and	 formally	reviewed	 as	 a	 business	 proposition	 by	 the	 Corporate	 Executive	 Team	 in	 2012.	 	 The	 first	employee,	and	head	of	the	new	NMD	group	started	in	November	2012,	with	one	senior	scientist	joining	at	 the	same	time.	 	The	 first	searches	of	 journals,	 conference	proceedings	and	meetings	took	place	in	early	2013	to	identify	potential	research	collaborators	and	the	areas	for	focus.	The	team	was	slowly	expanded	in	2013,	to	five.		By	late	2013,	15	collaborative	R&D	projects	were	in	place	 with	 academic	 researchers.	 	 In	 2013,	 the	 firm	 also	 organized	 a	 conference	 to	 enable	researchers	to	connect	and	map	out	the	key	challenges.	In	2014,	further	senior	team	members	were	recruited	and	a	corporate	venture	arm	was	created	(to	support	 investment	 in	attractive	start-ups	 in	 relevant	 fields).	 	 All	 team	 members	 recruited	 were	 experienced	 in	 R&D	 in	 the	incumbent	 firm	 or	 had	 specific	 technical	 or	 domain	 expertise.	 While	 investments	 remained	small,	 funding	 decisions	were	made	 via	 an	ad	hoc	 governance	 process	 signed	 off	 by	 a	 senior	‘sponsoring’	executive,	but	by	mid	2015,	the	increasing	investments	and	team	size	resulted	in	a	new	 Investment	 Board	 being	 formed	 with	 senior	 executives	 and	 external	 experts	 as	 board	members.	 	By	 late	2015	 the	 team	had	grown	 to	15,	with	over	30	 collaborative	projects	and	3	start-ups	 invested.	 In	 2016,	 the	 team	 size	 had	 grown	 to	 35,	 with	 35	 collaborative	 projects,	investments	in	6	start-ups,	and	at	the	end	of	the	case	study	period	a	major	Joint	Venture	with	a	global	 technology	 company	 was	 completed,	 confirming	 the	 ongoing	 success	 and	 intent	 to	progress	the	disruptive	innovation.		A	summary	timeline	of	the	case	history	is	provided	in	Table	6-6.						
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Table	6-6	Case	NMD	study	key	events	Sep	2011	 Initial	internal	White	Paper	recommending	the	venture.		Internal	positioning.		Sep	2012		 Formal	agreement	at	Corp	Exec	Team	to	progress	venture.	Nov	2012		 Team	Leader	 (NMD1)	starts	 in	 role.	 	1st	 recruit	 (NMD4)	 in	 role	 to	manage	pre-clinical	R&D	activities	Jan-Mar	2013		 Screening	potential	collaborators,	academics	and	journal	reviews	Apr	2013		 Nature	article	–	engaging	wider	scientific	community.	Jun	2013		 NMD	commits	to	fund	20	academic	projects	(exploratory	grants).	Aug	2013		 Via	Corporate	Venture	arm,	venture	fund	($50M)	and	Open	Innovation	Challenge	(OIC)	created	to	respond	to	perceived	‘gaps’	in	ecosystem.		Oct	2013	 Early	R&D	projects	with	academia	–	funded	by	firm,	ca	$200-250k	per	project.	Dec	2013	 First	of	15	collaborative	R&D	projects	announced	Dec	2013		 Firm	 Hosted	 International	 Conference	 -	 150	 researchers	 present,	 used	 to	 define	 the	wider	‘ecosystem’	challenge	and	technology	gaps.		Dec	2013	 Open	Innovation	Challenge	(OIC)	defined	Feb	2014	 New	Scientist	publication	–	aimed	at	further	engaging	ecosystem	Jun	2014		 Nature	Review	publication	-	aimed	at	further	engaging	ecosystem	Jun	2014	 Expanded	 team,	 NMD2	 joins	 to	 address	 delays	 in	 OIC	 progress	 and	 manage	 funding	relationships	Aug	2014	 Reviewed	OIC	approach.		New	White	Paper	written	for	internal	engagement	Oct	2014	 NMD5	joins	from	Cambridge	Uni.	to	work	on	neural	interfaces	Dec	2014	 32	collaborative	R&D	projects	now	in	place.	OIC	increased	fund	(from	£1M	to	£5M)	and	revised	process	–	ten	selected	firms	for	phase	1.		Jan	2015	 Memo	to	CET	to	obtain	support	for	developing	proposals	and	full	business	plan	Jan-Mar	2015	 OIC	 -	 25	 applicants,	 10	 selected	 for	 phase	 1	 projects,	 contracts	 drafted	 and	 in	 place.		Agreed	phased	expansion	of	internal	team	Mar	2015	 42	collaborative	R&D	projects	in	place	(25	biology	and	17	technology)	May	2015	 OIC–review	meeting	with	the	10	projects	and	potential	technology	partners.		Jun	2015	 Formal	CET	review	of	strategy,	approach	and	support	Jul	2015	 New	Investment	Board	in	place,	agreed	program	and	support	funding	proposals	Jul	2015	 Revised	Business	Plan	and	Budget	plans	(2015-2017)	Aug	2015	 OIC	Phase	1	readout	from	10	teams	and	16	potential	technology	partners	attended,	and	selected	3	Phase	2	teams	and	tech	partners	to	deliver	chronic	implantable	platforms.			Sep	2015	 Number	of	R&D	projects	reduced,	ca	30	running.		Oct	2015	 Start	engagement	of	UK	funding	bodies	and	charities,	aim	to	extend	to	EU	in	near	future	Nov	2015	 Venture	 Fund-	 3	 start-ups	 funded.	 Discussions	 to	 increase	 number	 of	 invested	companies.		Q1	2016	 Engaged	Asian	funders.			In	discussions	to	set	up	major		JV.	Aug	2016	 Announce	JV	with	major	Tech	company	(to	complete	1	Dec	2016)	30	in	internal	team.			50	collaborators.			OIC	5	teams	(3	funded,	2	self-funded).		Funding	in	US,	EU,	in	development	in	Asia.		5	start-ups	VC	funded.		Dec	2016	 JV	finalised	and	in	place.	NMD1	appointed	President	of	new	JV.	Q2	2017	 Target	for	first	clinical	study	to	start		
6.4.2 Case Evidence The	research	followed	the	methodology	defined	in	Section	4.	 	 	During	the	case	study	data	was	collected	from	interviews,	observations	and,	public	and	company	documents	(obtained	under	a	confidentiality	 agreement).	 A	 summary	 of	 the	 interviewees,	 observations	 and	 documents	accessed	is	provided	in	Table	6-7.	The	interviewee	sources	are	included	in	Appendix	A4.		
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Table	6-7	Case	NMD	study	data	sources	
Data	Sources		 Details		 Aspects	studied		Case	Interviews		 16	 interviews:	 12	 interviews	 of	 8	 senior	NMD	 leaders	 over	 the	 case	 period,	 and	 4	interviews	 with	 3	 senior	 leaders	 with	external	 collaborators.	 Totalling	 over	 18	hours	(ranging	from	45	mins	to	120	mins).	
Identification	 of	 patterns	 in	capability	change;	manifestations	of	skilful	 agency	 and	 existing	innovation	capabilities		Internal	 strategic	documents		 R&D	Investment	Strategy	documents,	NMD	White	Paper,	NMD	Manifesto	and	Business	Plan,	 Project	 Update	 Reports	 and	Investment	Board	review	papers.		
Identification	of	patterns	in	broader	capability	 change;	 and	 existing	innovation	performance	Observations		 Project	Investment	Board	Meetings	(1)	 Articulation	 of	 new	 R&D	expectations,	 leadership	 challenges	and	 new	 investment	 strategy	 and	structures	Company	 Public	Documents	 and	website	 Annual	 Reports,	 R&D	 Pipeline	 Reports	between	2013	and	2016.	Open	 Innovation	and	News	Releases,	from	2013	to	2016.	 Company	 trends	 and	 performance	data.	Public	information	on	the	new	venture	Business	 Press	and	 Industry	documents		 18	 Public	 News	 Items,	 company	 press	releases,	 public	 reports	 (e.g.	 NIH)	 and	papers	related	to	the	venture	(published	in	journals	including	Nature,	etc.)		
Dynamics	of	proposed	technological	innovation	 and	 engagement	 with	external	stakeholders		
	
6.4.3 Analysis Coding	 followed	 the	 process	 described	 in	 Section	 4.	 	 Initial	 coding	 was	 based	 upon	 the	exploratory	framework.		The	main	events	identified	in	the	exploratory	framework	under	factors	F1	 to	 F12	 were	 summarised	 and	 then	 subject	 to	 the	 ECPO	 analysis	 to	 identify	 plausible	mechanisms.		The	ECPO	analysis	for	this	case	is	included	in	Appendix	A5.	During	the	case,	simple	ecosystem	 maps	 were	 developed	 based	 upon	 interview	 evidence	 (Figure	 6-13).	 	 A	 basic	roadmap	 was	 also	 developed	 to	 understand	 timelines	 (Figure	 6-14).	 Further	 coding	 was	developed	from	patterns	of	observations	and	potential	causal	mechanisms.	 	 	 In	conducting	the	analyses,	potential	responses	to	the	research	sub-questions	were	considered.		
6.4.4 Findings 
Ecosystem	Evolution	The	evidence	shows	NMD	growing	their	ecosystem	significantly	from	a	few	players	(e.g.,	three	researchers),	 identified	 from	a	 systematic	 search,	 to	 a	 complex	 network	 of	 over	 50	 academic	collaborators,	 ‘tens’	 of	 alliances	 with	 start-ups	 and	 technology	 companies,	 and	 a	 major	 joint	venture.	Additionally,	strong	links	were	built	with	funding	bodies	and	investors	to	help	create	a	viable	ecosystem.			At	the	end	of	the	case	period	links	were	also	being	developed	to	regulators.		The	only	actors	not	substantially	engaged	were	end	customers	and	patients,	but	 the	case	 firm	indicated	 that	 this	was	by	design,	until	 they	had	god	clinical	evidence.	 	The	resulting,	but	still	evolving,	ecosystem	is	depicted	in	Figure	6-15.		
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Figure	6-13	Case	NMD	ecosystem	evolution	during	case	period		
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Figure	6-14	Case	NMD	ecosystem	roadmap	(trends)	developed	from	case	evidence	
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Figure	6-15	Case	NMD	overall	ecosystem	identifying	key	actor	types	and	relationships		
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Initial	search	and	exploration	The	NMD	group	needed	to	develop	searches	for	distant	technological	domains	and	to	establish	new	 partnerships.	 	 The	 head	 of	 the	 group	 (NMD1)	 explained:	 “The	path	dependency	does	not	
really	exist.	There	have	been	neuro	prosthetics	 since	1962	with	bladder	 implants	and	there	have	
been	 pacemakers	 since	 the	 1950s,	 but	 this	 needs	 a	 different	 approach.	 We	 don’t	 know	 the	
fundamental	details	yet,	we	are	still	exploring	that	space,	in	terms	of	the	biology	and	technology”.		Also,	 the	 initial	 systematic	 searches,	 using	 existing	 capabilities,	 were	 not	 wholly	 successful,	requiring	adoption	of	modified	approaches:	“We	also	tried	to	use	classic	approaches,	so	we	put	a	
problem	out	and	asked	for	input,	proposals	…but	that	gave	us	a	very	low	hit	rate.	 	Probably	only	
one	in	50	responses	turned	into	something.	The	rest	ended	up	cold.	So,	it	only	added	a	little	to	our	
network”.	 Similarly,	 existing	 open	 innovation	 processes	 were	 also	 tried	 but	 these	 were	 also	modified	(by	funding	the	competitors	and	increasing	funds)	to	ensure	engagement	and	success	(NMD4):	“…	the	way	the	program	had	been	designed	it	assumed	people	could	participate	with	their	
own	 funding.	 	 	 Which	 was	 a	 mistake.	 	 But	 after	 about	 6	 months	 and	 engagement	 with	 the	
community	it	became	clear	we	needed	to	fund	internally”.		
Building	external	credibility	and	legitimacy	The	ecosystem	was	nascent,	with	limited	institutional	support	(in	terms	of	government	funding,	venture	 funds,	 and	 support	 organisations).	 	 To	 overcome	 this	 the	 NMD	 group	 engaged	with	academics	to	develop	a	position	paper	(in	Nature),	helping	to	identify	and	legitimize	the	domain.		Using	 this	 as	 a	 platform,	 to	 highlight	 the	 importance	 of	 the	 field,	 government	 funding	 was	attracted	 to	 support	 academic	 research.	 	 	 This	 funding	 was	 supplemented	 by	 company	 R&D	funds	for	projects	not	suitable	for	government	funding.			As	well	as	positioning	the	field,	there	was	a	need	to	establish	their	own	role	within	it:	“[potential	
collaborators]	concerned…whether	our	IP	position	was	genuine.	If	you	recall,	we	said	that	everyone	
would	retain	their	IP.	And	there	was	a	lot	of	scepticism	about	whether	we	were	genuine	about	that”	
[NMD2].	 	 	 The	 nascent	 ecosystem	 was	 further	 supported	 by	 providing	 opportunities	 for	researchers	 to	 engage	 and	network,	 and	 then	positioning	 their	 activities	 in	more	mainstream	channels:	 “On	 average	 every	 year	 we	 have	 had	 our	 network	meetings	 where	 we	 bring	 all	 our	
funded	PIs	together.		And	we’ve	had	on	average	two	meetings	per	year.	In	addition	to	that	what	has	
changed,	this	year,	is	that	because	we	have	now	been	funding	research	for	the	last	3	years	we	have	
now	started	to	publically	disclose	the	outcomes	and	output	from	all	that	funded	work,	through	a	
number	of	channels”.	[NMD2].		Investment	funding	was	also	provided	to	start-ups	in	the	form	of	a	 corporate	 venture	 fund,	 modelled	 on	 a	 similar	 fund	 the	 firm	 operated	 in	 mainstream	biotechnology.	 	 	 To	 support	 researchers	 and	 start-ups	 a	 specialist	 research	 organisation	was	
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contracted	 to	provide	development	 support	 services,	mirroring	 an	 internal	 capability	 used	 to	support	biotech	partners.				Building	cross-industry	alliances	was	not	simple,	 the	 lack	of	domain	knowledge	and	perceived	risks	 act	as	barriers	 to	 engagement:	 “A	surprising	challenge	was	that	 the	Tech	companies	were	
actually	 quite	 risk	 averse.	 They	 are	 doing	 something	 completely	 new.	 They	 all	 see	 potential	 in	
health	applications,	but	are	not	sure	how	to	play	or	where	to	engage.	They	worry	about	things	like	
scale,	…,	and	liability.	But	having	someone	like	us	on	board	is	helping.	We	know	the	space	and	are	
seen	as	someone	who’s	hand	they	can	hold.”	[NMD2]	
	
Creating	Positional	Advantage	The	early	strategic	intent	was	to	establish	a	sufficiently	leading	position	to	assess	the	potential	of	 the	new	 field:	 “During	the	first	two	years	our	objective	will	be	to	enter	and	gain	a	leadership	
position	in	a	way	that	establishes	the	magnitude	of	 the	long-term	product	opportunity”	–	[Initial	Business	Case	Paper	NMD].	As	the	field’s	legitimacy	was	established	their	role	moved	to	that	of	‘advantage	seeking’:	“We	partner	with	experts	wherever	they	are	and	drive	much	of	our	research	
through	 partnerships.	 We	 integrate	 a	 global	 network;	 it	 allows	 us	 to	 set	 direction	 and	 be	 the	
natural	owner	of	future	products”	–	[Internal	Business	Plan	–	NMD].			This	 was	 achieved	 in	 several	 ways.	 	 Their	 increasing	 role	 within	 the	 ecosystem	 created	positional	power,	with	access	to	key	research	partners	and	institutions.	The	corporate	venture	funding	 provided	 opportunities	 to	 invest	 and	 appropriate	 value	 from	 related	 ventures.	 	 The	open	innovation	program	reinforced	their	central	role,	providing	funds	to	address	a	key	gap	in	the	 technology	 platform.	 	 Although	 the	 IP	 generated	 was	 made	 freely	 available	 to	 academic	researchers,	the	incumbent	firm	established	a	position	to	commercially	exploit	it.		
Building	Value	Networks	By	 building	 a	 network	 of	 academic	 partnerships	 they	 were	 able	 to	 position	 themselves	 to	leverage	 future	 research	 funding	 (NMD1):	 “…what’s	 turning	 into	 reality	 is	 that	 we	 are	 the	
downstream	partners.		So,	we	can	propose	joint	research	with	academics	to	apply	for	this	funding.			
In	 company	 terms,	we	 believe	 that	 these	 funding	 programs	 can	not	 only	 feed	 new	 ideas	 or	 new	
disease	opportunities	in	to	our	development	pipeline.		But	it’s	also	a	way	for	us	to	get	more	leverage	
in	the	early	research.’	
	NMD	 also	 positioned	 themselves	 to	 be	 able	 take	 greater	 control	 of	 the	 IP	 and	 future	 value:	‘Typically,	 we	 used	 1-2	 year	 partnerships,	 whilst	 we	 were	 exploring	 and	 knew	 there	 would	 be	
attrition	in	terms	of	science	and	partners.			That	was	part	of	our	model.			Much	of	the	value	we’ve	
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created	has	come	 from	partnerships	we’ve	created	with	academics.	 	 	The	real	balancing	act	 this	
year	has	been	 to	 leverage	 the	 IP	we’ve	 jointly	created	and	use	 this	as	basis	 for	 [JV].	 	 The	deal	 is	
really	conditioned	on	being	able	to	bring	this	IP.			[JV	partner]	tends	to	work	with	IP	on	outside,	but	
we	have	or	want	on	the	inside.’	
	They	 built	 partnerships	 in	 an	 exploratory	 way,	 making	 bigger	 commitments	 as	 knowledge,	confidence	and	trust	increased:	“For	academic	[partnerships]	it	was	exploratory,	there	were	many,	
so	we	expected	that.	We	tried	several	to	see	what	floats	and	then	built	with	a	few.		As	you	know,	the	
ones	we	 started	with	were	 not	 the	 ones	we	 have	 today.	 	 	We	 had	 not	 expected	 that	 for	 the	 big	
partnership.	 	 But	 in	 fact,	 that’s	 also	 how	 it	 played	 out.	 	 So,	 we	 had	 to	 learn	 and	 change.”	 	By	forming	a	joint	venture	with	a	global	technology	company,	the	first	in	this	field,	they	generated	a	significant	 capability	 to	 explore	 and	exploit	 innovations,	 by	being	 able	 to	 accelerate	progress:	“So,	the	driver	was	-	how	to	we	rapidly	access	the	technology	and	engineering	capability	to	build	a	
game	changing	device”.	
	But	 information	 is	 selectively	 revealed,	 to	 build	 a	 stronger	 position	 to	 give	 them	 strategic	advantage	as	an	early	mover	(NMD1):	“But	for	later	work,	that’s	more	commercial,	we	are	more	
opaque.	I’m	happy	for	the	competition	….	To	lull	them	into	thinking	or	seeing	this	is	just	[NMD]	and	
[partner]	working	on	a	‘moonshot’,	10	years	away...	and	not	being	hopeful	about	us	being	in	clinic	
in	the	next	3	years.		But	equally	there	is	no	benefit	to	overhype	it.			So	we	want	to	make	progress	for	
the	next	year	or	so	first”.			
Building	Internal	legitimacy	and	acceptance	Like	most	early	innovations	there	was	a	need	to	focus	on	de-risking	and	gaining	credibility	(by	delivering	small	but	consistent	patterns	of	success):	“We	will	take	an	emerging	approach	to	our	
investment	direction.	To	start,	we	will	place	a	number	of	carefully	chosen	but	 small	exploratory,	
milestone-based	 investments	 across	 a	 spectrum	 of	 […].	We	 will	 then	 gradually	 double	 down	 on	
areas	and	partners	that	show	the	best	delivery	and	the	greatest	promise.”	[Internal	Business	Plan	NMD].		The	 venture	 was	 managed	 by	 a	 small	 team,	 composed	 of	 experienced	 internal	 leaders,	supplemented	by	external	technical	expertise.	Like	many	potentially	disruptive	internal	venture,	there	was	a	strong	senior	sponsor	and	 to	a	 large	degree	 the	venture	was	 ‘firewalled’	 from	the	rest	of	 the	organisation	until	 it	had	developed	sufficient	credibility.	 	The	governance	structure	was	then	modelled	on	existing	internal	investment	boards.			
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Although	existing	capabilities	were	utilised	as	a	basis,	the	group	had	to	develop	new	approaches	including:	 access	 to	 agile	 short-term	 internal	 funding,	 support	 investment	 decisions	 by	engagement	with	ecosystem	stakeholders	 to	 identify	and	validate	requirements,	new	forms	of	partnerships,	new	open	innovation	projects	and	corporate	venturing.		All	were	initially	modelled	on	existing	structures.		So,	whilst	there	was	a	need	for	change,	they	were	at	the	same	time	aware	that	support	for	their	activities	would	be	higher	if	these	are	perceived	as	resembling	approaches	elsewhere	 in	 the	 company.	 	 This	 ‘familiarity’	was	explained	by	NMD1,	as	part	 of	a	strategy	 to	ensure	a	degree	of	alignment,	but	still	be	able	to	do	what	was	needed:	“We	got	early	buy-in	to	the	
proposition,	aligned	to	a	wider	R&D	Strategy,	but	the	actual	buy-in	was	at	[corporate	team].		As	it	
was	very	small	(in	terms	of	money)	we	managed	to	ring	fence	it	outside	Pharma	R&D	and	kept	it	
simple	 until	 we	 had	 good	 evidence,	 and	 partners,	 and	 confidence	we	 could	 deliver	 the	 promise.	
Then,	yes,	we	did	 formalize	it	more,	we	needed	 that	 to	 justify	 the	 increased	amounts	of	 resource	
and	spend,	and	the	scrutiny	required.	The	structures	looked	similar	or	‘familiar’	–	like	a	[…]	and	an	
Investment	Board.	So,	we	looked	like	we	were	on	the	same	playing	field	as	other	R&D	groups,	and	in	
practice	we	were,	although	clearly	were	making	different	decisions,	and	we	used	different	criteria.”		
Summary	of	capability	development	The	case	firm	already	had	many	established	process	and	capabilities	for	innovation	in	their	field.		Where	existing	capabilities	(particularly	technical)	did	not	exist,	they	used	external	partners	or	recruited	 specific	 skills	 to	 address	 this.	 	 The	 NMD	 team	 remained	 relatively	 small	 for	 a	 long	period.		This	was	a	deliberate	decision	to	avoid	being	seen	to	use	significant	internal	resources	and	more	importantly	as	they	knew	they	needed	significant	external	input,	as	identified	in	the	NMD	 Business	 Case	 proposal:	 “This	 effort	 will	 be	 lead	 by	 a	 ‘virtual’	 [NMD]	 team.	 …	 Credible,	
integrative	leadership	across	a	major	network	of	academics,	business	leaders	and	funding	bodies	
will	 be	 key.	 …The	 team	 will	 only	 expand	 further	 if/when	 the	 management	 of	 the	 network	 so	
requires”.	 	 	By	keeping	the	team	small	and	focussed	and	working	with	external	resources,	they	were	able	to	minimise	internal	‘disruption’	and	develop	in	an	agile	way.			The	 NMD	 group	 engaged	 with	 many	 of	 these	 existing	 organisational	 routines,	 and	 indeed	modified	 them	 to	 progress	 the	 potentially	 disruptive	 convergent	 innovation.	 	 	 Few	 existing	processes	were	simply	replicated;	most	underwent	modest	changes.		No	process	appears	to	have	been	radically	changed.	The	group	therefore	appear	to	have	developed	their	innovation	by	using	many	but	relatively	minor	modifications	 to	a	suite	of	existing	organisational	routines,	 thereby	creating	 a	 new	 capability	 that	 complemented	 the	 external	 technological	 capabilities	 in	 their	value	network.			 	
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6.5 Case 3 – DH1 
6.5.1 History and Background The	venture	is	a	new	entrepreneurial	‘start-up’	within	the	NHS	in	Northern	England.			The	focus	of	the	unit	is	to	develop	digital	solutions	(e.g.,	using	mobile	technologies)	to	improve	patient	care	pathways,	outcomes	and	experience,	and	 to	help	 improve	NHS	services.	 	 	The	 innovations	are	convergent	 involving	 clinical	 and	 social	 care	 pathways,	 a	 range	 of	 technologies	 and	 digital	solutions.				The	venture	started	in	January	2014,	with	a	proposal	by	an	entrepreneurial	and	passionate	NHS	manager	to	make	better	use	of	digital	to	improve	services	and	outcomes.	The	aim	was	to	harness	digital	technologies	 to	 improve	NHS	and	care	services	and	to	enable	patients	and	carers	to	be	more	 empowered	 in	 the	 management	 of	 their	 condition.	 	 To	 progress	 this	 program	 several	fundamental	challenges	needed	to	be	addressed.	 	Firstly,	the	proposed	venture	did	not	fit	 into	any	existing	organisational	structure,	and	in	 fact,	 spanned	many	organisations	both	within	the	NHS	and	 in	community	care.	 	The	venture	was	also	aiming	 to	develop	 technologies	which	 the	incumbent	 organisations	 (local	 NHS	 Trusts)	 had	 little	 or	 no	 expertise	 in,	 not	 just	 in	 terms	 of	technology,	 but	 also	how	 to	develop	 such	 a	 technology.	 	 It	 therefore	 required	 to	work	with	 a	diverse	 range	of	 technology	providers	 and	digital	 technology	 companies	 to	provide	 solutions,	most	of	whom	were	unknown	at	the	outset	of	the	venture.		The	case	research	started	during	the	first	year	of	the	venture’s	existence	and	followed	the	new	unit	for	nearly	two	years	(until	December	2016),	so	provides	evidence	from	close	to	its	inception	through	a	major	milestones	whereby	significant	investment	and	commitment	was	made,	and	the	venture	was	put	on	a	long	term	and	sustainable	footing.			A	summary	timeline,	highlighting	key	events	in	the	case	history	is	provided	in	Table	6-8	
	
6.5.2 Case Evidence  Case	Research	 followed	the	methodology	developed	 in	Section	4.	 	 	During	the	case	study,	data	was	 collected	 from	 interviews,	 observations	 and,	 from	 public	 and	 company	 documents	(obtained	under	a	confidentiality	agreement).	A	summary	of	the	interviewees,	observations	and	documents	accessed	is	provided	in	Table	6-9	and	the	interviewees	are	summarised	in	Appendix	A4.		
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Table	6-8	Case	DH1	study	key	events	
Date	 Event	Jan	2014		 Formed	 DH1	 (1	 secondment	 and	 1	 grad	 trainee),	 working	 from	 local	 NHS	 offices.	 	 	 Pilot	Funding	from	several	NHS	Trusts	and	a	CCG.		Won	SBRI	Award	with	App	developer.		Feb	2014		 DH1	held	first	“Health	Hack”	day	to	engage	patients,	providers	and	developers	Mar	2014	 Outlined	ideas	to	innovate	in	NHS	using	digital	/	mobile	(communicated	via	web	and	social	media)	Apr	2014		 DH1	held	first	Care	Planning	workshops	May	2014		 DH1	provided	first	guidance	for	mobile	Health	developers	Oct	2014		 DH1	hosted	Mental	Health	and	Chronic	fatigue	workshops.			Portfolio	of	over	10	projects.		Nov	2014	 Case	interviews	started	Nov	2014		 Small	 DH1	 team	 in	 place	 (3,	 plus	 part-timers).	 ‘Heart	 of	 Habitat’	 sessions	 start	 creating	opportunities	 to	 bring	 people	 together	 on	 a	 more	 regular	 basis.	 Co-authored	 Conference	paper	for	International	Journal	of	Integrated	Care.	Jan	2015		 Completed	first	year	with	over	15	projects	ongoing.		Held	workshops	to	‘catalyse’	additional	projects.	Mar	2015	 25	small,	medium,	large	projects	in	progress.	(Project	list	available)	–	mainly	at	‘catalyse’	and	early	‘incubation’	phase.	Jun	2015		 Completed	development	of	first	App	under	SBRI	grant	for	Chronic	pain.	Jul	2015		 Moved	 into	 new	 independent	 offices.	 	 Team	 now	 5	 people	 full/part-time.	 Engaged	 in	Accelerated	Access	Review	(NHS	England),	NHS	Digital.	,	Sep	2015		 First	 complete	 project	 delivered.	 	 Bespoke	 SMS	 application.	 	 	 Delay	 in	 handover,	 due	 to	customer	availability.		Oct	2015		 Re-branded	themselves	broadening	beyond	‘health’	to	include	community	and	care.	Revised	Stakeholder	analysis	to	better	map	out	key	groups	locally	and	nationally.	Reviewed	Business	Model	 using	 Business	 Canvas	 (e.g.,	 Osterwalder).	 	 	 As	 part	 of	 business	 planning	 ahead	 of	proposed	spin-out	at	end	2015	/	early	2016.	Dec	2015		 Targeted	spin-out	Board	meeting.	Jan	2016	 Board	meeting	did	not	take	place.	Have	in-principle	agreement	to	continue,	have	sufficient	near	term	funding	and	continue	to	develop	plans.	Still	reviewing	business	structure	options.	Recruited	 more	 staff	 to	 support	 growing	 workload.	 Winning	 new	 contacts,	 now	 with	different	and	more	diverse	partners.	Growing	their	network	and	ecosystem.	Mar	2016		 DH1	provided	input	into	NHS	Framework	(influencing	at	national	level)	May	2016		 Moved	to	new	location,	as	team	grew	(now	6	full-time,	plus	part-timers	and	contracts)	and	funding	more	secure.		Procurement	Framework	in	place,	giving	greater	flexibility	to	operate	with	 developers.	 Final	 business	 structure	 still	 being	 developed.	 	 Deposited	 first	 Code	 in	GitHub.	Working	more	widespread	 geographically	 (other	 regions).	 Providing	 solutions	 on	both	mobile	and	web.	Expanding	ecosystem,	e.g.	Barcelona.	DH1	see	role	as	a	change	in	focus	from	helping	connect	to	delivering	solutions.		Engaged	to	provide	solutions	for	NHS	England.	Business	plan	in	place.	Aug	2016		 Co-design	“Our	GP’	for	NHS	Scotland	to	provide	new	digital	services	Sep	2016		 Continue	to	engage	others,	with	more	diversity	including	academic	papers,	medical	journals,	community.		Continuing	to	build	ecosystem.			Have	secure	funding	for	next	18-24months.		Dec	2016	 Expanded	 facilities.	 	 New	 contracts	with	 other	 Trusts.	 Considering	 creating	 space	 for	 co-locating	start-ups.						
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Table	6-9	Case	DH1	study	data	sources	
Data	Sources		 Details		 Aspects	studied		Case	Interviews		 15	interviews	of	6	senior	managers	and	business	leaders	over	the	case	period,	totalling	over	15	hours	(ranging	from	30	mins	to	90	mins).	
Identification	of	patterns	in	capability	change;	manifestations	of	skilful	agency	and	existing	innovation	capabilities		Internal	strategic	documents		 7	Business	Plans,	internal	Board	and	governance	reports,	and	project	status	reports	 Identification	of	patterns	in	broader	capability	change;	and	engagement	with	ecosystem	
Observations		 6	Workshops,	project	meetings,	and	internal	team	meetings	 Observation	of	innovation	practices	and	working	with	partners	Company	Public	Documents	 5	reports	and	general	communications	 Company	communication	to	various	fora	Company	Website	 News	updates,	thought-pieces	and	open	calls	for	input	from	2014	to	2016.	 Public	information	on	the	new	ventures	and	engagement	Academic,	Business	Press	and	Industry	documents		
21	Public	documents	including	Reports	and	papers	DH1	contributed	too,	other	documents	on	initiatives	related	to	ecosystem			
Examples	of	engagement	with	others,	and	driving	forces	elsewhere	in	ecosystem		
	
6.5.3 Analysis  Coding	 followed	 the	 process	 described	 in	 Section	 4.	 	 Initial	 coding	 was	 based	 upon	 the	exploratory	framework.	The	main	events	identified	in	the	exploratory	framework	under	factors	F1	 to	 F12	 were	 summarised	 and	 then	 subject	 to	 the	 ECPO	 analysis	 to	 identify	 plausible	mechanisms.		The	ECPO	analysis	for	this	case	is	included	in	Appendix	A5.				
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Figure	6-16	Case	DH1	ecosystem	evolution	during	case	period	
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6.5.4 Findings 
Ecosystem	evolution	The	evolution	of	 the	ecosystem	over	approximately	24-month	period	 is	shown	in	Figure	6-16.		From	the	start	of	 the	case	DH1’s	ecosystem	was	already	partially	developed	with	several	NHS	Trusts,	 CCGs,	 patient	 groups	 and	developers	 engaged	 in	 activities.	 	 The	 initial	 focus	were	 the	users:	 the	 patients,	 carers	 and	providers.	 	 The	 evidence	 suggests	 that	 DH1	was	 also	 focussed	developing	many	new	partnerships	over	the	life	of	the	venture.		Whilst	the	initial	focus	was	local,	they	 actively	 engaged	more	 diverse	 actors	 and	 spread	 their	 geographic	 and	policy	 reach	 (i.e.,	active	exploration	and	evolution).			The	 other	 main	 change	 to	 the	 ecosystem	was	 around	 governance	 and	 funding.	 Initially	 DH1	reported	 to	many	 Trusts	 and	 a	 CCG,	 as	 their	 funders.	 This	 resulted	 in	 some	 bureaucracy	 and	inefficiency	for	issues	involving	cross-funder	decisions.			Change	to	this	governance	‘system’	was	slow,	with	several	solutions	proposed	and	reviewed	and	re-reviewed.	Ultimately,	they	moved	to	a	 simpler,	 smaller	 structure	 with	 a	 new	 Board	 that	 provided	 the	 diverse	 input	 and	 agility	required.		The	resulting,	but	still	evolving,	ecosystem	is	shown	in	Figure	6-17.		
	
Figure	6-17	Case	DH1	overall	innovation	ecosystem	showing	key	actor	types	and	
relationships					
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Building	external	credibility	and	legitimacy	DH1	developed	several	innovations,	in	partnerships	with	users,	funding	bodies	and	developers.	Each	product	met	a	specific	need,	but	they	were	also	engaged	in	creating	a	broader	capability,	essentially	 a	 ‘platform’,	where	 products	 and	 code	 from	 different	 solutions	 could	 be	 used	as	 a	building	block	for	future	innovations.		Most	solutions	were	purely	digital	but	disrupted	existing	clinical	and	care	pathways.		The	 new	 DH1	 group	 was	 small,	 flexible	 and	 highly	 empowered.	 The	 CEO,	 being	 an	 NHS	employee,	was	trusted	by	local	providers.				From	the	outset,	they	were	deeply	engaged	with	the	local	ecosystem,	using	a	combination	of	meetings,	workshops	(see	Figure	6-18)	and	social	media	tools	to	network	with	patients,	providers	and	others.		A	key	objective	was	to	ensure	 that	 innovations	met	patients’	needs,	 so	 they	regularly	engaged	them,	 as	 further	 explained	 (DH1-1):	 “Another	 approach	 is	 that	 Conferences	 rarely	 engaged	
patients.	We	are	therefore	going	to	run	a	one	day	conference	–	that	helps	positioning	–	on	people	
driven	 health	 and	 well-being	 …	 Run	 as	 an	 ‘un-conference’.	 So,	 the	 input	 is	 all	 from	 personal	
experience,	and	participant	led.”			
		Early	on	they	mapped	and	identified	key	stakeholders	in	terms	funders,	customers’	groups	and	patient	groups.		There	is	also	evidence	of	engaging	in	the	ecosystem	more	widely	(i.e.	with	other	tech	start-ups	or	network	organisations	like	DHACA	and	within	the	wider	NHS).		
	They	also	recognised	that	just	attending	events	was	not	enough	to	become	credible	and	visible,	DH1-1:	“It’s	also	important	that	what	we	have	done	is	visible,	so	people	can	see	our	track	record.	
Figure	6-18	Case	DH1	observation	at	design	event	
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So,	another	 important	part	of	our	role	 is	 to	curate	and	make	public.	So,	you	will	 find	searchable	
content	on	our	website,	 in	our	blogs	etc.”.	 	This	 approach	was	 increasingly	 recognised	by	other	stakeholders	 and	Trust	Board	members	 (DH1-3),	as	 valuable:	“…	it	provides	focused,	dedicated	
resource	 that	 is	 key	 and	 critical	 to	 service	 development.	 And	 also,	 the	 expertise	 of	 [DH1]:	
developing	 relationships,	 networks	 and	 contacts,	 ….	 They	 offer	 service	 driven	 solutions.	 They	
understand	NHS,	health	and	services.	They	provide	-	Drive,	Resource,	Energy.”	
	Having	developed	a	position	of	credibility	locally,	they	worked	in	the	broader	ecosystem	and	at	national	 level,	 increasing	 their	network	 and	 sphere	of	 influence,	 as	 indicated	 (DH1-1):	 “When	
presenting	 to	work	stream	1.2	 [National	 level	NHS	work	 stream]	 it	was	clear	that	 there	is	a	 lot	
going	on,	on	the	supply	side,	and	to	incentivize	industry	to	partake,	but	little	to	help	build	demand	–	
in	the	NHS	and	services”.	For	example:	“...	as	well	as	incentivized	development,	there	are	efforts	to	
ensure	standards,	they	are	assessed	by	clinicians.	So,	there	is	a	real	move	to	stimulate	the	supply	
side	on	priorities.	And	reduce	people	delivering	things	that	are	not	needed.	But	the	demand	side	not	
so	well	developed.”	
	
Value	Network	Development	As	highlighted	above,	much	of	the	search	and	exploratory	activity	was	based	upon	networking	and	building	relationships	through	meetings,	conferences	and	workshops.	They	also	used	open	calls	where	appropriate,	via	 the	 internet:	 “What	we	did	in	December	was	an	open	call,	we	were	
looking	to	incentivize	interest.	So	we	got	several	teams	and	questions.	Many	of	the	solutions	people	
were	looking	for	are	website	based	(quite	common)	or	something	to	do	with	workflow	(which	is	IT	
related).”	The	exchanges	were	 also	used	 to	help	develop	 their	 own	value	network,	which	was	largely	 built	 through	 networking	 and	 relationship	 building:	 “Our	 ecosystem	 is	 a	 lot	bigger.	 It’s	
mainly	through	networking.	We	attend	and	event	or	conference	or	we	run	an	event	for	people.	….	
So	 the	 process	 is	we	might	meet	 or	 find	 we	meet	 several	 times	 at	 different	 events	 and	make	 a	
connection.	If	there	is	some	common	ground	and	common	culture,	we	might	look	to	work	together.”					The	basis	for	working	together	was	more	than	just	a	connection,	there	needed	to	be	alignment	of	capabilities	 and	 culture,	 (DH1-1):	 “I’d	 describe	 the	 common	 interest	 as	 something	more,	 there	
needs	to	be	 ‘congruence’	a	real	alignment,	not	just	in	terms	of	the	outcome,	but	also	cultural	and	
how	you	are	going	to	do	 it.	Connections	do	not	 just	happen.	You	need	 to	 ‘cultivate’	 to	create	the	
right	opportunities.	That	is	where	I	see	this	spirit	of	generosity	and	being	open,	learning	together	
as	being	important.”	
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Their	 search	 and	 network	 building	 approach	 was	 therefore	 exploratory	 and	 evolutionary,	developing	as	their	connections	and	relationships	developed	and	as	new	information	and	needs	arose.			
Developing	a	business	model	and	advantageous-position	DH1	followed	a	‘classic’	model	of	initially	pitching	to	local	enterprise	boards,	getting	some	seed	funding	and	interest,	and	then	using	that	to	build	upon	their	own	network.		They	also	used	the	Business	Model	Canvas	(Osterwalder	 et	 al.,	 2010)	 to	develop	 their	 initial	 business	model	 (see	Figure	6-19).		However,	this	was	later	changed,	as	the	one-off	design	did	not	fit	emerging	needs.			They	initially	created	a	local	positional	advantage,	seen	as	‘people	to	go	to’	(DH1-5):	“I	think	they	
offer	co-design	and	the	mix	of	creative	mind	sets,	design	mind	sets	and	clinical	need.	The	brokering	
of	 different	 resources.	We	 value	 [DH1]s	world	 view	 and	 insights.	 And	 the	 network	 behind	 those	
insights.”.	 	 The	 combination	 of	 delivery	 and	 visibility,	 and	 increasing	 networking	 provided	opportunities	to	engage	more	widely:	“We	are	well	connected	locally	and	continue	to	spend	a	lot	
of	time	networking.	We	are	always	making	new	connections.	We	are	reasonably	well	known	locally,	
so	people	come	looking	for	us	too.	More	broadly	we	are	connected	to	NIB	and	some	of	their	work	
streams;	so	that	gives	us	an	opportunity	to	influence	at	national	level,	particularly	on	Open	Source	
software	strategy…”.	
		As	a	 result,	 they	 gained	 increasing	 influence	 at	national	 level,	DH1-1:	 “I	sit	on	two	groups	at	a	
National	 work	 stream	 level.	 We	 are	 working	 on	 tech	 enabled	 commissioning	 -	 helping	
Figure	6-19	Case	DH1	example	business	model	'design'	activity	
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commissioners	 for	 technology.	 The	 digital	 context	 has	 moved	 on	 recently,	 with	 the	 recent	
announcement	on	mental	health	on-line	platforms	and	NHS	Choices”.			Towards	 the	end	of	the	case	period,	 the	group	had	grown	modestly	(still	 less	 than	10	people)	and	was	actively	looking	to	provide	co-working	space	for	digital	health	start-ups,	to	help	foster	their	ecosystem,	(DH1-1):	“One	thing	we	are	beginning	to	explore	is	creating	our	own	ecosystem,	
environment	for	digital	health	start-ups.	There	is	still	little	in	the	area,	except	for	us,	but	we	don’t	
have	space.	We	are	looking	to	create	some	space	with	us,	for	start-ups	and	developers	to	work.	That	
would	help	them	and	build	our	own	ecosystem”.		
Management	and	Capability	Development	The	initial	team	was	very	small	with	only	one	secondment	and	an	industrial	placement	student.	The	first	secondee	(and	leader)	was	highly	motivated	and	entrepreneurial,	seeking	to	use	digital	technology	to	improve	services	and	outcomes.	She	skilfully	navigated	the	existing	structures	to	obtain	 funding	and	sufficient	endorsement	 to	proceed	without	 formal	governance	at	 the	early	stages.	Many	of	the	early	team	members	had	provider	(NHS)	experience	but	little	start-up	and	innovation	 experience.	 So,	 the	 team	 had	 to	 learn	 by	 using	 existing	 processes	 working	 with	others	and	from	experiential	learning,	DH1-1	stating	that	they:	“Use	existing	on-line	capabilities	
to	see	what	works	and	doesn’t	work,	then	tailor	a	better	solution”.	 	Many	of	their	early	processes	used	co-creation	approaches,	so	 learning	was	rapid.	 	They	 evolved	 their	processes	 frequently,	using	 feedback	 from	events	 (DH1-1):	 “Doing	it	the	way	we	did	in	December	spreads	the	team	to	
thin,	and	we	cannot	engage	to	help	develop	the	business	cases.	In	future,	we	will	be	more	focused.”			As	workload	and	funding	increased	the	team	was	grown	organically.			They	evolved	the	project	management	 and	 reporting	 tools	 used	 as	 they	 evolved,	 using	 Lean	 Start-up	 (Ries,	 2011)	practices.	Major	workloads,	such	as	software	development	were	outsourced	to	contractors.		But	they	sought	to	be	able	to	re-use	work	to	improve	efficiency	(DH1-1):	“One	of	the	first	things	we	
are	 doing	 though	 is	 understanding	 how	 to	 create	 code	 in	 GitHub	 repository	 for	 code.	 This	 will	
enable	us	to	re-use	and	share	code,	making	future	develops	simpler	and	cheaper.	We	are	currently	
doing	technical	due	diligence,	to	ensure	can	properly	document	and	can	re-use	the	code.”			Existing	 process,	 at	 times,	 were	 limiting,	 (DH1-2):	 “At	 the	 moment	 the	 process	 is	 an	 NHS	
Procurement	process,	it	 is	very	laborious.	We	can	readily	get	developers	on	to	a	list	for	Discovery	
Day	input	etc.,	but	then	the	build	stage	is	a	lot	more	regimented.	We	cannot	use	a	list	of	preferred	
suppliers	and	 then	select	 from	one	of	 them;	it’s	not	allowed	by	NHS	Procurement.	We	have	 to	go	
through	a	full	procurement	process,	with	lots	of	documentation.”	requiring	DH1	to	seek	ways	 to	work	 around	these	 and	develop	 alternatives.	 	As	 the	 scale	 increased	more	 formal	governance	
	128		
arrangements	 were	 put	 in	 place,	 but	 these	 were	 often	 unsatisfactory	 in	 terms	 of	 getting	decisions	made.	Eventually	a	new	‘board’	was	created	that	provided	the	agility	and	governance	to	meet	DH1	and	stakeholders	needs,	as	described	by	the	CEO:	“We	have	not	gone	with	the	model	
we	discussed	before.	We	have	now	decided	that	it	makes	sense	to	remain	wholly	within	the	NHS.	At	
least	for	now.	There	was	a	lot	of	feedback	that	our	position,	in	the	NHS,	was	important	to	credibility	
and	trust.	We	didn’t	want	to	undermine	that.	What	we	have	continued	to	work	on	is	creating	a	new	
Board,	so	that	we	can	simplify	our	governance.”		In	summary,	DH1	started	by	using	many	existing	processes,	and	modified	them	to	progress	their	innovations.	 	 	 Few	 existing	 processes	 were	 simply	 replicated;	 most	 underwent	 some	modest	changes.		No	process	appears	to	have	been	radically	changed,	except	for	the	desire	to	streamline	procurement	 processes.	 	 The	 group	 therefore	 appear	 to	 have	 developed	 using	 many,	 but	relatively	minor,	 modifications	 to	 a	 suite	 of	 existing	 processes,	 to	 create	 a	 new	 routines	 and	develop	their	innovations.			 	
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6.6 Case 4 – MLD 
6.6.1 History and Background The	 venture	 is	 a	 ‘start-up’	 developing	 a	 novel	 digital	 diagnostic	 product,	 using	 a	 machine	learning	 algorithm	 to	 identify	 patient	 risk	 of	 cognitive	 impairment.	 	 The	 venture	 requires	combining	 biomedical	 science,	 device	 and	 analytics,	 and	 has	 the	 potential	 to	 disrupt	 existing	clinical	pathways.		The	venture	started	in	April	2013	with	two	founders,	both	working	part-time.	During	the	case	period,	 the	MLD	 venture	 progressed	 from	 an	 exploratory	 study,	 to	 a	multi-million	 dollar	 VC	funded	start-up,	a	value	network	of	contractors	and	alliance	partners	(technology,	quality	and	clinical),	with	the	technology	working	on	the	preferred	platform	and	user	studies	ongoing.	Plans	were	in	place	for	a	formal	clinical	trials	and	regulatory	submissions	in	the	EU	and	USA.					The	research	followed	the	venture	for	over	two	years	(until	early	2017),	so	provides	evidence	from	 close	 to	 its	 inception	 through	 early	 development	 and	 a	 major	 milestones	 whereby	significant	investment	and	commitment	was	made.			A	summary	timeline,	highlighting	key	events	in	the	case	history	is	provided	in	Table	6-10.		
6.6.2 Case Evidence  Case	Research	 followed	the	methodology	developed	 in	Section	4.	 	 	During	the	case	study,	data	was	 collected	 from	 interviews,	 observations	 and,	 from	 public	 and	 company	 documents	(obtained	 under	 a	 confidentiality	 agreement).	 A	 summary	 of	 the	 sources	 (interviewees,	observations	and	documents	accessed)	 is	provided	 in	Table	6-11.	 	Further	 information	on	 the	interviewees	 is	provided	 in	Appendix	A4.	Direct	observation	at	meetings	and	workshops	with	innovators,	 investors	 and	 other	 key	 stakeholders	 also	 provided	 evidence	 of	 practices	 and	capabilities.	All	data	was	securely	stored	on	a	confidential	cloud	server	and	uploaded	into	NVivo	CADQAS	software	for	analysis.		
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Table	6-10	Case	MLD	study	key	events	
Date	 Event	Apr	2013	 MLD1	 formed	 company	 based	 upon	 research	 conducted	 by	 MLD2	 in	 neurosciences	 and	computing		Jun	2013		 Raised	 £Xk	 via	 a	 CE	 competition,	 using	 this	 they	 filed	 a	 patent	 and	 conducted	 the	 pilot	study/preliminary	trial	–	ca	40	individuals	healthy	and	with	disease	Dec	2013	to	Feb	14	 Develop	 prototype	 test	 on	 PC	 and	 conduct	 Pilot	 study.	 Complete	 pilot	 study	 and	 conduct	analyses.		Evidence	is	positive.	Feb	2014		 Develop	Web	Application	version	built	and	tested	–enabled	access	to	wider	‘test’	groups	Q2	2014	 Continued	to	enter	competitions	and	build	business	case	and	IP	position.	Won	small	awards	-	CE	and	with	IUK	to	fund	some	web	based	development.		Oct	2014	 Had	 TSB	 bid	 with	 Cambridge	 Uni	 in	 pipeline	 but	 lead	 investigator	 pulled	 out	 due	 to	workload,	so	bid	failed.	Dec	2014		 Entered	OneStart	competition.			Selected	as	semi-finalist.			Held	meetings	with	investors	/	VCs	(observed)	Jan	2015		 Discuss	options	with	entrepreneurs,	VCs	and	potential	team	members.	Decide	some	current	‘associates’	are	not	focussed	or	contributing.		Revise	team.		Bring	new	Chairman	(MLD3)	on	Board.		Continue	to	pitch	to	events	and	VCs.	Major	review	of	business	plan	Mar	2015	 Now	 have	 business	 plan	 in	 place.	 	 Continue	 to	 engage	 potential	 investors	 and	 alliance	partners	in	clinical	research	etc.)	as	they	build	their	ecosystem	and	business	case.		Mar	2015	 Engage	potential	investor	(MLD4)	in	discussions.	Apr	2015		 Meet	[major	Tech	company]	for	potential	alliance	(observed).		Did	not	make	OneStart	final.	Started	 more	 systematic	 review	 of	 ecosystem	 and	 value	 proposition,	 to	 better	 articulate	benefits	 and	 potential	 partners.	 Engaged	 NIHR	 DEC–	 potential	 joint	 project	 to	 do	market	research	May	2015		 Still	 in	 discussions	 with	 MLD4	 investment	 fund,	 potential	 interest	 in	 investment	 and	 on	philanthropic	grounds.	Appoint	new	Medical	Director	from	EL	NHST	Jul	2015		 Investment	from	MLD4	not	forthcoming.		Terminate	Chairman	over	poor	performance.		Nov	2015	 Meet	EL	NHS	Trust	to	discuss	options	for	clinical	study	Dec	2015	 Complete	LOI	and	agreement	for	VC	funding	of	ca	$1.25M	Q1	2016	 Conduct	 exploratory	 larger	 trial	 to	 demonstrate	 algorithm	 works	 on	 simple	 device	(Raspberry	Pi).				Mar	2016		 Review	regulatory	options,	following	discovery	of	new	FDA	approved	product	(using	similar	approach).			Determine	there	is	still	an	opportunity,	but	want	more	in-depth	market	research	on	competition.	Apr	2016	 Review	options	for	platform.	 	 	Conduct	some	further	market	research	with	potential	users.			Mobile	is	preferred.		Focus	on	iPad	as	initial	offering.			May	2016	 Medical	 Director	 moves	 to	 another	 NHS	 Trust.	 	 	 Begin	 discussions	 to	 engage	 them	 and	memory	clinics	and	local	GPs.	Ongoing	process	of	customer	input	Jun	2016		 Engage	consultant	to	undertake	market	research	on	competitors.		Conclude	MLD	is	still	well	positioned	as	features	and	value	proposition	is	different	/	better.	Start	discussions	with	ON	(IT	and	gaming	company)	to	build	early	prototypes	for	tablets	/	iPad	application	Sep	2016	 Develop	 new	 website	 and	 marketing	 materials.	 	 In	 discussion	 with	 User	 Needs	 /	 User	Experience	consultants	(BA)	to	help	in	UI	design	Oct	2016	 visit	Canadian	brokers	to	progress	potential	IPO.	Increasing	funding	to	around	$4M.		Delays	in	payments	by	VC	backers.		Have	iOS	/	iPad	version	developed.	Dec	2016	 engage	Regulatory	consultant	and	quality	person	to	help	put	regulatory	strategy	and	quality	management	system	in	place.			Start	UI	studies	in	USA	using	iPad	version.	Jan	2017	 Bridge	funding	obtained	for	IPO.	Met	Accenture	for	potential	alliance.	Re-engage	[major	Tech	company].	 New	 discussions	 with	 UK	 KOL	 –	 agree	 to	 support	 project	 and	 trials.	 Recruit	employees	for	software	development	and	project	management					
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Table	6-11	Case	MLD	study	data	sources	
Data	Sources		 Details		 Aspects	studied		Case	Interviews		 15	interviews	of	4	senior	managers	and	business	leaders,	totalling	over	15	hours	(ranging	from	30	mins	to	90	mins).	
Identification	of	patterns	in	capability	change;	manifestations	of	skilful	agency	and	existing	innovation	capabilities		Internal	strategic	documents		 21	documents	including	Business	Plans,	internal	reports,	project	status	reports,	grant	applications	and	emails	
Identification	of	patterns	in	broader	capability	change;	and	engagement	with	ecosystem	
Observations		 15	Meetings,	presentation	and	Workshops,	and	internal	team	meetings	 Observation	of	innovation	practices	and	working	with	partners	Company	Website	 Company	information	2016	 Public	information		Academic,	Business	Press	and	Industry	documents		 2	Public	documents		 Driving	forces	elsewhere	in	ecosystem			
6.6.3 Analysis  Coding	 followed	 the	 process	 described	 in	 Section	 4.	 	 Initial	 coding	 was	 based	 upon	 the	exploratory	framework.	The	main	events	identified	in	the	exploratory	framework	under	factors	F1	 to	 F12	 were	 summarised	 and	 then	 subject	 to	 the	 ECPO	 analysis	 to	 identify	 plausible	mechanisms.		The	ECPO	analysis	for	this	case	is	included	in	Appendix	A5.		
6.6.4 Findings 
Ecosystem	evolution	The	evolution	of	the	ecosystem,	over	approximately	21-month	period,	is	shown	in	Figure	6-20.	As	a	start-up,	MLD	have	virtually	no	ecosystem	to	start	with,	so	required	new	interactions	with	technology	companies,	funding	bodies,	and	others.		During	the	early	case	MLD	were	exploratory	as	they	tried	to	identify	the	most	appropriate	partners.	They	built	from	a	core	of	NHS	contacts	to	network	with	key	opinion	 leaders.	 	 Via	 their	 slowly	 growing	network,	 they	 attracted	 external	investment	from	a	VC,	and	potential	IPO.				The	 value	 network	 consists	 of	 a	 range	 of	 contractors,	 consultants	 and	 technology	 companies.	The	resulting,	but	still	evolving,	ecosystem	is	shown	in	Figure	6-21.	
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Figure	6-20	Case	MLD	ecosystem	evolution	during	case	period		
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Figure	6-21	Case	MLD	overall	innovation	ecosystem		
Managing	relations	in	ecosystem	Identifying	 the	 insightful	 and	 useful	 actors	 in	 the	 ecosystem	was	 slow	 at	 first,	 and	 relied	 on	introductions,	as	described	(MLD1):	“So	we	sent	a	cold	call	email	out	to	the	likely	stakeholders.	We	
probably	 only	 got	 a	 couple	 back.	 But	we	 had	 a	 discussion	with	 them	 and	 they	 introduced	 us	 to	
others.”.		Building	their	network	continued	to	prove	difficult	and	slow,	explained	by	the	CEO	as:	
“To	 be	 honest,	 it’s	 a	 bit	 like	 Brownian	 motion.	 You	 are	 forever	 moving	 around,	 bumping	 into	
different	people.	And	you	cannot	predict	beforehand	whether	 they	will	add	value	or	not,	or	even	
immediately	after.	Also,	its	something	about	when	you	do	business	and	have	the	meeting.	So,	it’s	not	
pre-determined,	it	seems	completely	random.	You	might	expect	them	to	be	interested	based	on	your	
prior	knowledge,	but	it’s	not	always	like	that,	and	it	might	just	be	timing	or	it	doesn’t	fit	their	exact	
interest”.	
	Access	 to	 the	 medical	 community	 was	 particularly	 difficult	 as	 competitor	 firms	 had	 already	established	 links	with	many	 clinicians,	 but	 following	 a	 connection	with	one,	 the	network	was	expanded,	 (MLD1):	 “...	 he	 provides	 credible	 expertise,	 especially	 to	medical	 community.	And	 can	
access	NHS	network	to	help	progress	trials	but	has	little	experience	in	this	area,	so	will	be	learning	
and	of	value	to	him”.		
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The	 challenges	of	 developing	 an	 ecosystem	were	 summarised	by	 the	CEO	as:	 “So,	you	have	 to	
invest	in	relationships,	and	it	consumes	your	resources.	But	back	to	our	network,	we	are	building	it,	
we	have	the	first	few	critical	ones	in	place	and	then	we	are	working	through	them,	to	see	more”.	
	
Building	external	legitimacy	and	credibility		As	well	as	building	their	ecosystem,	there	was	a	need	to	be	“seen	as”	credible	to	investors	and	potential	partners.	Early	feedback	indicated	that	the	new	technology	was	not	well	understood,	explained	 by	MLD1:	 “Feedback	 from	bids	was	 that	we	need	 to	make	 ‘more	 inventive’	 or	 its	not	
properly	understood.	…	Can	we	describe	what	is	new	or	challenging	about	it?”.		
	As	the	venture	developed,	the	innovation	gained	credibility,	largely	by	addressing	the	feedback	and	 improving	 their	 messaging	 such	 that	 they	 were	 seen	 as	 offering	 potential	 in	 the	 eyes	 of	investors	 (MLD4):	 “I	 think	 the	 technology	 is	 novel.	 I’ve	 had	my	 own	 people	 do	 some	 basic	 due	
diligence,	so	I	am	aware	of	…	and	others,	but	this	appears	different.	If	it	works,	it	offers	a	different	
approach,	and	importantly	an	earlier	diagnosis.”		
	This	credibility	being	achieved	through	a	combination	of	engaging	diverse	audiences,	delivering	specific	outputs	and	evidence,	and	by	careful	(re-)positioning.		
	
Value	Network	Development	As	 highlighted	 above,	 much	 of	 the	 early	 ecosystem	 activity	was	 based	 upon	 networking	 and	building	 relationships	 through	 meetings.	 Their	 search	 and	 network	 building	 approach	 was	exploratory	and	evolutionary,	developing	as	 their	connections	and	relationships	grew	but	was	not	always	successful	and	often	needed	multiple	interactions,	(MLD1):	“We	find	people,	we	might	
make	a	little	progress.	But	they	don’t	all	work	out.	We	are	continually	exploring	new	possibilities,	in	
terms	 of	 partners,	 investors	 and	 people	 we	 could	 work	 with	 for	 trials	 etc.	 I	 think	 one	 of	 the	
challenges	 here	 is	 unless	 you	 have	 the	 finance	 in	 place	 and	 can	 buy	 services,	 you	 need	 to	 have	
several	options	in	play,	because	one	might	not	come	off,	and	you	don’t	have	any	leverage.	So,	they	
can	just	walk	away.	So,	building	the	network	is	critical.”		By	 steadily	 building	 relationships	 and	 credibility,	 they	 developed	 a	 viable	 value	 network	 of	clinical	partners,	specialist	contractors,	technology	companies	and	investors.							
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Developing	a	business	model	and	advantageous-position	Considerable	 time	was	 spent	developing	a	 viable	business	plan	 and	model.	 	 	 The	process	was	iterative	 and	 evolved	 as	 they	 engaged	with	 potential	 customers,	 investors	 and	 other	 opinion	leaders.		An	example	of	an	exchange	that	changed	their	perception	was	explained	(MLD1),	thus:	
“When	we	 first	 started	we	 though	 that	 pharma	might	 be	 sweet	 spot,	 as	 the	 test	would	 support	
prescriptions.	But	after	talking	to	J&J	and	Roche	we	realised	we	were	not	aligned.	Their	focus	is	on	
biomarkers	that	specifically	link	to	their	drugs”	Following	such	 feedback,	 they	decided	to	 formally	map	the	key	customers,	by	 type	and	assess	what	would	create	value	 for	each	of	 them	and	how	to	deliver	 it.	This	value	analysis	helped	 in	defining	 several	 potential	 products,	 with	 several	 different	 business	 models	 and	 means	 to	capture	value.	They	then	focussed	their	initial	offering	(MLD1):	“So,	our	entry	point	is	going	to	be	
the	one	that’s	easiest	and	quickest	to	validate	and	the	fastest	to	adopt.	In	terms	of	unmet	need,	we	
think	screening	is	the	biggest	opportunity,	with	a	high	value”.			
Management	and	Capability	Development	The	 MLD	 team	 developed	 by	 building	 on	 the	 skills	 of	 the	 team	 members,	 contractors,	 their	network	 and	by	 learning.	 Several	 of	 the	 team	members	who	 joined	were	 experienced,	 and	 so	able	 to	 enhance	 the	organisations	 capabilities,	 but	not	 all	 capabilities	were	 acquired.	 	 Several	routines	 (such	 as	 their	 quality	 Standard	 Operating	 Procedures)	 were	 developed	 through	 an	initial	design	and	then	a	trial	and	error	process,	so	the	process	of	building	capability	was	largely	evolutionary	and	experiential.				 	
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6.7 Case 5 – DH2 
6.7.1 History and Background The	 innovation	 organisation	 is	 a	 ‘start-up’,	 DH2,	 formed	 by	 an	 entrepreneur	 with	 a	 strong	personal	 interest	 and	 extensive	 commercial	 experience.	 	 	 The	 focus	 of	 the	 organisation	 is	 to	develop	 digital	 solutions	 (e.g.,	 using	 mobile	 technologies)	 to	 improve	 patient	 care	 pathways,	outcomes	 and	 experience,	 for	 diabetes	 and	 respiratory	 diseases.	 	 	 The	 innovations	 are	convergent	 involving	 clinical	 and	 social	 care	 pathways,	 a	 range	 of	wearable	 technologies	 and	digital	solutions	(particularly	analytics	and	‘big	data’).					The	venture	started	 in	August	2013.	 	The	 case	research	started	during	 the	second	year	of	 the	venture’s	 existence	 and	 followed	 the	 start-up	 until	 December	 2015,	 so	 provides	 evidence	through	major	milestones	whereby	significant	investment	and	commitment	was	sought.	 	 	As	it	turned	 out	 the	 venture	 failed,	 being	 unable	 to	 attract	 sufficient	 funding	 in	 enough	 time	 to	maintain	a	competitive	position	versus	other	innovators.			A	post-mortem	was	carried	out	after	the	venture	failed	to	better	understand	the	factors	that	they	believed	impacted	this.		A	summary	timeline,	highlighting	key	events	in	the	case	history	is	provided	in	Table	6-12.		
6.7.2 Case Evidence Case	Research	 followed	the	methodology	developed	 in	Section	4.	 	 	During	the	case	study,	data	was	 collected	 from	 interviews,	 observations	 and,	 from	 public	 and	 company	 documents	(obtained	under	a	confidentiality	agreement).	A	summary	of	the	interviewees,	observations	and	documents	accessed	is	provided	in	Table	6-13.		Further	information	on	interviewees	is	provided	in	Appendix	A4.	Direct	observation	at	meetings	and	workshops	with	innovators,	 investors	and	other	 key	 stakeholders	 also	 provided	 evidence	 of	 practices	 and	 capabilities.	 All	 data	 was	securely	stored	on	a	confidential	cloud	server	and	uploaded	into	NVivo	software	for	analysis.		
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Table	6-12	Case	DH2	study	key	events	
Date	 Event	Aug	2013		 Idea	proposed	(founder	1	part-time).		Nov	2013	 Met	GSK	at	Medical	Day	with	Harper	McCleod.			Discussion	led	to	follow	up	meeting.	Dec	2013	 Introduced	to	Commercial	lead	and	team	in	Respiratory	Commercial	at	GSK.	 	Some	challenges	–	“sounds	like	great	solution,	but	more	pharmacy	than	pharmaceutical”.	Jan	2014	 Presented	 to	 Innovation	 Team	 (at	 GSK),	 based	 upon:	 software	 on	mobile,	 with	 connected	 inhaler	 and	 wearable	device	 (Fitbit	 like)	 to	 monitor	 activity	 and	 sleep,	 plus	 some	 respiratory	 indicators.			Focus	of	pitch	was	on	adherence.	GSK	want	to	see	a	demonstrator	before	they	can	decide.	Q1	2014		 DH2	began	to	develop	solution	focused	on	adherence.	April	2014	 DH2	formally	registered	in	Companies	House	May	2014		 Working	with	IDEO	in	US,	Health	SF.			USP	pitched	as	“Condition	PA”.			Got	feedback	to	forget	hardware,	others	will	do	 that.	 	 Just	 pull	 in	 APIs.	 IDEO	 suggested	 interest,	 but	 concept	 needed	 more	 validation.	 	 Working	 with	 3	entrepreneurial	partners	to	develop	design	and	business	plan.			Need	€30k	to	progress.			
	 Working	part-time	whilst	trying	to	raise	funds	for	prototype	Sep	 2014-	March	2015	 Pitched	 to	 Scottish	 Enterprise	 High	 Growth	 Start-up	 as	 potential	 investors.	 	 	 Being	 part	 of	 SE	 high	 growth	programme,	 central	 belt,	 only	 1%	 start-ups	 meet	 criteria,	 good	 DD	 for	 investors.	 Gave	 £5k	 grant	 to	 create	demonstrator.		 	Put	in	front	of	Walgreen	(Pharmacy)	and	got	positive	feedback,	they	put	DH2	in	touch	with	Apple.	They	wanted	to	showcase	internally	but	DH2	didn’t	give	permission.		 	 	Have	an	initial	non-working	prototype	and	some	specifications	for	the	device,	app	and	data	analytics	that	are	required.	Decided	to	focus	on	asthma	and	with	pharmacies,	although	pharma	remains	the	priority.	April	2015		 CEO	moved	to	full-time	–	effort	is	more	on	fund	raising	and	trying	to	identify	work	with/engage	strategic	partners.		For	Walgreens,	we	made	decision	from	financial	plan,	to	park	until	further	down	line.	 	As	DH2	would	have	had	to	develop	and	manufacture	hardware.	May	2015	 Case	Started	Jun	2015		 Had	follow	up	meeting	in	June	with	GSK	commercial	Director.		Out	of	GSK	meeting,	it	was	determined	that	they	also	needed	hardware.		DH2	plan	to	stick	to	asthma,	but	with	pharma.	 		But	GSK	are	so	slow	(or	less	interested	as	have	own	developments);	so,	AZ	also	considered	as	next	partner	option.	Jun	2015		 Chair	instrumental	in	identifying	key	people	for	team.		They	put	team	together	for	a	few	weeks.	From	May	to	June	in	‘acting	capacity’	to	see	who	committed	and	how	they	worked	together.	Gave	them	exposure	to	the	project,	DH2,	and	each	other.		From	interview	feedback	they	believe	it	went	well	and	had	makings	of	strong	experienced	team	Jul	2105	 DH2	have	hardware	specification	for	device	and	software	specification	(software	engineers	that	Chairman	has	used	before,	more	than	just	programmers,	they	are	data	scientists,	and	into	analytics).		DH2	started	work	on	the	User	Interface	(UI)	and	the	data	science	models,	and	early	coding	stage,	but	not	usable	yet.		Aug	2015	 Strategy	1	–	DH2	have	defined	a	route	to	market.		Focus	is	on	Asthma.		Focus	on	big	pharma	as	target	customer,	with	UK/EU	 target	 geography,	 and	 offering	 SaaS.	 Strategy	 1	 aiming	 to	 raise	 funding	 in	 three	 tranches	 -	 £150k,	 then	£250k,	then	£800k	(for	launch).	Strategy	2	-	(on	back	burner,	due	to	need	to	focus)	target	would	be	diabetes.	Customers	would	be	Pharmacies-	like	Walgreens	but	the	geography	would	be	USA	(v	UK/EU)	and	we	would	be	via	a	licence	rather	than	offer	SaaS.		DH2	in	discussions	to	set	up	meetings	with	VCs	and	high	net	worth	individuals	(HNWI)	as	potential	investors.	Sep	2015	 Found	out	about	Adherium’s	IPO	(New	Zealand	start-up	with	a	Aus	$35M	prospectus)	the	day	before	DH2	were	due	to	see	the	first	round	of	major	investors.	As	a	result,	DH2	declined	the	pitch.	DH2	then	decided	that	they	had	lost	too	much	time	(versus	competition)	and	did	not	have	sufficient	momentum	to	continue	as	per	current	business	plan.	They	did	not	 have	well	 developed	back-up	 plan.	They	perceived	 the	risk	 to	 investors	was	 too	high,	 so	valuations	would	suffer.		Decided	to	review	strategic	options.	Dec	2015		 Following	review,	the	Venture	was	terminated	in	December.	 		Post-mortem	interview	conducted	with	DH1-1.	Main	aspects	appeared	to	be	lack	of	understanding	of	emerging	ecosystem	(esp.	competitors),	some	internal	commitment	issues	and	delays	in	obtaining	funding	seen	as	main	causes	by	Chairman.		Case	closed.	Dec	2016	 Firm	formally	removed	from	Companies	House	register										
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Table	6-13	Case	DH2	study	data	sources	
Data	Sources		 Details		 Aspects	studied		Case	Interviews		 7	interviews	of	2	senior	managers	and	1	other	business	leader	over	the	case	period,	totalling	over	7	hours	(ranging	from	45	mins	to	90	mins).	
Motive	for	venture.			Innovation	approaches	used.			Identification	and	development	of	network.	Decision	making.	Internal	strategic	documents		 Master	pitch	deck.		Internal	email	 To	help	verify	the	interview	data	and	provide	context.	Company	Public	Documents	 2	communication	and	briefing	documents	 To	help	verify	the	interview	data	and	provide	context.	Academic,	Business	Press	and	Industry	documents		
6	Public	documents	including	competitor	documents,	and	partnering	requirements	 To	help	provide	context.	
	
6.7.3 Analysis  Coding	 followed	 the	 process	 described	 in	 Section	 5.	 	 Initial	 coding	 was	 based	 upon	 the	exploratory	framework.	The	main	events	identified	in	the	exploratory	framework	under	factors	F1	 to	 F12	 were	 summarised	 and	 then	 subject	 to	 the	 ECPO	 analysis	 to	 identify	 plausible	mechanisms.		The	ECPO	analysis	for	this	case	is	included	in	Appendix	A5.	
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Figure	6-22	Case	DH2	ecosystem	evolution	during	case	period		
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6.7.4 Findings 
Ecosystem	evolution	
Evolution	of	Ecosystem	over	approximately	12-month	period	is	shown	in		Figure	6-22.		For	this	case,	it	is	noticeable	that	there	is	limited	evolution	and	it	remains	focussed	on	a	tight	network	of	potential	partners	and	investors.	This	is	markedly	different	to	other	cases.		Uniquely	amongst	the	cases,	they	had	no	established	academic	partnerships	or	relationships.			The	evidence	suggests	that	the	case	firm	was	focussed	a	few	key	partnerships	over	the	life	of	the	venture	(see	Figure	6-23).		The	focus	being	‘big	pharma’,	‘big	pharmacy’	and	‘big	tech’	companies	–	but	they	found	it	difficult	to	obtain	traction	and	make	significant	progress.			
	
Figure	6-23	Case	DH2	overall	innovation	ecosystem	showing	actor	types	and	key	
relationships	
	
Managing	relations	in	ecosystem	The	case	firm	had	developed	their	innovation,	via	non-functional	prototypes,	up	to	specifications	for	a	working	prototype.	But	could	not	raise	the	 immediate	 funding	 to	progress	 the	next	step.			Their	 funding	 search	 was	 initially	 focussed	 locally,	 on	 the	 back	 of	 receiving	 the	 Scottish	Enterprise	award,	but	they	struggled	to	attract	investors,	despite	interest	from	major	partners.			Several	 reasons	 for	 this	 are	 hypothesised	 and	 suggested	 by	 the	 case	 firm,	 ranging	 from	limitations	in	the	local	investment	community	(as	perceived	by	the	CEO),	to	a	lack	of	clarity	in	the	business	model	and	potential	value.			Consequently,	they	looked	further	afield	for	investors.			Here	too,	they	ran	into	challenges	in	terms	of	the	value	proposition	and	what	market	was	best,	
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with	 divergent	 views	 from	 different	 investors.	 The	 challenge	 as	 summarised	 by	 DH2-1	 was:	”People	 have	not	 really	 caught	 on	 to	 the	 fact	 that	 its	 a:	Different	 opportunity,	Different	market,	
Different	investor	community”.				Their	limited	resources	and	limited	engagement	also	meant	they	had	frequent	surprises	as	new	actors	emerged,	DH2-1:	“[E]	just	arrived	on	our	door	a	few	weeks	ago.	We’d	not	planned	it.	But	we	
need	to	decide	quickly	is	it	a	go	or	not	…	We	need	to	have	a	good	reason	as	to	why	we’d	come	off	
strategy	path	one.”	
	These	 delays	 in	 building	 relations	 and	 finding	 investors,	with	 the	 knock-on	 effect	 in	 terms	 of	project	delays,	were	probably	a	major	contributor	to	the	venture	failing.			
Building	external	credibility	and	legitimacy	DH2	 followed	 a	 ‘traditional’	 model	 of	 pitching	 to	 local	 enterprise	 board,	 getting	 some	 seed	funding	 and	 interest,	 and	 then	 using	 that	 to	 build	 upon	 own	 network.	 	 Apart	 from	 formal	meetings	and	repeated	 interactions	with	a	 few	potential	partners,	 there	 is	 limited	evidence	of	engaging	in	the	ecosystem	more	widely	(i.e.	with	other	tech	start-ups	or	network	organisations	like	DHACA).	A	consequence	of	this	was	they	were	often	blind	to	other	developments	and	one	finally	resulted	 in	DH2	being	 terminated,	as	summarised	(DH2-1):	“[AD]	was	like	a	big	flag…	a	
yellow	warning.	They	had	already	got	completed	data.	We	knew	about	 [N6],	as	 they	were	called	
before	they	went	public.	[AD]	is	a	great	name,	as	its	all	about	adherence.	But	it	was	a	surprise.	They	
announced	at	the	IPO	that	they	had	40	projects	in	29	countries	and	14	studies	ongoing.	But	that	
was	somewhat	missed.	We	were	under	the	impression	they	were	doing	environmental	studies,	but	
they	were	doing	clinical.	So,	we	were	12-18	months	behind	them”.			
Value	Network	Development	Despite	the	increasing	complexity	as	other	ventures	moved	into	a	similar	space,	DH2	kept	their	own	network	tight.	They	made	it	clear	that	they	wanted	to	work	with	one	or	two	big	partners	and	form	a	team	around	a	few	well-known	individuals.		This	was	perceived	as	keeping	focus	and	reducing	risk.		What	did	become	evident	from	the	research	and	interviews	was	that	they	did	not	establish	 what	 value	 meant	 to	 different	 end	 customers	 and	 downstream	 partners	 and	 had	conflicting	feedback	on	this.	 	This	would	indicate	inadequate	development	of	relationships	and	their	value	network.		
Developing	a	business	model	and	advantageous-position	Considerable	time	was	spent	reworking	business	plan	and	model.		The	process	was	iterative	and	evolved	as	they	engaged	with	potential	customers,	investors	and	other	opinion	leaders.		Almost	
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all	major	organisations	wanted	more	evidence	before	committing	to	invest	or	partner.	They	also	got	 divergent	 views	 on	 where	 the	 value	 was	 –	 pharma	 thought	 it	 was	 pharmacy,	 investors	thought	it	was	payers.	 	This	not	only	impacted	the	potential	customer	and	business	model	but	also	impacted	the	product	design	and	service	required.		
Management	and	Capability	Development	On	 paper	 the	 management	 team	 appeared	 strong	 (possibly	 the	 strongest	 of	 all	 the	 cases	observed	in	this	research,	 in	terms	of	experience	and	seniority	of	previous	roles).	 	Despite	this	the	 venture	 failed.	 	 A	 post-mortem	 interview	 identified	 several	 perceived	 reasons	 for	 the	venture	failure.		These	were	explained	as	a	lack	of	understanding	of	ecosystem	and	competitor	positions	and	delays	in	securing	funding.				From	the	analysis,	there	is	evidence	that	the	team’s	experience	and	strong	governance	may	have	been	a	contributing	factor,	in	describing	the	CEO’s	action	(DH2-1)	stated:	“She	can	have	lots	of	interesting	conversations,	but	they	might	not	help	take	
her	forwards.	There	has	to	be	a	reason;	an	intent”.		They	 appear	 to	be	highly	 reliant	 on	 their	prior	 success	 and	experience,	 but	did	not	 appear	 to	fully	recognise	that	the	context	was	different.		Also,	having	selected	what	they	thought	was	the	best	model,	they	were	reluctant	to	change	“without	reason”,	however	the	initial	model	was	based	upon	information	from	limited	engagement	with	ecosystem	stakeholders.			
Why	 do	 they	 adopt	 these	 approaches?	 -	There	 was	 a	 strong	 belief	 they	 knew	 what	 the	 right	solution	is,	and	the	right	approach	to	fund	and	develop	it.	The	CEO	has	personal	experience	of	caring	for	people	with	the	disease,	and	so	has	a	strong	personal	drive	to	find	a	better	solution.		There	was	a	sense	that	they	needed	to	focus,	as	resources	were	tight,	so	alternative	options	were	not	developed.	Where	they	undertook	development,	they	moved	to	near	complete	solutions,	as	summarised	by	DH2-1:	“We	have	looked	at	strategic	positioning.	The	software	is	specified,	actually	
it’s	 about	 60%	done	 (as	 a	 favour).	 	We	are	 close	 to	 having	 it	 fully	 specified.	 Then	we	had	demo	
hardware.	 	 If	 you	 remember	 we	 had	 someone	 from	 FoxConn	 Europe.	 	 So,	 we	 had	 a	 device	 and	
Bluetooth.			We	had	also	worked	out	our	Big	Data	app.	But	needed	to	confirm	the	algorithm.”			So,	they	appear	to	have	progressed	the	development	significantly,	but	with	limited	external	input.	
	The	 case	 findings	 are	 as	 not	 as	 clear	 as	 in	 other	 cases	 (e.g.	 DH1,	 NMD,	 MLD)	 but	 provides	evidence	of	some	search	and	sense-making	activities.			What	is	most	striking	is	that	these	appear	to	 be	 far	 less	 exploratory	 and	 engaging	 than	 other	 cases	 and	 the	 evidence	 for	 sustaining	 the	ecosystem	is	weak.	 	 	The	fact	that	still	venture	failed	may	in	part	be	because	of	limited	search	and	 sense-making	 before	making	 selection	 decisions	 and	as	 a	 result,	 failure	 to	 build	 stronger	relations	in	the	ecosystem.		
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7 Cross Case Analyses  
7.1 Cross-Case Analyses and Review As	identified	in	the	methodology	(Chapter	4),	in	critical	realism	(CR)	the	cross-case	analyses	are	not	carried	out	in	the	last	phase	of	the	research,	but	data	gathering	and	analyses	take	place	in	parallel,	as	there	is	a	need	for	reflection	as	the	research	proceeds	(Easton,	2010;	Sayer,	1992).	So,	 during	 the	 interviews	 and	 coding	 some	 analysis	 was	 undertaken	 to	 find	 similarities	 or	differences	 between	 cases	 and	 then	 refine	 categories	 (for	 further	 coding)	 from	 that	 data	(Saldaña,	2013).	This	also	involved	recoding	earlier	evidence	as	new	categories	were	unearthed.			In	addition	to	coding,	use	was	made	of	the	Memo	feature	in	NVivo	(Bazeley	and	Jackson,	2013)	to	capture	 reflections	 and	 developing	 thoughts,	 which	 is	 recommended	 to	 aid	 research	transparency		(Bringer	et	al.,	2004).			A	consideration	in	the	cross-case	analyses,	implicit	within	CR	methodology,	is	that	the	context	in	each	 case	 is	 different	 so	 direct	 reading	 from	 one	 case	 to	 another	 requires	 care.	 Cross-case	comparisons	 were	 largely	 interpretative,	 achieved	 by	 reviewing	 the	 evidence,	 context	 and	emerging	patterns	and	potential	models.			The	researcher	perspectives	on	these	were	captured	in	NVivo	Memo	feature	and	used	to	guide	further	coding	and	other	analyses.			Initial	cross-case	Memos	 followed	 the	 Exploratory	 Framework	 themes.	 	 	 As	 ideas	 and	 themes	 emerged	 other	coding	and	new	Memo	notes	were	made	to	capture	plausible	explanations,	these	are	described	in	the	following	sections.			
7.2 Understanding the ecosystem and their relationships within it As	 indicated	 above,	 as	 patterns	 emerged	 in	 each	 case,	 which	 were	 running	 in	 parallel,	similarities	 and	 differences	were	 explored	 and	 captured	 in	NVivo	 (see	 example	 Appendix	 A6	Figure	 1	 	 Ecosystem	 understanding	 and	 relationship	 building).	 	 The	 first	 stage	 of	 cross-case	analysis	 essentially	addressed	 the	 research	 sub-question:	How	do	they	manage	relations	in	the	
ecosystem?		All	 case	 firms	 initially	 struggled,	 unsurprisingly,	 with	 a	 lack	 of	 ecosystem	 understanding.	Conceptually	the	ecosystem	could	be	considered,	as	described	in	a	recent	systematic	review	of	ecosystem		literature		(Aarikka-Stenroos	and	Ritala,	2017),	as	a	 ‘category	2’	(Aarikka-Stenroos	and	Ritala,	2017,	fig.	1),	with	“new	connections	being	formed”.	“replacing	or	disrupting	existing	ecosystems”	and	“blurry,	emergent	and	non-linear	boundaries”;	all	of	which	would	add	 to	 the	ambiguity	and	complexity.			
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Case	 NMD	 began	 by	 conducting	 a	 structured	 search	 and	 identified	 potential	 contacts	 and	knowledge,	but	 found	the	searches	 limited,	so	changed	to	a	more	explorative	approach.	 	 	DH1	were	well	connected	locally,	and	from	the	outset	sought	to	understand	and	connect	by	building	relationships	with	 a	 range	 of	 different	 actors.	 	 CMTI,	 like	NMD,	 started	with	 some	 structured	searches,	 but	 then	 moved	 to	 exploratory	 searches	 to	 identify	 useful	 knowledge	 and	 new	partners.	From	the	outset	MLD	connected	locally	and	used	their	existing	network	to	expand	to	new	connections.	 	 	DH2	also	 explored	new	connections	and	networks,	 but	appear	 to	be	more	focussed,	 with	 less	 evidence	 of	 trying	 to	 connect	 distantly	 in	 knowledge	 terms.	 	 This	 is	 not	surprising	given	limited	resources.				There	appears	to	be	evidence	of	structured	searches	not	working,	at	least	initially.	This	could	be	explained	by	lack	of	codified	information	or	knowing	who	to	connect	to.			Several	cases	tried	this	approach,	 but	 then	 modified	 their	 search	 methods.	 Cases	 moved	 to	 use	 a	 more	 exploratory	approach,	by	using	the	‘network	of	their	network’	 to	expand	searches.	 	They	also	searched	via	physical	 meetings,	 at	 conferences,	 one-to-one	meetings	 and	 events,	 so	 searches	 appear	 to	 be	intimately	 linked	 to	 building	 relationships	 and	 potential	 partners,	 as	 well	 as	 accessing	knowledge.		So,	this	‘understanding’	process	has	multiple	outcomes.		
7.3 Customers and developing value propositions A	 key	 step	 in	 developing	 an	 innovation	 is	 obtaining	 customer	 input	 to	 identify	 a	 value	proposition	(Khalifa,	2004).		Evidence	of	customer	engagement,	developing	business	models	and	value	 propositions	was	 reviewed	and	 captured	 via	NVivo	Memos.	 	 	 An	 example	 of	 the	memo	development	is	shown	in	Appendix	A6	Figure	2.		None	 of	 the	 cases	 had	 a	 well-defined	 business	 model	 for	 their	 new	 venture.	 	 Although	 DH1	‘designed’	 a	 model	 using	 Osterwalder’s	 ‘Canvas’	 (2010),	 they	 ended	 up	 changing	 it	 and	continued	to	evolve	it	during	the	research.		This	would	add	further	weight	to	the	argument	that	‘designing’	a	business	model,	is	not	viable	in	the	context	of	an	emerging	ecosystems,	and	that	a	more	evolutionary	approach	is	required.		NMD	had	not	developed	a	business	model	(by	the	end	of	the	case	research)	by	intent,	they	explained	this	by	stating	that	they	wanted	to	wait	for	clinical	data	as	they	knew	this	was	critical	to	their	customer	engagement.	CMTI	evolved	their	model	and	value	proposition,	narrowing	it	from	their	initial	intent.	It	started	with	a	broad	model,	aiming	at	supporting	a	wide	range	of	‘convergence’	activities,	but	over	the	course	of	time,	they	focused	it,	building	more	on	their	existing	capabilities,	rather	than	trying	to	move	into	a	radically	new	area.		MLD	developed	multiple	business	models,	 in	part	because	 their	 technology	offered	a	potential		‘platform’	(Gawer	and	Cusumano,	2013).	This	then	provided	the	means	to	offer	different	models	for	different	customer	types	and	they	expected	to	use	a	combination	of	these.	DH2	had	an	initial	
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model	defined,	but	on	engagement	with	potential	investors,	changed	it	several	times,	ultimately,	they	struggled	to	find	a	business	model	and	value	proposition	that	worked	across	their	multiple	stakeholders.			All	 cases	 used	 a	 more	 evolutionary	 path	 to	 understand	 the	 value	 proposition	 and	 potential	business	models,	 they	were	not	designed	per	se.	 	They	engaged	via	their	networks	and	shared	information	with	 the	 intent	 of	 better	 understanding	 potential	 positioning	 of	 their	 innovation.		Because	of	these	engagements,	they	tended	to	make	many	minor	changes	to	the	proposed	value	proposition	 and	 business	 model.	 	 	 That	 also	 resulted	 in	 one	 case	 in	 changes	 to	 their	 value	network	(for	example	MLD	moving	to	a	mobile	platform,	and	needing	‘gaming-like’	capability).				
7.4 Identifying and manging potential partners Having	identified	knowledge	and	actors	in	the	ecosystem,	a	key	step	is	then	to	form	partnerships	and	value	networks	(Gilsing	et	al.,	2008;	Harrington	and	Srai,	2016)	to	create	value.		All	cases	appeared	to	use	transient	relationships	at	first.	Partnerships	are	typically	formed	for	a	specific	outcome	(i.e.	to	create	data,	or	address	a	risk),	that	partnership	might	then	be	renewed	or	not,	depending	on	whether	it	was	needed	for	the	next	step	and	how	the	previous	partnership	had	 performed.	 Once	 a	 partnership	was	 initiated,	 several	 innovators	 expressed	 the	 desire	 to	work	again	with	the	same	partner	if	the	above	criteria	were	met.	Both	NMD	and	DH1	identified	the	 importance	 of	 not	 just	 seeking	 complementarities	 but	 also	 ‘congruence’,	 shared	 aims	and	values:	“I’d	describe	the	common	interest	as	something	more,	there	needs	to	be	‘congruence’	a	real	
alignment,	not	just	in	terms	of	the	outcome,	but	also	cultural	and	how	you	are	going	to	do	it.”	DH1-1.		Even	if	there	was	an	opportunity	to	collaborate,	other	factors	may	influence	an	actor’s	decision	to	engage,	[NMD]:	“You	might	expect	them	to	be	interested	based	on	your	prior	knowledge,	but	it’s	
not	always	like	that,	and	it	might	just	be	timing	or	it	doesn’t	fit	their	exact	interest”.				In	 summary,	 in	 nascent	 ecosystems,	 forming	 partnerships	 appears	 to	 be	more	 transient	 than	existing	 literature	 would	 suggest.	 It	 is	 suggested	 that	 the	 reason	 for	 this	 is	 it	 enables	 the	innovator	to	continue	to	explore	the	ecosystem	and	actors,	and	to	identify	and	build	necessary	capabilities,	but	without	long-term	commitment	until	a	suitable	alliance	partner	(or	optima)	is	identified.	 	 Appendix	 A6	 Figure	 3	 provides	 an	 example	 of	 the	 cross-case	 NVivo	 Memo	 for	partnership	development.			
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7.5 Governance, leadership and decision making The	 cases	 demonstrated	 a	 range	 of	 approaches	 to	 governing	 the	 innovation	 and	 supporting	value	network	(see	Appendix	A6	Figure	4,	for	NVivo	Memo).	Unexpectedly	in	all	the	cases	there	was	a	need	for	agility.		Established	firms	put	in	place	mechanisms	to	provide	an	overall	approval	of	the	strategy,	but	then	invariably	used	small	empowered	teams	to	execute	it	[NMD]:	“Once	it’s	
all	approved	we	will	have	a	highly	empowered	autonomous	team	to	give	us	the	agility	we	need.”		Where	more	senior	approval	was	required,	the	mechanisms	are	kept	simple	[NMD]:	“So,	we	were	
agile	where	we	 just	 needed	 []	 sign	 off	 on	 individual	 projects	 (after	 overall	 CET	 endorsement)	
using	 one	 pagers	 and	 probably	 got	 90%	 approved.”	 	 Conceptually	 this	 aligns	 with	 the	 extant	literature	on	managing	potentially	disruptive	 innovations	 in	 incumbent	 firms	(Gwynne,	1997).			The	 classic	 ‘stage	 gates’	 (Cooper,	 1990)	were	not	 evident.	 	 This	 can	be	 explained	because	 the	criteria	could	not	be	sufficiently	defined	and	the	innovation	process	itself	was	still	evolving,	so	decision	points	 for	 the	 new	 technologies	were	 not	 established.	 	 However	 this	 does	 not	mean	there	was	 an	 absence	 of	 governance,	 but	 that	 a	more	 directional	 and	 strategic	 approach	was	required.			Smaller	organizations	used	a	range	of	approaches	to	provide	effective	governance,	but	key	is	the	maintenance	of	regular	contact,	for	example	[MLD]:		we	are	still	managing	most	of	our	work	
through	informal	meetings,	emails,	Skype	calls	etc.	We	keep	our	formal	meetings	to	a	minimum.	It	
seems	to	work,	our	partners	seem	happy	with	the	approach	and	we	continue	to	make	progress.				When	 questioned	 about	 ability	 to	 use	 existing	 governance	 structures	 (in	 larger	 firms)	 they	responded,	that	they	were	generally	inappropriate	[NMD]:	“it’s	not	in	their	remit.	And	they	don’t	
have	the	right	members.	So,	we	are	bringing	in	external	ones,	from	medical	devices,	tech	company	
backgrounds.	It	may	be	three	internals,	three	externals	or	four	internals	and	four	externals.	But	not	
bigger	than	that.”	The	key	 issue	being	suggested	was	 that	existing	structures	did	not	have	 the	required	 knowledge	 and	 capabilities	 to	 make	 the	 necessary	 judgments.	 Interestingly,	 large	organizations	 were	 prepared	 to	 engage	 the	 ecosystem	 and	 collaborators	 to	 ensure	 that	investment	decision	criteria	made	sense	[NMD]:	“The	team	has	worked	together	with	a	group	of	
subject	 matter	 experts	 to	 define	 the	 following	 detailed	 success	 criteria,	 building	 on	 high-level	
specifications	for	the	device	and	its	functionality.”			Both	 DH1	 and	 NMD	 (large	 incumbent	 organisations)	 and	 CMTI	 (medium	 sized	 incumbent)	employed	small	dedicated	teams	with	access	to	diverse	external	resources.	They	all	described	a	desire	to	work	in	a	lean,	agile	way,	with	‘virtual’	teams	of	external	expertise.	These	teams	all	had	good	sponsorship	from	senior	leaders	and	highly	credible	leaders	(who	were	trusted	internally).		This	 combination	 of	 supportive	 sponsorship	 and	 trusted	 capable	 leaders,	 appears	 to	 be	
		 147	
important	 in	 enabling	 teams	 to	 act	 in	 an	 ‘action-orientated’	way,	 aligned	around	 the	 venture,	rather	than	being	encumbered	by	bureaucracy	or	extensive	internal	debate.		It	may	also	suggest	that	 the	 team	 should	 align	 its	 innovation	 culture	 around	 the	 technology	 with	 the	 fastest	‘clockspeed’	 (Fine,	 1998)	 in	 the	 ‘convergence’,	 albeit	 with	 appropriate	 checks	 for	 safety	 and	regulatory	requirements.	 	So,	 for	 example	DH1	aligned	around	digital	and	mobile	approaches,	rather	 than	 clinical	 pathways.	 	 Similarly,	 NMD	 initially	 aligned	 around	 emerging	 biology	 and	around	 electronics	 and	 materials	 technologies,	 rather	 than	 traditional	 pharmaceutical	approaches.		This	suggest	that	teams	should	be	small,	with	trusted,	highly	capable	and	intuitive	leaders,	working	extensively	with	diverse	external	partners	in	as	agile	a	way	as	regulation	and	safety	permit.			This	 evidence	 points	 to	 the	 need	 for	 agile	 governance,	 with	 directional,	 rather	 than	 defined	decision	 criteria.	 	 Given	 the	 inherent	 risks	 in	 convergent	 innovation,	making	use	of	 the	wider	network	 is	 valuable	 in	 helping	 to	 validate	 investment	 decisions	 or	 reduce	 uncertainty.		Importantly,	it	also	appears	to	reduce	the	risk	of	inertia,	internal	filters	or	biases	in	the	decision	process.		
7.6 Comparison of large (incumbent) and small (start-up) organisations Although	there	are	a	 limited	number	of	cases,	a	simple	analysis	of	 larger	organisations	(NMD,	DH1	 and	 CMTI)	 and	 start-ups	 (DH2	 and	 MLD)	 was	 conducted	 (Appendix	 A6	 Figure	 5).		Surprisingly,	there	were	many	similarities.			Both	large	and	small	cases	evolved	their	innovation	processes.	 	 Both	 needed	 to	 create	 a	 position	 of	 ‘credibility’	 in	 the	 emerging	 ecosystem.		Importantly	this	was	identified	as	important	even	for	large	organisations	where	the	ecosystem	was	 new	 or	 they	 were	 seen	 to	 be	 new	 to	 the	 ecosystem.	 	 Both	 large	 and	 small	 firms	 were	prepared	to	adopt	transient	relationships	and	use	agile	governance.		The	main	differences	stem	from	 the	 large	 organisations	 need	 to	 adapt	 their	 existing	 process	 and	 provide	 a	 degree	 of	separation	 from	 the	 existing	organisation,	 especially	 early	 in	 the	development.	 	 Smaller	 firms	(MLD	 and	 DH2)	 lacked	 physical	 and	 financial	 resources	 and	 so	 could	 not	 make	 significant	commitments	or	investments	in	the	ecosystem	in	the	same	way	as	larger	firms	(DH1	and	NMD),	but	nonetheless	recognised	a	need	to	remain	connected	and	build	relationships,	thus	needing	to	invest	time	and	effort	to	establish	position	in	their	ecosystem.					
7.7 Micro-processes underpinning the innovation activities From	the	above	analyses,	it	is	evident	that	across	all	five	cases	some	similarities	in	activities	and	underlying	approaches	were	present.		The	ECPO	analyses	for	the	cases	suggested	some	common	
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causal	mechanisms,	 it	 is	postulated	 that	 these	are	 ‘micro-processes’	 than	underpin	 innovation	capabilities.			The	 evidence	points	 to	 a	need	 for	 searching,	 for	both	knowledge	 and	 for	new	partners	 in	 the	emerging	 ecosystem	 in	 all	 the	 cases.	 	 These	 searches	 are	 not	 systematic	 (although	may	 have	started	 so),	 but	 rely	 more	 on	 an	 exploratory,	 evolutionary	 approach	 to	 seek	 out	 distant	knowledge	 and	partners.	The	 searches	 are	 accompanied	by	 a	 sense-making	 (and,	 importantly,	
sense-giving)	process	to	enable	innovators	to	exchange	knowledge	with	other	actors	or	identify	other	actors	to	engage.	Many	of	these	exchanges	appear	to	take	place	face-to-face,	and	so	social	aspects	 help	 in	 the	 sense-making	 and	 sense-giving	 aspects.	 	 There	 is	 then	 a	 need	 to	make	 a	selection,	or	decision.		No	firm	has	infinite	resources,	so	decisions	are	fundamentally	about	using	their	 available	 resources	 to	 invest	 in	 the	 innovation	 or	 address	 a	 risk	 or	 support	 part	 of	 the	ecosystem	likely	to	be	critical	for	success.			The	investment	decision	making	process	appears	to	use	broad	criteria	rather	than	strict	criteria	or	‘stage	gates’	(Cooper,	2008).		An	example	of	the	NVivo	Memo	for	these	micro-processes	is	shown	in	Appendix	A6	Figure	6.		As	part	of	 the	CR	methodology,	alternative	explanations	were	also	explored,	so	 that	 the	most	plausible	 explanation	 could	 be	 identified.	 As	well	 as	 conducting	 this	 analysis	 for	 each	 case,	 a	wider	 cross-case	 analysis	 was	 conducted	 identifying	 a	 range	 of	 alternative,	 theory	 driven,	explanations	 for	 the	 observations.	 These	 are	 exemplified	 in	 Error!	 Reference	 source	 not	
found..		These	analyses	drawn	upon	several	alternative	theories.		Some	provide	a	plausible	but	incomplete	explanation.			The	 five	 micro-processes	 suggested	 by	 the	 case	 and	 cross-case	 analyses	 are	 summarised	 in	Table	7-1	to	Table	7-5.			
Table	7-1	Searching:	evidence	and	insights	from	cases	
Process	 Example	Case	Evidence	 Insights	
Searching	(strategic	and	creative)		Sources:	(Garud	2012;		Pandza		2009)		
• “So,	…	it	was	structured	to	an	extent.	A	bit	like	a	
structured	fishing	expedition.	We	tried	many	
different	ways”.		NMD	
• “It’s	fairly	structured.	We	started	with	people	we	
know.	But	are	now	expanding	the	interviews,	
talking	to	their	suggested	contacts.	We	want	to	
extend	our	search	beyond	the	usual	suspects”.		CMTI.	
• “We	had	the	concept,	but	we	didn’t	know	anyone	in	
the	field	[xxx]	or	anything	related…	So	we	sent	a	
cold	call	emails	out	to	the	likely	stakeholders.	We	
probably	only	got	a	couple	back.	But	we	had	a	
discussion	with	them	and	they	introduced	us	to	
others.”		MLD		
Searches	 are	 often	 a	combination	of	structured	searching	 (of	 known	domains)	 and	 (often)	snowballing,	 using	 the	network	 of	 your	 network	to	 expand	 the	 search	 to	new	 areas,	 but	 in	 a	structured	 way	 to	 help	address	 ‘distant’	knowledge	
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Table	7-2	Sense-making:	evidence	and	insights	from	cases	
Process	 Example	Case	Evidence	 Insights	
Sense-making	(and	sense-giving)		Sources:	(Sitoh	et	al.,	2014;	Thomas	et	al.,	1993;	Weick,	1995)	
• “So	it’s	like	a	bit	like	a	deep	dive	in…and	reflecting	
and	then	looking	in	another	area…an	iterative	
process…and	trying	to	make	sense	of	it,	so	do	I	
have	enough	information,	is	it	meaningful?	Can	I	
identify	a	hypothesis?”	NMD		
• “..	focused	mainly	on	the	value	proposition,	who	the	
key	customers	were	and	then	how	to	identify	key	
stakeholders	(in	clinical)	to	help	create	‘pull’.	MLD		
• “Another	approach	is	that	Conferences	rarely	
engage	patients.	We	are	therefore	going	to	run	a	
one	day	(un)conference	–	that	helps	positioning	–	
on	‘people	driven’	health	and	well	being,	…	So	the	
input	is	all	from	personal	experience,	and	
participant	led”	DH1	
• “We	want	some	diversity”	CMTI	
• “To	be	honest,	it’s	a	bit	like	Brownian	motion.	You	
are	forever	moving	around,	bumping	into	different	
people.	And	you	cannot	predict	before	hand	
whether	they	will	add	value	or	not,	or	even	
immediately	after….You	might	expect	them	to	be	
interested	based	on	your	prior	knowledge,	but	its	
not	always	like	that,	and	it	might	just	be	timing	or	
it	doesn’t	fit	their	exact	interest”	MLD	
Sense-making	 through	developing	 ‘propositions’	and	 wide	 engagement	 in	ecosystem,	 often	 going	beyond	 immediate	 contact	and	 network	 to	 ‘test’	 the	idea		Involving	 the	 ‘unusual’	suspects	helps	improve	the	sense-making	process.		The	 ability	 to	 connect	 and	make-sense	 depends	 not	just	 on	 content,	 but	 on	timing	and	mutual	 interest	(and	 the	 stakeholders’	current	priority).			Sense-giving	 is	 important	to	 build	 credibility	 and	engage	ecosystem	actors.					
Table	7-3	Selecting:	evidence	and	insights	from	cases	
Process	 Example	Case	Evidence		 Insights	
Selecting		Sources:	(Daft	and	Weick,	1984;	Dean		Jr	and	Sharfman,	1996)		
• “The hard choice is going to be – how much do we 
have a starting point that is much simpler and 
cruder than the ultimate goal, but while still 
maintaining a strategic differentiation from the 
[xxx] industry of today?” NMD 
• “…, after the community identified the ‘problem’ we 
went out and consulted to confirm we had identified 
the right problem and decision criteria, … and 
finally we checked that the community would be 
prepared to participate. So it was methodical, but it 
evolved” NMD 
• So we knew that technologically it was different, that 
we’d need different criteria and that things like 
safety data would be different to a molecular 
medicine. So we’d also need to judge the portfolio 
using different criteria. NMD 
• “We have introduced new decision points – 
Providers need to provide data at Discovery Day… 
If we progress, we build a prototype and seek further 
use/provider feedback. Again, if no demand, or 
prototype and spec are not right we can pull out...” 
DH1 
Selection	often	involves	broad	strategic	aims,	rather	than	precise	criteria	and	tries	to	balance	making	near-term	progress	against	longer	strategic	aims.				Engaging	the	ecosystem	in	defining	success	also	helps	to	build	confidence	in	the	decision-making	process.			The	decision	is	more	about	interpretation	than	process	in	an	uncertain	environment		
						
	150		
Table	7-4	Shaping:	evidence	and	insights	from	cases	
Process	 Example	Case	Evidence		 Insights	
Shaping		Sources:	(Chandler	et	al.,	2011;	Read	and	Sarasvathy,	2005;	Sitoh	et	al.,	2014)			
• “We	were	a	driver	behind	the	concept	of	BE,	with	
people	wonder	why	we	are	in	this	are?	and	why	are	
we	 calling	 it	 BE	 and	 not	 neuromodulation	 like	
everyone	 else.	 But	 people	 are	 now	 beginning	 to	
realise	the	potential.	[investment]	represents	a	sort	
of	 transition….	 It’s	 more	 than	 just	 developing	
technology”	NMD	
• 	“So	to	start,	we	are	probably	going	to	position	
ourselves	in	‘convergence’	as	a	‘Future	Health	
Campus’.	That	will	encompass	Regenerative	
Medicine,	Precision	Medicine,	Bioelectronics	and	
Digital	Health,	which	is	sort	of	pervasive.”	CMTI	
• We	 are	 reasonably	 well	 known	 locally,	 so	 people	
come	 looking	 for	 us	 too.	 More	 broadly	 we	 are	
connected	to	NIB	and	some	of	their	work	streams;	
so	 that	 gives	 us	 an	 opportunity	 to	 influence	 at	
national	 level,	 particularly	 on	 Open	 Source	
software	strategy.	DH1	
	
Innovators	invest	time	in	helping	shape	the	ecosystem	and	create	a	compelling	‘vision’	as	well	as	driving	the	innovation	itself.			Shaping	can	be	by	influence	rather	than	direct	enactment	or	physical	capability	building.		
		
Table	7-5	Sustaining:	evidence	and	insights	from	cases	
Process	 Example	Case	Evidence		 Insights	
Sustaining		(Smith	2013;	Rong	2013)	
• “So,	you	have	to	invest	in	relationships,	and	it	
consumes	your	resources.	But	back	to	our	network,	
we	are	building	it,	we	have	the	first	few	critical	
ones	in	place	and	then	we	are	working	through	
them,	to	see	more.”	MLD	
• “We	have	done	something	that	is	very	distinct	from	
other	OI	ventures.	We	want	there	to	be	broader	
access	to	the	platform	to	help	move	the	science	
forward.	We	see	this	as	a	‘Grand	Challenge’	a	bit	
like	HGP.	So	we	have	said	we	will	allow	the	winner	
to	retain	the	IP,	but	with	conditions.	Those	are:	
they	must	make	it	broadly	accessible	to	the	
community.	[NMD]	has	the	1st	option	to	license	it	
to	research	and	clinical	use.”	NMD	
• “Investments	internally	at	[NMD]	will	be	held	at	a	
minimum	during	the	exploratory	years	with	all	
hands-on	R&D	taking	place	at	partnering	
organisations	and	with	the	[NMD]	team	being	lean	
and	focused	on	evaluating,	coalescing	funding,	and	
strategically	integrating	different	strands.”	NMD	
• How	can	we	find	out	who’s	key	and	engage	them?			
Or	which	offering	is	most	tractable?	To	reduce	
risk”	MLD	
• “We	are	well	connected	locally	and	continue	to	
spend	a	lot	of	time	networking.	We	are	always	
making	new	connections….	More	broadly	we	are	
connected	to	[National	Groups]	…;	so	that	gives	us	
an	opportunity	to	influence	at	national	level”		DH1	
Investment	not	just	in	the	technology	or	innovation,	but	in	the	wider	ecosystem,	and	in	relationships		In	order	to	sustain	the	innovation,	risk	reduction	is	critical	and	needs	to	be	addressed	early	without	losing	sight	of	long	term	objective.		Innovators	may	actively	build	and	nurture,	engaging	at	all	levels	influencing	and	funding	to	create	a	viable	ecosystem.			Start-up	and	SME’s	are	less	likely	to	undertake	major	shaping	activities,	like	funding	wider	ecosystem	activities,	but	they	still	need	to	invest	in	continuing	to	build	connections,	network	and	access	to	ecosystem	resources.				These	 tables	 highlight	 the	 source	 extant	 literature	 to	 support	 the	 proposed	 process,	 some	example	 case	 evidence	 and	 broader	 insights	 from	 the	 cases.	 	 	 This	 combination	 of	 searching,	
sense-making	(and	giving)	and	selection	are	common	to	all	cases.		These	three	processes	appear	
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to	be	antecedents	or	pre-cursors	to	two	types	of	investment,	described	here	as	shaping	(Table	7-4)	and	sustaining	(Table	7-5).			The	 cross-case	 evidence	 for	 ‘sustaining’	 appears	 to	 show	 two	 distinct	 patterns.	 	 	 Large	organisations,	with	 access	 to	 considerable	 resources	 appear	 to	be	prepared	 to	 go	beyond	 just	supporting	their	immediate	venture.			Given	the	nascent	nature	of	the	ecosystem,	there	is	a	need	to	 help	 ‘kick	 start’	 the	 whole	 field.	 	 	 As	 described	 by	 NMD-1:	 “But	 its	 actually	 more	 about	
stimulating	the	ecosystem,	in	practice	we	cannot	access	that	funding,	only	academics	can.	It	might	
seem	a	little	altruistic	but	it’s	really	about	helping	to	catalyze	the	field”.	Similar	sentiments	were	expressed	by	DH1	and	CMTI.	 	 The	 investment	 is	more	 than	altruistic,	 it’s	a	 recognition	of	 the	need	to	invest	for	the	longer-term	to	create	potential	value.	For	the	smaller	organisations,	this	is	not	an	option,	 they	do	not	have	adequate	resources	and	 funds.	 Instead	they	seek	 to	build	and	maintain	relationships,	even	if	not	immediately	valuable.			Whilst	 these	 five	 ‘micro-processes’	 appear	 to	 underpin	 the	 innovation	 activities,	 they	 do	 not	appear	 to	 create	 or	 transform	 organizational	 capabilities	 per	 se.	 	 In	 that	 sense	 they	 are	 not	dynamic	 capabilities,	 although	 they	bear	 some	 similarities	 to	Teece’s	 (2007)	 ‘sense,	 seize	 and	transform’	 they	 are	 conceptually	 different.	 	 This	 is	 addressed	 in	 more	 depth	 in	 the	 later	Discussion	chapter.		As	these	‘micro-processes’	are	repeatedly	used	and	appear	to	form	patterns	they	 can	be	 considered	as	 characteristic	 of	 organisational	 routines	 (Becker,	 2004;	Nelson	and	Winter,	 1982),	 that	 form	 the	basis	 on	 an	 innovation	 capability.	 	 These	patterns	 are	discussed	below.		Having	identified	similar	patterns	of	processes	in	each	case,	a	further	review	was	undertaken	to	assess	 the	 extent	 to	 which	 these	 processes	 co-occurred.	 	 For	 example,	 in	 the	 coding,	 did	references	to	‘searching’	and	‘sense-making’	tend	to	occur	together?		The	analysis	(Appendix	Error!	Reference	source	not	 found.),	shows	the	extent	to	which	each	of	 the	 5S	micro-processes	 co-occurred	 and	may	 be	 inter-related,	 providing	 an	 insight	 to	 how	these	 processes	 operate	 together,	 rather	 than	 in	 isolation	 (Table	 7-6).	 	 	 The	 consistency	 of	patterns	 of	 searching,	 sense-making	 and	 selecting	 co-existing	 across	 all	 cases,	 suggest	 these	work	 together.	The	evidence	 for	other	patterns	of	 co-existence	 is	 less	strong,	but	 it	 suggested	that	 the	 searching,	 sense-making	 and	 selecting	 work	 to	 enable	 either	 shaping	 decisions	 (the	primary	 objective	 of	 an	 innovator)	 or	 sustaining	 (to	 help	 de-risk	 the	 innovation	 and	environment).		
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An	 inference	 from	 this	 is	 that	 the	proposed	micro-processes	 act	 together	 in	 ‘activity	 systems’	(Rivkin	and	Siggelkow,	2007;	Siggelkow	and	Porter,	2008).		In	four	of	the	cases	there	is	evidence	that	 the	micro-processes	 of	 search,	 sense-making	 and	 selection	 operate	 as	 a	 ‘system’,	 herein	named	‘navigate’,	as	innovators	attempt	to	explore	and	understand	the	ecosystem.	 	The	micro-processes	of	sense-making	(and	sense-giving),	selection	and	shaping	form	a	‘system’	named	here	as	 ‘negotiate’	 as	 innovators	 uses	 knowledge	 and	 understand	 to	make	 decisions	 and	 create	 or	shape	a	position	with	other	actors.		The	final	cluster	sense-make,	select	and	sustain,	reflect	the	need	 to	 invest	 in	 activities	 that	 support	 the	 innovation,	 but	may	not	directly	 contribute	 to	 its	creation.				
Table	7-6	Analysis	of	5S	process	co-occurrences	across	cases	
		This	 could	 include	 providing	 support	 to	 partners,	 to	 help	 reduce	 risk,	 or	 enabling	 the	development	of	knowledge	or	capabilities	in	the	wider	ecosystem,	that	can	be	drawn	upon	later.	
Case
Total	Case	
interviews	
(when	
analysed)
Activity	
system	
'cluster' Coding	-	5S	micro-Processes
Interviewees	
with	coding	
Coding	
Occurences Comments	-	Notes	and	exmaples
CMTI 6 Navigate Search	-	Sense 3 8 Extrensive	evidence	of	systematic	and	snowball	searches
Navigate Sense	-	Select 3 4 Building	'database'	of	ecosystem
Navigate Search	-	Select 1 2 To	help	make	sense	and	support	decisions
Navigate Search	-	Sense	-	Select 1 2 Have	identified	fields	they	will	support
Negotiate Select	-	Shape 2 2 Engaging	firms	and	investors
Negotiate Sense	-	Shape 2 5 Seeking	feedback	from	them
Negotiate Sense	-	Select	-	Shape 3 3 engaging		investors,	wider	community	to	help	shape
Nurture Select	-	Sustain 4 7 have	idenfited	investments	need	to	support	ecosystem
Nurture Sense	-	Sustain 2 4 working	on	obtaining	funding
Nurture Select	-	Shape	-	Sustain 4 5
NMD 12 Navigate Search	-	Sense 6 9 extensive	search	-	systematic,	then	more	exploratory
Navigate Sense	-	Select 5 10 and	sense-making	processes,	engaging	widely
Navigate Search	-	Select 4 4 identified	focus	areas	and	partners
Navigate Search	-	Sense	Select 3 5 continue	to	evolve	partners
Negotiate Select	-	Shape 3 4 shaping	ecosystem	(conferecnes),	engaging	investors	and	funders
Negotiate Sense	-	Shape 3 9 seek	feedback	to	support	decisions
Negotiate Sense	-	Select	-	Shape 3 4 proactively	managing	ecosystem,	identifying	new	networks
Nurture Select	-	Sustain 3 7 putting	in	place	sustaining	infrastructure,	funding
Nurture Sense	-	Sustain 2 5 multiple	investment	streams,	mlutiple	development	projects
Nurture Select	-	Shape	-	Sustain 1 2
DH1 14 Navigate Search	-	Sense 4 4 wide	engagement,	especially	patient	groups	and	practitioners
Navigate Sense	-	Select 2 2 use	engagment	to	make	sense	and	build	business	case
Navigate Search	-	Select 4 4 only	progress	projects	with	user/patient	input	and	evidence
Navigate Search	-	Sense	-	Select 1 1 focus	on	things	they	know	from	customers	are	important
Negotiate Select	-	Shape 2 4 engage	wider	community	to	build	ecosystem
Negotiate Sense	-	Shape 2 4 seen	as	key	players	locally	and	at	National	level,	influence
Negotiate Sense	-	Select	-	Shape 1 1 access	to	funding,	evolving	business	model	for	more	flexibility
Nurture Select	-	Sustain 2 6 beginning	to	shape	ecosystem
Nurture Sense	-	Sustain 3 6 looking	to	put	code	in	open	source	repository	for	others	to	use
Nurture Select	-	Shape	-	Sustain 1 1
MLD 10 Navigate Search	-	Sense 4 13 lot	of	early	searches,	hard	to	find	right	connections
Navigate Sense	-	Select 4 4 engagements	appear	good,	but	often	'fail'		.		Need	to	keep	searching
Navigate Search	-	Select 1 1 identifed	potential	partners
Navigate Search	-	Sense	-	Select 1 1 have	developed	value	propositions	based	on	stakeholder	input
Negotiate Select	-	Shape 1 4 have	reasonable	idea	on	direction	and	shape	of	product	/	BM
Negotiate Sense	-	Shape 3 2 seeking	investors	to	progress
Negotiate Sense	-	Select	-	Shape 2 2 investment	in	process
Nurture Select	-	Sustain 6 9 Have	small	network	of	support,	building	coalitition	with	practitioners
Nurture Sense	-	Sustain 4 4 Continue	to	manage	networks,	to	maintain	links
Nurture Select	-	Shape	-	Sustain 4 4
DH2 5 Navigate Search	-	Sense 1 2 much	less	evidence	,	of	wide	search,	using	known	network
Navigate Sense	-	Select 1 1 limited	'search'	-	knowns	only	until	late	on,	then	realise	not	enough
Navigate Search	-	Select 0 0 made	decisions	on	pathway	with	limited	feedback	and	input??
Navigate Search	-	Sense	-	Select 0 0 no	evidence?
Negotiate Select	-	Shape 1 1 maintain	focus	on	original	BM	
Negotiate Sense	-	Shape 1 1 not	clear	on	BM,	keeps	changing	each	time	they	engage.
Negotiate Sense	-	Select	-	Shape 1 1 identified	competitors	better	funded	and	well	aahead
Nurture Select	-	Sustain 0 0 re-checked	interviews,	lots	of	data,	but	little	on	shaping/sustaining
Nurture Sense	-	Sustain 0 0 no	evidence?
Nurture Select	-	Shape	-	Sustain 0 0
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It	 is	 interesting	 to	note	here	 that	 case	DH2	 shows	 the	 least	 evidence,	 even	allowing	 for	 fewer	interviews)	 than	 other	 cases.	 	 This	 would	 suggest	 that	 these	 processes	 were	 not	 as	 well	established.	This	cluster	is	denoted	‘nurture’	and	could	be	considered	similar	to	that	discussed	by	Rong	(Rong	et	al.,	2013;	Rong	and	Shi,	2015).		However,	a	difference	in	perspective	is	that	in	this	 research	 the	 ‘nurturing’	 is	 not	 simply	 that	 of	 the	 ‘extended	 value	 network’	 or	 their	‘innovation’	 as	 is	 largely	 suggested	 by	 innovation	 ecosystems	 literature	 (Adner	 and	 Kapoor,	2010;	 Autio	 and	 Thomas,	 2014)	 but	 the	 wider	 ecosystem,	 thereby	 ensuring	 adequate	institutional	players	and	infrastructure	support	are	 in	place.	This	 is	evident	 in	 the	activities	of	NMD,	DH1	and	CMTI.		
7.8 Credibility-seeking and Advantage-seeking activities There	 is	 direct	 evidence	 from	 both	 the	NMD	 and	DH1	 cases	 of	 the	 organisations	 engaging	 in	activities	to	create	a	legitimate,	credible	and	visible	position	(the	use	of	these	terms	is	defined	here	as	-	a	position	of	legitimacy	is	one	where	your	being	present	in	the	ecosystem	is	accepted,	
credibility	comes	from	doing	something	tangible	or	having	a	position	of	power,	and	being	visible	is	being	recognised	by	others	as	doing	so).			NMD	 built	 their	 position	 through	 engagement,	 enabling	 others	 to	 engage	 (via	 conference’s),	funding	 other	 researchers’	 work,	 curating	 a	 journal	 article	 and	 investing	 in	 start-ups.	 Their	position	on	sharing	IP	helped	address	initial	scepticism	by	academic	researchers.	DH1	started	as	a	 small	 venture,	 but	 worked	 with	 the	 local	 community	 of	 healthcare	 providers	 and	 patient	groups	 to	 be	 credible	 ‘connectors’	 and	 ‘creators’.	 They	 then	 had	 to	 work	 further	 to	 build	 a	credible	position	as	deliverers	and	influence	more	widely	in	the	ecosystem.				This	 position	 of	 credibility	 is	 suggested	 as	 an	 important	 precursor	 to	 adopting	 an	 advantage-seeking	 position.	 This	 approach	 is	 distinct	 from	 that	 in	 established	 ecosystems,	 where	 the	innovator	is	(usually)	already	credible	and	may	even	have	a	dominant	position.	This	implies	an	additional	 step	 is	 required	 for	 innovation	 in	nascent	 or	 emerging	 ecosystems,	 and	 convergent	innovation,	where	partners	may	not	‘be	seen	as’	natural	inhabitants	in	the	emerging	ecosystem.	This	 step	 appears	 to	be	 required	 even	 for	 large	organisations,	 if	 they	move	 into	 a	nascent	or	convergent	 field.	 	 Example	 evidence	 of	 how	 the	 case	 firms,	 particularly	NMD,	 DH1	 and	 CMTI	achieved	this	are	summarised	in	Table	7-7.							
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Table	7-7	Credibility-seeking	and	advantage-seeking	actions	
Credibility-seeking action Advantage seeking-action 
Description Example Quote / Evidence Description Example Quote / Evidence 
Research Contracts 
share IP rights with 
academic R&D and 
other collaborators. 
• “[collaborators] concerned…whether our IP position 
was genuine. … we said that everyone would retain 
their IP. And there was a lot of skepticism about 
whether we were genuine about that” – NMD 
• “.. ‘white label products’ and open source, so 
solutions can be shared as part of an open library, ...” 
DH1  
Positioned as a ‘hub’ in 
network, and providing 
funds, support services and 
influencing research 
direction. 
• “..what’s turning into reality is that we are the downstream 
partners.  So we can propose joint research with academics 
to apply for this funding…we believe that these funding 
programs can not only feed new ideas or new disease 
opportunities in to our development pipeline.  But it’s also 
a way for us to get more leverage in the early research.” – 
NMD 
• [CMTI] will evolve the Open Innovation concept to address 
an emerging unmet need for company incubation and 
integration in the field of Convergent Medical Technology 
(CMT) in the UK. [CMTI] aims to identify disruptive 
technology for commercialisation that will provide 
solutions to biological problems and result in patient 
benefit longer term. – CMTI Strategic Plan 
 
Funding start-ups 
via new corporate 
Venture Fund. 
• “Through our $50m venture capital arm, [NMD] 
Venture Capital, we are investing in start-ups and 
technology platforms that aim to advance the 
development of bioelectronic medicines.” [NMD 
website]  
Renegotiated Collaboration 
IP positions to take full 
ownership (in return for 
royalties, funds) for later 
value capture. 
• “Much of the value we’ve created has come from 
partnerships we’ve created with academics.   The real 
balancing act this year has been to leverage the IP we’ve 
jointly created and use this …in a constructive way…we 
look to take control, via buy-out or licensing or royalties so 
we have exclusivity and ownership. – NMD 
 
Create and fund 
Open Innovation 
challenge to address 
‘technology gaps’ 
identified by 
ecosystem 
• “… after the community identified the ‘problem’ we 
went out and consulted to confirm we had identified 
the right problem and decision criteria, … confirm 
this was critical and finally we checked that the 
community would be prepared to participate”. - NMD 
Hold right to exploit and 
capture value from Open 
Innovation IP for 
commercial use. 
• “So we have said we will allow the winner to retain the IP, 
but with conditions.   Those are: they must make it broadly 
accessible to the community.  [NMD] has the 1st option to 
license it for research and clinical, commercial use”. - 
NMD 
Open access of IP 
from Open 
Innovation 
Challenge to 
research 
community. 
• “Acceptance of the prize will require, .. that the .. 
winner … release all relevant research data and 
information into the public domain.  This …will allow 
other investigators, including those at [NMD], the 
right to utilise the work for future research purposes 
while permitting the … winner … to retain 
commercial rights.” –[NMD website] 
Joint Venture formed with 
major technology partners.  
• “So the driver was - how do we rapidly access the 
technology and engineering capability to build a game 
changing device”.   -NMD 
• “It’s a big initial investment, so you want to be able to 
capture the value. So the deal needed to allow us to be able 
to capture the value.”  - NMD 
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Credibility-seeking action Advantage seeking-action 
Description Example Quote / Evidence Description Example Quote / Evidence 
 
 
Develop paper for 
major scientific 
journal, to position 
the field and their 
role to attract other 
researchers and 
funding 
• “Realizing the vision of a new class of medicines 
based on modulating the electrical signalling patterns 
of the peripheral nervous system needs a firm research 
foundation. Here, an interdisciplinary community puts 
forward a research roadmap for the next 5 years”. 
[Nature 2014] 
Influence on national level 
bodies to develop digital 
health strategy and policy 
• “We are doing some work at National level, for NHS 
England.   We are also working with Integrated Care 
Pioneers – conducting workshops and interviews to try and 
identify what are the barriers to digital in HCPs.” – DH1 
Special sessions at 
existing academic 
conferences to 
present collaborative 
R&D findings 
• “we have now started to publically disclose the 
outcomes and output from all that funded work, 
through a number of channels” – NMD 
• “Our ecosystem is a lot bigger.  It’s mainly through 
networking.   We attend and event or conference or 
we run an event for people.” – DH1 
  
Creating visible 
content for others to 
engage with 
• “It’s also important that what we have done is visible, 
so people can see our track record. So, another 
important part of our role is to curate and make 
public. So, you will find searchable content on our 
website, in our blogs etc.” – DH1 
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7.9 Development of new capabilities The	small	start-up	organisations	had	few	capabilities	to	start	with.	The	case	evidence	suggests	that	 they	 incrementally	 built	 capabilities,	 mainly	 through	 experiential	 learning.	 	 This	 is	unsurprising	 and	 consistent	with	 the	 extant	 literature.	 The	 evidence	 for	 this	 approach	 is	 less	compelling	 for	 the	 incumbent	 firms.	Whilst	incumbent	 firms	did	evolve	processes,	based	upon	feedback	and	knowledge	gained,	their	also	made	changes	indicating	they	had	a	clearer	picture	of	what	 needed	 to	 be	 done	 differently,	 pointing	 to	 a	 degree	 of	management	 agency	 (Garud	 and	Gehman,	2012).				Existing	 theory	about	dynamic	capabilities	and	ambidextrous	organisations	do	not	adequately	address	 these	 observations.	 	 For	 example,	 the	 dynamic	 capability	 perspective	 suggests	 that	existent	organisational	routines	for	innovation	could	be	deployed	to	create	something	radically	new	(di	Stefano	et	al.,	2014;	Teece,	2012)	but	this	implies	they	an	incumbent	firm	(such	as	NMD	or	 DH1)	 requires	 ambidextrous	 structures	 and	 appropriate	 social	 practices	 to	 balance	exploitative	and	exploratory	innovation.			Similarly,	 if	 exploratory	 new	 product	 development	 capabilities	 exist,	 embedded	 within	 an	incumbent	firm,	then	it	is	possible	to	argue	that	it	could	develop	a	disruptive	technology	without	changes	 in	 organizational	 capabilities.	 An	 incumbent	must	 confront	 technological	 and	market	uncertainties,	but	will	unambiguously	know	how	to	act.		This	is	not	the	case	in	the	cases	of	NMD,	DH1	and	CMTI.	They	did	not	know	how	to	act,	but	instead	developed	new	approaches,	using	a	combination	 of	 changes	 to	 existing	 routines,	 exploratory	 actions	 and	management	 agency	 to	guide	 decisions.	 	 The	 early	 reliance	 on	 replication	 of	 existing	 processes	 suggests	 any	accompanying	 organizational	 capability	 will	 have	 continuity	 with	 the	 existing	 pool	 of	organisational	routines.	This	insight	has	implications	for	both	the	ambidexterity	alternative	and	the	dynamic	capability	concept.	 	Changes	in	organizational	capabilities	are	needed	because	the	organisational	 routines	 adequate	 for	 navigating	 an	 established	 ecosystem	 are	 imperfect	 for	navigating	and	building	a	nascent	one.		The	 evidence	 from	 cases	 DH1	 and	 NMD	 point	 to	 the	 skilful	 agency	 of	 managers	 in	 shaping	processes	 and	 routines	 to	meet	 the	 needs	 of	 the	 convergent	 innovation.	 	 For	 example,	 NMD	adopted	different	 approaches	 to	open	 innovation	and	 to	 corporate	 venture	 investments	(than	had	been	previously	employed	in	the	incumbent	firm).	 	Similarly,	DH1	used	more	agile	project	management	 and	decision	 processes	 from	 the	 outset,	 although	 they	 then	 evolved	 these.	 They	both	also	used	modified	governance	structures	from	the	outset.	This	allowed	them	to	negotiate	the	 internal	organisations	and	maintain	an	agile	approach	 to	 the	 innovation,	enabling	 them	to	
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engage	and	make	use	of	 the	nascent	ecosystem	and	actors.	 	The	question	as	 to	whether	 these	represent	dynamic	capabilities	is	addressed	in	the	later	discussion	(Chapter	8).		
7.10 Implications for the proposed Convergent Innovation Framework The	Exploratory	Framework	was	developed	during	 the	preliminary	 research	phase,	 as	both	 a	proposed	 ‘framework’	and	as	an	 investigational	tool.	Based	upon	the	case	evidence	and	cross-case	 findings,	 an	 analysis	 of	 the	 original	 twelve	 factors	 (see	 Table	 5-4)	 and	 these	 research	findings	was	conducted.			The	 cross-case	 evidence	 suggests	 that	 some	 factors	 are	 probably	 less	 important	 than	 at	 first	thought	and	there	are	several	that	could	be	recombined	to	provide	a	more	holistic	perspective.	It	is	 also	 evident	 that	 the	 factors	 themselves	 need	 some	 refinement	 to	 address	 the	 research	findings,	 for	 example-	 F1:	 “Firm	undertakes	 activities	 to	map	and	understand	 the	 ecosystem	 to	
keep	pace	with	its	evolution	and	develop	it”	-	appears	too	generic	and	does	not	adequately	convey	the	difference	in	approaches	identified	in	the	case	studies,	and	therefor	required	in	convergent	innovation.	 	 An	 alternative,	 and	 more	 precise,	 description	 of	 F1	 is	 proposed	 as:	 “Use	 active,	
exploratory	and	evolutionary	searches	 to	 identify	and	understand	diverse	knowledge	and	actors.		
Develop	 from	 diffuse	 knowledge	 to	more	 codified.	 Develop	 both	 knowledge	 and	 relationships	 to	
build	a	credible	position	in	the	nascent	ecosystem,	to	enable	later	advantage-seeking	actions.”		As	 another	 example,	 for	 the	 factor	 -	 F5:	 “Map	and	understand	key	 value	 creation	and	 capture	
steps	(linked	to	business	model)”	-	is	better	combined	with	the	business	model	factor,	F4,	and	re-worded	as	–	“Use	the	'value	proposition'	as	a	vehicle	to	engage	and	refine	offering.		Identify	value	
perspectives	of	customers	and	stakeholders.	Refine	business	model	to	address	pathway	challenges.	
Integrate	business	model,	innovation	and	value	network	development.”		Similar	revisions	are	proposed	across	all	the	original	factors,	as	summarised	in	Figure	7-1.		The	final	columns	identify	the	suggested	re-clustering	and	revised	wording	for	the	framework.		
7.11 Cross-case summary The	 cross-case	 analyses,	 although	 limited,	 identify	 several	 patterns	 that	 suggest	 potential	models	and	frameworks	(see	Figure	7-2).		These	include:	several	micro-processes	that	underpin	the	innovation	processes	and	capabilities,	the	use	of	these	processes	in	an	activity	systems	that	enable	 innovators	 to	 navigate,	 negotiate	 and	 nurture	 their	 innovation,	 the	 need	 to	 establish	legitimacy	 and	 then	 credibility-seeking	 behaviours	 before	 adopting	 advantage-seeking	behaviours.	 	 	 Firms	appear	 to	 evolve	 capabilities	 through	 a	 combination	 of	 skilfully	managed	
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small	 changes	 across	 multiple	 processes.	 	 	 Governance	 and	 decision	 making	 is	 agile,	 using	stakeholders	 to	help	 in	guiding	key	decisions.	These	 findings	are	now	discussed	in	the	 light	of	the	literature.					
		 159	 	Figure	7-1	Revisions	to	convergent	innovation	framework	from	case	evidence	
Factor Original	Factor	Wording Strong	Cross-
Case	Evidence	for	
original	factor
Navigate-	
search,	sense-
make,	select
Negotiate	-	
credibility	and	
advantage-
seeking
Nurture	-	
shape	and	
sustain
Governance	-	
directional	and	
diverse
Team	
capabilities,	
autonomy	and	
agency
Value	
Networks	-	
transient,	
flexible
Evolving	
Business	
Model	-	linked	
to	innovation,	
VN	and	
Capability	
changes	-	
multiple	broad	
and	shallow
Integration	and	
Risk	
Management
Rationale Revised	Factor	Working	 Revised	Factor
F1 Ecosystem	and	
Market	
understanding
Firm	undertakes	activities	to	map	
and	understand	the	ecosystem	to	
keep	pace	with	its	evolution	and	
develop	it.
Yes	-	NMD,	DH1,	
CMTI,	mld
High	-	critical	
to	
understanding	
ecosystems	
and	its	
evolution
Med	--	need	to	
understand	
and	build	
credibility	
Med	-	
delivering	
tangible	
outputs	
important	to	
build	credibility
High	-	core	
team	needs	
diverse	skills,	
judgement		
and	
empowerment	
so	can	operate	
broadly	and		
High	-	
ecosystem	
and	customers	
needs	evolve,	
so	maintaining	
understanding	
critial	to	
business	
Med-	
approach	to	
understanding	
ecosystem	
evolves
Refine	wording	to	
address	need	to	
search	and	sense-
make
Use	active,	exploratory	and	
evolutionary	searches	to	
identify	and	understand	
diverse	knowledge	and	
actors.		Develop	from	diffuse	
knowledge	to	more	codified.	
Develop	both	knowledge	and	
relationships	to	build	a	
Ecosystem	
understanding	and	
relationships	within	it
F2 Stakeholder	
Management
Map	and	engage	stakeholders	
through	the	life-cycle	of	the	
development	process	to	facilitate	
progress,	and	evolve	relationships	
over	time.
Yes	-	NMD,	DH1,	
CMTI,	mld
High	-	critical	
to	
understanding	
stakeholders	
and	their	
needs
Med	--	need	to	
understand	
and	build	
credibility	
High	-	
delivering	
tangible	
outputs	
important	to	
build	credibility	
and	advantage	
position
Med	-	external	
experts	and	
stakeholders	
provide	
broader	
capability	and	
challenge	to	
key	investment	
Med	-	core	
team	needs	
good	skills	in	
buidling	
credibility	and	
relations	with	
external	actors
High	--	need	to	
understand	
and	build	
credibility	to	
access	the	
right	partners
High	-	
ecosystem	
and	
stakeholders	
perceptions	
evolve,	so	
maintaining	
understanding	
Include	in	refined	
Ecosystem	
Understanding	factor
F3 Customer	
Engagement
Routines	and	capabilities	to	engage	
early	in	the	development	process	
with	customers	to	inform	
product/service	design	and	the	
potential	business	model	options
Yes	-	DH1,	MLD High	-	critical	
to	
understanding	
who	the	'right'	
customers	to	
engage	are
Med	--	need	to	
understand	
and	build	
credibility	
High	-	
delivering	
tangible	
outputs	
important	to	
build	credibility	
and	advantage	
Med	-	core	
team	needs	
good	skills	in	
engaging	with	
potential	
customers
High	-	
ecosystem	
and	customers	
needs	evolve,	
so	maintaining	
understanding	
critial	to	
Refine	wording	to	
address	need	to	
manage	wider	
ecosystem	
relationships
Engage	potential	customers	
and	users	early,	and	maintain	
engaging	througout	
development.	Use	to	address	
innovation	and	adoption	
challenges.	
Customer	
engagement
F4 Business	Model	
development
Map	and	understand	the	links	
between	the	business	model	and	
the	required	activities	and	
capabilities.
Yes	-	DH1,	MLD Med-	need	to	
identify	key	
customers	and	
decision	
makers	to	
provide	input
High-	need	to	
repeatedly	
engage	to	
evolve	
understanding,	
credibility	and	
eventual	
Med	-	need	to	
invest	in	
innovation	
(value	
proposition)	
and	business	
model	
High	-	
ecosystem	
and	customers	
needs	evolve,	
so	maintaining	
understanding	
critial	to	
Med-	
approach	to	
understanding	
ecosystem	
evolves
Med	-	need	to	
integrate	BM	
risks	with	other	
risks
Refine	wording	to	
address	need	to	
manage	wider	
ecosystem	
relationships
Use	the	'value	proposition'	as	
a	vehicle	to	engage	and	
refine	offering.		Identify	value	
perspectives	of	customers	
and	stakeholders.	Refine	
business	model	to	address	
pathway	challenges.	
Business	model	
development	and	
integration
F5 Value	Attributes Map	and	understand	key	value	
creation	and	capture	steps	(linked	
to	business	model)
Yes	-	DH1,	MLD Med	-	value	
atrributes	only	
part	of	
assessment	
needed	to	
build	business	
Include	in	Business	
model	development
F6 Governance Active	senior	management	support	
and	engagement	in	investment	
decisions.		Adequate	knowledge	for	
project	selection	and	progression	
through	objective	decision	gates.		
Yes	-	NMD,	DH1,	
CMTI,	but	also	
needed	to	bring	
external	expertise	
to	support	
decisions.		
Med	-	
governance	
need	broad	
understanding	
for	key	
strategic	and	
investment	
Med	-	
governance	
need	broad	
understanding	
for	key	
strategic	and	
investment	
Med	-	
governance	
need	broad	
understanding	
for	key	
strategic	and	
investment	
High	-	
governance	
team	needs	
senior	
leadership	to	
build	internal	
acceptance,	
High	-	
governance	
team	needs	
senior	
leadership	to	
build	internal	
acceptance,	
Med	-	alliance	
management	
is	flexible	and	
light	touch
Med	-	
governance	
support	neded	
to	address	
conflicts	
between	
existing	and	
Med-	
governance	
also	provides	
some	early	
'protection'	in	
incumbent	
firms
Med	-	need	to	
address	
integrated	
risks	in	
governance
Refine	to	broader,	
directional	criteria,	
with	external	or	
ecosystem	input	as	
key
Active	senior	management	
support	and	engagement	in	
key	investment	decisions.		
Provide	support	to	address	
intenral	conflicts.	Use	
external	expertise	to	
supplement	and	challenge	
Flexible	governance
F7 Gate	Criteria Objective	Go	/	no	go	decision	
criteria	to	determine	progressing	to	
next	phase,	that	consider	external	
capabilities	and	paths.
No,	use	broad	
criteria	and	
external	
ecosystem
Limited	
knowledge	
makes	
codifying	
requirements	
difficult,	so	
High	-	little	
evidence	of	
defined	
criteria.			
Where	used	
they	are	
Low	-	more	
reliant	of	
knowledge	
and	judgement	
of	team,	than	
defined	criteria
Low	-	
decisions	on	
nascent	value	
networks	more	
about	
relational	
Criteria	evolve	
during	
development
Refine	Factor	to	
broader,	directional	
criteria,	with	external	
or	ecosystem	input	
as	key
Decision	criteria	are	broad	
and	directional,	supported	by	
external	expertise	or	
ecosystem	actor	input.		
Criteria	are	refined	based	on	
knowledge	and	progress.
Decision	criteria
F8 Process A	process	or	methodology	exists	to	
guide	process	development	and	
quality	management
No,	process	
evolves	through	
broad,	shallow	
changes
Low	-	
governance	
processes	are	
miniimal	and	
evolve
High	-	limited	
processes	in	
place.		Use	
existing	
process	and	
then	make	
Med	-	limited	
processes	in	
place.		Need	
to	balance	
between	
Analytic	and	
Initial	processes	
unlikely	to	be	
adequate.			Muitple	
incremental	but	
broad	changes	less	
likely	to	create	risk	or	
Evolve	processes,	using	
broad	but	shallow	approach	
to	minimise	risk	and	non-
acceptance
Business	processe	
and	evolution
F9 Risk	
Management
Risk	management	processes	are	in	
place	to	address	patient	and	user	
safety	risks,	and	the	combination	of	
technological	risks,	product	
integrations	risks	and	business	and	
Yes,	but	
integration	critical
High	-	need	to	
address	
integrated	
risks	
Existing	Factor,	
requires	refinement
Risk	management	in	place	to	
address	integration	of	
technological	(including	
patient	and	user	risks),	
business	model	risks,	value	
Integrated	Risk	
Management
F1
0
Alliance	Partners Inter-organizational	co-operation	
via	clarity	in	objectives	and	scope.	
Accessing	capabilities	through	
alliance	partners,	adopting	different	
alliance	management	approaches	
to	different	partners.	
No,	early	clarity	
difficult.		First	
steps	are	more	
about	
understanding,	
finding	
congruence	-	
using	transient	
High	-	
identifying	
potential	
partners	
challenging.			
Unlikely	initial	
partners	will	
be	reatined	in	
Med-	need	
flexible	
alliances.		
Med	-	
important	to	
build	credibility	
High	-	
governance	
team	and	
external	
expertise	to	
reduce	risks
Med-	core	
team	need	
flexible	
approach	to	
managing	
partners	and	
alliances
High	-	building	
traansient	VNs	
key	to	building	
credibility	and	
capability.
Med-	
approach	to	
understanding	
ecosystem	
evolves
Med	-	need	to	
integrate	BM	
risks	with	other	
risks
Refine	wording	to	
reflect	need	for	
building	relationships	
and	transient	value	
networks
Use	ecosystem	relationships	
to	develop	flexible	and	
transient	value	networks	
before	committing	to	long	
term	alliances.
Agile	Value	Networks
F1
1
Project	Team	 The	core	team	has	leadership,	
expertise	and	experience,	and	
balances	autonomy,	accountability	
and	empowerment	within	the	
governance	framework
Yes	-	NMD,	DH1,	
CMTI	(less	so	in	
start-ups)
High	-	
evidence	that	
core	team	
needs	
expertise,	
accountability	
and	
No	change The	core	team	has	
leadership,	expertise	and	
experience,	and	balances	
autonomy,	accountability	and	
empowerment	within	the	
governance	framework
Empowered	Project	
Team
F1
2
Support	
infrastructure
Firm	builds	and	makes	use	of	
ecosystem	and	infrastructure	to	
complement	own	capabilities	and	to	
support	development	of	innovation	
culture
Yes,	NMD,	CMTI,	
DH1	-	but	more	
about	helping	
build	supporting	
infrastructure,	as	
institutional	gaps	
exist
Med-	need	to	
identify	gaps	in	
support	
infrastructure,	
which	may	
evolve	as	
needs	change
Med	-	
Providing	
support	to	
ecosystem	
enhances	
negotiating	
position
High	-	
providing	
tangible	
support	
important	to	
build	credibility	
and	advantage	
Med	-	
evidence	that	
core	team	
needs	ability	to	
understand	
support	nedds	
and	find	range	
Med	-	support	
maybe	
provided	from	
amongst	value	
network	
partners
Refine	wording	to	
address	need	to	
support	ecosystem	
infrastructure
Innovator	invests	in	helping	
support	(nurture)	nascent	
ecosystem,	addressing	
insitutional	gaps,	and	
contributes	support	to	
maintain	viable	infrastructure.
Support	infrastructure
Extent	that	Research	Findings	are	linked	to	or	influence	prior	Factors
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	 	 Cross-Case Evidence  	Causal Objects identified 
in  
Case ECPO analysis Object CMTI NMD DH1 MLD DH2 
Proposed  
micro-processes 
Activity Systems and 
Approach 
Search o1 Y Y Y Y y S1 Navigate 
Sense-make o2 Y Y Y Y y S2   
Select o3 Y Y Y Y y S3 Negotiate 
Shape o4 Y Y Y Y y S4   
Sustain o5 Y Y Y y n S5 Nurture 
                  
Legitimacy-seeking o6 Y Y Y Y n S4, S5 Legitimacy / Credibility 
Advantage-seeking o7 Y Y Y y y S4, S5 Advantage 
                  
Broad-shallow capability 
development o8 y Y Y y n/a S3, S4, S5 Capability development 
                  
Nascent Value Network o9 y Y Y Y n S3, S4, S5 Relational approach 
Agile governance o10 Y Y Y y y S3 
 
Broad criteria (engage 
externally) 
Key: Y - good evidence y - partial, n- none 	 	 	 	 	 	Figure	7-2	Cross-Case	ECPO	analysis	to	support	proposed	causal	mechanisms		
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8 Discussion  
8.1 Introduction In	 this	 chapter,	 the	 results	 and	 findings	 are	 discussed	 in	 the	 light	 of	 existing	 theory,	 with	suggestions	for	new	models,	concepts	and	frameworks.			
8.2 Ecosystem Understanding Methodologies	for	understanding	business	and	innovation	ecosystems,	especially	nascent	ones,	are	 not	 well	 developed	 (Autio	 and	 Thomas,	 2014;	 Oh	 et	 al.,	 2016).	 Consequently,	 tools	 for	practitioners	to	understand	these	complex	ecosystems	are	not	readily	available.	Where	people	have	studied	ecosystems,	it	is	often	more	by	an	analogy	(den	Hartigh	and	van	Asseldonk,	2004;	Oh	et	 al.,	 2016)	 than	any	 systems-based	approach.	 	As	part	 of	 this	 research,	 a	more	 systemic	approach	for	studying	ecosystems	was	developed.	The	implications	of	this	and	the	potential	to	develop	tools	for	practitioners	are	considered	below.			The	initial	research	phase	in	this	study	aimed	to	address	conceptual	aspects,	including	ecosystem	
boundaries	and	the	key	issues	and	perspectives	of	ecosystem	actors.		Analyses	were	undertaken	to	 examine	 stakeholder	 influence,	 impact	 and	 identity,	 helping	 to	 determine	 the	 system’s	boundary	 and	 perspectives	 taken	 by	 actors.	 Boundary	 determination	 was	 by	 a	 population-
community-identity	approach	(Post	et	al.,	2007;	Santos	and	Eisenhardt,	2005).	Ecosystems	were	mapped	 at	 several	 levels	 to	 produce	 an	 overall	map	 and	more	 detailed	 views	 in	 and	 around	specific	 issues	 such	 as	 investment	 funding.	 This	 provided	 an	 approach	 to	 address	multi-level	features	inherent	in	any	such	system	(Gupta	et	al.,	2007;	S.	W.	J.	W.	J.	Kozlowski	and	Klein,	2000).		It	 could	 be	 argued	 that	 in	 nascent	 ecosystems,	 this	 approach,	 is	 more	 appropriate	 than	 an	alternative,	 such	 as	 using	processes	 and	 functions	 (Post	 et	 al.,	 2007),	 as	 these	 have	 yet	 to	 be	routinely	 established.	 	 It	 therefore	 suggests	 that	 approaches	 to	 boundary	 determination	 are	linked	to	the	ecosystem	lifecycle.		As	 previously	 identified,	 convergence	 brings	 increased	 complexity.	 But	 the	 healthcare	 and	innovation	 ecosystems	 already	 exhibit	 considerable	 complexity.	 	 Developed	 from	 the	 Phase	 1	ecosystem	 interviews	 in	 this	 research,	 Figure	 8-1	 presents	 a	 top-level	 ecosystem	 map	 for	healthcare	innovation	in	the	UK.		It	also	represents	the	landscape	into	which	all	five	cases	were	located.			
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Mapping	 at	 this	 level	 (as	 is	 often	 done)	 is	 considered	 inadequate	 to	 describe	 the	 nuances	inherent	in	the	ecosystem.		To	address	this	sub-system	maps	were	developed	(see	section	6.2.2)	using	 a	 combination	 of	 interview	 data	 and	 documentation.	 Methodologically	 they	 follow	 soft	systems	approaches	 (Checkland	and	Scholes,	 1990).	 These	 provide	 an	 opportunity	 to	 explore	specific	processes	and	environments	 that	represent	context	 for	case	 innovators’	decisions	and	actions.			There	 is	evidence	 that	 four	cases	organisations:	DH1,	NMD,	MLD,	and	CMTI	attempted	to	map	their	ecosystem	and	conduct	stakeholder	analyses.	In	some	(NMD	and	CMTI),	this	was	extensive,	using	a	range	of	techniques.		Others	(DH1	and	MLD)	simply	captured	information	from	various	encounters	and	events,	then	reviewed	these.	 	During	the	nascent	phase	of	an	ecosystem,	these	actors	may	change	significantly,	as	some	leave	and	new	actors	emerge,	requiring	any	mapping	to	be	dynamic.		A	further	challenge	is	the	complexity	of	the	value	system	where	multiple	‘customers’	and	other	actors	play	critical	roles	in	the	adoption	chain	(Adner,	2012).		Within	healthcare	systems	there	are	 different	 perspectives	 of	 value	 by	 different	 actors.	 	 The	 previously	 developed	 Figure	6-6depicts	 the	 system	 of	 patients,	 practitioners	 (such	 as	 physicians,	 doctors	 and	 nurses),	providers	 (such	 as	 clinics	 and	 hospitals)	 or	 pharmacies	 and	 payers	 (government	 and	 private	health	insurers)	(Department	of	Health-	UK	Government,	2013).	 	Whilst	these	 ‘customers’	may	be	 the	 end	 user	 or	 payer,	 there	 are	 also	 other	 intermediaries	 that	 need	 to	 be	 considered,	including	 organisations	 such	 as	 NHS	 Procurement	 who	 determine	 ‘approved	 suppliers’	 and	contract	terms.			These	challenges	are	not	unique	to	the	UK.		A	similar	map	could	be	drawn	up	for	other	countries	and	the	6Ps	 identified:	patient,	practitioner,	provider,	pharmacy,	procurement	and	payers,	can	be	found	in	most	major	healthcare	systems	(Thomson	et	al.,	2013).		Another	 factor	 having	 significance	 for	 innovators	 was	 the	 limited	 institutional	 frameworks,	making	traditional	innovation	approaches	less	applicable			
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Figure	8-1	Overall	UK	healthcare	innovation	ecosystem	
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The	method	 framework	 developed	 (see	 Table	 4-3)	 provides	 the	 foundation	 for	 a	 tool	 set	 for	practitioners.	Whilst	not	developed	here,	 such	a	 framework	could	help	 innovators	address	 the	complexity	 through	 the	 concepts	 of	 perspectives,	 boundaries,	 structure	 and	 relationships,	dynamics	 and	 co-evolution,	 provide	 a	 more	 thorough	 way	 to	 map	 and	 understand	 their	ecosystems.	The	application	of	the	framework	and	summary	research	method	implications	are	discussed	in	Chapter	4.	Using	this	methodology	in	the	initial	ecosystem	research	demonstrated	that	the	conceptual,	physical	and	temporal	dimensions	of	ecosystems	can	be	incorporated	in	an	analysis	 of	 systems-based	 organizing.	 This	 approach	may	 be	 of	 greater	 relevance	 in	 studying	nascent	or	highly	dynamic	systems.	By	mapping	ecosystems	at	multiple	levels,	further	insights	helped	to	explain	aspects	of	the	case	firms’	behaviour	that	were	not	apparent	at	the	macro-level,	such	as	access	to	investment	funding.	Furthermore,	the	nature	and	quality	of	relationships	could	only	be	determined	by	more	detailed,	lower	level	mapping.	The	use	of	a	multiple	snapshot	view	to	understand	system	dynamics	made	it	possible	to	map	the	evolution	of	the	ecosystem	and	the	case	 firms	within	 it,	 illuminating	 how	 firms	 developed	 their	 value	 networks	 in	 these	 nascent	ecosystems.	 This	 approach	 moves	 beyond	 previous	 structural	 mapping	 approaches	 (Moore,	1993;	 Rong	 and	 Shi,	 2009)	 and	 those	 considering	 value	 and	 exchanges	 (Adner	 and	 Kapoor,	2008;	Urmetzer	et	al.,	2016)	to	explicitly	consider	relationships	and	the	influence	these	have	on	activities	and	dynamics.			Whilst	the	approach	and	framework	developed	is	potentially	generic,	it	has	only	been	applied	in	limited	examples,	and	so	would	benefit	 from	wider	application,	and	 testing,	 to	help	refine	 the	methodology.		The	 initial	 research	 findings	 from	 the	 ecosystem	 interviews	 identify	 a	 complex	 environment,	providing	the	context	for	innovation,	where:	
• Knowledge	 and	 capabilities	 are	 diffuse	 (and	 spread	widely),	 and	 that	 diverse	 approaches	and	duplication	of	effort	amongst	actors	is	evident.									
• The	 emerging	 ecosystem	 is	 not	well	 understood,	 new	 agile	 entrants	 and	 new	models	 are	meeting	risk	averse	and	fragmented	stakeholders.	
• The	 emerging	 ecosystem	 contains	 organizations	 with	 wide	 variations	 in	 culture	 and	capabilities,	 and	 typically,	 there	 is	 a	 lack	 of	 customer	 engagement	 and	 understanding	 of	future	business	models.	
• New	assets	and	investments	carry	higher	risk	and	have	less	understood	investment	decision	criteria.	
• Public	R&D	funding	and	venture	capital	investment	are	not	well	developed	and,	in	addition,	Regulation,	Legal	and	IP	issues	are	more	ambiguous	in	the	emerging	ecosystem.	
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• The	Value	Networks	and	Supply	Chains	require	new	alliances	and	new	models	to	address	the	lack	of	infrastructure	and	support	organizations.		
8.3 Underpinning Processes for Innovation  The	 following	 section	 discusses	 the	 proposed	 micro-processes	 (organisational	 routines)	underpinning	convergent	innovation.		
8.3.1 Searching Some	 innovators	 used	 structured	 and	 systematic	 searches,	 at	 least	 initially.	 	 	 Some	 also	 used	open	 innovation	and	 crowdsourcing,	 but	 to	 limited	 effect.	 	Why	were	 these	 traditional	search	methods	not	effective	 in	 this	environment?	 	 It	 is	suggested	 there	are	 two	primary	reasons	 for	this,	which	are	developed	later	in	this	chapter:		
• to	 conduct	 a	systematic	 search	 and	 to	 crowdsource,	 the	 issue	or	 information	 required	needs	to	be	codified	in	some	way.	This	implies	a	level	of	understanding	that	may	not	be	initially	available	in	convergent	innovation.	
• to	attract	others	(e.g.	to	join	a	crowdsourced	initiative)	the	innovator	needs	to	be	visible,	legitimate	 and	 credible.	 The	 actor’s	 engagement	 needs	 to	 be	 “seen	 as”	 valid	 by	 other	actors.		Four	of	 the	 five	 cases	 started	with	 some	 systematic	 or	 crowdsourced	 type	 searches,	 but	 they	evolved	to	more	exploratory	search	processes.	This	often	involved	engaging	the	network	of	their	network,	using	‘snowballing’	to	expand	searches	and	using	contacts	from	meetings	and	events	to	further	their	search.	 	What	appears	key	to	many	of	the	searches	was	building	of	some	form	of	relationships	with	others.			Searching	 is	 considered	 strategic	 in	 the	 sense	 that	 it	 is	 critical	 to	 the	 venture	 (Pandza	 and	Thorpe,	2009).	So,	 it	needs	 to	be	active,	deliberate	and	directed	(Zollo	and	Winter,	2002),	but	also	 creative,	 evolutionary	 and	adaptive	 	 (Stack	 and	 Gartland,	 2003).	 Interestingly,	 there	was	little	 evidence	 of	 using	 intermediaries	 or	 knowledge	 brokers	 as	 has	 been	 suggested	 by	 other	authors	(Birkinshaw	et	al.,	2007;	Obstfeld,	2005).	This	may,	in	part,	be	due	to	the	nature	of	the	convergence	and	the	 limited	ability	 to	codify	knowledge	and	search	requirements.	 It	may	also	be,	that	such	brokers	with	the	relevant	knowledge	breadth	did	not	exist	or	lacked	credibility.		Or,	that	with	no	clear	domain	and	no	leading	actors,	those	with	knowledge	were	simply	unaware	of	other	actors	who	may	be	relevant.		Consequently,	the	cases	engaged	in	exploratory	searches	that	were	strongly	linked	to	direct	engagement	and	building	relationships.		
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Three	 cases	 (NMD,	 DH1	 and	 CMTI)	 were	 instrumental	 in	 helping	 develop	 a	 knowledge	ecosystem	(Clarysse	et	al.,	2014).	This	was	most	evident	 in	 the	case	NMD,	where	 they	 funded	conferences	and	events	with	the	express	aim	of	encouraging	knowledge	exchange	and	building	the	 network	 understanding.	 They	 later	 pushed	 for	 special	 topics	 at	 established	 academic	conferences	 to	 ‘spread	 knowledge’.	 	 Similar	 knowledge	 sharing	 events	 were	 also	 curated	 by	CMTI,	 who	 organised	 a	 series	 of	 workshops	 and	 summits.	 	 In	 case	 DH1	 there	 were	 also	deliberate	 attempts	 to	 create	 and	 curate	 events	 that	 fostered	 knowledge	 exchange	 across	 a	diverse	 audience	 of	 patients,	 practitioners,	 providers,	 payers	 and	 developers.	 The	 early	formation	of	a	knowledge	ecosystem	(Valkokari,	2015)	is	consistent	with	the	evolutionary	path	of	convergence	suggested	by	Hacklin	and	Wallin	 (2013).	 	What	 the	case	evidence	additionally	suggests,	is	the	need	for	innovators	to	actively	participate	in,	and	shape	these	activities.			
8.3.2 Sense-making (and sense-giving) The	importance	of	sense-making	in	any	new	venture	or	innovation	is	well	established	(Garud	et	al.,	2013;	Sutcliffe	et	al.,	2005;	Weick,	1995).	But	there	is	also	a	need	for	sense-giving	(Gioia	and	Chittipeddi,	 1991)	 in	 order	 to	 engage	 potential	 collaborators	 and	 to	 help	 establish	 common	understanding.	 It	 is	 suggested	 that	 this	 is	 achieved	 through	 the	 revealing	of	 some	knowledge	through	 ‘boundary	 objects’	 (Carlile,	 2004,	 2002;	 Leigh	 Star	 and	 Griesemer,	 1989)	which	 help	others	 to	understand	through	processes	of	 transferring,	 translating	and	 transforming	 (Carlile,	2004).			Where	the	actors’	domain	knowledge	is	similar,	a	transfer	process	is	adequate,	but	as	the	knowledge	distance	increases,	there	is	a	need	to	translate	or	transform	that	knowledge	to	enable	exchange	 of	 understanding.	 	 	 Based	 on	 the	 case	 evidence,	where	 knowledge	 and	actors	were	often	distant,	 the	 translate	and	transform	approaches	appear	more	evident	and	would	explain	the	need	for	direct	engagement,	rather	than	via	a	third	party	or	on-line	search.		Given	 the	 inherent	 risks	 in	 exchanging	 knowledge	 with	 others	 (i.e.,	 that	 you	 may	 give	 away	intellectual	property),	there	is	evidence	of		‘selective	revealing’	(Alexy	et	al.,	2013)	as	innovators	navigate	and	negotiate	a	position.	 	This	was	more	evident	in	cases	NMD	and	MLD	and	to	some	extent	DH1.	NMD	set	up	collaborative	agreements	to	ensure	control	of	knowledge	with	rights	to	
both	 parties,	 although	 the	 knowledge	 was	 pre-competitive	 and	 earlier	 than	 downstream	exploitative	 processes	 (Valkokari,	 2015).	 	 These	 agreements	 appeared	 to	 help	 build	 trust	amongst	diverse	actors.	 	NMD	also	chose	to	only	partially	reveal	some	aspects	of	their	venture	until	 they	held	 some	positional-advantage,	 as	 summarised	by	NMD-1:	 “…	 for	later	work,	that’s	
more	commercial,	we	are	more	opaque.	I’m	happy	for	the	competition	….	thinking	or	seeing	this	is	
just	 [NMD]	working	on	a	 ‘moonshot’,	 10	 years	 away...	 and	not	 being	hopeful	 about	 being	 in	 the	
clinic	 in	 the	next	 3	 years.	 	 But	 equally	 there	 is	no	benefit	 to	 overhype	 it.	 	 	 So,	we	want	 to	make	
progress	for	the	next	year	or	so,	first”.		
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	So,	 there	 is	 a	 careful	 balancing	 act	 required:	 a	 need	 to	 engage,	 to	 be	 credible,	 to	 reveal	 and	exchange,	but	also	not	give	away	value.		The	revealing	is	selective	(Alexy	et	al.,	2013).		Building	on	 a	 combination	 of	 case	 evidence,	 supported	 by	 prior	 literature,	 Figure	 8-2	 suggests	 a	non-deterministic	 approach	 for	 how	 these	 exploratory	 and	 evolutionary	 processes	 may	 operate	together,	 balancing	 knowledge-building	 processes	 with	 relationship-building	 processes.	 	 To	explore	 boundaries,	 to	 find	 distant	 knowledge	 and	 partners,	 there	 is	 a	 ‘divergent’	 phase,	exploring	breadth	rather	than	depth	(Laursen	and	Salter,	2006).	Here	snowballing	is	often	used	to	extend	the	search.		Several	of	the	cases	(NMD,	CMTI,	MLD)	deliberately	pushed	their	searches	wide.	This	approach	makes	sense	given	the	desire	to	access	and	obtain	long-term	value;	Rivkin	and	 Siggelkow	 (2007)	 identify	 that	 in	 complex	 systems,	 broader	 exploration	 delivers	 greater	long-run	 value.	 	 	 Activities	 are	 aimed	 at	 basic	 understanding	 and	 building	 credibility.	 As	knowledge	 is	gained,	 enabling	better	 codification,	and	as	 relationships	are	 formed	(increasing	their	 network	 and	 legitimacy),	 crowdsourcing	 may	 become	 appropriate.	 	 Later	 the	 searches	appear	to	converge,	focussing	on	the	network	and	knowledge	of	greatest	value	(and	with	move	to	exploitative	actions).			
8.3.3 Selecting The	 approaches	 used	 by	 all	 cases	 to	make	decisions	 varied,	 but	 tended	 to	 use	 broad	 criteria,	rather	 than	 specific	 ‘decision	 gate’	 criteria,	 as	 often	 identified	 in	 the	 innovation	 literature	(Cooper,	 1990;	 Cooper	 and	 Kleinschmidt,	 2007).	 	 	 This	 broad	 approach	 aligns	 more	 with	thinking	in	“fuzzy	front	end”	innovation	(Khurana	and	Rosenthal,	1997;	Koen	et	al.,	2014,	2001).		Several	 cases	 used	 ecosystem	 actors	 to	 help	 in	 decision	 processes.	 Case	 NMD	 used	 the	ecosystem	 to	 help	 define	 the	 problem,	 the	 criteria	 and	 sense-check	 solutions	 as	 part	 of	 their	open	innovation	challenge.	Similarly,	DH1	used	stakeholders	to	define	problems,	shape	solutions	and	provide	 information	 to	underpin	decisions.	 CMTI	used	 the	 ecosystem	 to	 help	 shape	 their	strategic	decisions.	This	approach	not	only	helps	reduce	risk,	but	also	helps	build	relationships,	a	network	position,	increasing	their	perceived	credibility	and	legitimacy.		Interestingly	few	innovators	used	partners	they	already	had	established	relationships	with	(i.e.	prior	to	the	venture).		The	reasoning	posed	for	this	is	that	they	are	seeking	new	knowledge	and	complementary	capabilities	and	 in	convergence	 these	are	unlikely	to	be	 in	 their	existing	value	network.		CMTI	approached	previous	investors	for	funding,	but	also	engaged	new	ones.	The	only	case	that	significantly	‘went	back	to	people	they	already	knew’	was	DH2.			
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8.3.4 Shaping Innovation	is	essentially	a	creative	process	(Adner	and	Kapoor,	2008;	Alvarez	and	Barney,	2007;	Sydow	 et	 al.,	 2012),	 with	 a	 balancing	 of	 both	 path	 dependency	 and	 path	 creation	 processes	(Sarasvathy,	 2001;	 Sarasvathy	 and	 Dew,	 2005)	 and	 may	 require	 path	 breaking	 (Aarikka-Stenroos	and	Ritala,	2016;	Karim	and	Mitchell,	2000;	Sydow	et	al.,	2009).	To	do	this	firms	need	processes	 to	synthesise	 the	knowledge	and	potential	partners	across	 the	ecosystem.	 	There	 is	evidence	 in	 all	 cases	 of	 firms	 attempting	 to	 and	 succeeding	 in	 shaping	 their	 innovations.	 The	evidence	is	more	nuanced	however,	in	how	firms	undertook	this.				NMD	had	a	clear	idea	of	where	they	wanted	to	be	from	the	outset	(as	described	in	their	‘White	Paper’):	“Bioelectronics	promises	to	be	a	major	source	of	future	medicines.	The	launch	of	…	aims	to	
give	 [NMD]	 a	 leadership	 position	 in	 this	 emerging	 field.	 A	 network	 of	 research	 partners	 with	
multiple	disease	test	beds	and	gate	keeper	technologies	will	be	integrated	by	a	‘virtual’	team	with	a	
£[X-Y]m	 budget	 ...	 The	 output	 should	 crystallise	 the	 extent	 to	 which	 bioelectronics	 can	 be	 a	
sustainable	 [NMD]	innovation	 leg.	 	 	However,	 the	process	 to	 achieve	 this	was	not	as	 clear.	 	By	engaging	a	nascent	ecosystem,	building	a	credible	position	within	it,	and	by	providing	resources,	they	could	take	an	increasingly	central	and	influential	position.	That	enabled	them	to	shape,	not	only	 the	 innovation,	but	also	 the	value	network	and	wider	ecosystem.	 	 	 In	case	DH1,	although	they	 did	 not	 make	 investments	 on	 the	 scale	 of	 NMD,	 they	 continually	 engaged	 the	 local	ecosystem	and	built	a	network	at	national	level	that	positioned	them	as	credible	and	influential.				Case	MLD,	 a	 start-up	 with	 limited	 positional	 power,	 relied	more	 heavily	 on	 internal	 creative	processes	and	 then	building	relationships	with	a	diverse	range	of	partners.	 Initial	attempts	 to	find	 investors	 resulted	 in	 repeated	 failures,	 but	 these	were	overcome,	 by	using	 less	 specialist	investors	and	 then	using	 the	 ‘network	of	 their	network’	 to	 find	additional	 investors.	Similarly,	the	 value	 networks	needed	were	 developed	 through	 building	 on	 ‘networks	 of	 their	 network’,	and	engaging	others	with	potentially	complementary	capabilities.	At	CMTI	the	shaping	process	was	initially	quite	ambitious	but	after	extensive	engagement	and	review	it	became	more	about	building	 on	 and	 extending	 capabilities	 and	 partnerships,	 and	 therefore	 appears	 to	 be	 more	incremental	in	terms	of	approach.	DH2	had	a	clear	idea	of	their	innovation	and	how	they	wanted	to	position	it,	but	never	managed	to	create	a	position	of	influence	or	credibility	before	options	and	funding	ran	out.			The	inference	from	these	cases	is	that	‘shaping’	an	innovation,	through	creative	processes	is	not	sufficient.	 	Unlike	existing	 industries	or	established	 innovation	ecosystems,	both	start-ups	and	large	 established	 firms	 (moving	 from	 their	 incumbent	 domain)	 must	 first	 establish	 this	
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credibility	 and	 legitimacy.	 	 There	 are	 antecedents	 to	 the	 formation	 of	 value	 propositions	 and	value	networks.			
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Figure	8-2	Evolutionary	search	and	sense-making	processes	evident	in	case	research	
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8.3.5 Sustaining In	 any	 innovation,	 there	 is	 a	need	 to	 invest	 in	activities	 that	de-risk	 the	 venture	 (Kayis	 et	 al.,	2007).			In	several	cases,	there	was	evidence	of	investment	in	developing	support	capabilities,	in	the	value	network	and	even	the	wider	ecosystem.		Case	NMD	invested	significantly	in	supporting	other	 ecosystem	 actors	 (i.e.,	 by	 sponsoring	 events	 and	 conferences),	 in	 funding	 an	 enabling	technology	 (via	 an	 open	 innovation	 challenge)	 to	 address	 an	 ecosystem	 gap	 and	 directly	supported	 actors	by	 funding	 research	 and	 investing	 in	start-ups.	DH1	engaged	and	 supported	the	 wider	 ecosystem,	 by	 funding	 events	 (e.g.	 ‘Discovery	 Days’)	 and	 workshops.	 They	 also	provided	 resources	 to	other	 stakeholders	on	 a	pro	bono	 basis	 (e.g.,	 for	 a	 charity)	 as	part	 of	 a	culture	 of	 building	 relationships;	 described	 by	 the	 CEO	 (DH1-1)	 as:	 “Connections	 do	 not	 just	
happen.			You	need	to	‘cultivate’	to	create	the	right	opportunities.			That	is	where	I	see	this	spirit	of	
generosity	and	being	open,	 learning	together	as	being	important”.	 	Towards	the	end	of	 the	 case	period	they	were	also	exploring	the	possibility	of	creating	an	innovation	space	for	other	digital	health	 start-ups,	 thereby	 further	 sustaining	 the	 ecosystem,	 and	 strengthening	 their	 position.		Similarly,	CMTI	hosted	events	with	the	express	intent	of	helping	build	a	network.			For	smaller	start-ups,	such	as	MLD	and	DH2,	with	limited	resources,	it	is	still	important	to	build	a	 position	 of	 credibility	 and	 trust.	 	 MLD	maintained	 links	with	 a	 diverse	 group	 of	 clinicians,	venture	 funds	 and	 developers,	 and	 used	 these	 as	 opportunities	 to	 help	 develop	 their	 value	proposition	and	value	network;	important	precursors	to	obtaining	investment.	DH2	on	the	other	hand,	focussed	on	a	much	narrower	set	of	actors,	and	this	may	have	been	a	contributor	to	their	failure.			
8.3.6 Micro-processes for innovation These	five	micro-processes	appear	to	underpin	all	innovation	activities,	including	the	innovation	itself,	 the	 development	 of	 the	 business	 model	 and	 the	 nascent	 value	 network.	 	 It	 should	 be	pointed	out	at	this	juncture	that	whilst	these	processes	are	not	dynamic	capabilities.	 	Dynamic	capabilities	 are	 “the	 capacity	 of	 an	 organization	 to	 purposefully	 create,	 extend,	 or	 modify	 its	
resource	base”	(Helfat	et	al.,	2007,	p.	4),	that	is	they	are	organization	transformational	processes,	not	innovation	processes.	The	mechanism	for	the	development	of	these	innovation	capabilities,	and	the	relevance	of	dynamic	capabilities,	is	further	addressed	in	Section	8.8.			
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8.4 Innovation Activity System It	 is	 suggested	 that	 these	 five	micro-processes	 to	 –	 searching,	 sense-making,	selecting,	 shaping	
and	 sustaining	 do	 not	 operate	 in	 isolation	 or	 in	 a	 linear	 manner,	 as	 is	 often	 depicted	 in	innovation	literature	(see	for	example,	Cooper,	1990;	Cooper	and	Kleinschmidt,	2007).		There	is	some	 inter-relation	and	sequencing	(e.g.,	 searching	before	sense-making).	 	Reviewing	 the	case	evidence	 (see	 Chapter	 7	 cross-case	 analyses)	 suggests	 that	 searching,	 sense-making	 and	selecting	 operate	 collectively,	 that	 then	 inform	 shaping	 and	 sustaining	 activities.	 But	 having	made	a	sustaining	or	shaping	decision	there	is	a	need	to	revisit	the	searching,	sense-making	and	selecting	 as	new	 knowledge,	 partners	 and	 decisions	 are	 required.	 These	 groupings	 of	 ‘micro-processes’	can	 therefore	be	conceived	 to	operate	as	non-deterministic	processes	as	part	of	an		‘activity	system’	(Siggelkow	and	Porter,	2008)	and	the	early	formation	of	organisational	routines	(Becker,	2004;	Nelson	and	Winter,	1982)			The	proposed	combinations	of	micro-processes	are	depicted	in	Figure	8-3	as	three	groupings	in	an	activity	system	with	phases	that	navigate,	negotiate	and	then	nurture.							
8.4.1 Navigate A	nascent	and	emerging	ecosystem,	can	be	considered	as	an	unfolding	and	evolving	landscape.			To	understand	and	survive	 in	this	environment	it	 is	considered	necessary	 to	search	and	make	sense,	before	making	decisions	(Kahneman	and	Tversky,	2007).	These	actions	are	 largely	pre-competitive,	 they	 are	 about	 building	mutual	 understanding	 (Helfat	 and	 Peteraf,	 2015).	 	 They	require	a	degree	of	collective	agency	(Sydow	et	al.,	2012)	with	both	parties	being	prepared	 to	exchange	knowledge	 (as	 information	or	network	 contacts)	 through	boundary	objects	 (Carlile,	2004,	 2002;	 Leigh	 Star	 and	 Griesemer,	 1989)	 that	 enable	 the	 actors	 to	 transfer,	 translate	 or	transform	knowledge.	 	Cases	NMD,	DH1	and	CMTI	used	flexible	approaches	to	identify,	engage	and	build	relationships.	 	This	was	 less	evident	 in	MLD,	and	almost	non-existent	 in	 the	case	of	DH2.		
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Figure	8-3	Navigate,	Negotiate	and	Nurture	as	a	convergent	innovation	activity	system		At	 this	stage	 the	ecosystem	could	be	considered	as	a	knowledge	ecosystem	(Valkokari,	2015).	The	ecosystem	is	fluid,	the	focus	of	attention	may	move	as	new	knowledge	is	gained	(Dobusch	and	 Schoeneborn,	 2015)	 and	 as	 new	 actors	 join	 and	 leave.	 	 So,	 the	 knowledge	 ecosystem	 is	evolutionary	and	can	be	considered	incomplete	(Garud	et	al.,	2008).		Knowledge	ecosystems	are	not	 entirely	 self-organized	due	 to	 the	 existence	of	 some	 level	 of	 intentional	action	(Valkokari,	2015),	here	on	 the	part	of	innovators.	The	case	evidence	shows	DH1	and	NMD	as	taking	a	co-ordinating	role,	and	this	being	an	intent	for	CMTI.			A	 challenge	 in	 this	 environment	 is	 searching	 too	 widely,	 losing	 efficiency	 as	 the	 knowledge	distance	extends	(Nooteboom	et	al.,	2007)	or,	searching	too	narrowly	and	missing	opportunities	(Enkel	and	Heil,	2014b).		The	evidence	suggests	that	a	moderating	factor,	aiding	this	navigation	may	be	 the	 relationships	 themselves.	As	 these	 form,	 they	 enable	organisations	 to	make	more	informed	 choices	 about	 the	 depth	 and	 breadth	 of	 searches.	 	 Searching	 and	 sense-making	processes	 are	 linked	 to	 the	 absorptive	 capacity	 (Cohen	 and	 Levinthal,	 1990)	 and	 key	 to	innovation	capability	(Ferreras-Méndez	et	al.,	2015).		The	need	for	a	wide	search	scope	suggests	a	 decentralised	 group	 and	 activity	 (Enkel	 and	 Heil,	 2014b),	 which	 was	 evident	 in	 the	 cases	studied.		Larger	organisations	devolved	the	search	processes	to	small,	flexible	organisations	who	were	intimately	engaged	in	the	innovation.			
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8.4.2 Negotiate To	 progress	 an	 innovation,	 there	 is	 a	 need	 to	 develop	 common	 cause	 and	 a	 pathway	 (Geels,	2005;	Geels	and	Schot,	2007).	 Importantly	 the	 innovator	must	be	able	 to	 ‘take	a	position’	and	transition	 from	exploratory	 activities	 to	 exploitative	 activities	 (Colombo	et	 al.,	 2006;	Kim	and	Atuahene-Gima,	 2010).	 This	 requires	 innovators	 to	 address	 both	 positional	 and	 relational	perspectives	(Dyer	and	Kale,	2007).					To	 be	 able	 to	 negotiate	 there	 is	 a	 need	 for	 both	 credibility	 and	 legitimacy,	 and	 to	 be	 visible	within	the	ecosystem	(Aarikka-Stenroos	and	Lehtimaki,	2014).		It	is	suggested	that	these	result,	in	part,	 from	 the	nurturing	activities	 (below),	whereby	 the	 innovator	 creates	 tangible	 outputs	(demonstrating	 commitment),	and	 supports	 others	 in	 the	 ecosystem.	 	This	was	 evident	 in	 the	NMD	and	DH1	 cases,	who	both	 committed	 to	building	 a	position	of	 credibility,	 and	providing	support	to	the	wider	ecosystem.		Case	CMTI’s	strategy	was	to	provide	infrastructure	and	support	to	 convergent	 ecosystems,	 but	 invested	 in	building	 an	understanding	 and	partnerships	before	making	 a	major	 commitment.	 	MLD,	 whilst	 not	 having	 the	 resources	 to	 invest	 heavily	 in	 the	ecosystem,	nonetheless	invested	in	maintaining	diverse	and	strong	relationships.	This	enabled	the	cases	 to	access	 further	knowledge	and	 form	new	alliances	 (Wang	and	Rajagopalan,	2015),	which	 are	 critical	 to	 access	 complementary	 capabilities	 or,	 to	 enhance	 their	 own	 capabilities.	These	 partnerships	were	 formed	 and	 re-formed	 by	MLD,	 NMD,	 DH1	 and	 CMTI.	 	 They	 can	 be	viewed	 as	 non-deterministic	 where	 the	 outcome	 is	 not	 pre-ordained,	 equally	 they	 are	 not	arbitrary,	and	have	been	described	as	non-ergodic	(Sydow	et	al.,	2012).		This	approach	enables	innovators	to	selectively	reveal	knowledge	and	their	position	(Alexy	et	al.,	2013)	as	part	of	the		negotiation	process.				
8.4.3 Nurture The	 innovation	 environment	 under	 conditions	 of	 convergence	 are	 complex	 (Rikkiev	 and	Mäkinen,	 2013)	 with	 a	 lack	 of	 stable	 institutional	 support	 or	 frameworks.	 Further,	 the	innovation	may	actually	disrupt	established	institutional	norms	in	terms	of	regulative	(rules)	 ,	normative	(values)	and	cultural	 (beliefs)	elements	(Scott,	1995,	p.	56).	 	Such	 innovations	may	disrupt	 entire	 ecosystems	 (Ansari	 et	 al.,	 2016)	 or	 create	 entirely	 new	 ones.	 As	 previously	identified	there	 is	a	need	 for	both	shaping	and	sustaining	decisions	 to	progress	an	 innovation.		These	were	most	evident	in	NMD	and	DH1,	but	were	present	to	some	degree	in	MLD	and	CMTI.				This	combination	supports	the	argument	for	both	path	creation	and	path	dependent	approaches	(Sydow	 et	 al.,	 2012).	 These	 activities	 often	 go	 beyond	 those	 needed	 for	 the	 immediate	innovation,	but	may	provide	support	to	the	wider	ecosystem,	in	a	form	of	‘nurturing’	(Rong	et	al.,	2013).	 	 These	nurturing	 activities,	 creating	outputs	 and	new	knowledge	on	 the	one	hand	and	supporting	others,	and	the	wider	ecosystem,	on	the	other	hand	-	are	suggested	as	key	parts	of	a	
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process	to	build	legitimacy	and	credibility,	and	in	building	relationships	as	well	as	knowledge.		Furthermore,	 it	 is	 suggested	 that	 these	 are	 pre-cursors	 to	 building	 an	 ‘advantage-seeking’	position.			
8.5 Nascent Value Network Formation As	 convergence	 requires	 new	 capabilities	 (Enkel	 and	 Heil,	 2014b),	 the	 organization	 has	 a	number	of	options	for	building,	acquiring	or	accessing	these	(Barney,	1999;	Gulati	et	al.,	2012).	Given	the	challenges	in	internal	development	or	in	outright	acquisition,	alliance	formation	and	management	(Schreiner	et	al.,	2009)	would	appear	to	be	a	critical	capability	in	the	development	of	‘nascent	value	networks’.		All	five	cases	of	attempted	to	build	new	value	networks.		However,	these	 initially	 tended	 to	 be	 short-term	 or	 transient.	 	 	 The	 networks	were	 often	 created	 for	 a	specific	purpose,	 to	create	knowledge,	deliver	defined	output	or	address	a	known	risk.	 	Those	networks	then	evolved	as	the	needs	of	the	innovator	firm	evolved.				Value	networks	are	essential	 for	 innovators	 to	deliver	and	appropriate	value,	but	much	of	 the	extant	 literature	 focusses	 on	 established	 industries	 and	 relatively	 stable	 environments.		Convergence	 creates	 conditions	 of	 higher	 uncertainty	 and	 instability.	 As	 a	 consequence,	 the	traditional	criteria	(for	examples,	see	Hitt,	Dacin,	Levitas,	Arregle,	&	Borza,	2000;	Li,	Eden,	Hitt,	&	Ireland,	2008),	are	not	considered	appropriate.					Traditional	 value	network	 theory	would	 suggest	 that	higher	 levels	 of	 network	 integration	 are	considered	important	indicators	of	performance	(Prajogo	and	Olhager,	2012).	However	much	of	that	extant	research	is	focussed	on	established	or	mature	industries.	This	research	focussed	on	convergence	 and	 nascent	 ecosystems	 suggests	 that	 such	 an	 approach	 is	 less	 plausible.	 Early	alliance	 formation	 requires	 a	 balancing	 of	 tendencies	 for	 both	 exploration	 and	 exploitation	(Lavie	and	Rosenkopf,	2006),	the	evidence	from	this	research	suggests	that	the	domain	dictates	that	explorative	action	is	required	first.		The	search	for	insightful	stakeholders	and	then	sense-making	 is	 critical,	 but	 different	 stakeholders	 have	 different	 (and	 sometimes	 conflicting)	perspectives	 about	 value	 (Garriga,	 2014).	 Diversity	 in	 innovation	 alliances	 is	 recognised	 as	important	 (see	 for	 example,	 Nieto	 &	 Santamaria	 2007),	 in	many	 of	 the	 cases	 the	 innovators	found	that	later	collaborators	were	often	not	those	they	had	engaged	early	on,	and	so	building	flexibility	into	the	collaboration	practices,	and	undertaking	activities	to	demonstrate	‘credibility’	are	potentially	important	precursors	to	accessing	tertius	iungens	actors	(Obstfeld,	2005);	those	actors	who	enable	and	potentially	catalyse	further	interactions	and	network	building.	In	all	the	cases,	 those	 interactions	 were	 invariably	 face	 to	 face,	 reinforcing	 the	 importance	 of	 direct	engagement	(Nonaka	and	Konno,	1998)	and	the	socialization	aspects	(Dingler	and	Enkel,	2016).		
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Bringing	 together	 these	 insights	 from	 the	 cases,	 a	 suggested	 suite	 of	 activities	 emerges,	 as	depicted	in	Figure	8-4.				An	observation	is	that	the	process	of	forming	nascent	value	networks	is	not	a	‘design’,	but	is	an	active,	exploratory	and	evolutionary	process.	Innovators	cycle	through	activities	as	they	aim	to	navigate	(the	nascent	ecosystem),	negotiate	 (a	position	within	 it)	and	nurture	(the	 innovation	and	their	value	network).	Case	evidence	supporting	the	suggested	links	to	the	innovation	micro-processes	is	summarised	in	Table	8-1.					Tsanos	 et	 al.	 (2014)	 identify	 that	 these	 antecedents	 are	 important	 in	 building	 supply	 chain	collaborations.	Such	actions	also	build	trust	(Larson,	1992;	Todeva	and	Knoke,	2005),	however	this	trust	appears	to	be	needed	beyond	simple	dyadic	relationships,	instead	requiring	that	trust	to	be	built	within	the	context	of	the	emerging	network	or	ecosystem,	 through	both	action	and	visibility.		The	 processes,	 are	 thus	 more	 complex	 and	 nuanced	 than	 implied	 in	 extent	 alliance	 forming	literature.			The	case	evidence	would	point	to	both	‘emergent’	and	‘engineered’	processes	(Doz	et	al.,	2000)	being	adopted.	 	 	Whilst	considerable	evidence	 for	an	 ‘engineered	process’	exists,	via	options	exploration,	aligning	domain	interests	and	filling	structural	holes,	there	is	also	evidence	of	 ‘emergent	processes’	with	a	need	for	similar	interests,	defining	boundaries,	and	evidence	of	learning.			
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Figure	8-4	Suggested	processes	for	formation	of	Nascent	Value	Networks	
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Table	8-1	Summary	case	evidence	of	micro-processes	in	value	network	formation	
Activity Example actions CMTI DH1 NMD MLD DH2 
Searching Exploratory 
search, beyond 
normal network 
Yes Yes Yes Yes Partial, 
Narrow 
search 
Sense-
making 
Engaging diverse 
actors to 
understand value 
and risks 
Yes Yes, 
extensive 
Yes, 
extensive 
Yes Limited 
Selecting Directional 
criteria, use 
ecosystem to aid 
Yes Yes, 
Partial 
Yes Yes, 
Partial 
No 
Shaping Invest in 
innovation, value 
network and 
business model 
Yes, 
multiple 
options 
Yes, 
multiple 
options 
Yes, 
multiple 
options 
Yes, 
multiple 
options 
Yes, 
focused 
Sustaining Invest in building 
relationships, 
creating credibility 
and legitimacy 
Yes Yes Yes Yes, 
Partial 
No 
		These	 approaches	 would	 support	 that	 moving	 into	 ‘uncharted	 territory’,	 where	 ‘potential	
partners	are	neither	actors	you	can	easily	 identify	nor	are	 they	 (once	you	 find	 them)	 likely	 to	be	
keen	 to	 engage	 with	 you’	 (Birkinshaw	 et	 al.,	 2007),	 requires	 different	 network	 building	approaches.		However,	this	research	would	suggest	that	alternative	paths	to	those	identified	by	Birkinshaw	et	al.	(2007,	p.	81)	are	available	to	innovators.			None	of	the	five	cases	attempted	to	use	 ‘knowledge	 brokers’	 or	 ‘independent	 network-builders’	 but	 instead	 invested	 and	 directly	engaged	themselves,	and	took	advantage	of	opportunities	that	arose	through	those	connections.	It	is	suggested	that	in	such	networking	activities,	the	act	of	direct	engagement	was	a	precursor	to	building	credibility	and	trust,	and	 importantly	by	directly	engaging,	the	 innovator	can	build	meaningful	domain	knowledge	and	understanding.		The	 uncertain	 nature	 of	 the	 environment	 also	 makes	 decision	 processes	 challenging,	organizations	appear	more	 likely	 to	rely	on	 interpretation	and	broad	criteria	 (Daft	and	Weick,	1984;	 Dean		 Jr	 and	Sharfman,	 1996),	 as	part	 of	 their	 ‘exploitative’	 learning	process	 (Kim	and	Atuahene-Gima,	 2010).	 The	 evidence	 that	 innovators	 engaged	 their	 ecosystem	 to	 help	 in	investment	decisions	has	the	internal	effect	of	reducing	risk	and	the	external	effect	of	being	seen	to	 value	 the	 other	 ecosystem	 or	 network	 actors;	 this	 reciprocity	 being	 important	 in	 building	wider	trust.		So,	focusing	on	value	creation	alone	is	insufficient,	there	is	also	a	need	to	invest	in	the	 value	 network	 and	 the	 ecosystem	 itself	 (Smith,	 2013),	 thus	 these	 relationship	 specific	
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investments	help	to	sustain	the	innovation,	and	ecosystem,	by	making	and	encouraging	network	connections	(Garriga,	2014).				Higher	 levels	 of	 network	 integration	 are	 considered	 important	 indicators	 of	 performance	(Prajogo	and	Olhager,	 2012).	Whilst	 this	may	hold	 for	 established	 industries	and	 their	supply	chains,	 developing	 a	 highly-integrated	 value	 network	 at	 this	 phase	 in	 the	 innovation	 and	ecosystem	lifecycle	was	not	observed;	the	one	case	that	attempted	something	akin	to	this	failed.	The	evidence	suggests	that	whilst	highly	integrated	networks	may	be	a	longer-term	goal,	there	is	a	need	to	develop	flexible	and	looser	networks	first.			The	reasoning	suggested	for	this	is	-	that	innovators	first	need	to	build	their	ecosystem	credibility,	and	to	build	knowledge	and	capability,	to	make	better	decisions	on	 longer	 term	partners.	 	 	For	an	 incumbent	 firm,	 there	are	also	 the	challenges	of	internal	acceptance	whilst	the	innovation	risks	are	still	high	(Tushman	and	Reilly,	1996),	 which	 is	 addressed	 later.	 	 	 For	 the	 start-up	 firm,	 creating	 highly	 integrated	 networks	implies	a	resource	commitment	and	early	focus	that	may	increase	risk.	Considering	this	in	terms	of	a	pathway,	knowledge	distance	and	network	integration	(Figure	8-5)	for	both	incumbent	and	start-up	firms,	route	C	carries	higher	risk	for	the	reasons	explained	above.	 	 	Of	the	5	cases,	the	one	 failure	 was	 effectively	 attempting	 the	 direct	 route	 C,	 the	 four	 other	 cases	 adopted	approaches	 analogous	 to	 route	 A-B.	 So,	 instead	 of	 building	 highly	 integrated	 networks	 it	 is	observed	that	 firms	 initially	move	 to	establish	many	 looser,	 shorter	 term	relationships,	before	making	a	commitment	to	longer	term	alliances.		
	
Figure	8-5	Suggested	migration	paths	for	start-up	and	incumbent	firms	to	form	integrated	
value	networks		Comparing	configuration	concepts	in	mature	supply	networks	(Harrington	et	al.,	2012;	Srai	and	Gregory,	 2008),	 ‘emerging’	 contexts	 (Harrington	 and	 Srai,	 2016),	 and	 ‘nascent’	 contexts,	structure	may	 be	 regarded	 as	 the	 most	 critical	 in	 a	 mature	 context	 and	 is	 focused	 on	 tier	structure	 and	 shape,	 addressing	 increasing	 geographical	 dispersion	 and	 integrating	mechanisms.	 With	 limited	 structure	 in	 an	 ‘emerging’	 context,	 partner	 and	 process	 selection	
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(customers	and	suppliers)	and	developing	longer	term	relationships	(new	and	existing)	may	be	most	critical	and	include	the	set-up	of	new	partnering	arrangements	within	emerging	clusters	of	activity	at	a	new	location,	while	leveraging	critical	elements	of	pre-existing	supply	networks	that	may	be	well	established	and	relevant	to	an	‘emerging’	context.	However,	 in	the	case	of	nascent	networks	it	is	argued	that	as	early	networks	are	often	transitory	in	nature,	relational	aspects	(i.e.	building	quality	external	relationships)	may	be	more	critical	than	traditional	criteria	for	partner	selection.		
Table	8-2	Activities	underpinning	the	configuration	of	nascent	value	networks	
Configuration 
Elements 
Navigate Negotiate Nurture 
Relationships Exploratory Searches 
Sense-make (and 
sense-giving) 
Initiate collaborations 
(short-term) 
Build legitimacy 
(internally and externally) 
Structure Widen connections and 
access to knowledge 
Seek 
complementarities 
Build credibility (by 
delivering tangible 
outcomes or commitments) 
Network 
Dynamics 
Continue to search, as 
new knowledge 
emerges 
Assess chronicity and 
alignment 
Look for ‘congruence’ 
Continue to invest in 
ecosystem relationships 
Governance and 
coordination 
Senior sponsorship and 
agency to support 
exploration of domain 
and opportunities 
Agile governance 
direction rather than 
detail driven  
Flexible contracts 
Use network to aid 
decision making 
Build an advantage-
seeking position built upon 
credibility and increasing 
capability 
Support 
infrastructure 
Identify gaps in 
support network 
Invest in support 
activities 
Invest in ecosystem 
knowledge and freedom to 
operate 
‘Product’ Engage potential 
‘customers’ to help 
with product definition 
Identify value 
attributes in eyes of 
potential customers 
Reduce early risks 
Shape innovation 	The	framework	(Table	8-2)	synthesises	the	value	network	configuration	elements,	identified	by	Harrington	and	Srai	(2016),	with	the	proposed	activity	system	and	identifies	the	underpinning	activities	required	by	innovators	in	nascent	ecosystems	to	form	nascent	value	networks	as	they	navigate,	negotiate	and	nurture.			
8.6 Value Analysis and Business Modelling A	 requirement	 for	 innovation	 is	 to	 identify	 and	 create	 value	 (Adner	 and	Kapoor,	 2008).	 	 	 As	previously	 identified	 the	 complex	 value	 system	 in	 healthcare	 makes	 this	 task	 complex.	 The	plethora	of	potential	customers	and	adoption	chains,	often	specific	to	a	clinical	or	care	pathway,	make	generalisation	impossible.		The	cases	studied	were	all	pre-commercialisation,	so	business	models	had	not	been	fully	developed.			However,	some	of	the	challenges	in	identifying	value	and	the	business	model	emerged	during	the	research.		
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	For	 example,	 DH2	 failed	 to	 find	 a	model	 that	 worked	 across	 the	 different	 stakeholders	 they	engaged.	 Each	 time	 they	 met	 potential	 partners	 or	 investors,	 a	 different	 approach	 was	suggested.	NMD	 recognised	 that	 the	new	venture	would	 entail	 new	business	models	 and	had	developed	some	options,	but	decided	to	defer	a	decision	until	they	had	more	clinical	data.		DH1	undertook	a	formal	design	using	the	business	model	canvas	(Osterwalder	et	al.,	2010),	but	then	subsequently	modified	 it	 and	 used	multiple	 business	models,	 depending	 on	 the	 client.	 	 	 This	evidence	would	suggest	that	far	from	being	the	suggested	‘design	process’,	(Osterwalder,	2004;	Osterwalder,	 Pigneur	 and	 Smith,	 2010;	 Osterwalder	 and	 Pigneur,	 2013),	 the	 process	 for	convergent	 innovation	 is	 more	 evolutionary	 and	 exploratory.	 	 A	 design	 process	 might	 be	appropriate	where	there	is	limited	uncertainty	and	high	levels	of	stability.			Where	this	is	not	the	case,	 then	 the	 combination	of	navigation	 and	negotiation	 previously	 suggested	are	 considered	more	appropriate.				A	 challenge	 facing	 innovators	 in	 this	 field	 are	 the	 different	 perceptions	 of	 value	 by	 different	actors.	 This	 is	 not	 unique	 to	 healthcare,	 but	 it	 is	 particularly	 complex.	 As	 many	 of	 the	innovations	will	 transform	 the	 care	 pathway,	 there	 is	 also	 a	 path-breaking	 (Karim	 and	Kaul,	2015;	 Karim	 and	Mitchell,	 2000;	 Sydow	 et	 al.,	 2009)	 issue	 in	 the	 potential	 customers’	 value	networks	 to	 be	 addressed.	 MLD	 recognised	 that	 they	 needed	 different	 business	 models	 in	different	territories	and	for	different	applications,	so	they	undertook	activities	to	help	develop	these	which,	by	way	of	an	example	of	the	challenges,	are	illustrated	in	Figure	8-6	and	Figure	8-7	below.						
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Figure	8-6	Example	business	models	considered	by	Case	MLD	(extracted	from	MLD	Investor	presentation)					
	
 Target ‘customer’ Business Model Development plan  Platform Competitive advantage 
Diagnostic Screening Primary Care (e.g. 
GP) or 
commissioning group 
 
Private care 
Charge per test 
(Equipment FOC or 
nominal) 
Regulatory development 
and application 
Multiple Simple, short, no expert 
required, language 
independent 
Post diagnosis monitoring Primary or secondary 
care or 
commissioning group 
 
Subscription Peer reviewed 
Publication based on the 
trials 
Web based 
(JavaScript) 
Outpatient compatibility  
Full service diagnostic 
support 
Secondary care (e.g. 
memory clinics and 
specialists 
 
Private care 
Charge per test and 
equipment 
Follow up on initial 
regulatory application 
Software and add-on 
hardware  
Improved sensitivity 
with AI algorithm  
Home health monitor Consumer direct or 
via health technology 
partners 
Subscription or 
Licensing 
Partnership with health 
monitor providers 
Stand alone or add-on 
to other existing 
health monitor 
platform  
Compatibility with 
different platforms   
Drug discovery and 
development 
Pharmaceutical 
company 
Licensing Peer reviewed 
Publication  
Basic test plus add-on 
hardware 
Repeatability with 
isolating learning effects 
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Figure	8-7	Example	of	value	analysis	undertaken	by	case	MLD		
Product Screening	tool Diagnostic	aid
Description
A	primary	care	tool	that	enables	GPs	to	screen	patients	for	[conditions]	in	surgery	waiting	time,	so	can	quickly	
assess	and	refer	to	specialist	care	if	at	risk
A	tool	applied	by	specialists	at	the	beginning	of	the	diagnosis	process	working	as	a	compimentory	to	the	existing	
settings	such	brain	scan,	biomarkers,	neuropsychological	assessment
Stakeholders:
Who	is	the	user?
Patient	in	waiting	room Ultimately	the	Patient	in		specialist's	clinic.							However	Health	Care	Professionals	(HCP;	Secondary	Care,	GPs)	
might	contract	to	use	the	service;	via	GP	Federations	/	Commissioning	Groups
Who	is	the	use	decision	maker	(to	use)?
Ultimately	GP	asks	Patient	to	do	test.	Supported	NHS	guidelines	for	mental	health	assessment	e.g.	everyone	
aged	over	55
Specialist
Who	is	the	buy	decision	maker	(to	buy	
or	contract)?
Funding	Primary	Care	-	via	NHS	England	or	CCG CCG	/	Trust	Memory	Clinic
Who	pays	for	it	(ie	pays	MLD)? Clinic	or	CCG? CCG	/	Trust	Memory	Clinic
Value	Proposition:
How	does	this	improve	outcome	for	
patient?		Implications?
comforting	worried	well-earlier	referal	and	intervention-	biggest	implication	is	that	some	might	not	want	to	
know	due	to	the	stigma	attached:	"no	tretment"
Earlier	(pre-symptom)	detection	equals	better	patient	outcome
How	does	this	simplify	or	improve	
pathway	for	patient?	Implications?
Ease,	no	need	for	expert,	time	efficient,	can	be	run	outside	the	GPs	visit	room	 earlier	diagnosis	equals	earlier	intervention.	Portable	so	can	be	patients	or	care	homes.	Potentially	more	
sensivity	diagnosis.
How	does	this	add	value	to	GP? Simplifies	GP	assessment/screening	by	avoiding	doing	MMSE	etc n/a
How	does	this	add	value	to	Specialist?
Increases	likelihood	they	will	see	earlier	to	intervene.		But	may	increase	their	case	load	(at	least	intitally) more	sensitive,	earlier	diagnosis	earlier	intervention	better	outcome	in	terms	of	treatment	options.			Reduces	
diagnostic	time	/	cost
How	does	this	add	value	to	funder?
Save		GPs	time:	http://www.nice.org.uk/Media/Default/standards-and-
indicators/qof%20indicator%20key%20documents/NM09%20Cost%20statement.pdf
Major	cost	savings	come	from	not	referring	health	individuals:	http://www.cambridgecognition.com/file-
uploads/Final_Poster_Housden_Model_UK_primary_care-pp070714-iii.pdf
How	does	this	change	patient	
management	pathway?	Implications?
It	generates	a	database	of	patients	mental	health	status	at	primary	care	which	can	be	updated	regularly earlier	intervention,	but	care	options	remain	similar
On	what	basis	do	they	pay	MLD? Fee	per	test	(more	preferable	but	might	come	to	a	huge	number)/licence	base Contract	for	service	or	subscription	model?
Impact:
How	does	this	change	overall	
treatment/care	cost/efficiency?
saves	cost	on	false	positives	and	false	negatives-	earlier	referals reeuced	diagnosis	time/cost	and	potential	for	earlier	intervention	reducing	lifetime	costs
What	new	costs	and	what	cost	savings	
result	from	adoption?		Who	else	
benefits?
Cost:	test-Test	platform	(PC,tablet	etc)-nurse	time	-	potentially	more	referals?-more	early	treatment	cost...	
Savings:	GPs	time-less	patients	involvement	in	treatment-less	false	positives-	
Cost	of	test-	saving	specialists	time-	replacing	other	more	expensive	cognitive	tests	such	as	[xxx]
Evidence	Required:
What	evidence	is	needed	to	convince	
users?
Safety	/	user	experience	data	-	easy	to	use Safety	/	user	experience	data	-	easy	to	use
What	evidence	is	needed	to	convince	
practioners	(GP/specialist)?
Clinical	trials:	comparative	study	vs	cognetive	assessment	tools	applied	at	primary	care	e.g.	MMSE,	Cantab,	etc	
Time	savings	potential-	additional	revenues
Clinical	trials:	comparative	study	vs	cognetive	assessment	tools	applied	at	primary	care	e.g.	MMSE,	Cantab,	etc	
Time	savings	potential-	additional	revenues
What	evidence	is	needed	to	convince	
payers?
Cost	of	current	referals	today	vs	DMT	cost-	Improved	treatment	cost	and	oucome Cost	of	current	diagnosis	with/out	DMT-	Improved	treatment	cost	and	oucome
Who	else	needs	to	be	convinced? Charities	/	Patient	Support	Group	/	Local	Specialists	/	 NICE?	
What	evidence	do	they	need?
Robust	and	useful	clinical	data:	sensitivity,	specificity,	reproducability,	accessibility,	health	economics,	
contribution.
Earlier	diagnosis	has	a	positive	impact	on	overall	care
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	A	sample	of	the	business	model	options	and	potential	‘customers’	for	MLD	(extracted	from	their	investor	 ‘pitch	 deck’)	 are	 illustrated	 in	 Figure	 8-6.	 Within	 one	 territory	 (the	 UK)	 they	 have	options	 for	 seven	different	 customer	 types	 using	 three	 different	 appropriation	 approaches	 to	yield	 five	different	business	models	 for	 essentially	 the	 same	 technology	 and	 innovation.	 	 This	high-level	analysis	provides	some	understanding	of	needs,	but	a	deeper	analysis	is	required	to	identify	the	specific	value	attributes	necessary	to	meet	customers’	needs	and	perceptions.			An	example	of	this	complexity	is	further	demonstrated	by	the	later	analysis	undertaken	by	MLD	to	try	to	understand	options	for	the	different	propositions	(Figure	8-7).		They	identified	several	and	 the	 relevant	 stakeholders	 for	 each,	 and	attempted	 to	 identify	what	 constituted	value	 and	how	this	might	inform	decisions	and	payment.			These	 analyses	 attempt	 to	 address	 some	 fundamental	 concepts	 in	 value	 analysis	 (Allee,	 2008,	2000)	and	understanding	what	value	is	(Bowman	and	Ambrosini,	2000),	how	it	is	created,	and	captured,	and	the	various	user	or	consumers	perspectives	of	value	(Priem,	2007).	 	Essentially,	this	is	part	of	a	sense-making	process	(Weick,	1995),	as	innovators	aim	to	position	the	venture	and	the	innovation	with	potential	investors,	alliance	partners,	customers,	users	and	payers.		But	these	 engagements	 result	 in	 perspectives	 on	 value	 that	 are	 at	 the	 levels	 of	 the	 individual,	organisation	and	society,	requiring	a	multi-level	perspective	(Lepak	et	al.,	2007).		A	conceptual	model	of	the	process	enacted	by	the	case	innovators	and	stakeholders	is	depicted	in	Figure	8-8.				Here	the	innovator	develops	a	proposition	and,	as	part	of	a	sense-making	process,	tests	it	with	stakeholders	and	potential	users,	providers	and	payers.		The	proposition	is	assessed	in	terms	of	its	 potential	 to	 transform	 outcomes,	 pathways	 and	 economics,	 its	 use	 value	 (Bowman	 and	Ambrosini,	 2010),	 at	 an	 individual,	 organisational	 and	 societal	 level	 (Lepak	 et	 al.,	 2007).	 The	interactions	with	stakeholders	result	 in	 ‘exchanges’	 that	 translate	or	 transform	(Carlile,	2004)	the	 proposition	 and	 enable	 the	 innovator	 to	 assess	 unrealised	 or	 wasted	 value	 (Yang	 et	 al.,	2014),	and	what	else	may	be	required	to	create	or	capture	value.			
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Figure	8-8	Conceptual	model	of	value	analysis	via	exchange		These	activities	are	proposed	as	part	of	 the	 ‘navigate’	 and	 ‘negotiate’	 activities,	 that	help	with	sense-making	 and	 advantage-seeking.	 The	 outcome	 of	 which	 is	 a	 decision	 to	 shape	 the	innovation,	or	put	in	place	mechanisms	to	sustain	it.			This	would	imply	that	the	development	of	the	 business	model	 is	 intimately	 linked	 to	 the	 innovation	process,	 the	 formation	 of	 the	 value	network	and	organisational	capabilities	required.	This	 link	and	the	complex	value	system	 into	which	 the	 innovation	 is	 placed,	 suggest	 that	 the	 business	model	 is	 more	 than	 just	 ‘a	 model’	(Baden-Fuller	and	Morgan,	2010),	or	a	series	of	processes,	but	instead	is	part	of	a	system.		A	business	model	that	is	viewed	as	more	systemic	supports	the	argument	that	business	models	can	be	considered	as	‘value	creating	systems’	(Fuller	et	al.,	2000).		So,	conceptualising	a	business	model	with	activity	system	perspective	(Zott	and	Amit,	2013,	2010)	may	be	more	appropriate,	or	 taken	 further,	 recognised	 as	 a	 complex	 system	 in	 its	 own	 right	 (Velu,	 2016).	 	 Given	 the	interconnectedness	 and	 the	 potential	 for	 convergent	 innovations	 to	 transform	 healthcare	systems’	value	networks,	with	potentially	disruptive	and	path-breaking	changes,	these	could	be	perceived	as	‘systemic	interventions’	or	‘systemic	innovation’	(Midgley,	2015,	2014,	2000).			It	 is	 clear	 from	all	 the	 cases	 that	 the	business	models	were	not	 ‘designed’	(Osterwalder	 et	al.,	2010)	but	instead	evolved	through	multiple	interactions	and	engagements	with	stakeholders	in	the	 value	 system.	 In	 that	 sense,	 they	 could	be	 considered	 ‘emergent’	 (Mintzberg,	 1978).	 	 	 But	these	 activities	 do	 not	 take	 place	 in	 a	 stable	 (or	 quasi–stable)	 environment,	 the	 innovation	ecosystem,	actors	and	value	systems	are	evolving,	adding	to	the	complexity.	 	Conceptually	this	challenge	 could	 be	 considered	 to	 be	 analogous	 to	 an	 ‘adaptive	 walk	 in	 a	 rugged	 landscape’	(Kauffman	and	Levin,	1987).		There	are	multiple	options	available	to	innovators,	potentially	with	
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multiple	 local	 optima.	 	 The	 innovators	 aim	 is	 to	 develop	 a	 business	 model	 that	 provides	advantage	 over	 competitors.	 	 But,	 a	 distinction	 between	 the	 original	 biological	 ‘rugged’	landscape	 and	 associated	NK	models	 (Kauffman	 and	 Levin,	 1987;	 Kauffman	 and	Weinberger,	1989)	and	the	‘performance’	landscape	(Rivkin	and	Siggelkow,	2007)	in	business	and	innovation	ecosystems,	 is	 that	 in	 the	 former,	 the	 landscape	 is	 assumed	 to	be	 random,	whereas	 the	 latter	involves	human	agents.	 	Nevertheless,	the	concept	of	using	the	evolving	business	model	as	the	basis	for	value	exchanges	to	navigate	and	then	negotiate	in	a	performance	landscape	provides	a	potentially	 useful	 conceptual	 model	 for	 business	 modelling	 and	 innovation	 in	 nascent	ecosystems,	and	one	worth	further	exploration.		As	changes	in	healthcare	systems	and	technology	innovations	continue	to	evolve	new	pathways,	new	 landscapes,	 new	 ecosystems	 and	 new	 business	 models	 will	 emerge.	 Evidence	 of	 these	changes	 can	 be	 found	 in	 drives	 to	 move	 from	 ‘healthcare’	 (and	 associated	 treatment)	 to	‘wellness’	(Roco	and	Bainbridge,	2013)	and	more	sustainable	models	(Christensen	et	al.,	2009).	New	models	 beyond	 the	 plethora	 already	 identified	 in	 this	 sector	 (Sabatier	 et	 al.,	 2010)	 will	likely	 emerge,	 requiring	 innovators	 to	undertake	more	 exploratory	 searches,	 consider	diverse	alternative	options	or	develop	entirely	new	ones.			
8.7 Leadership and governance CMTI,	 DH1	 and	 NMD	 (incumbent	 organisations)	 all	 employed	 small	 dedicated	 teams	supplemented	with	external	resources.		These	small	teams	provided	an	entrepreneurial,	start-up	like	 capability.	 	 This	 is	 unsurprising	 given	 the	 extensive	body	of	 literature	on	 entrepreneurial	activities	(for	example	Den	Ven,	1993;	Eckhardt,	2003;	García-Morales	et	al.,	2006;	Garud	and	Karnøe,	 2003).	 More	 interestingly,	 in	 all	 three	 cases	 the	 selected	 leader	 not	 only	 possessed	entrepreneurial	 attributes	 expected	 to	 develop	 the	 innovation,	 but	 also	 had	 the	 authority,	credibility	and	confidence	(Burgelman,	2002;	Rosenbloom,	2000)	of	the	senior	leadership,	and	were	able	to	skilfully	navigate	the	internal	organisation	and	culture.		For	example,	in	case	NMD,	the	option	to	select	an	external	leader,	although	they	possessed	superior	technical	and	network	knowledge,	was	 considered	but	 rejected	 in	 favour	of	 an	 internal	 candidate,	 precisely	 for	 their	ability	to	manage	the	internal	organisation	and	culture,	as	summarised	by	NMD1:	“To	make	this	
venture	a	success	we	need	to	do	two	things	–	make	the	right	scientific	calls	(and	clearly	the	external	
candidates	were	better	placed	to	do	this),	but	we	also	needed	to	navigate	the	internal	organisation.		
And	 the	 view	 was	 that	 they	 would	 not	 be	 able	 to	 do	 that	 as	 well”.	 This	 points	 to	 leaders	 in	convergent	innovation	not	only	needing	technology	entrepreneurship	(Garud	and	Karnøe,	2003;	Gavetti	 and	 Levinthal,	 2000;	 Teece,	 2012),	 with	 the	 requisite	 intuitive	 and	 less	 analytical	approach	 (Armstrong	 and	 Hird,	 2009),	 but	 also	 to	 be	 culturally	 skilful	 agents	 capable	 of	
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navigating	 internal	power	 structures	 in	order	 to	 legitimize	 a	potentially	disruptive	 innovation	(Lounsbury	and	Glynn,	2001).				In	these	three	incumbent	cases,	the	ventures	had	senior	leadership	support,	and	were	somewhat	separated	from	the	rest	of	the	organisation	during	their	formative	stages	(Gwynne,	1997).	The	organisations	put	in	place	agile	governance	structures	evolving	from	early	informal	signoff	by	a	senior	 leader	 to	 a	 new	 governance	 body	 or	 board	 with	 the	 internal	 and	 external	 knowledge	experts	to	support	decision	making.		The	literature	on	governance	process	for	innovation	or	new	product	development	is	limited	(Baker	and	Bourne,	2014;	Kijkuit	and	van	den	Ende,	2007)	but	has	largely	focussed	on	frameworks	that	balance	the	need	for	creativity	and	control	(Peters	and	Waterman,	 1982;	 Simons,	 1994),	 such	 as	 a	 stage	 gate	 (Cooper,	 1990).	 	 	 The	 evidence	 in	 this	research	 points	 to	 a	more	 nuanced	 approach,	 with	 broad,	 directional	 criteria	 and	 the	 use	 of	external	actors	to	help	support	decision	making.		Extensions	to	the	stage	gate	approach,	such	as	its	use	in	open	innovation	(Gronlund	et	al.,	2010)	point	to	a	mix	of	closed	and	open	innovation	criteria	 being	 used.	 However	 this	was	 not	 observed	and,	 further,	 had	 the	 suggested	model	 of	open	innovation	criteria	been	followed	(Gronlund	et	al.,	2010,	fig.	2),	 it	 is	unclear	whether	the		ventures	would	have	been	progressed.			In	 all	 cases,	 the	 innovators	 lacked	 ‘hard	 data’	 to	 support	 traditional	 decision	 criteria,	 instead	they	 were	 largely	 interpretive	 (Dougherty,	 1992),	 where	 sense-making	 (Weick,	 1995)	 and	shared	 understanding	 are	 important.	 A	 broad	 range	 of	 criteria	 were	 considered	 but	interpretation	was	more	qualitative	or	semi-quantitative;	more	akin	to	those	suggested	for	front	end	 innovation	 (Koen	 et	 al.,	 2001).	 This	 in	 part	 is	 thought	 due	 to	 limited	 codification	 of	information	 or	 that	 information	 across	 multiple	 technological	 domains	 somehow	 needed	integrating.	 The	 use	 of	 external	 expertise	 and	 challenge	 helps	 to	 overcome	 internal	 bias	 and	inertia	(Nooteboom,	2000),	and	face-to-face	interaction	further	facilitates	interpretation	(Daft	et	al.,	 1987),	 but	does	present	a	model	 for	 governance	 and	decision	making	under	 conditions	of	convergence.			This	 research	 indicates	 that	 there	 is	 a	 potential	 gap,	 as	 approaches	 in	 closed	 innovation	 and	open	 innovation	 do	 not	 appear	 to	 address	 the	 challenges	 in	 terms	 of	 the	 implications	 for	governance	and	decision	making	that	result	from	convergent	or	cross-industry	innovation.			
8.8 Development of Innovation and Organisational Capabilities This	research	fundamentally	asks	the	question	‘how’	do	firms	innovate.			This	question	inevitably	addresses	the	subject	of	routines	and	capabilities.		In	this	section,	an	argument	will	be	developed	
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to	describe	how	these	routines	and	capabilities	may	be	developed,	and	why,	which	will	then	be	synthesised	with	the	frameworks	and	approaches	developed	so	far.			In	 this	 research	 three	 incumbent	 case	 firms	 and	 two	 start-ups	 were	 studied.	 One	 of	 the	supplementary	 questions	 arising	 during	 the	 research,	 in	 the	 case	 of	 incumbent	 firms,	 is	 -	
whether	 developing	 something	 ‘convergent’	 and	 potentially	 disruptive	 also	 requires	 doing	 it	
differently?			Innovations	themselves	can	be	a	source	of	new	organisation	capabilities	 (Greve,	2013),	but	 in	engaging	 with	 the	 above	 question,	 two	 underlying	 puzzles	 emerge.	 First,	 the	 literature	 on	organizational	capabilities	has	largely	embraced	a	stark	dichotomy	between	sustaining	existing	organizational	capability	and	developing	a	new	one	(di	Stefano	et	al.,	2014;	Helfat	and	Peteraf,	2003).	 Second,	 reciprocal	 relationships	 between	 managerial	 agency	 and	 organizational	capability	have	mostly	escaped	scholarly	attention	(Argote	and	Greve,	2007;	Garud	and	Gehman,	2012).	Instead,	the	focus	has	been	on	how	organisational	routines	determine	managerial	action	and	 much	 less	 on	 how	 managers	 as	 knowledgeable	 agents	 deploy,	 modify	 and	 enact	organizational	capabilities.						
8.8.1 Sustaining ‘old’ versus developing ‘new’ organizational routines 	The	literature	on	organizational	capabilities	has	always	been	more	comfortable	with	explaining	gradual	 change	 (Helfat	 and	 Winter,	 2011;	 Nelson	 and	 Winter,	 1982)	 than	 with	 clarifying	emergence	 of	 novelty.	 The	 intellectual	 legacy	 of	 the	 evolutionary	 framework	 emphasizes	habitual	 and	 experiential	 learning	 (Winter,	 2013;	 Zollo	 and	 Winter,	 2002)	 and	 hence	 it	 is	assumed	 organizational	 capability	 predominantly	 changes	 through	 selective	 reactivation	 or	minor	modification	of	past	patterns	and	routines.	From	this	evolutionary	perspective,	changes	to	the	 organizational	 routines	 and	 the	 actual	 practice	 of	what	managers	do	 and	 how	 they	 get	 it	done	(Birkinshaw	et	al.,	2008)	are	hardly	ever	large	and	discontinuous.	When	examining	radical	innovation,	Kapoor	and	Klueter	(2015)	argue	that	the	use	of	alliances	and	acquisitions	increase	the	likelihood	of	incumbents	successfully	developing	disruptive	technologies.			This	 accumulative	 sustainment	of	 existing	organizational	 capability	 is	 then	 sharply	 contrasted	with	 situations	where	 firms	 are	 confronted	with	 a	major	 external	 jolt	 (Henderson	 and	 Stern,	2004;	Peteraf	and	Reed,	2007;	Rosenbloom,	2000).	Bresman	(2013)	for	example	suggests	that	in	high	velocity	environments,	groups	engaged	in	radical	innovation	cannot	simply	learn	from	the	experience	 of	 others.	 In	 this	 context,	 existent	 organizational	 capabilities	 prove	 to	 be	 mostly	inadequate	 and	 hence	 managers	 at	 incumbent	 firms	 face	 not	 only	 technological	 and	 market	uncertainties,	 but	 also	 organizational	 uncertainties	 of	 how	 to	 develop	 new	ways	 to	 innovate.	
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This	 dichotomy	 between	 sustaining	 existing	 organizational	 capabilities	 for	 innovation	 versus	developing	 entirely	 new	 ones	 leads	 to	 two	 different	 implications	 for	managers	 at	 incumbent	companies.	They	should	either	replicate	(Szulanski,	1996;	Winter	and	Szulanski,	2001)	existing	organizational	capabilities	and	 learn	 ‘as	they	go’,	or	radically	depart	from	the	existing	ways	of	how	they	innovate.			
8.8.2 Managerial agency for changes and internal acceptance  What	informs	a	direction	of	change	and	what	managers	consider	when	they	deploy	and	modify	innovation	processes	 is	of	 importance	 to	understand	the	role	of	managerial	agency	 in	shaping	organizational	routines.	The	extant	literature	treats	the	role	of	managerial	agency	for	change	in	different	ways.	Managers	with	superior	cognitive	competency	are	considered	capable	of	sensing	entrepreneurial	opportunities	and	these	guide	any	subsequent	organizational	actions	(Gavetti,	2012;	 Gavetti	 and	 Levinthal,	 2000;	 Teece,	 2012,	 2007).	 An	 alternative	 perspective,	 that	attributes	 powerful	 agency	 to	 managers,	 emphasizes	 leadership	 and	 authority	 (Burgelman,	2002;	Rosenbloom,	2000)	as	instrumental	for	major	changes.			These	two	perspectives	are	sharply	contrasted	with	the	view	that	managers	at	incumbent	firms	are	more	likely	sources	of	cognitive	inertia	(Christensen	and	Bower,	1995;	Tripsas	and	Gavetti,	2000),	 which	 partly	 explains	 the	 failure	 of	 incumbent	 firms	 to	 develop	 a	 disruptive	 or	discontinuous	 innovation.	Not	only	 are	 they	 incapable	of	 changing	organizational	 capabilities,	but	 these	 deep-rooted	 organisational	 routines	 act	 as	 core	 rigidities	 (Leonard-Barton,	 1992)	trapping	 managers	 into	 existent	 ways	 of	 doing	 things.	 This	 suggests	 that	 managerial	 agency	within	an	incumbent	firm	contains	activities	of	issue-selling	to	the	higher	authority	(Dutton	and	Ashford,	 1993)	 and	 skilful	 framing	 of	 how	 disruptive	 innovation	 may	 support	 competitive	advantage	(Pandza,	2011).	Managers	are	 therefore,	not	only	cognitively	competent	actors,	but	also	 culturally	 skilful	 agents	 capable	 of	 navigating	 internal	 power	 structures	 to	 legitimize	 a	potentially	disruptive	innovation	(Lounsbury	and	Glynn,	2001).			The	 evidence	 from	 the	 three	 incumbent	 firms	 supports	 that	 they	were	 all	 capable	 of	making	changes	 and	 overcoming	 inertia.	 	 Of	 the	 three	 cases,	 NMD,	 provided	 the	 most	 compelling	evidence	and	provided	sufficient	insights	to	suggest	a	mechanism	by	which	they	created	these	new	capabilities.			As	has	been	highlighted	earlier,	there	is	a	need	for	innovators	to	create	both	credibility	and	legitimacy	in	the	new	field.		This	is	considered	a	necessary	precursor	to	taking	an	advantage-seeking	position.			Being	able	to	take	an	advantage-seeking	position	is	considered	a	necessary	step	in	overcoming	internal	resistance.	 Simply,	 if	 the	organisation	 cannot	 see	potential	 value	 in	any	new	venture,	
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and	that	venture	represents	a	perceived	risk,	then	it	will	resist.		But	the	perception	of	the	risk	is	also	a	critical	factor.		Doing	things	that	are	new,	potentially	disruptive	and	less	understood	are	often	 perceived	 as	 riskier	 (Kahneman	 and	 Tversky,	 2007),	 it	 is	 therefore	 suggested	 that	 the	steps	to	doing	something	different	or	new,	should	minimise	the	perceived	risk.				The	 findings	 lead	 to	 the	 proposition	 that	 conceptualizing	 a	 change	 in	 capabilities,	 requires	understanding	the	structure	of	this	change,	identifying	drivers	that	direct	managers	modifying	existing	 organisational	 routines	 and	 recognizing	 the	 role	 of	 organizational	 capability	 for	increasing	 acceptance	 of	 a	 venture	 inside	 an	 incumbent	 firm.	 	 Figure	 8-9	 depicts	interrelationships	 between	 structure	 of	 change	 in	 organizational	 capabilities,	 drivers	 for	 this	change	that	predominantly	stem	from	a	necessity	to	build	and	navigate	an	emergent	innovation	ecosystem	 and	 an	 importance	 to	 prevent	 a	 perceived	 uncertainty	 of	 developing	 new	organizational	capabilities	to	obstruct	internal	acceptance	of	a	venture.		
8.8.3 Structure of Change in Capability for convergent Innovation The	in-depth	evidence	from	the	NMD	case	indicates	that	a	sharp	conceptual	distinction	between	existent	 and	 new	 organizational	 capabilities	 fails	 to	 adequately	 describe	 changes	 that	 are	required	 when	 a	 group	 in	 an	 incumbent	 firm	 develops	 potentially	 disruptive	 technology.	Likewise,	they	are	not	explained	by	changes	in	existing	organizational	capabilities	for	innovation	sustained	through	experiential	learning,	as	the	dynamic	capability	literature	would	suggest	(di	Stefano	 et	 al.,	 2014;	 Teece,	 2012).	 Nor	 do	 these	 capabilities	 act	 as	 core	 rigidities	 (Leonard-Barton,	 1992),	 underpinning	 cognitive	 inertia	 (Tripsas	 and	 Gavetti,	 2000)	 and	 hampering	internal	acceptance	of	convergent		innovation.				
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Figure	8-9	Suggested	model	of	capability	development		The	 evidence	 broadly	 supports	 an	 argument	 that	 a	 convergent	 innovation	 and	 accompanying	search	 in	 a	 distant	 knowledge	 domain	 increase	 the	 likelihood	 for	 existing	 organizational	capabilities	 to	 be	 modified	 and	 hence	 organizational	 innovation	 (Birkinshaw	 et	 al.,	 2008)	accompanies	 the	 development	 of	 a	 convergent	 technology.	 This	 does	 not	 suggest	 existent	capabilities	 become	 obsolete	 or	 radically	 new	 ones	 need	 to	 be	 developed.	 It	 is	 argued	 that	instead	 of	 categorizing	 change	 in	 organizational	 capabilities	 in	 terms	 of	 its	magnitude	 or	 ‘old	versus	new’	dichotomy,	it	is	more	appropriate	to	explore	the	structure	of	this	change.		Adopting	 a	 systemic	 perspective	 on	 organizational	 capability	 (Winter,	 2003)	 enables	 us	 to	describe	 the	 structure	 of	 change	 with	 the	 dimensions	 of	 breadth	 and	 depth.	 The	 breadth	 of	change	 indicates	 the	 number	 of	 organisational	 routines	 that	 require	 change	 to	 support	innovation	 in	a	new	technological	domain.	The	depth	of	change	denotes	a	degree	 to	which	an	organisational	 routine	 needs	 to	 be	 altered	 for	 supporting	 the	 development	 of	 a	 convergent	innovation.			The	evidence	suggests	that	an	incumbent	firm	makes	changes	in	the	underlying	organizational	capabilities	 characterized	 by	 many	 constitutive	 organisational	 routines	 being	 altered	 (high	
breadth	of	change),	yet	the	degree	of	change	within	these	processes	will	be	mostly	gradual	(low	
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depth	of	change).	In	other	words,	the	development	of	convergent	technology	requires	relatively	incremental	 changes	 across	many	organisational	 routines.	 	 This	might	be	 seen	 as	 remarkably	similar	to	the	exploratory	and	evolutionary	nature	of	start-up	firms	capability	development	as	an	effectuation	process	(Berends	et	al.,	2014).			An	 established	 firm	 with	 a	 history	 of	 technological	 innovation	 will	 possess	 multiple	organisational	routines	that	support	innovation	capability.	They	attempt	to	replicate	(Szulanski,	1996)	 innovation	 capabilities	 that	 proved	 to	 be	 adequate	 for	 conducting	 local	 searches	 in	 a	familiar	 domain	 (e.g.	 clinical	 and	 biology)	 for	 exploring	 a	 technologically	distant	domain	 (e.g.	microelectronics	 and	 digital).	 This	 initial	 reliance	 on	 replication	 suggests	 any	 accompanying	organizational	innovation	will	have	continuity	with	the	existing	pool	of	organisational	routines	and	hence	depth	of	change	will	more	likely	be	low.	This	insight	has	an	interesting	implication	for	the	ambidexterity	debate	and	the	dynamic	capability	concept.				A	 structurally	 separated	 group	 that	 explores	 a	 distant	 and	 convergent	 domain	 will,	 at	 least	initially,	deploy	 the	same	organizational	capabilities	 for	managing	innovation	 in	a	 familiar	and	core	 knowledge	 domain.	Most	 of	 these	 organisational	 routines	 however,	 could	 not	 simply	 be	sustained	through	the	mechanism	of	learning	by	doing	and	require	a	significant	level	of	strategic	agency	to	direct	necessary	modifications	to	support	distant	searches	for	innovation.		
	
8.8.4 Drivers of Change in Organizational Capability  The	evidence	from	the	case	studies	provide	insights	into	what	necessitates	this	change	and	what	considerations	inform	managers	when	changing	multiple	organisational	routines.		It	has	been	widely	accepted	 that	 the	development	of	disruptive	 innovation	requires	managing	relations	in	a	complex	ecosystem	(Adner	and	Kapoor,	2010)	and	skilfully	balancing	the	need	to	induce	 cooperation	 with	 advantage-seeking	 competitive	 actions	 (Gnyawali	 et	 al.,	 2006).	 The	extant	 research	 has	mostly	 investigated	 how	 a	 disruptor	 navigates	 an	 established	 ecosystem	whose	members	 are	 highly	 likely	 hostile	 to	 the	 innovation	 (Ansari	 et	 al.,	 2016).	What	 is	 less	often	studied	 is	how	a	resource	rich	 incumbent	creates	and	orchestrates	a	nascent	ecosystem	that	 enables	 integration	 of	 highly	 dispersed	 expertise.	 Such	 an	 emergent	 ecosystem	 has	 the	characteristic	 of	 an	 organizational	 field	 in	 flux,	 with	 undefined	 industrial	 borders	 and	 an	amorphous	network	of	organizations	and	individuals	that	are	potentially	relevant	for	exploring	and	 developing	 a	 convergent	 and	 potentially	 disruptive	 innovation	 (Meyer	 et	 al.,	 2005).	 The	cases	 show	 that	 this	 emergent	 nature	 is	 the	 most	 influential	 factor	 that	 necessities	 multiple	modifications	 in	 existent	 capabilities.	 Each	 studied	 incumbent	 company	 was	 clearly	 in	possession	 of	 numerous	 organisational	 routines	 for	managing	 relationships	 in	 the	 biomedical	
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ecosystem	 and	managers	 initially	 intended	 to	 replicate	 them	within	 the	 emerging	 ecosystem.	The	cases	encountered	multiple	limitations	that	required	changes	in	organisational	routines.	It	is	argued	that	these	changes	in	organizational	capabilities	are	needed	because	the	organisational	routines,	which	are	adequate	for	navigating	an	established	ecosystem	are	imperfect	for	building	a	 nascent	 one.	 It	 is	 suggested	 that	 the	 more	 nascent	 and	 less	 configured	 the	 innovation	ecosystem,	 the	 higher	 the	 need	 for	 broad	 changes	 in	 organisational	 routines	 that	 constitute	organizational	capabilities	at	an	incumbent	firm.		The	nascent	nature	of	 the	 innovation	ecosystem	also	 influences	 the	managerial	considerations	that	guide	modifications	of	 the	existent	processes.	To	 induce	cooperation	in	such	an	emerging	field,	they	should	first	legitimize	the	ecosystem	and	second,	legitimize	the	firm	position	within	it.	It	 is	 important	 to	 assert	 that	 these	 legitimacy-driven	 actions	 and	 accompanying	 framing	strategies	directly	impact	changes	in	organisational	routines.	For	example,	framing	collaboration	as	‘open’	is	not	sufficient	if	not	accompanied	with	concrete	changes	in	how	a	firm	manages	its	IP.			These	legitimacy-driven	actions	appear	dominant	at	the	very	early	stages	of	creating	a	nascent	innovation	ecosystem.	When	the	ecosystem	becomes	better	configured,	these	actions	are	quickly	accompanied	 with	 more	 assertive	 advantage-seeking	 actions	 that	 aim	 to	 appropriate	 future	value	for	the	innovation.		
8.8.5 Structure of Change in Capability and Internal Acceptance  The	 evidence	 also	 infers	 that	 strategic	 actions	 within	 the	 innovation	 ecosystem	 and	 the	identified	structure	of	change	in	organizational	capabilities	affect	the	prospect	of	the	convergent	venture	to	be	accepted	internally.		It	 is	 intriguing	 that	 in	 the	 specific	 NMD	 case	 no	 significant	 internal	 objections,	 driven	 by	cognitive	 inertia	and	dominant	logic	 (Bettis	and	Prahalad,	1995;	Tripsas	and	Gavetti,	2000)	to	the	 innovation	 initiative,	 were	 observed.	 Similarly,	 DH1	 and	 CMTI	 progressed	without	major	objections.		Therefore,	multiple	explanations	have	been	considered.		One	possibility	is	that	these	potentially	disruptive	technology	initiatives	are	still	in	their	infancy	and	it	is	simply	too	early	to	expect	any	serious	internal	opposition.	This	explanation,	is	considered	less	plausible	because	the	establishment	 of	 an	 ambitious	 joint	 venture	with	 a	major	 information	 technology	 firm	 in	 the	case	 of	 NMD,	 and	 a	 major	 investment	 at	 CMTI,	 clearly	 indicate	 a	 serious	 commitment	 to	 an	emergent	 field.	 The	 innovation	 initiative	 at	 NMD	 has	 a	 strong	 champion	 in	 a	 very	 senior	executive	 also	 supports	 the	 argument	 of	 an	 organizational	 culture	 open	 to	 efforts	 that	 may	potentially	 make	 existent	 business	 obsolete.	 	 	 	 However,	 other,	 potentially	 more	 captivating	evidence	 that	 links	 internal	 acceptance	 with	 the	 structure	 of	 change	 in	 organizational	
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capabilities	 as	 well	 as	 with	 advantage-seeking	 actions	 within	 the	 nascent	 ecosystem	 is	suggested.	 Informants	 from	 the	 group	 leading	 the	NMD	 innovation	 initiative	 agreed	 that	 it	 is	important	‘not	to	be	seen	as	any	different’	to	the	other	innovation	groups.	It	is	acceptable	for	the	group	 to	 be	 seen	 as	 exploring	 a	 radically	 new	 technology	 and	 business	 model,	 but	 it	 is	 also	important	 to	 conduct	 this	 exploration	 by	 using	 similar	 innovation	 processes	 as	 other	 groups.	This	inevitably	triggers	a	parallel	with	Ansari’s	et	al.,	(2016)	assertion	that	disrupters	are	well	advised	 to	 avoid	 framing	 themselves	 as	 being	 disrupters.	 Their	 example	 emphasizes	 the	importance	of	framing	for	the	external	audience.	This	study	indicates	that	being	seen	internally	as	 innovating	 in	 a	 familiar	 way	 helps	 to	 avoid	 opposition.	 What	 counts	 is	 not	 only	 internal	framing	and	effective	issue-selling,	but	also	the	structure	of	change	in	organizational	capabilities	(high	breadth,	but	 low	depth)	 that	create	an	 internal	perception	of	 low	uncertainty	related	 to	required	organizational	change.			Therefore,	 it	 is	 proposed	 that	 the	 likelihood	 for	 a	 convergent	 innovation	 initiative	 to	 receive	internal	 support	 in	 an	 incumbent	 firm	 increases	 if	 changes	 in	 organizational	 capabilities	 for	innovation	are	perceived	as	continuous	and	consistent,	and	hence	less	uncertain.	In	other	words,	decision-makers	 at	 the	 incumbent	 organization	 will	 be	 tolerant	 to	 technical	 and	 market	uncertainty	(Danneels,	2002),	yet	they	will	be	much	less	willing	to	accommodate	radical	changes	in	underlying	capabilities	for	innovation	(uncertainty	of	how	the	convergent	innovation	is	done).			Looking	 to	 other	 incumbent	 firm	 evidence,	 DH1	 although	 developing	 potentially	 disruptive	innovations	and	using	novel	processes	to	engage	patients	and	users,	nonetheless	used,	at	 least	initially,	 recognisable	processes	 to	 set	up	 contracts	 and	manage	projects	 and	 reporting.	 	 They	modified	 these,	 to	 better	 suit	 their	 needs,	 but	 their	 use	 of	 small	modifications	 to	 established	processes,	provides	 further	evidence	of	 the	proposed	mechanism.	 	 	They	also	build	credibility	within	the	ecosystem	and	produced	tangible	outputs,	demonstrating	their	potential	value	to	the	incumbent	 organisation.	 The	 third	 case,	 CMTI,	 provides	 less	 compelling	 evidence,	 in	 part	because	 those	 processes	 were	 not	 directly	 observed	 to	 the	 same	 degree,	 but	 provides	 some	evidence	of	building	credibility	and	then	moving	 to	a	position	of	advantage,	without	making	a	step	change	in	‘how’	they	operated	or	governed.			Returning	 to	 the	 initial	dichotomy	 identified	between	old	and	new	organizational	 capabilities,	the	 development	 of	 a	 convergent	 technology	 will	 almost	 inevitably	 require	 changes	 in	organizational	 capabilities.	The	 existent	 organizational	 capabilities	however,	 do	not	necessary	act	 as	 core	 rigidities	 that	underpin	 cognitive	 inertia.	They	more	 likely	provide	a	useful	 initial	ingredient	 for	 a	 knowledgeable	 manager	 that	 skilfully	 balances	 between	 necessary	
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modifications	across	multiple	organisational	routines	and	sustaining	a	perception	of	continuity	between	the	old	and	the	new	ways	of	doing	innovation	at	an	incumbent	company.						In	 studying	 and	 identifying	 this,	 the	 challenge	 of	 Garud	 et	 al.	 to	 use	 “multi-level,	 longitudinal	
perspective,	and	 follow	events	 implicating	actors,	artifacts,	and	institutions	over	time”	 	 (2013,	 p.	803)	is	partially	addressed.		It	also	responds	to	the	challenge	of	addressing	context	and	sub-text	of	agency	to	identify	not	only	how,	but	also	why,	innovators	develop	these	capabilities.			
8.9 Updated Convergent Innovation Framework  Returning	to	the	overall	research	objectives,	and	the	final	objective:	towards	the	development	of	
a	 more	 integrated	 approach	 to	 link	 the	 key	 and	 relevant	 aspects	 of	 the	 innovation	 ecosystem,	
business	model	and	value	network.			The	development	of	this	framework	started	with	the	Exploratory	Framework,	developed	during	the	 Phase	 1	 research	 and	 was	 developed	 from	 a	 combination	 of	 induction	 from	 ecosystem	interviews	together	with	relevant	literature	and	is	described	in	Chapter	5.		This	was	then	used	as	an	exploratory	tool	for	the	case	study	research.			Findings	from	each	case	were	mapped	against	the	Framework	Factors	(see	Chapter	6	on	Case	findings),	then	cross-case	analyses	examined	the	application	of	the	exploratory	framework	factors	across	each	case.		The	 proposed	 and	 revised	 Convergent	 Innovation	 Framework	 considers	 three	 areas:	 the	development	and	management	of	relationships	in	the	ecosystem,	leadership	and	management	of	investments	and	capabilities,	and	building	value	networks,	alliances	and	support.			
8.9.1 Development and management of relationships in the ecosystem Given	 that	 convergent	 innovation	 ecosystems	are	 invariably	 nascent,	with	diffuse	 and	distant	actors	and	knowledge,	the	development	and	management	of	those	relationships	and	the	access	to	 knowledge	 and	 future	 partners	 it	may	 bring	 is	 a	 key	 activity.	 	 The	 need	 to	 orchestrate,	 or	purposefully	build	and	manage	relationships	has	been	identified	(Dhanasai	and	Parkhe,	2009),	but	 is	 comparatively	 understudied	 (Still	 et	 al.,	 2014).	 	 This	 research	 and	 the	 suggested	framework	support	the	argument	that	firms	employ	both	tangible	(i.e.	outputs)	and	intangible	(i.e.	relational)	mechanisms	to	build	and	manage	their	position	within	the	ecosystem	(Ritala	et	al.,	2013).		A	key	step	is	to	build	symbiotic	relationships	(Fransman,	2007),	which	is	challenging	in	 a	 regime	 where	 actors	 operate	 at	 different	 ‘clockspeed’	 (Fine,	 1998)	 and	 have	 different	capabilities	(Jacobides,	2006).	Whilst	the	ultimate	objective	for	the	innovator	is	to	create	value	(Adner	and	Kapoor,	2008;	Di	Gregorio,	2013;	Lepak	et	al.,	2007)	and	then	capture	or	appropriate	
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it	(Bowman	and	Ambrosini,	2000;	Lepak	et	al.,	2007),	it	is	suggested	in	this	research	that	there	are	 precursors	 or	 antecedents	 to	 being	 able	 to	 do	 this.	 These	 lie	 in	 the	 need	 to	 build	 trust	(Gassmann	et	al.,	2010b;	Hurmelinna-Laukkanen	et	al.,	2012),	and	learning,	by	a	combination	of	activities	 that	demonstrate	 credibility	 through	visible	 commitment	 (e.g.	 by	delivering	 tangible	outcomes	or	making	investments)	and	legitimacy	(e.g.,	by	entering	agreements	that	are	seen	to	be	 ‘fair’).	 	 This	 combination	of	 activities	 enables	 innovators	 to	build	knowledge,	 relationships	and	credibility,	which	then	positions	them	to	take	more	advantage-seeking	actions.	The	building	of	 learning,	trust	and	ability	 to	take	control	can	be	viewed	as	co-evolving	(Inkpen	and	Currall,	2004).			
8.9.2 Leadership and management of investments  The	importance	of	leadership	in	innovation	is	well	documented,	whether	that	be	from	a	failure	to	recognise	disruptions	(Rosenbloom,	2000;	Rosenbloom	and	Christensen,	1994),	 leading	 the	innovation	(Adams	et	al.,	2006),	creating	the	culture	(Leonardi,	2011)	or	providing	appropriate	governance	(Baker	and	Bourne,	2014).				What	 appears	 to	 be	 key	 for	 convergent	 innovation	 is	 to	 build	 a	 degree	 of	 protection	 (from	corporate	rejection)	early	in	the	venture,	at	least	until	there	is	evidence	to	support	the	potential	value	 at	 an	 acceptable	 risk.	 	 Unlike	 established	 business	 and	 new	product	 development,	well	defined	decision	criteria	appear	little	used,	with	innovators	relying	more	on	broader	criteria	and	in	using	 external	 expertise	or	 ecosystem	actors	 to	help	 reduce	bias	 	 (Dosi,	1997;	Garud	et	al.,	2014)	and	gaps	 in	knowledge	(Boschma,	2005).	 	 	 There	 is	a	need	to	build	new	organisational	capabilities,	 here	 it	 is	 suggested	 that	 management	 agency,	 using	 multiple	 broad	 but	 shallow	changes	to	existing	capabilities,	evolutionary	in	nature,	is	likely	to	yield	these	and	avoid	internal	conflict.	 It	 would	 also	 suggest	 that	 there	 is	 a	 complex	 interplay	 between	 the	 components	 of	innovation	capability,	across	governance,	process	and	decision	making,	with	similarities	seen	in	radical	innovation	(Slater	et	al.,	2014).			The	 other	 key	 consideration	 is	 how	 the	 complexity	 of	 the	 multiple	 challenges	 are	 managed.	There	is	a	need	to	address	integration	at	multiple	levels,	but	it	is	also	suggested	that	rather	than	try	to	minimise	complexity,	via	approaches	like	modularity,	innovators	embrace	the	complexity	(Garud	et	al.,	2013)	and	use	a	range	of	approaches	to	address	it.	
	
8.9.3 Building Value Networks, Alliances and Support The	 need	 to	 build	 a	 value	 network	 is	 key	 to	 delivering	 and	 capturing	 value	 (Dhanasai	 and	Parkhe,	 2009;	 Garcia-Castro	 and	 Aguilera,	 2015;	Hurmelinna-Laukkanen	 et	 al.,	 2012).	 	 	 Other	
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alliances	may	also	be	important	in	building	knowledge	or	creating	future	opportunities.	 	For	a	venture	 to	 succeed	 there	 is	 a	need	 for	 a	 value	network	 to	be	 in	place,	 and	 there	 is	 a	need	 to	overcome	institutional	barriers	(Aarikka-Stenroos	and	Ritala,	2016),	and	to	address	the	lack	of	institutional	support.	In	nascent	ecosystems	these	are	not	well	established,	therefore	innovators	need	to	consider	the	implications	and	how	to	support		the	building	of	a	viable	ecosystem	(Rong,	2011).	 	 Similarly,	 the	 understanding	 of	 the	 venture	 by	 potential	 partners	may	 be	 poor.	 	 This	implies	that	previously	identified	approaches	to	partner	selection	(Emden	et	al.,	2006)	and	the	extent	 to	 which	 there	 is	 co-vision,	 co-design	 and	 co-creation	 (Liu	 and	 Rong,	 2015)	 may	 be	limited	in	nascent	ecosystems.		This	research	identifies	that	it	appears	to	be	appropriate	to	take	a	 more	 transient	 approach	 and	 use	 these	 to	 build	 relationships,	 before	 moving	 to	 a	 more	advantage-seeking	 position	 and	 committing	 to	 long-term	 alliances	 and	more	 integrated	 value	networks	for	co-creation.		
8.9.4 Conceptual model of convergent innovation In	 seeking	 to	 integrate	 the	 research	 findings,	 a	 single	 conceptual	 relational	 framework	 is	proposed	(Figure	8-10).		The	framework	links	the	innovator	organisation	via	relationships	(and	value	exchanges)	with	the	wider	ecosystem,	customers,	collaborators	and	their	value	network,	through	the	application	of	the	underpinning	processes	 that	enable	navigation,	negotiation	and	nurturing	of	the	innovation,	business	model	and	value	network	as	the	innovator	seeks	to	achieve	key	 objectives	 to	 build	 credibility	 then	 advantage	 by	 employing	 incremental,	 but	 systemic,	changes	of	existing	routines	which	help	maintain	internal	(organisational)	relationships.		These	capabilities	 are	 relational	 (Dyer	 and	 Kale,	 2007;	 Dyer	 and	 Singh,	 1998),	 	 rooted	 in	 the	organisations	 ability	 to	 build	 inter-firm	 capabilities	 to	 manage	 knowledge,	 alliances	 and	potential	value.		But	given	the	nature	of	the	innovation,	there	is	also	a	need	to	build	or	maintain	intra-firm	relationships	to	avoid	inertia	or	rejection.				
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Figure	8-10	Relational	Framework	for	convergent	innovation		
8.9.5 A Revised Convergent Innovation Framework The	 convergent	 innovation	 framework,	was	 initially	 developed	 by	 using	 induction	 to	 identify	key	 dimensions	 from	 the	 initial	 ecosystem	 interviews	 (Table	 5-2),	 together	 with	 relevant	literature	and	abduction	(Table	5-4).		This	initial	framework	was	then	tested	using	pilot	studies,	and	used	as	an	investigational	framework	for	the	case	studies.	Following	the	case	studies	it	was	reviewed	and	refined	(Figure	7-1).		The	revised	Convergent	Innovation	Framework	(Table	8-3)	provides	 a	 more	 systemic	 approach	 to	 explicitly	 link	 the	 activities	 of	 developing	 an	understanding	of	 the	 ecosystem,	 the	 value	 creation	 and	 capture	 activities	 and	 the	 capabilities	required	 to	 co-evolve	 the	 innovation,	 business	model	 and	value	network,	 thus	 addressing	 the	previously	identified	gaps	in	the	literature	and	meeting	the	research	objective.				It	also	provides	outline	guidance	for	innovators	in	this	or	similar	fields,	with	nascent	or	emerging	ecosystems.								
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Table	8-3	Revised	Convergent	Innovation	Framework	
 Factor (F) Example Activities and Capabilities 
Development and management of ecosystem relationships 
F1 Ecosystem 
understanding and 
relationships 
within it 
Use active, exploratory and evolutionary searches to identify and 
understand diverse knowledge and actors.  Develop from diffuse 
knowledge to more codified. Develop both knowledge and 
relationships through credibility-seeking actions in the nascent 
ecosystem, to enable later advantage-seeking actions. 
F2 Customer 
engagement 
Engage potential customers and users early, and maintain 
engagement throughout development. Use to address innovation 
and adoption challenges.  
F3 Business model 
development and 
integration 
Use the 'value proposition' as a vehicle to engage and refine the 
innovation.  Identify multiple value perspectives of customers and 
stakeholders. Refine business model to address pathway 
challenges. Integrate business model with innovation and value 
network development. 
Leadership and Management of investments  
F4 Flexible 
governance 
Active senior management support and engagement in key 
investment decisions.  Provide support to address internal conflicts. 
Use external expertise to supplement and challenge own 
knowledge. 
F5 Broad Decision 
criteria 
Decision criteria are broad and directional, supported by external 
expertise or ecosystem actor input.  Criteria are refined based on 
knowledge and progress. 
F6 Empowered 
Project Team 
The core team has leadership, expertise and experience, and 
balances autonomy, accountability and empowerment within the 
governance framework 
F7 Business process 
and capability 
evolution 
Evolve processes, using broad but shallow changes to minimise risk 
and non-acceptance 
F8 Integrated Risk 
Management 
Risk management in place to address integration of technological 
(including patient and user risks), business model risks, value 
network risks and organisational risks.  Balance agency, relational 
and process foci to analytical and synthesis approaches. 
Building Value Networks, Alliances and Support 
F9 Agile Value 
Networks 
Use ecosystem relationships to develop flexible and transient 
nascent value networks before committing to long term alliances. 
F10 Alliances and 
Support 
infrastructure 
Innovator invests in helping support (nurture) nascent ecosystem, 
addressing institutional gaps, and contributes support to maintain 
viable infrastructure. 	
8.10 Sensitivity analysis of proposed models Within	 the	 limited	 research	 timeframe,	 it	 is	 not	 practically	 possible	 to	 conduct	 an	 empirical	‘validation’	of	the	models	proposed	in	this	project.		Instead	a	sensitivity	analysis	was	conducted	to	 assess	 the	 proposed	 models	 to	 changes	 in	 context,	 and	 thereby	 evaluate	 their	 potential	validity.				
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This	research	focuses	explicitly	on	early	stages	of	ecosystem,	namely	the	nascent	and	emerging	phases.	Others	have	described	ecosystem	evolution	in	terms	of	birth,	expansion,	leadership,	and	self-renewal	 (Moore,	 1993)	 or	 development,	 growth	 and	 maturity	 (Rong	 and	 Shi,	 2009).	 A	recent	 paper	 identifies	 four	 categories	 of	 ecosystem,	 given	 the	 emergent	 properties	 of	 the	studied	ecosystems	(Aarikka-Stenroos	and	Ritala,	2017).	From	this	analysis,	‘Category	2’	would	be	 the	 most	 appropriate	 for	 the	 nascent	 or	 emergent	 phase,	 with	 co-evolutionary	 logic	 and	‘blurry,	 emergent	 ,	 non-linear	 boundaries’	 (Aarikka-Stenroos	 and	 Ritala,	 2017).	 	 Growth	 and	Expansion	is	best	categorised	as	‘Category	1’	with	growth	and	competition,	and	Leadership	and	Maturity	addressed	by	Categories	3	and	4	with	stable	business	exchanges	and	value	co-creation	in	more	service	orientated	ecosystems.		Taking	these	ecosystem	categories	and	lifecycle	phases	up	 to	 ‘maturity’,	 the	model	 components	 proposed	 can	 be	 analysed	 in	 terms	 of	 attributes	 and	focus,	and	in	terms	of	ecosystem	roles	(Iansiti	and	Levien,	2004)	or	entrants	(Smith,	2013).			The	analysis	is	summarised	in	Table	8-4.			This	analysis	would	suggest	 that	the	proposed	models	(summarised	 in	Figure	8-10),	 including	the	 five	 micro-process	 (or	 routines),	 supporting	 the	 innovation	 activity	 system	 and	 its	governance,	 and	 the	 credibility	 and	 advantage	 seeking	 behaviours	 remain	 relevant,	 but	 the	emphasis	or	actor	 focus	 in	each	 changes	as	 the	ecosystem	evolves	and	different	categories,	 in	terms	 of	 co-evolutionary	 logic	 (Aarikka-Stenroos	 and	 Ritala,	 2017),	 become	 dominant.		Furthermore,	 the	 evolution	 in	 actor	 focus,	 as	 the	 context	 and	 lifecycle	 change	 reinforce	 the	arguments	that	in	complex	systems,	such	as	innovation	and	business	ecosystems,	that	context	is	critical	 and	 influences	 actions	 and	 behaviours.	 	 	 Suggested	 behaviours	 or	 actor	 focus	 are	identified	 for	 each	 phase	 using	 example	 literature	 in	 in	 Table	 8-4.	 	 This	 research	 therefore	identifies	 new	 patterns	 of	 behaviour	 for	 nascent	 and	 emerging	 ecosystems	 that	 could	 then	evolve	 into	more	 established	 patterns	 (as	 identified	 in	 previous	 literature)	 as	 the	 ecosystem	matures	and	the	co-evolutionary	logic	changes.												
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Table	8-4	Sensitivity	analysis	of	proposed	models	
	 Ecosystem	lifecycle	phase	(from	Moore,	and	Rong	and	Shi)	
Components	
from	models	
developed	
Birth	or	
Development	
(Nascent	and	
Emerging)	
Growth	or	Expansion		 Leadership	or	Maturity		
Context		 Evolutionary,	with	blurred	boundaries,	emergent	designs	and	networks	(Category	2)	
Growth	and	competition.		Schumpeterian	destruction,	new	entrants.	(Category	1)	
Seeking	to	maintain	stability.	Codification	of	knowledge,	modulatory,	Emergence	of	dominant	design.		(Category	3	and	4)	
	 	 	 	
Searching	 Exploratory	–	wide,	then	focussed.		Search	approach	evolves	as	new	knowledge	and	actors	identified.		
Exploratory,	increasing	systematic	as	knowledge	is	codified	and	risk	/	opportunity	factors	identified	
Systematic,	as	knowledge	codified	and	dominant	designs	established	(Suarez	and	Utterback,	1995)	
Sense-
making	
Focussed	on	translation	and	transforming	(Carlile,	2004)	
Focussed	on	translation	and	transfer	(Carlile,	2004)	 Largely	focussed	on	transfer,	as	knowledge	is	well	codified	(Carlile,	2004)	
Selecting	 Broad,	directional	criteria		 Criteria	more	focussed,	specific	criteria	being	established	(Cooper,	2008)	
Defined	decision	criteria	(Cooper,	2008)	
Shaping	 Challenging	as	value	perception	and	customers	not	established.		Essentially	path	creation	focussed.	(Garud	et	al.,	2010;	Sarasvathy,	2011)	
Effectuation	and	path	creation	(Garud	et	al.,	2010;	Sarasvathy,	2011).		Emergence	of	path	dependency	(Dosi,	1982).	
Largely	path	dependent	(Dosi,	1982)	
Sustaining		 Need	to	address	institutional	and	ecosystem	support	gaps	
Institutional	gaps	are	largely	addressed,	focus	moves	to	competitive	networks	(Nelson,	2008)	
Moves	to	focus	on	efficiency	and	on	ecosystem	renewal	(Anggraeni	et	al.,	2007)			 	 	 	
Credibility-	
seeking	and	
Advantage-		
seeking	
actions	
Actors	largely	engaged	in	credibility-	seeking	actions,	before	moving	to	advantage-seeking	actions.	
New	entrants	must	address	need	for	credibility.		Increasing	dominant	actors	seek	to	reinforce	advantage	position	
For	established	actors,	credibility	and	advantage	already	exists,	for	new	entrants	need	to	address	risks	of	entering	ecosystem	(Smith,	2013)	
Governance	 Focus	on	direction,	value	creation	and	managing	risk.		Agile	governance,	broad	criteria	and	external	expertise	
Focus	on	building	a	portfolio	of	innovations.		Increasingly	codified	criteria	and	internal	expertise.	
Focus	on	portfolio	and	innovation	productivity.	Internal	expertise.	Established	criteria		
Actor	Roles	 Heterogeneous	roles	as	actors	develop	propositions,	credibility	and	advantage	
Emergence	of	dominators,	niche	players	and	commodity	actors	(Iansiti	and	Levien,	2004)	
Emergence	of	Dominant	or	Keystone	role	(Iansiti	and	Levien,	2004)	
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9 Conclusions 
9.1 Introduction This	 study	 has	 examined	how	 organisations	 innovate	 to	 develop	new	 healthcare	 and	medical	technology	products	under	 conditions	of	 convergence	with	partners	 from	different	 industries.			It	 is	 specifically	 focussed	 on	 early	 innovation,	 where	 the	 ecosystem	 is	 nascent.	 	 This	 topic	 is	increasingly	 important	 in	practice,	 as	 innovation	 increasingly	 takes	place	 in	more	diffuse	 and	complex	 environments	 (Enkel	 and	 Gassmann,	 2010;	 Hacklin	 and	Wallin,	 2013).	 Despite	 this	there	has	been	limited	research	of	‘how’	such	innovation	is	undertaken	(Garud	et	al.,	2013)			The	key	objective	of	this	study	was	to	identify	how	firms	develop	convergent	technology	in	these	emergent	healthcare	 technology	ecosystems,	with	 an	 emphasis	 on	 the	organisational	 routines	(Becker,	 2004;	 Nelson	 and	 Winter,	 1982)	 underpinning	 value	 creation	 and	 value	 capture	activities	(Bowman	and	Ambrosini,	2010)	and	the	capabilities	required.			
9.2 Summary of main conclusions The	convergent	or	cross	industry	innovation	creates	increased	complexity	and	uncertainty,	but	also	results	in	the	formation	of	new	ecosystems.			These	nascent	ecosystems	provide	the	context	and	environment	in	which	innovators	must	strive.		The	focus	of	this	research	is	to	understand:	“How	do	organisations	innovate	in	complex,	highly	dynamic	convergent	and	emergent	healthcare	
ecosystems?”		The	key	findings	that	emerge	from	the	case	research	are:		
• The	development	of	the	innovation,	business	model	and	value	network	are	underpinned	by	
five	interrelated	micro-processes	(as	pre-cursors	to	organisational	routines)	that	involving	
searching,	sense-making,	selecting,	shaping	and	sustaining.		These	five	processes	operate	in	patterns,	but	are	non-deterministic	 to	enable	an	organisation	to	navigate	(the	nascent	ecosystem),	 negotiate	 (a	 position	 within	 it)	 and	 nurture	 (both	 the	 innovation	 and	ecosystem).	
• The	cases	suggest	that	an	initial	objective	for	an	innovator	organisation	is	to	seek	legitimacy	and	 a	 credibility-seeking	 position	 in	 the	 ecosystem	 as	 a	 precursor	 to	 moving	 to	 an	
advantage-seeking	position.	
• In	 nascent	 ecosystems	with	 distant,	 diffuse	 knowledge	 and	 actors,	 the	 cases	 suggest	 that	
relational	capabilities	are	critical	to	access	both	new	knowledge	and	new	partners.		
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• Case	studies	suggest	that	the	development	of	new	capabilities	is	largely	from	broad	(wide	ranging)	but	incremental	(shallow)	changes	to	organisational	routines,	as	these	create	the	perception	of	lower	risk	and	enhance	internal	acceptance.				A	 conceptual	 model	 integrating	 these	 components,	 providing	 a	 link	 from	 the	 ecosystem,	 via	drivers	to	activities	and	processes	(organisational	routines)	is	depicted	in	Figure	9-1.		
	
Figure	9-1	Model	for	convergent	innovation	in	nascent	ecosystems			
9.3 Key Insights Several	key	insights,	from	the	ecosystem	interviews	and	case	findings,	are	summarised	below.		An	 early	 requirement	 in	 convergent	 innovation	 and	 nascent	 ecosystem	 is	 access	 to	 new	knowledge	 (Enkel	 and	 Heil,	 2014b;	 Hacklin	 and	 Wallin,	 2013)	 requiring	 a	 ‘creative	 search’	(Pandza	and	Thorpe,	2009).		However,	rather	than	using	structured	or	systematic	searches,	the	case	evidence	points	to	the	use	of	more	exploratory	searches	(Billinger	and	Schumacher,	2014),	in	 conjunction	 with	 the	 development	 of	 relationships	 with	 ecosystem	 actors.	Managing	 and	
building	relations	in	a	nascent	ecosystem	are	identified	as	a	critical	step	for	innovators.		The	case	evidence	 suggests	 that	 it	 provides	 the	 primary	 vehicle	 to	 access	 dispersed	 and	 distant	knowledge,	 and	 facilitate	 sense-making	 and	 sense-giving	 (Pandza	 and	 Thorpe,	 2009;	 Weick,	
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1995)	and	a	mechanism	to	develop	the	innovation,	business	model	and	nascent	value	networks.		This	insight	supports	recent	research	identifying	the	importance	of	direct	engagement	(Nonaka	and	 Konno,	 1998)	 and	 ‘socialisation	 effects’	 (Dingler	 and	 Enkel,	 2016)	 in	 cross	 industry	innovation.	 	 	 These	 relationally	 focussed	 activities	 aim	 to	 address	 two	 key	 drivers,	 first	 to	achieve	credibility	(i.e.	 to	 legitimise	 your	presence	 in	 the	 field	as	potential	 collaborator).	 	 The	cases	 identify	 that	 even	 large	 and	 established	 firms	 need	 to	 address	 this	 as	 they	 undertake	convergent	 innovation.	 In	 effect	 they	 are	 moving	 into	 ‘uncharted	 territory’	 where	 ‘potential	partners	are	neither	actors	you	can	easily	identify	nor	are	they	(once	you	find	them)	likely	to	be	keen	to	engage	with	you’	(Birkinshaw	et	al.,	2007),	and	so	requires	different	network	building	approaches.	Once	credibility	 is	established,	 the	 innovator	can	 then	move	 to	advantage-seeking	actions,	 implicit	 in	 innovation	 (Adner	 and	 Kapoor,	 2010;	 Tidd	 and	 Bessant,	 2013)	 and	entrepreneurialism	(Sarasvathy	and	Dew,	2013).		These	 activities	 are	 underpinned	 by	 a	 set	 of	 micro-processes	 that	 are	 used	 to	 undertake	exploratory	searching,	provide	sense-making	(and	sense-giving),	to	inform	decisions	by	selecting	thus	 shaping	and	 sustaining	 the	 innovation,	 the	 value	network	 and	ecosystem.	 	The	 identified	micro-processes	 provide	 a	 plausible	 explanation	 of	 underpinning	 organisational	 routines	(Nelson	 and	Winter,	 1982)	 and	a	 foundation	 for	 a	 relational	 approach	 (Dyer	 and	Kale,	 2007;	Dyer	and	Singh,	1998)	to	innovation.	Together	these	routines	form	a	non-deterministic	activity	system	that	enable	an	innovator	to	navigate	(the	ecosystem),	negotiate	(a	position	within	it)	and	
nurture	(the	innovation	and	ecosystem).			There	is	limited	literature	on	the	formation	of	nascent	and	emerging	value	networks	(Sebastiao	and	Golicic,	 2008).	 	 Traditional	approaches	 to	 value	network	partner	 selection	do	not	 appear	appropriate,	 instead	 a	 more	 transient	 and	 relational	 approaches	 are	 suggested	 from	 the	research	 cases	 during	 the	 nascent	 phase.	 	 Diversity	 in	 innovation	 alliances	 is	 recognized	 as	important	 (for	example	Nieto	&	Santamaria	2007),	 in	many	of	 the	cases	 the	 innovators	 found	that	 later	 collaborators	 were	 often	 not	 those	 they	 had	 engaged	 early	 on	 and	 so	 building	flexibility	into	the	collaboration	practices,	and	undertaking	activities	to	demonstrate	‘credibility’	are	potentially	important	precursors	to	accessing	tertius	iungens	actors	(Obstfeld,	2005);	those	actors	who	enable	and	potentially	catalyse	further	interactions	and	network	building.		Innovation	requires	organisations	to	develop	new	capabilities	(Helfat	et	al.,	2007;	David	J	Teece,	2010;	Teece	et	al.,	1997;	Tidd	and	Bessant,	2013).	The	case	evidence	suggests	that	developing	capabilities	 for	 a	 convergent	 innovation	 requires	 mostly	 incremental	 changes	 (low	 depth	 of	change)	 across	 many	 organisational	 routines	 (high	 breadth	 of	 change),	 which	 create	 an	
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impression	 of	 low	 uncertainty	 of	 organizational	 change	 and	 thus	 increase	 the	 internal	acceptance.		The	findings	support	the	argument	that	innovators	require	a	more	‘systemic’	view	of	innovation	(Garud	 et	 al.,	 2013;	 Midgley	 and	 Lindhult,	 2017)	 and	 governance	 approaches.	 	 The	 nascent	nature	of	the	field	means	that	investment	decisions	are	hard	to	assess	using	specific	criteria,	to	overcome	this	there	is	evidence	that	innovators	actively	use	their	ecosystem	relationships	(for	example	 with	 stakeholders	 and	 external	 experts	 as	 investment	 board	members)	 and	 to	 help	understanding,	 avoid	 bias	 and	 reduce	 risk.	 The	 active	 but	 evolutionary	 approaches	 identified	above	 suggest	 analogies	 to	 an	 adaptive	 walk	 (Kauffman	 and	 Levin,	 1987)	 in	 a	 rugged	(performance)	landscape	(Siggelkow	and	Levinthal,	2003)	to	evolve	the	innovation.		The	 research	 findings	 are	 summarised	 in	 a	 convergent	 innovation	 framework	with	 identified	factors	to	manage	ecosystem	relationships,	lead	and	manage	the	capability	development,	and	to	build	value	networks,	alliances	and	support.		
9.4 Review of objectives and methodology  The	research	set	out	to	address	the	question:	“How	do	organisations	innovate	in	complex,	highly	
dynamic	convergent	and	emergent	healthcare	ecosystems?”	 	The	rationale	for	using	a	two-phase	research	methodology	was	that	as	the	innovation	ecosystem	was	nascent,	an	initial	phase	was	needed	to	understand	that	ecosystem,	to	ensure	the	research	objectives	were	valid,	to	provide	
context	for	the	case	enquiry.	
9.4.1 Research objectives The	early	research	identified	the	need	to	develop	a	better	understanding	of	the	context	in	which	convergent	innovation	was	taking	place.	 	This	led	to	the	first	objective	to	develop	an	ecosystem	
‘research	approach’	 to	 improve	understanding	of	 systems-based	 forms	of	organising,	providing	a	
context	for	later	research.			As	part	of	the	preliminary	research	a	framework	was	developed	and	used	to	analyse	the	ecosystem	and	individual	cases.			The	key	research	objective,	in	direct	response	to	the	main	research	question	was	to	identify	how	
firms	 develop	 convergent	 innovations	 in	 nascent	 ecosystems,	 with	 a	 focus	 in	 this	 research	 on	innovation	in	healthcare	technologies.			The	core	of	the	case	research	and	the	resulting	models	and	frameworks	directly	respond	to	this	objective.	 	This	in	part	also	to	make	a	contribution	to	gaps	 identified	 by	 Garud	 et	 al.	 	 (2013)	 by	 undertaking	 a	more	 contemporaneous	 research	 of	innovation	processes.		
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The	 final	 objective	was	 to	 identify	more	 systemic	 approaches	 to	 innovation	 that	 embrace	 the	inherent	 complexity.	 This	 objective	 has	 in	 part	 been	met	 by	 the	 development	 of	 the	 activity	system	 model	 and	 convergent	 innovation	 framework,	 as	 these	 aim	 to	 integrate	 activities	 in	innovation.			There	is	however	thought	to	be	scope	to	further	develop	the	integration	concept.					The	key	objectives	are	 therefore	considered	 to	have	been	met.	 	 The	 following	section	reviews	specific	methodological	implications.			
9.4.2 Research methodology 
9.4.2.1 Development of an ecosystem ‘research’ approach and framework The	 importance	 of	 context	 in	 understanding	 complex	 systems	 is	 well	 reported	 (Pawson	 and	Tilley,	1997;	Roberts,	2014;	Sayer,	1992).		There	was	a	need	to	establish	ecosystem	boundaries	and	describe	the	key	phenomena	that	would	potentially	influence	all	cases.	An	early	review	of	both	 ecosystem	 and	 value	 network	 literature	 established	 that	 there	 was	 no	 prevailing	 or	accepted	methodology	 for	this.	 	Further	 investigation	 identified	a	plethora	of	approaches	with	implicit	methodological	assumptions.	 	Given	 the	 lack	of	 understanding	of	 the	 ecosystem	 to	be	investigated,	it	was	determined	that	a	more	robust	approach	was	required.	This	formed	the	first	research	objective.	 	Consequently,	the	PBSRDC	approach	was	developed	by	combining	systems	theory	and	related	methodologies,	as	described	in	Chapter	4.	This	framework	was	used	as	part	of	 the	 overall	 ecosystem	 investigation	 and	 for	 each	 case.	 The	 framework	 identifies	 three	 key	considerations	(conceptual,	physical	and	temporal)	and	 the	 implications	 in	 terms	of	theoretical	consideration,	method	of	inquiry	and	typical	research	questions.				The	framework	was	applied	to	the	initial	ecosystem	investigation	and	this	increased	confidence	that	 the	 proposed	 approach	 provides	 a	 pragmatic	 method	 for	 ecosystem	 study.	 	 Whilst	 the	approach	and	framework	developed	is	intended	to	be	generic,	it	has	only	been	applied	in	limited	examples,	 and	 so	 would	 benefit	 from	 wider	 application	 and	 testing	 to	 help	 refine	 the	methodology.				
9.4.3 Case Research Approach Recognising	that	the	aim	was	to	understand	innovation	processes	and	practices	in	an	emerging	field,	obtaining	contemporaneous	data	via	longitudinal	studies	was	deemed	important	(Garud	et	al.,	 2013).	 	 The	 longitudinal	 case	 studies,	 although	 limited	 in	 number,	 provide	 in-depth	 and	contemporaneous	data,	with	 evidence	 captured	 in	near	 real-time.	This	 approach	also	 reduced	the	risks	of	post-event	filtering	and	recall	failures	(Flick,	2009)	and	enabled	follow-up	of	specific	
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themes	 in	 subsequent	 interviews	 and	 observations	 (Easton,	 2010),	 thus	 providing	 more	 in-depth	insights	into	observed	actions	and	decisions.	 	 	The	mix	of	incumbent	firms	and	start-ups	exhibiting	similar	approaches	and	mechanisms	increases	confidence	in	the	findings.	As	well	as	seeking	direct	case	evidence,	context	was	provided	by	obtaining	data	from	the	wider	ecosystem.		This	 context	 is	 crucial	 to	 the	 critical	 realist	 approach	 adopted	 for	 these	 case	 studies	 (Easton,	2010;	Vincent	and	Wapshott,	2014).			As	one	of	the	five	longitudinal	cases	resulted	in	company	failure,	it	was	possible	to	explore	differences	between	this	case	and	others	to	support	arguments	for	plausible	causation	mechanisms.				
9.4.4 Research reliability and validity  Despite	 the	 focussing	 on	 exploratory	 studies	 in	 a	 diffuse	 and	 evolving	 environment,	 the	methodology	 was	 designed	 to	 provide	 reliability,	 validity	 and	 rigour	 	 (Gibbert	 et	 al.,	 2008;	Gibbert	and	Ruigrok,	2010).			To	 build	 internal	 validity,	 the	 research	 framework	 (e.g.	 exploratory	 framework	 and	 case	protocol)	was	derived	 (abducted)	 from	 a	 combination	 of	 interview	 data	 and	 literature.	 	 	 The	analysis	procedures	used	 accepted	 literature	 sources	 and	 recognised	 research	methodologies,	such	as	the		Gioia	method	(2012)	(to	ensure	that	the	ecosystem	was	defined	as	close	as	possible	to	the	words	and	intent	of	the	interviewees)	and	in	later	case	analyses	using	the	ECPO	approach,	which	was	derived	from	Sayer	(1992),	Danermark	et	al.	(2002)	and	Easton	(2010).		More	 broadly,	 this	 research	 has	 been	 reviewed	 against	 six	 criteria	 identified	 to	 judge	 realist	research	(Healy	and	Perry,	2000).		Largely,	they	follow	the	expectations	identified	by	Yin	(2014)	for	 case	 research,	 but	 deviate	 to	 meet	 the	 requirements	 for	 critical	 realist	 research,	 where	epistemological	and	ontological	differences	occur.	These	criteria	are	summarised	 in	Table	9-1,	along	 with	 example	 literature	 sources	 for	 each	 criterion	 and	 a	 summary	 of	 the	 evidence	 or	approach	from	this	research	to	support	that	these	criteria	being	met.												
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Table	9-1	Summary	of	validity	and	reliability	considerations	for	this	research	
Criteria	 Example	Sources	 Research	Examples	Ontology	-	recognise	research	as		‘’world	three’		 (Magee,	1985)		 Research	philosophy	and	methods	are	rooted	in	realism	(Chapter	4)	Contingent	validity	-	Causal	mechanisms	influenced	by	context	 (Pawson	and	Tilley,	1997)	 Methods	applied	determine	causation	by	considering	context	and	tendencies	using	ECPO	process	(Figure	4-12),	detailed	in	Appendix	A5.	Multiple	perspectives	are	applied	 (Danermark	et	al.,	2002)	 Research	used	sources	from	multiple	interview	sources,	documentation	and	observations	to	provide	multiple	perspectives.	Methodological	Trustworthiness	 (Healy	and	Perry,	2000)	 Research	database	in	secure	Dropbox	environment,	analysis	using	NVivo	and	use	of	quotations	Analytic	generalisation	 (Yin,	2014)	 No	claim	is	made	as	to	wider	generalisation,	as	this	research	can	be	considered	as	exploratory	and	theory	building.		Construct	validity	 (Gibbert	et	al.,	2008;	Yin,	2014)	 Use	of	original	interviews	and	observations,	data	triangulation,	and	reviews	with	key	informants.	Documented	approach	for	data	collection	and	analysis.			
9.4.5 Limitations There	are	several	limitations	to	this	research.			First,	it	is	restricted	to	convergent	innovation	in	healthcare	technologies.	This	limits	the	generalisability	of	any	findings.	 	Secondly,	and	possibly	foremost,	is	that	the	number	of	cases	is	small,	with	only	five,	limited	by	the	practicality	of	access	to	 firms	 willing	 and	 able	 to	 permit	 contemporaneous	 and	 longitudinal	 studies	 of	 their	 key	innovations.			However,	the	limited	number	of	cases	is	countered	by	having	in-depth	and	diverse	sources.	 There	 is	 also	 substantial	 evidence	 from	multiple	 sources,	which	 increase	 confidence.		Whilst	the	cases	are	longitudinal,	they	are	limited	to	around	15-24	months	in	duration	and	no	definitive	statement	on	the	success	of	the	innovations	can	be	made.	However,	each	case	included	at	 least	 one	 major	 ‘inflection	 point’	 (e.g.,	 a	 major	 investment	 decision,	 go/no	 go	 milestone,	formation	 of	 new	 organisation	 or	 structure)	 that	 provides	 an	 indicator	 of	 expected	 success.		Given	 that	 no	 outcome	 for	 each	 innovation	 project	 was	 observed,	 this	 research	 cannot	determine	explicit	 factors	 for	success,	only	 that	certain	 factors	appear	 to	create	opportunities,	create	capabilities	and	avoid	limitations.			Of	 the	 five	 cases,	 four	were	 ongoing	 at	 the	 end	 of	 the	 research	 period.	 	 One	 firm	 failed	 (and	closed),	but	given	the	nature	of	the	research,	this	is	an	important	observation.	 	Because	of	this	failure,	 the	 number	 of	 interviews	 conducted	 for	 this	 case	 is	 less	 than	 intended,	 however	 two	factors	mitigate	 this:	 one	was	 the	 ability	 to	 undertake	 a	 ‘post	mortem’	 interview	 that	 helped	
		 209	
identify	 some	 of	 the	 reasons	 for	 failure,	 secondly,	 the	 interviews	were	 supplemented	 by	 nine	documents	 which	 help	 to	 corroborate	 findings.	 	 Understanding	 failure	 is	 relevant	 and	 by	identifying	differences	in	patterns	of	actions	in	‘successful’	and	‘failing’	firms	provides	additional	evidence	to	support	the	suggested	causal	mechanisms.				A	further	limitation	of	this	research	is	that	it	is	qualitative	only.		Given	the	nascence	of	the	field,	with	 limited	cases	and	data	available,	 this	was	deemed	the	only	viable	approach.	 	As	such,	no	claims	 are	 made	 for	 wider	 generalisability.	 	 This	 research	 is	 fundamentally	 exploratory	 and	theory	building,	not	theory	testing.	 	Given	the	nature	of	the	findings	to	date	and	importance	of	the	 field	and	phenomena,	 it	 is	hoped	that	subsequent	studies	(with	combination	of	qualitative	and	quantitative	approaches)	can	be	developed	to	test	the	models	and	frameworks	suggested.			The	 research	philosophy	employed	–	 critical	 realism	–	provided	a	useful	approach	 to	unearth	mechanisms	in	a	complex	and	evolving	environment	where	context	is	important.	The	analytical	retroduction	 process	 is	 essentially	 creative,	 and	whilst	 attempts	were	made	 to	 identify	 other	plausible	 mechanisms	 and	 eliminate	 these,	 it	 is	 not	 possible	 to	 say	 with	 certainty	 this	 was	comprehensive	 and	that	 some	mechanism	was	not	 overlooked.	 	 	One	 further	 limitation	of	 the	critical	 realist	 approach	 employed	 is	 the	 difficulty	 in	 conducting	 the	 analyses.	 	 Tools	 such	 as	NVivo	employed	here,	make	qualitative	analysis	and	coding	simpler,	but	 the	multi-perspective	approach	required	to	conduct	the	ECPO	analysis	could	not	be	undertaken	in	NVivo	and	required	large	 amounts	 of	 data	 to	 be	 transferred	 to	Microsoft	 Excel	 for	 analysis.	 	 This	 imposed	 some	constraints	on	the	types	of	analysis	and	linkages	that	could	be	assessed.		In	summary,	causal	mechanisms	have	been	identified	by	developing	plausible	explanations	and	by	the	identification	and	elimination	of	alternatives.	Future	research	might	attempt	to	conduct	a	broader	comparative	analysis	of	the	identified	causal	mechanisms	to	highlight	those	which	offer	the	 strongest	 and	most	 robust	 explanatory	 power	 (Hodgson,	 2004;	 Sayer,	 1992).	 This	would	entail	 using	 a	 wider	 data	 set	 or	 seeking	 to	 assess	 the	 mechanisms	 in	 other	 domains	 of	convergent	innovation.		
9.5 Implications and contribution to theory This	 research	 was	 undertaken	 primarily	 as	 a	 contribution	 to	 the	 innovation	 management	agenda.	 	 It	 focuses	 specifically	 on	 ‘convergence’	 or	 ‘cross-industry’	 innovation.	 	 From	 an	empirical	perspective,	 it	addresses	convergence	in	healthcare	and	medical	technologies,	which	has	had	little	prior	research,	and	as	such	addresses	a	gap	in	the	field.		It	also	aims	to	address	a	specific	 challenge	 in	 innovation	 research	 that	 of	 understanding	 ‘how’	 by	 identifying	 the	underlying	processes		(Garud	et	al.,	2013).		
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	The	first	contribution	from	this	research,	focussed	on	the	field	of	convergent	or	cross	industry	innovation	 is	 a	 Convergent	 Innovation	 Framework.	 	 	 The	 framework	 identifies	 key	 factors	identified	as	required	in	convergent	innovation.			It	extends	the	work	on	convergence	of	Rikkiev	and	Makinen	 (2013),	 on	 cross	 industry	 innovation	 by	 Enkel	 (for	 example	 Dingler	 and	 Enkel,	2016;	Enkel	and	Gassmann,	2010;	Enkel	and	Heil,	2014a,	2014b;	Heil	and	Enkel,	2015)	and	also	Adner	 (2008;	 2010)	 by	 taking	 an	 innovation	 ecosystem	 perspective	 and	 adopting	 a	 more	relational	approach	(Dyer	and	Kale,	2007).			Specifically	addressing	a	mechanism	for	the	innovation,	five	non-deterministic	micro-processes	(5S)	are	proposed	to	cover	searching,	sense-making,	selecting,	shaping	and	sustaining.			Evidence	was	found	for	the	existence	of	these	processes	and	mechanisms	in	case	research	in	both	small	and	large	firms	and	in	the	incubator	case.		These	5S’s	appear	to	play	a	key	role	in	value	creation	and	provide	a	simple	explanation	of	the	underpinning	mechanism	and	routines	for	co-evolution	within	 a	 nascent	 ecosystem.	 	 It	 is	 further	 suggested	 that	 these	 micro-processes	 form	 the	foundations	of	activity	systems	(Siggelkow	and	Porter,	2008)	to	navigate,	negotiate	and	nurture	the	 innovation,	 business	model	 and	 value	 network,	with	 early	 activities	 to	 build	 a	 credibility-
seeking	 position,	 followed	 by	 later	advantage-seeking	 actions.	 These	 are	 relational	capabilities	(Dyer	 and	 Kale,	 2007;	 Dyer	 and	 Singh,	 1998)	 are	 considered	 to	 be	 important	 precursors	 for	developing	business	models,	value	networks	and	organisational	capabilities.	In	line	with	the	call	from	 Garud	 et	 al.	 (2013),	 this	 research	 embraces	 the	 concept	 that	 innovation	 requires	innovators	 to	 embrace	 the	 complexity,	 rather	 than	 try	 to	 manage	 it.	 The	 complexity	 of	convergent	 innovation	requires	 innovators	to	 integrate	diverse	knowledge,	 integrate	 technical	systems,	business	models,	value	networks	and	organisations.			An	approach	to	this	integration	is	proposed	 in	 the	 relational	 model	 developed	 for	 convergent	 innovation.	 	 Thus,	 this	 research	contributes	to	innovation	and	organisational	capabilities	agendas.		The	organisational	challenges	presented	by	undertaking	convergent	and	potentially	disruptive	innovation	 require	 that	 organisations	 have	 capabilities	 that	 are	 unlikely	 to	 be	 present	 in	 the	existing	 or	 start-up	 organisation	 (Birkinshaw	 et	 al.,	 2016;	 Rosenbloom,	 2000;	 Teece,	 2012).		There	 is	 a	 need	 to	 build	 new	 capabilities,	 and	 the	 extant	 literature	 suggests	 that	 these	 are	developed	or	acquired	by	employing	dynamic	capabilities	(Helfat	et	al.,	2007;	Teece	et	al.,	1997)	or	 by	 exhibiting	 organisational	 ambidexterity	 (Raisch	 and	 Birkinshaw,	 2008;	 Tushman	 and	O’Reilly,	2011).	 	 In	 this	 research,	 three	 incumbent	 case	 firms	 and	two	start-ups	were	 studied.	The	existent	organizational	capabilities	do	not	however	necessarily	act	as	core	rigidities.	They	are	more	 likely	a	useful	 initial	 ingredient	 for	a	knowledgeable	manager	 that	skilfully	balances	between	 necessary	 modifications	 across	 multiple	 organisational	 routines	 and	 sustaining	 a	
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perception	of	continuity	between	the	old	and	the	new	ways	of	doing	innovation	at	an	incumbent	company.	 	 By	 adopting	 an	 approach	 using	 systemic,	 but	 incremental	 changes,	 there	 is	 a	perception	of	“familiarity”,	that	reduces	the	risk	of	inertia	or	rejection	by	the	organisation	and	so	increases	 the	 likelihood	 of	 internal	 acceptance.	 	 The	 case	 evidence,	 thus,	 suggests	 a	 more	nuanced	explanation	 for	building	organisational	 capabilities,	 as	a	 contribution	 to	 the	dynamic	capabilities	field	(Helfat	et	al.,	2007;	Teece,	2007;	Teece	et	al.,	1997).			The	 business	 model	 literature	 largely	 focuses	 on	 the	 model	 itself	 or	 on	 archetypes,	 but	 the	evolutionary	nature	of	 the	business	model	and	the	role	of	business	modelling	are	 increasingly	important	 in	 the	 research	 agenda.	 	 It	 is	 suggested	 that	 	 contrary	 to	 approaches	 like	 those	 of	Osterwalder	 (2010),	 the	 business	 model	 is	 not	 a	 ‘design’,	 but	 evolves	 (Baden-Fuller	 and	Mangematin,	 2015a,	 2013).	 	 In	 developing	 a	 business	model	 there	 is	 intent,	 but	 there	 is	 also	emergence.	 	 This	 is	 analogous	 to	 Mintzberg’s	 (1978)	 patterns	 in	 strategy	 formation.	 	 The	contribution	to	business	model	literature	is	that	the	business	model,	or	more	strictly	the	value	proposition,	 is	 not	 just	 a	 linking	mechanism	 between	 ecosystem	 and	 value	 network	 (Baden-Fuller	and	Mangematin,	2015a),	but	also	acts	in	a	dynamic	way	as	a	 ‘boundary	object’	(Carlile,	2004;	Leigh	Star,	2010;	Leigh	Star	and	Griesemer,	1989).		This	provides	a	mechanism	to	explore	and	evolve	the	innovation	through	‘value	exchanges’	(Bowman	and	Ambrosini,	2010,	2000)	as	the	 innovator	 takes	 ‘an	 adaptive	walk’	 (Kauffman	 and	 Levin,	 1987),	 developing	 the	 potential	value	 proposition	 with	 multiple	 stakeholders	 in	 the	 evolving	 ecosystem.	 	 These	 exchanges	provide	the	basis	for	‘business	modelling’	and	make	a	contribution	to	the	business	model	agenda,	and	in	part	addressing	the	limited	research	in	the	field	of	business	modelling	(Baden-Fuller	and	Mangematin,	2015a).			Although	 limited	 to	 a	 few	 cases,	 taking	 a	 contemporaneous	 and	 longitudinal	 case	 approach	addresses	an	identified	gap	in	the	 literature	on	 ‘how’	organizations	develop	value	networks	 in	this	 context	 (Harrington	 and	 Srai,	 2016).	 	 A	model	 for	 value	 network	 formation	 is	 proposed,	using	 multiple	 transient	 partnerships	 to	 build	 knowledge	 and	 capabilities	 before	 selecting	 a	longer-term	 partner.	 	 This	 approach	 underpinned	 by	 the	 navigate,	 negotiate	 and	 nurture	activities	is	aligned	to	network	configuration		principles	(Harrington	and	Srai,	2016;	Srai	et	al.,	2014),	thus	contributing	to	the	value	network	literature.			Finally,	despite	the	significant	interest	in	business	ecosystems	in	the	current	literature,	there	are	limited	 systems-based	 approaches	 to	 ecosystem	 investigation	 (Oh	 et	 al.,	 2016;	 Ritala	 and	Almpanopoulou,	2017).			An	approach	for	studying	ecosystems,	consistent	with	systems	thinking	and	theory	has	been	developed	and	initially	tested.			The	PBSRDC	methodology	provides	a	step	forward	in	developing	a	systems-theory	consistent	approach	that	addresses	the	need	for	taking	
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different	 perspectives,	 making	 an	 explicit	 boundary	 definition,	 defining	multi-level	 structures	and	relationships	and	understanding	both	dynamics	and	co-evolution.		As	such,	it	contributes	to	systems-forms	of	organisation	research	methodology	and,	specifically,	the	ecosystems	literature.			
9.6 Implications and contribution to practice This	 research	 suggests	 new	 approaches	 to	 innovation	management	 in	 a	 complex	 health	 care	setting.		From	 a	 practice	 perspective,	 the	 research	 provides	 mechanisms	 for	 building	 relational	capabilities	 considered	 critical	 to	 innovation	delivery.	 	 In	nascent	 ecosystems	and	 convergent	innovation,	 the	 ability	 to	 search	 and	 sense-make	 is	 key.	 Understanding	 the	 nascent	 and	emerging	ecosystem	is	vital	to	access	knowledge,	identify	risks	and	identify	potential	partners.	The	importance	of	engaging	diverse	stakeholders	early	in	the	venture	is	emphasised.		Searches	are	 exploratory,	 but	need	 to	be	directed	 and	active.	Using	 the	 ‘network	of	 your	network’	 and	snowballing	 appear	 to	 be	 effective	 approaches.	 Given	 the	 knowledge	 ambiguity,	 face-to-face	interactions	are	preferred.	But	to	access	knowledge,	innovators	may	need	to	selectively	reveal	to	build	 credibility	 and	 legitimacy,	 especially	 if	 the	 field	 is	 distinct	 from	 their	 current	 business.	Building	 trusting	 relationships	 is	 therefore,	 critical.	 	 Later,	 approaches	 such	 as	 crowdsourcing	may	 be	 appropriate	 as	 knowledge	 is	 codified	 and	 the	 innovator	 has	 established	a	position	 of	credibility,	 but	 undertaking	 such	 activities	 early	 is	 likely	 to	 be	 unfruitful	 and	 potentially	wasteful.	 	The	need	to	build	credibility	 in	the	ecosystem	appears	paramount,	 in	the	cases,	even	large	 incumbent	 organisations	 struggled	 to	 attract	 interest	 or	 engagement	 until	 they	 had	demonstrated	via	actions	their	intent	and	were	seen	as	legitimate,	trustworthy	and	credible	by	other	 stakeholders.	 Here,	 innovators	 need	 to	 invest	 in	 actions	 that	 not	 only	 progress	 their	innovation,	but	in	those	actions	that	help	shape	and	sustain	the	ecosystem	itself,	thus	providing	a	viable	and	diverse	cluster	of	potential	relationships,	partners	and	a	supporting	infrastructure.		These	 steps	 are	 precursors	 to	 moving	 to	 an	 advantage-seeking	 position,	 which	 enables	 the	innovator	to	take	more	exploitative	actions.	
	An	 approach	 to	 building	 nascent	 value	 networks	 is	 suggested	 that	 requires	 multiple	engagements	with	 diverse	 stakeholders	 to	 create	 credibility	 and	 visibility;	 necessary	 to	 form	alliances.	 	 Whilst	 these	 relationships	 may	 be	 transient,	 they	 provide	 innovators	 with	 an	opportunity	 to	 shape	 outcomes	 and	 their	 value	 network.	 The	 insights	 provide	 potentially	important	areas	for	innovators	to	focus	on	in	terms	of	approaches	to	identify	collaborators	and	looking	for	congruence	beyond	just	technical	capabilities.	Building	strong	relationships	too	early	may	be	risky.	Relational	 considerations	are	potentially	more	 important	 in	 in	partner	selection	for	nascent	value	network	formation.		
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	Relationships	 in	 the	 wider	 ecosystem	 also	 help	 in	 supporting	 key	 decisions,	 either	 to	 help	identify	the	right	 ‘problem’	or	the	criteria	for	selection.	 	 	 Innovators	engage	their	ecosystem	in	key	 decisions,	 for	 example	 by	 employing	 them	 as	 external	 input	 in	 governance	 boards	 or	advisory	teams,	which	has	the	by-product	of	helping	further	build	trust	and	legitimacy.			With	 the	 inherent	 complexity	 and	 uncertainty	 in	 convergent	 innovation,	 it	 is	 unlikely	 that	 a	business	model	can	be	‘designed’.		Innovators	should	therefore	look	to	use	the	ecosystem	actors	and	a	series	of	potential	‘value	exchanges’	to	evolve	the	design	and	business	model.	If	the	market	and	 ecosystem	 are	 not	 well	 defined,	 any	 ‘design’	 is	 likely	 flawed,	 so	 experimentation	 and	evolution	are	critical.				The	 internal	 organisational	 support	 for	 the	 new	 venture	 is	 also	 influenced	 by	 how	 the	innovation	 is	managed:	doing	something	different	(i.e.	developing	a	convergent	 technology)	 is	fine,	provided	how	this	is	done	is	not	seen	as	too	different	(and	therefore	perceived	as	riskier).	The	 findings	 have	 direct	 relevance	 for	 managers	 in	 incumbent	 firms.	 It	 is	 suggested	 that	deploying	 existing	 organisational	 routines	 is	 an	 appropriate	 starting	 point	 for	 managing	innovation	 in	 a	distant	domain,	 but	managers	will	 need	 to	 implement	numerous	 incremental	changes	 across	 a	 wide	 range	 of	 organisational	 routines.	 Although	 these	 changes	 will	 not	 be	perceived	 as	 radical,	 the	 very	 breadth	 of	 modifications	 indicates	 a	 significant	 managerial	challenge.	The	internal	organizational	support	for	the	new	and	potentially	disruptive	innovation	is	also	influenced	by	how	the	uncertainty	of	any	accompanying	change	in	organizational	routines	is	 perceived	 by	 decision-makers	 and	 other	 groups	 involved	 in	 innovation	 processes.	 Doing	something	different	(i.e.	developing	a	convergent	technology)	may	not	give	a	license	to	do	it	in	a	different	 way.	 Managers	 leading	 a	 convergent	 and	 potentially	 disruptive	 innovation	 should	avoid	 “being	 seen	as”	 acting	 radically	different	and	 this	 requires	 skilful	 navigation	of	 internal	interests	and	framing	of	how	the	innovation	is	done.			
9.7 Impact and dissemination During	 this	 research,	 several	 opportunities	 arose	 to	 disseminate	 part	 of	 the	 findings	 to	organisations	and	institutions	and	thus	to	achieve	a	degree	of	impact.			Towards	the	later	stages	of	 this	 research	 several,	 further	 opportunities	 arose	 to	 provide	 input	 to	 innovator	 firms,	including	a	few	of	the	cases.		Other	examples	of	research	dissemination	and	potential	impact	include:	
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• Presentation	 of	 convergent	 innovation	 and	 ecosystem	 challenges	 to	 Stevenage	Bioscience	Catalyst,	which	was	used	to	help	inform	their	future	strategy	and	investment	(January	2016)	
• Presentation	 of	 convergent	 innovation	 and	 implications	 for	 innovators	 and	 adoption,	provided	 to	 Health	 Enterprise	 East	 (April	 2016),	 to	 provide	 input	 to	 support	 for	entrepreneurs	and	innovators	
• Presentation	 to	 researchers	 and	 leaders	 at	 the	 Research	 Centre	 for	 Pharmaceutical	Engineering	(RCPE),	TU	Graz	(May	2017).		
9.8 Concluding remarks and areas for future work This	research,	for	practical	reasons,	was	limited	to	convergent	innovation	in	health	care	in	the	UK.	As	activities	are	context	sensitive,	 further	research	studying	 the	phenomena	 in	a	different	context,	 or	 geography	 (e.g.	 USA)	 would	 be	 a	 logical	 extension.	 As	 well	 as	 understanding	 the	implications	of	a	different	context,	such	a	study	would	help	the	generalizability	of	the	findings.			A	further	extension	would	be	to	consider	how	convergent	innovation	is	undertaken	in	different	contexts,	 including	those	in	different	convergence	domains	with	nascent	ecosystems	and	value	networks,	 this	 would	 be	 a	 useful	 extension	 to	 build	 a	 more	 comprehensive	 model	 of	 an	increasingly	important	area	of	innovation.			The	reliance	on	a	small	number	of	cases	and	close	engagement	with	its	idiosyncrasies	inevitably	limit	generalized	 induction.	For	example,	 the	 focus	on	early	stages	of	developing	a	potentially	disruptive	technology	for	medical	and	health	industry	prevents	investigating	managerial	actions	and	 organizational	 capabilities	 that	 become	 relevant	when	 this	 technology	 enters	 the	market	and	start	disrupting	its	members.	It	is	possible	that	in	the	latter	stages	the	internal	opposition	to	the	initiative	may	intensify.	It	is	expected	that	an	incumbent	introducing	convergent	innovation	in	a	highly	regulated	field	of	medicine	will	face	similar	challenges	as	those	identified	by	Ansari	et	al.,	(2016)	when	studying	the	disruptor’s	dilemma,	but	the	current	stage	of	this	venture	does	not	permit	investigation	of	this	empirically.		In	 terms	 of	 organisational	 routines	 and	 capabilities,	 there	 are	 three	 implications	 for	 future	research.	First,	would	be	to	encourage	a	more	thorough	investigation	of	how	incumbents	engage	with	 potentially	 disruptive	 convergent	 technology	 in	 early	 stages	 of	 development	 as	 this	complements	innovation	research	that	mostly	investigates	ex-post	successes	or	failures.	Second,	that	 investigating	 disruptive	 and	 discontinuous	 changes	 potentially	 sheds	 more	 light	 on	reciprocal	 relationships	 between	 managerial	 agency	 and	 development	 of	 organizational	capabilities	 in	 general	 or	 innovation	 capabilities.	 Third,	 consistent	with	 Garud	 et	 al,’s	 (2013)	
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perspective	 on	 innovators	 embracing	 the	 complexity,	 there	 is	 evidence	 from	 the	 cases	 of	organisations	using	a	range	of	approaches	to	integrate	activities	and	embrace,	rather	than	try	to	reduce,	complexity.		This	is	not	reported	here	in	the	interests	of	brevity,	but	will	be	followed	up	in	future	research.		The	governance	and	decision	making	approaches	have	been	highlighted,	but	existing	approaches	in	both	closed	and	open	innovation	do	not	adequately	address	the	challenges.		Further	research	in	this	field,	and	particularly	the	role	of	interpretive	approaches	and	the	role	of	external	experts	warrants	further	attention.			This	 research	 has	 suggested	 several	 exploratory	 and	 evolutionary	 processes	 to	 support	convergent	 innovation.	 	 It	 has	 been	 tentatively	 suggested	 that	 these	 processes,	 to	 develop	knowledge,	the	innovation,	and	value	network	are	non-deterministic	and	analogous	to	adaptive	walks	(Kauffman	and	Levin,	1987).	 	Approaches	such	as	genetic	algorithms	(Grupe	and	Jooste,	2004;	Holland,	1992;	Kauffman	et	al.,	2000;	Mitchell,	1996)	may	provide	further	insights	to	the	underpinning	 process.	 	 	 Given	 the	 human	 interactions,	 approaches	 built	 upon	 anticipatory	
genetic	algorithms	(Kosorukoff,	2001;	Mocanu	and	Kalisz,	2012)	may	provide	a	fruitful	area	for	exploration	and	would	align	with	thinking	on	anticipatory	systems	(Louie,	2010)	and	systemic	approaches	(Fuller	et	al.,	2000;	Midgley,	2006,	2000).			Finally,	 as	part	 of	 this	 research,	 an	approach	 to	 studying	business	and	 innovation	 ecosystems	was	developed	(PBSRDC),	addressing	a	known	gap	in	the	literature,	but	the	approach	has	only	been	 tested	 to	 a	 limited	 extent.	 	 Further	 testing	 of	 this	 methodology	 in	 a	 range	 of	 different	ecosystems,	at	different	points	in	their	lifecycle	would	help	validate	the	proposed	approach	and	increase	its	generalisability.					 	
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Appendix A1 - Preliminary Interview Protocol 
	
Mark	A	Phillips	Rev	4	July	2014	
Emerging	Health	Care	Industrial	Ecosystem	–		
Understanding	the	Emerging	Landscape	-	Interview	Protocol	–	Exploratory	
Phase	
	
Purpose	To	gain	insights	from	a	wide	range	of	experts	and	interested	parties	(stakeholders)	into	defining	the	overall	‘system’	boundaries	and	to	identify	the	key	challenges	and	potential	opportunities	for	the	development	of	Emerging	Health	Care	systems	(and	specifically	Convergent	Medical	Technologies	(CMT)).			To	be	used	as	part	of	a	PhD	Research	Project.		These	insights	will	be	shared	with	interviewees	in	a	follow	up	(probably	via	email)	to	further	validate	the	key	or	summary	findings.		
	
Participants	
• A	diverse	cross-section	of	Stakeholders	in	the	Heath	Care	Industrial	system	(see	page	2)	
	
Approach	Following	an	initial	focus	group	meeting,	identify	likely	interviewees	/	stakeholders.			During	interviews	review	their	view	of	stakeholders	and	key	issues	and	opportunities.		Use	‘snowballing’	to	identify	additional	potential	interviewees.		
Early	Research	Hypotheses	(related	to	the	industrial	ecosystem)	
The	initial	research	focuses	on	two	distinct	stakeholder	groups	–	customers	(ie	NHS	Trusts,	CCGs,	service	
providers)	and	Industrial	System	stakeholders	(ie	pharma,	med	tech,	ICT,	funders,	academia)	
From	a	customer	or	patient	perspective:	
• Hypothesis	H1	–	There	is	a	increased	focus	on	patient	centric	approaches,	from	R&D,	through	to	
service	delivery	and	commissioning,	but	the	practical	implications	are	not	always	clear	
• Hypothesis	H2	–	current	suppliers	do	not	engage	with	customers	well	(or	tend	to	engage	late)	and	
have	limited	understanding	of	customers	needs	
• Hypothesis	H3	–	suppliers	do	not	have	appropriate	business	models	to	meet	customers	needs	
	
From	perspective	of	Emerging	Health	Care	Industrial	System	‘landscape”,	the	key	hypotheses	are:	
• Hypothesis	H4	–	There	is	not	a	clear	understanding	of	CMT,	and	there	are	divergent	views	across	
actors/stakeholders	
• Hypothesis	H5	–CMT	challenges	are	diverse	and	underestimated	
• Hypothesis	H6	–	The	potential	CMT	customers	are	not	clearly	defined	or	understood	
• Hypothesis	H7	–	There	is	limited	and	unfocussed	support	for	CMT	activities	in	UK		Interviews	will	be	conducted	in	March	through	July	1014	to	establish	the	system	boundaries	and	key	issues	to	help	shape	subsequent	research.		
	
Interviewees	–	customers	and	stakeholders		From	Burns	(Burns,	2002,	2012)	the	immediate	Value	Chain	consists	of:	
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	 Stakeholder	 Role	 Organisation	
Examples	
Rationale	for	inclusion	or		
exclusion	in	interviews	
Comments	–	
potential	
interviewees	1	 Patient	 Customer,	consumer,	payer	 n/a	 Exclude	-	Too	diffuse,	diverse	and	dependent	on	subject	knowledge.		 (Ethics	issues)	2	 Patient	Group	 Collective	of	
patient	interests	
SPRING	(Parkinsons)	 Consider	inclusion	of	1-2	groups	in	next	phase		 Shift	MS	3	 Provider	 Primary	Care	 • GP	Practices	 Consider	for	follow	up	(part	represented	by	CCGs)	 (Access	issues)	4	 Provider	 Secondary	Care	 • Hospital	Trust	
• Community	Care	Trust	
• Mental	Health	Trust	
Include	Hospital	Trusts	as	major	users	Consider	Community	and	MH	in	follow	up	Consider	Mental	Health	as	follow	up,	depending	on	CCG	priorities.	
Camden	NHS	Wittington	NHS	Kings	College	HNS	Leeds	&	York	NHS	5	 Provider		 Pharmacy	 • Boots	Alliance	
• Lloyds	 Key	community	providers	for	products	and	services	 Boots	Alliance	6	 Provider	 New	Integrator	 • ??	 Entrepreneur	/	innovator	looking	to	offer	provider	services?	 Scan	for	potential	integrator	7	 Payer	 Care	Funding	 • CCG		 Include	as	major	funders	and	commissioning	agents.	 Enfield,	Camden	CCGs	8	 Payer	 Insurance	 • Axa,	BUPA	 Consider	for	next	round	 (Access)	9	 Payer	 Medical	R&D	
Funding	
• AHSN		 Include	as	major	focus	in	NHS	Innovation	 Eastern	AHSN	10	 Producers	 Distributors	 NHS	SC	 Consider	in	later	phase	 Run	by	DHL	11	 Producers	 Pharma	R&D,	
and	supply	
GSK,	AZ,	generics	 Major	therapy	suppliers	and	R&D.		include	one	MNC	 GSK		/	J&J	12	 Producers	 Med	Tech	R&D	
and	supply	
GE,	Siemens	 Major	Med	Tech.	include	one	from	med	tech	or	diagnostics	MNC	 GE,	Roche	Diagnostics	13	 Producers	 Diagnostics	
R&D	and	supply	
GE,	Alere,	Roche,	Biomerieux	 Major	diagnostic.	include	one	from	med	tech	or	diagnostics	MNC	 Alere	/	Mologic	Imanova	14	 Producers	 eHealth	 TPP	/	DH	 Include	2-3	from	list	 Tbc	15	 Producers	 mHealth	 App	developer	 Include	2-3	from	list	 Via	NHS	Trust	16	 Producers	 Services	 Accenture,	TPP	 Include	2-3	from	list	 Accenture	17	 Producers	 Biotech	–	
therapy	
Phagenysis	 Include	2-3	from	list	–	SME	/	SU	 Phagenysis	18	 Producers	 Med	tech	/	
device	dev	
	 Include	2-3	from	list	–	SME	/	SU	 J&J	19	 Producers	 Suppliers	to	above	 Chemical,	electronics,		 Consider	in	future	phase,	as	suppliers	to	‘producers’	 	20	 Producer	 RTO	/	CRO	 PA	Consulting	Covance	 Consider	in	future	phase,	as	suppliers	to	producers	 	21	 Regulators	 Regulator	 MHRA	FDA	EMA		 Include	MHRA,	if	they	will	participate	 MHRA	Innovation?	22	 Funder	 Angel	/	cVC/	VC	
/	PE	
SVLS,	SROne	Imperial	Innov	Entrepreneurs	Fund	
Include		-	2-3	to	get	views	from	different	funders		 Imp	Innovation,	SR	One	
23	 Funder	 Crowd	source	 	 Lack	of	content	knowledge,	maybe	later	depending	on	other	funder	input.	 	24	 Funder	 Charity	/	Trust	 Wellcome	Trust	 Include,	as	major	funders	 Cancer	Research	UK	
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Proposed	Landscape	map	for	interview	(example	-part	populated	based	on	initial	‘focus	group’	meeting).		Will	use	a	blank	map	as	part	of	research	process.			
	
‘Customer’	stakeholders	
Semi-structured	Interview	questions	
Hypothesis	1	–	There	is	a	increased	focus	on	patient	centric	approaches,	from	R&D,	through	to	service	
delivery	and	commissioning,	but	the	practical	implications	are	not	always	clear	1.1	-	What	are	current	priorities	for	service	delivery?	1.2	–	To	what	extent	is	‘patient	centric’	embedded	into	commissioning,	R&D,	care	etc?	1.3	–	To	what	extent	do	you	see	an	increased	in	convergent	technologies	being	able	to	support	these	needs?		What	challenges	do	you	foresee?	
	
Hypothesis	2	–	current	suppliers	do	not	engage	with	customers	well	(or	tend	to	engage	late)	and	have	
limited	understanding	of	customers	needs	2.1	–	Have	you	come	across	recent	R&D,	new	products	or	services?		Did	they	meet	your	requirements?		If	not,	why?		What	would	you	have	liked	to	have	seen	differently?	2.2	–	To	what	extent	and	how	do	they	engage	with	you?			Is	the	timing	right?		Would	you	like	more,	less,	about	the	same	engagement?	
	
Hypothesis	3	–	suppliers	do	not	have	appropriate	business	models	to	meet	customers	needs	
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Industrial	Ecosystem	/	Value	Network		Stakeholders	
Semi-structured	Interview	questions	
Hypothesis	4	–	There	is	not	a	clear	understanding	of	CMT,	and	there	are	divergent	views	across	
actors/stakeholders	4.1	-	What	is	your	understanding	of	convergent	medical	technologies	(CMT)?	(Prompt	with	our	CMT	model,	if	necessary,	and	ask	for	feedback).			What	is	you	view	of	this	model?	4.2	-	What	was/is	your	‘role’?	
• Innovator	–	entrepreneur,	CMT	‘company’	(pharma,	biotech,	med	tech,	diagnostic,	eHealth,	mHealth,	other),	Supplier	(to	above)	
• Care	Delivery	(prescriber,	user),	Customer	/	Buyer	(patient,	HCP,	payer)	
• Funder	(VC,	PE,	other)	
• Regulatory	
• Academic,	Industry	Expert	or	consultant	4.3	-	Have	you	seen	any	good	examples	of	CMT	activity?		Summarise	(concept,	product,	development	phase).		
Hypothesis	5	–CMT	challenges	are	diverse	and	underestimated	5.1	-	What	are	the	biggest	challenges	in	developing	convergent	medical	technologies?	5.2	-	What	do	you	see	are	the	key	challenges	for	(your	domain):	
	
Hypothesis	6	–	The	customers	are	not	clearly	defined	or	understood?	6.1–	For	your	own	(or	an	example	CMT	product)	are	the	customers	and	value	clear?	
• How	is	value	defined	(by	whom)	and	how	do	you	see	it	being	captured?	
• Who	are	the	end	users?			Who	pays?		How?	On	what	basis?	
• What	is	the	proposed	business	model?		What	else	is	needed	for	it	to	be	successful?		
Hypothesis	7	–	There	is	limited	and	unfocussed	support	for	CMT	activities	in	UK?	7.1	–	What	support	exists	to	help	deliver	CMT	technologies?	7.2	-	What	would	be	the	most	useful	activities	or	capabilities	to	help	support	delivery	of	CMT?	7.3	-	What	role	could	(or	would	you	like	to	see)	SBC	play	in	helping	facilitate	CMT,	and	increasing	potential	value?		
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Appendix A2 – Case Study Protocol (extract) 		
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Case	Study	Data	Collection	Instruments	(extracted	from	protocol)		
Overview	of	the	Case	Study	
Background	
Globally, health care systems face major challenges to meet the ever-increasing societal demands and to control costs. Convergent technologies 
(those from other industries) have the potential to address some of these challenges, but they bring new complexities to innovators and the wider 
innovation ecosystem.  This research focuses on innovators developing products and services using convergent technologies for health care.   
 
This research, using an exploratory framework, interviews and a range of case studies, examines the challenges when developing convergent 
products and services for health care. 	
Aims	To	understand	how	organisations	(or	alliances	of	organisations)	undertake	product	development	of	convergent	medical	technologies	in	the	emerging	health	care	industrial	system:		
How	do	organizations	develop	convergent	technology	products	for	the	emerging	health	care	industrial	ecosystem?	
	In	 addressing	 this	 question,	 the	 other	 aim	 is	 to	 develop	 and	 refine	 a	 Framework	 for	 Convergent	 New	 Product	 Development	 and	 a	 model	 that	explicitly	links	value	attributes	to	capabilities	required.	
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Table	1	–	Systems	Methodology	(PBSRDC)	
Aspect	 Methodology	 Activities	
Boundary	 /	
Structural	
Define	 the	 system,	 system	 boundaries,	 identify	 and	 map	different	 system	 levels,	 hierarchies	 and	 sub-systems	(modules)	of	relevance	and	key	agents	at	the	micro-,	meso-	and	macro-levels	
• Identify	‘Stakeholder	‘system’	and	boundaries	
• Identify	Key	Actors.	
• Map	system	and	key	sub-systems		
Relationships	 Understand	 the	 key	 interdependencies	 and	 relationships	(e.g.	 contractual	 and	 governance)	 between	 agents,	subsystems	 and	 between	 different	 system	 levels,	with	 an	emphasis	 on	 differing	 agent	 perceptions,	 local	 causality,	non-linearities	and	dimensions	(e.g.	scale	and	power)	
• Develop	‘systems’	map	(using	SSM)	showing	key	relationships	between	key	actors	(stakeholders)	and	projects	in	this	domain.	
• Identify	influence-impact	relationships	between	key	stakeholders	
• Identify	different	perceptions	of	agents	about	key	issues	
Dynamics	 and	
co-evolution	
Understand	the	system	history.		Identify	major	inputs	and	outputs,	key	processes,	patterns	and	trends,	with	particular	attention	on	the	unexpected	or	‘new’	 • Describe	or	map	system/sub-system	background	(i.e.	historical	perspective	of	stakeholders)	• Map	 Trends	 e.g.	 –	 social,	 economic,	 technological,	 legal,	 political	 and	environmental	
• Map	recent	phenomena,	issues	and	opportunities	
Perspectives	
	
Use	 different	 views	 and	 perspectives	 (both	 spatial	 and	temporal)	 to	 broaden	 understanding,	 identify	 system	changes	and	provide	an	opportunity	for	‘triangulation’.	 • Use	combination	different	interviewees	and	investigation	approaches	to	provide	different	perspectives,	including:	o Infrastructure/	Incubator	perspective	
o Focal	firm	versus	alliance	partner	perspectives	
o MNC	perspective	and	SU/SME	perspective	
o Documents,	observation	versus	interviews	
o Snapshot	and	longitudinal	data		
Table	2	–	Stakeholder	Analysis	
Aspect	 Consideration	
Interest	 The	extent	to	which	the	issue	is	of	interest	or	value	to	a	stakeholder	
Influence	(power)	 The	relationship	between	the	stakeholder	and	organisation	(or	alliance)	and	where	the	balance	of	power	lies	
Network	Centrality	and	
Density	
The	position	of	the	organisation	and	stakeholder	in	relation	to	the	network	and	the	interconnectedness	of	that	network	
Relationships	and	
continuity	
The	‘jointness’	of	interests,	interactions	and	their	evolution	over	time.	
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Data	Collection	Questions		
Table	Q1	-	Collection	Instruments	–	General	(Project	Based	Case	Studies)	
Organization	
	
	
Project	/	Product	
	
	
Key	Alliance	Partners	
	(Develop	‘ecosystem	map’)	
	
Interviewee(s)	
	
	
Date(s)	 	
Background	 Information	 on	 Organisation,	 New	
Products	and	‘convergence’	
	
• What	is	the	project?	Or	innovation?		
• What	commitment	is	the	organisation	making?		
• Is	 it	 ‘strategic’	 and	 reflected	 as	 such?	 Or	 tactical	 or	experimental?	
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Table	Q2	–	Factors	in	Convergent	New	Product	Development	(for	key	organisations	in	convergent	project)	
	 Factor	 Example	 Questions	 Responses	
F1	 Ecosystem	 and	
Market	
understanding	
Organisation	undertakes	activities	to	map	and	understand	 the	 ecosystem	 to	 keep	 pace	with	its	 evolution,	 and	 seeks	 to	 shape	 or	reconfigure	it	to	realise	value.			
How	does	organisation	understand	ecosystem?		What	routines	are	in	place?	Do	 these	 assess	 trends,	 technologies	 from	 other	industries?	How	often	are	these	updated?	
	
F2	 Stakeholder	
Management	
Map	and	engage	stakeholders	through	the	life-cycle	of	 the	development	process	 to	 facilitate	progress,	and	evolve	relationships	over	time.	 How	 does	 organisation	 identify	 and	 engage	 key	stakeholders?	What	 assessment	 of	 key	 stakeholders	 is	 undertaken	during	development?	
	
F3	 Customer	
Engagement	
Routines	 and	 capabilities	 to	 engage	 early	 in	the	 development	 process	 with	 customers	 to	inform	 product/service	 design	 and	 the	potential	business	model	options	
How	 does	 organisation	 identify	 and	 engage	 key	customers?	Is	there	evidence	of	‘co-development’?	How	 does	 this	 inform	 product	 development,	 the	development	process	or	the	business	model?	
	
F4	 Business	 Model	
development	
Map	 and	 understand	 the	 links	 between	 the	business	model	and	the	required	activities	and	capabilities.	 How	does	the	organisation	define	the	business	model?	Is	the	link	to	the	required	capabilities	clear?	 	
F5	 Value	Attributes	 Map	 and	 understand	 the	 key	 components	 in	value	creation	and	value	capture	 Can	value	creation	and	capture	be	described?	How	is	 it	assessed	or	validated?	 	
F6	 Governance	 Active	 senior	 management	 support	 and	engagement	 in	 investment	 decisions.	Adequate	knowledge	for	project	selection	and	progression	through	objective	decision	gates.			
Are	 senior	management	 active	 sponsors,	 supporters	 of	convergence?	What	activities	do	they	undertake	to	support	this?	Are	they	engaged	in	governance?	What	 steps	 are	 taken	 to	 ensure	 adequate	 knowledge	(incl	 trends)	 to	assess	projects	(from	both	 internal	and	external	perspective,	including	Alliance	Partners)	
	
F7	 Gate	Criteria	 Objective	 Go	 /	 no	 go	 decision	 criteria	 to	determine	 progressing	 to	 next	 phase,	 that	consider	external	capabilities	and	paths.	 Are	there	criteria	for	project	progression?	Are	these	clear	and	objective?	Do	they	assess	both	internal	and	external	factors?	 	
F8	 Process	 A	 process	 or	 methodology	 exists	 to	 guide	process	development	and	quality	management	 Does	the	organisation	have	a	process	for	NPD?	How	does	 it	 compare	 to	 the	 ‘typical’	 NPD	 process	 (see	next	questionnaire)?	 	
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How	does	it	address	Alliance	partners?	
F9	 Risk	
Management	
Risk	 management	 processes	 are	 in	 place	 to	address	patient	and	user	safety	risks,	and	the	combination	of	technological	(execution)	risks,	product	 integration	 (co-innovation)	 risks	 and	the	business	and	commercial	(adoption	chain)	risks	
How	does	 the	organisation	assess	project	 and	business	model	risk?	Are	 there	 reviews	 that	 cover	 technological,	 integration	(co-ordination)	and	business	model	risks?		How	are	 these	 integrated	and	 reviewed?	 Is	 it	 explicitly	tied	to	the	governance	process?	
	
F10	 Alliance	Partners	 Inter-organizational	co-operation	via	clarity	in	objectives	 and	 scope.	 Accessing	 capabilities	through	 alliance	 partners,	 adopting	 different	alliance	management	 approaches	 to	 different	partners.	 	 Addressing	 issues	 across	 co-innovation	ecosystem.	
How	are	alliance	partners	managed?	What	is	the	nature	of	 the	 alliance	 (contractual,	 wider	 partnership,	 joint	venture?)	Is	the	same	approach	used	to	manage	all	partners?	If	not,	how	is	it	done?		What	is	relationship	to	‘lead	organisation’	
	
F11	 Project	Team		 The	 core	 team	 has	 leadership,	 expertise	 and	experience,	 and	 balances	 autonomy,	accountability	 and	 empowerment	 within	 the	governance	framework		
How	are	team	leaders	and	key	members	selected?	How	 accountable	 (and	 autonomous)	 is	 the	 team?	 To	whom	do	they	report?	Does	team	include	Alliance	Partners?	How?	
	
F12	 Support	
infrastructure	
Organisation	 builds	 and	 makes	 use	 of	ecosystem	 and	 infrastructure	 to	 complement	capabilities	and	support	development	 What	 support	 network	 or	 infrastructure	 has	 the	organisation	put	in	place?			What	 activities	 are	 undertaken	 to	 join,	 create	 or	 build	ecosystem?		
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Table	Q3	–	NPD	Process	Observations	(typical	process	for	comparison)	
Typical Stage Gate Pharmaceutical Therapeutic Medical Device or Diagnostic Health ICT / App Observations 
Key activities, gate progression/criteria, management 
 Basic Science Research, 
Disease mechanism 
Basic Science Research, Biological, 
opto electro mechanical basis 
  
Ideation	and	Screening	 Product Discovery, Target 
Identification and Risk 
Analysis 
Product Concept and Risk Analysis Product Concept and Risk 
Analysis 
 
Scoping	-	Technical	and	Market	Assessment	 Target Product Profile Design User Needs User Needs  
Candidate Selection Design Input Software Development 
Planning  
 
Early Development  Software Requirements 
Analysis 
 
Pre-clinical Testing (safety, 
DMPK) 
Proof of Concept Software Architectural 
Design 
 
Build	Business	Case	 Commit to FTIH Commit to Design Control   
Phase I - Safety Design Requirements, Detailed 
Design, Design Review 
Software Detailed Design  
Development	 Phase Iia - clinical efficacy Functional Testing, Design Review Software Unit 
Implementation and 
Testing, Review 
 
Commit to Full Product 
Development 
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Typical Stage Gate Pharmaceutical Therapeutic Medical Device or Diagnostic Health ICT / App Observations 
Key activities, gate progression/criteria, management 
Phase IIb trials - dose 
ranging studies, Phase !! 
Review.  Finalise 
formulation, process 
development 
Functional Integration, Detailed 
Engineering, Manufacturing 
verification and stability 
Software Integration and 
Integration Testing, 
Review 
 
Testing	and	Validation	 Phase III Clinical Trials, 
Market Access Studies, 
Verify manufacturing 
processes and stability 
Clinical or Laboratory Outcome 
Assessment, Verification and 
Validation of Performance and 
Safety 
Software System Testing 
and Verification, Review 
 
Launch	 Regulatory Approval and 
Launch, Validate 
manufacturing processes 
Regulatory Approval and Launch (Regulatory Approval and) 
Launch 
 
Follow-up	 Commercial Supply and 
Pharmacovigilance 
Commercial Supply and Post-
market Surveillance 
Software Release, 
Commercial Supply and 
Post-market Surveillance 
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Appendix A3 – Ecosystem Trend sources 
No.	 Reference	1	 “In	Vitro	Companion	Diagnostic	Devices-	Guidance	for	Industry	and	Food	and	Drug	Administration	Staff”	Issued	by	FDA	on:	August	6,	2014.	Accessed	29/09/14	at:	http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf	2	 Author	derived	-	Statistics	on	number	of	warning	letters	and	enforcement	notices	from	1997	to	2013.	Accessed	on	29/09/14	at:	http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/default.htm	3	 “Mobile	Medical	Applications	-	Guidance	for	Industry	and	Food	and	Drug	Administration	Staff”	Issued	by	FDA	on:	September	25,	2013.	Accessed	29/09/14	at:	http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM263366.pdf	4	 Regulation	 Of	 The	 European	 Parliament	 And	 Of	 The	 Council	 on	 medical	 devices,	 and	 amending	 Directive	 2001/83/EC,	Regulation	(EC)	No	178/2002	and	Regulation	(EC)	No	1223/2009	Issued	 by	 European	 Commission	 on	 26/09/2012.	 	 Accessed	 29/09/2014	 at:	 http://ec.europa.eu/health/medical-devices/files/revision_docs/proposal_2012_542_en.pdf	5	 Regulation	 (EC)	 no	1394/2007	of	 the	European	Parliament	 and	 of	 the	Council	 of	 13	November	2007	on	 Advanced	Therapy	Medicinal	Products	and	amending	Directive	2001/83/EC	and	Regulation	(EC)	No	726/2004		Issued	 by	 European	 Commission	 on	 10/12/2007.	 	 Accessed	 29/09/2014	 at:	 http://www.mhra.gov.uk/home/groups/es-herbal/documents/websiteresources/con014486.pdf	6	 Health	at	a	Glance	2013:	OECD	Indicators.		OECD	Publishing	2013		7	 NHS	 and	 social	 care	 funding:	 the	 outlook	 to	 2021/2022.	 Crawford,	Rowena	 and	Emmerson,	 Carl.	 	 2012	 ,	 Institute	 for	 Fiscal	Studies	/	Nuffield	Trust		8	 NHS	111	Leaflet.	2013.	NHS	England.		Accessed	on	29/09/2014	at:	http://www.nhs.uk/NHSEngland/AboutNHSservices/Emergencyandurgentcareservices/Pages/NHS-111.aspx		9	 Section	2.	Summary	Results,	2012-based	National	Population	Projections	Office	for	National	Statistics	2013	10	 Historic	and	Projected	Mortality	Data	from	the	Period	and	Cohort	Life	Tables,	2012-based,	UK,	1981-2062		Office	for	National	Statistics	2013	11	 Population	Ageing	in	the	United	Kingdom,	its	Constituent	Countries	and	the	European	Union,	Office	for	National	Statistics	2012	12	 Strategy	for	UK	Life	Sciences,	Office	for	Life	Sciences,	BIS,	2011	13	 The	future	of	High	Value	Manufacturing	in	the	UK:	Pharmaceutical,	Biopharmaceutical	and	Medical	Device	Sectors.	Technology	Strategy	Board,	2012		14	 List	of	Cleared	or	Approved	Companion	Diagnostic	Devices	(In	Vitro	and	Imaging	Tools),	FDA,	2014	Accessed	on	01/10/14	at:	http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm	15	 Ilic, D. 2012.  Stem cell and regenerative medicine. Regenerative Medicine, 7(6 Suppl.):59-63 16	 Technology Strategy Board.  2012. The future of High Value Manufacturing in the UK: Pharmaceutical, Biopharmaceutical and 
Medical Device Sectors 17	 Technology Strategy Board, UK Synthetic Biology Coordination Group. 2013. A Synthetic Biology Roadmap for the UK. 18	 BIS, 2011. Strategy for UK Life Sciences, UK Government 19	 Technology Strategy Board.  2011. Stratified Medicine in the UK Vision and Roadmap Stratified Medicine in the UK Vision and 
Roadmap 20	 Life	Science	Solutions.	Thomson-Reuters.	Accessed	on	01/10/2104	at:	http://lifesciences.thomsonreuters.com	21	 Kumar	 et	 al,	 2103,	 Mobile	 health	 technology	 evaluation:	 the	 mHealth	 evidence	 workshop,	 American	 Journal	 of	 Preventive	Medicine,	45(2):228	22	 Research2guidance,	2014,	mHealth	App	Developer	Economics,	Berlin		Accessed	on	01/01/14	at:	www.mhealtheconomics.com		23	 Quail M et al. 2012. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina 
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No.	 Reference	
MiSeq sequencers. BMC Genomics 13(1): 341 24	 The 100,000 Genomes Project, Genomics England. 2014.  Accessed on 4/10/2014 at: http://www.genomicsengland.co.uk/the-100000-
genomes-project/ 25	 Interviewee:	22	–	21/07/2014,	opportunities	in	whole	body	scanning	26	 SBC & MIMIT launch Open Innovation Challenge in Neurodegenerative Disease, May 2014 27	 	OneStart	accessed	on	5/10/2014	at	http://onestart.co/		28	 Interviewee:	14	–	13/05/2014	–	patient	 increasingly	want	 to	get	 involved	 and	provide	services	 to	 developers	 to	reduce	risk	and	cost.	29	 Interviewee:	23	–	29/07/2014	–	NHS	Trust	initiatives	to	develop	mHealth	Apps	to	meet	clinical	priorities	30	 Interviewee:	21	–	14/07/2014	–	community	pharmacy	providing	services	on	contract	to	NHS,	eg	diabetes	support	31	 Proteus Biomedical Announces License and Collaboration Agreement for Sensor-Based Pharmaceuticals. (2010) Accessed on 
08/08/2014 at: http://www.proteus.com/proteus-biomedical-announces-license-and-collaboration-agreement-for-sensor-based-
pharmaceuticals/ 
and http://www.proteus.com/technology/digital-health-feedback-system/ 32	 Mesko B, 2014. The Guide to the Future of Medicine. Accessed on 01/05/2014 at: www.medicalfuturist.com 33	 What Is Google Genomics? Google inc. 2014. 
Accessed on 08/08/2014 at: https://cloud.google.com/genomics/what-is-google-genomics 34	 Athamanolap P et al. 2014. Trainable High Resolution Melt Curve Machine Learning Classifier for Large-Scale Reliable Genotyping 
of Sequence Variants.  PloS one 2014 9(9): e109094  
 35	 Kumar S, et al. 2013. Mobile health technology evaluation: the mHealth evidence workshop. American Journal of Preventive 
Medicine. 45(2): 228-236 36	 Apple Health. 2014 Accessed on 07/10/2014 at http://www.apple.com/ios/whats-new/health/ 37	 Interviewee: 10 – 24/04/2014 – Aim for electrical neuro-modulation within 10 years.	 38	 High K et al 2014.  CRISPR technology for gene therapy. Nature Medicine. 20(5): 476-7 39	 Gibbs D et al 2014. Multi-omic network signatures of disease. Frontiers in genetics. 4(Jan): 309 40	 Tiny	robots	help	improve	3D	tissue	printing.	(2014,	Feb	11).	The	Engineer	(Online),	Retrieved	on	09/10/2014	from	http://search.proquest.com/docview/1497034717?accountid=9851 41	 Bose S et al 2013. Bone tissue engineering using 3D printing. Materials Today. 16(12):	496-504 42	 Kucukgul C et al. 2013. 3D Hybrid Bioprinting of Macrovascular Structures.  Procedia Engineering. 59: 183-192 43	 Kolesky D et al. 2014. 3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs. Advanced materials. 26(19): 3124-30  44	 Bersenev A and Levine B. 2014. Convergence of gene and cell therapy. Regenerative medicine. 7(Suppl 6): 50-56 45	 GE Healthcare. 2014.  GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing.  Business Wire. 30 Sept 
2014. 46	 Lu z. 2014. Theranostics: fusion of therapeutics and diagnostics. Pharmaceutical research. 31(6): 1355-7 47	 Foo J et al 2013. Next-generation sequencing diagnostics for neurological diseases/disorders: from a clinical perspective. Human 
genetics 132(7): 721-34 48	 Forster K et al. 2014. Machine learning, medical diagnosis, and biomedical engineering research – commentary. Biomedical 
Engineering online. 13(1): 94 49	 QMed 2014. The Multibillion-Dollar Deals Reshaping Medtech.   QMed 06/10/2014.  Accessed on 09/10/2014 at:  
http://www.qmed.com/news/multibillion-dollar-deals-reshaping-medtech-infographic 50	 HMRC 2014. About Venture Capital Trusts. Accessed on 08/10/2014 at: http://www.hmrc.gov.uk/guidance/vct.htm 51	 World Economic Forum & Harvard School of Public Health. 2011. The Global Economic Burden of Non-communicable Diseases. 52	 Lu T et al. 2014. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nature Biotechnology. 2014, 
Sept, 1-7 53	 Evaluate Pharma, 2014. World Preview 2014, Outlook to 2020.  Report. London. 54	 Evaluate MedTech, 2014. MedTech Half-Year Review 2014.  Report. London. 
 55	 A Parmar 2014. Regulatory Expert: 510(K) Not Appropriate Pathway For 3-D Printing. Medical Device and Diagnostic Industry News. 
30 October 2014. 56	 Bob Michaels 2014. How to Shrink Implantables Using Piezoelectricity and Ultrasound. QMed. 21 October 2014. 57	 T Klein 2014. Medtech Start-Ups: New Technology Enables Biocompatible Antibacterial Plastics.  EMDT.  3 November 2014. 
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No.	 Reference	58	 Newmarker C 2014. How a Shape Memory Polymer Could Drive Medical Device Innovation. QMed 30 October 2014. 59	 Sharp P et al 2011. The Third Revolution: The Convergence of the Life Sciences, Physical Sciences, and Engineering.  MIT (White 
paper on Convergence).  60	 “Molecular Diagnostic Instruments with Combined Functions”.  Issued by FDA 12 November 2014.  Accessed on 13/11/2014 at: 
http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm346553.pdf 61	 microCHIP corporate website.  Accessed on 13/11/14 at: 
http://www.mchips.com/technology/technology.html 62	 Autonomic Technologies corporate website.  Accessed on 13/11/14 at: 
http://www.ati-spg.com/europe/en/ati-neurostimulation-system/how-it-works/ 63	 Cal-MR: Center for Automation and Learning for Medical Robotics website.  Accessed on 13/11/14 at: http://cal-mr.berkeley.edu 64	 Rajan, Venkat, 2014. Next-generation Healthcare – Global Advanced Medical Technologies, Frost and Sullivan report: NDE7-01 65	 Rangesa, M, 2014. Top Technological Trends. Frost and Sullivan Report; D52F-T1 66	 Edacherian, S 2014, Private Equity and Venture Capital Investment in the Global Pharmaceutical and Biotech Industry. Frost and 
Sullivan Report: ND74-01 67	 Prasanna VK, 2011. Digital Pathology – Technology Penetration and Roadmap.  Frost and Sullivan Report: D2DF-01 68	 Khalil AS, Collins JJ. 2010. Synthetic Biology: applications come of age. Nature Reviews. Genetic. 11(5): 367-379 69	 Birmingham K et al (2014). Bioelectronic medicine: a research roadmap. Nature Reviews: drug discovery 13: 399 70	 BRAIN Working Group (2013).  Interim Report to NIH Director.  US NIH 71	 3D Bioprinting Market.  MarketResearch.com (2015) 	  		
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Appendix A4 – Ecosystem and case interview sources 	
Table	A4-0-1	Further	ecosystem	interview	sources	
ID	#	 Interviewee	Role	 Organisation	Type	 Date	 Approx.	
Interview	
Duration	
(mins)	ECO28	 Senior	Manager	 NICE	 26/02/2015	 60	ECO29	 Senior	Manager	 NIHR		 03/03/2015	 45	ECO30	 Director	 CEO	Innovator	 04/03/2015	 45	ECO31	 Professor	(biosciences)	 University	Research	 19/03/2015	 60	ECO32	 Professor	(additive	manufacture)	 University	Research	 08/04/2015	 60	ECO33	 Director	 Innovate	UK	 04/06/2015	 60	ECO34	 Senior	Manager	 MedCity	 11/06/2015	 60	ECO35	 Senior	Manager	 Office	Life	Sciences	 18/08/2015	 60	ECO36	 Senior	Manager	 PM	Catapult	 01/09/2015	 60	ECO37	 Director	 ITHealth	and	SBRI	 20/10/2015	 90	ECO38	 Director	 SBRI,	Health	Trust	 06/11/2015	 60	EC039	 Non-Exec	Director	 Health	Enterprise	 21/04/2016	 60			
Table	A4-0-2	Case	CMTI	interview	sources	
Informant	
Code	
Informant	title		 Number	of	Years	at	
current	company		
(or	in	industry)	
Number	of	
interviews	
Hours	
interviewed	CMTI1		 CEO		 3	(20	in	industry)	 2	 3.5	CMTI2		 Business	Development		 3	(10	in	industry)	 1	 1	CMTI3		 Board	Member,	and	Entrepreneur	 2	(25	in	industry)	 2	 2.5	CMTI4		 Convergent	Team	Member		 20	in	industry	 1	 1	CMTI5		 Board	Member,	Entrepreneur	 2	(26	in	industry)	 1	 1.5	CMTI6	 Chairman	 3	(30	in	industry)	 1	 0.5	CMTI7		 CEO	of	convergent	Innovator	 2	(14	in	industry)	 1	 0.5	CMTI8	 Convergence	Team	Member,	external	consultant	 1	(17	in	industry)	 1	 1				
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Table	A4-0-3	Case	NMD	interview	sources	
Informant	
Code	
Informant	title		 Number	of	Years	
at	current	
company	(or	in	
industry)	
Number	of	
interviews	
Hours	
interviewed	
NMD1	 Vice	President	and	Head	 10	(15	in	industry)	 4	 4	NMD2	 Business	Development	Director	 10	 3	 3.5	NMD3	 Head	of	Venture	Funding		 3	(11	in	industry)	 2	 2.5	NMD4	 Director	and	Head	of	Research	group		 18	 2	 2.5	NMD5	 Director	and	Head	of	Technology	 1	(6	in	academia)	 1	 1	NMD6	 Academic	Partner	(Professor)	 26	(academia)	 1	 1.5	NMD7	 Incubator	Partner	 4	(25	in	industry)	 2	 2	NMD8	 Incubator	Entrepreneur	 3	(20	in	industry)	 1	 1				
Table	A4-0-4	Case	DH1	interview	sources	
Informant	
Code	
Informant	title		 Number	of	Years	at	
current	company		
(or	in	industry)	
Number	of	
interviews	
Hours	
interviewed	DH1-1		 Founder	and	CEO		 3	(20	in	industry)	 8	 10	DH1-2		 Senior	Project	Manager		 2	(10	in	industry)	 2	 2	DH1-3		 Board	Member,	and	NHS	Trust	Director	 2	(22	in	industry)	 1	 1.5	DH1-4		 Board	Member,	and	Senior	Manager	in	Provider		 24	in	industry	 1	 0.5	DH1-5		 CEO	of	Technology	group	(developer)	 7	(26	in	industry)	 2	 1	DH1-6		 NHS	Trust	Finance	Director	(governance)	 21	in	industry	 1	 0.5				
Table	A4-0-5	Case	MLD	interview	sources	
Informant	
Code	
Informant	title		 Number	of	Years	at	
current	company		
(or	in	industry)	
Number	of	
interviews	
Hours	
interviewed	CMTI1		 CEO		 1	(3	in	industry)	 12	 12.5	CMTI2		 CSO		 1	(3	in	industry)	 1	 1.5	CMTI3		 Chairman	 <1(25	in	industry)	 1	 1	CMTI4		 Potential	Investor	/	VC	Fund	 5	(20	in	industry)	 1	 1				
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Table	A4-0-6	Case	DH2	interview	sources	
Informant	
Code	
Informant	title		 Number	of	Years	at	
current	company		
(or	in	industry)	
Number	of	
interviews	
Hours	
interviewed	DH2-1		 Founder	and	CEO	of	venture	 1	(15	in	industry)	 3	(1	joint)	 3	
DH2-2		 Chairman		 1	(30	in	industry)	 3	(1	joint)	 3.25	DH2-3	 Med	Tech	Consultant	(potential	future	Board	member)	 24	in	industry	 1	 0.5									
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Appendix A5 – Case ECPO analyses  	This	appendix	contains	the	causal	analysis,	using	the	ECPO	method	for	each	case.		
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A5.1	Case	CMTI	ECPO	analysis		See	Table	6-5	in	main	text.			 	
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A5.2	Case	NMD	ECPO	analysis	
 ECPO Analysis 
Case: NMD 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
e1 Meetings with 
researchers and 
other 
stakeholders (F1) 
c1 Nascent 
ecosystem, key 
actors not 
established, 
knowledge 
gaps in 
ecosystem 
p1 Need to 
identify 
potential 
partners, 
collaborators, 
sources of 
knowledge or 
experimental 
work needed 
to develop 
overall 
strategy and 
reduce risk 
x1,1 Systematic 
searching 
(literature) 
Garud, 
Pandza - 
strategic 
search.  
Ferreras-
Mendez et al. 
Salter. 
Yes - there is a 
need to 
identify where 
knowledge 
resides, it is 
new to the 
organization 
o1 Strategic Search (both 
local and distant - using 
structured and 
snowball approaches) 
02/10/15 NMD3 -  "[xx] is wide space and most of the 
work is in specific diseases, so that was our focus …. 
searching this way, the approach works well in 
molecular drug discovery, but for [xx] it is a little 
different.  We start by looking at the basics 
[DISTANT/BROAD] in physiology, what are the target 
functions, is there a neural complement, then we 
look to build evidence of innovative studies in the 
literature or other supporting things [LOCAL/DEEP} " 
c2 Limited 
funding of 
academic 
researchers 
x1.2 Use range of 
approaches to 
increasingly 
engage a wider 
audience. Use 
network to 
extend search 
(snowball) 
Goodman - 
snowball 
Yes - it is a 
novel area, so 
need to scan 
'distant' 
knowledge and 
sources 
o1 Strategic Search (both 
local and distant - using 
structured and 
snowball approaches) 
02/10/15 NMD3: "So, … it was structured to an 
extent. A bit like a structured fishing expedition. We 
tried many different ways”  
o1 Strategic Search (both 
local and distant - using 
structured and 
snowball approaches) 
02/10/15 NMD3: "...it’s like a bit like a deep dive 
in…and reflecting and then looking in another 
area…an iterative process…and trying to make sense 
of it, so do I have enough information, is it 
meaningful?" 
c1 Key ecosystem 
players not 
identified.  
x1.2 Use range of 
approaches to 
increasingly 
engage a wider 
audience 
Goodman - 
snowball 
Yes - as 
knowledge is 
new, there is a 
need to 
exchange and 
challenge to 
build 
understanding 
o1 Strategic Search (both 
local and distant - using 
structured and 
snowball approaches) 
22/10/16 NMD1: "We decided to hold a conference 
and persuaded the NIH (amongst others) to be 
involved, that encouraged attendance (from 
academics looking for funding) at the conference, and 
from that we found our next wave of collaborators.   
So of the original three, we are not actually working 
with them now.  But their interaction was important.  
Following the conference we identified and engaged 
10 others where there was a sweet spot, common 
interests and they formed the basis of the next wave 
of the network.  They helped us get to a proof of 
principle for the venture. We’ve now expanded that 
to over 30 collaborators and we also have 15 other 
collaborators working on technology challenges 
(Innovation Challenge).  We also have our Scientific 
Advisory Board for therapies and engineering, which 
opens up a wider and different network." 
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 ECPO Analysis 
Case: NMD 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
c3 Knowledge and 
technology 
gaps in 
ecosystem 
x1.3 Interchange of 
idea and 
challenges - 
sense-making 
Gioia, Weick, 
Daft and 
Lengel - 
sense-making 
Yes - as 
knowledge is 
new, there is a 
need to 
exchange and 
challenge to 
build 
understanding 
o2 Sense-making via 
diverse stakeholder 
interactions and an 
integrating role 
12/03/15 NMD4" ".. we engaged our external 
community, the institutions, academics and 
conference attendees and from their output we 
created a second white paper" 
x1.4 Acquisition of 
knowledge for 
NMD - direct 
purchase of IP 
Rong - 
nurture 
No - acquiring 
knowledge 
now offers 
some control, 
but risks 
undermining 
ecosystem 
(Rong) 
      
x1.5 Internet 
searches 
(systematic?) 
n/a No, Only 
partial 
solution, lacks 
ability to 
address 
equivocality 
(Daft) 
      
x1.6 Attend 
Conferences to 
meet, connect 
and share 
information 
Daft - 
diversify 
search 
Only partial, 
very limited 
network, 
attended but 
did not expand 
network  - 
close network 
      
e2 Creation of White 
Paper and other 
journal papers 
(F1) 
c2 Field not 
established or 
widely 
recognised.  
NMDs role in it 
not 
established.  
p2 Establish field 
and need for 
funds for basic 
research 
x2.1 Interchange of 
ideas and 
challenges - to 
create 
known/unknown 
knowledge 
domains 
Gioia, Weick, 
Daft and 
Lengel 
Yes - need to 
identify where 
knowledge 
resides 
o2 Sense-making via 
diverse stakeholder 
interactions 
12/03/15 NMD4" ".. we engaged our external 
community, the institutions, academics and 
conference attendees and from their output we 
created a second white paper" 
c3 Limited 
sources of 
funding 
x2.2 Raise awareness 
and 
understanding 
with funders 
Boundary 
object - 
educating 
potential 
collaborators 
- Carlile 
Yes, reduces 
perceived risk 
o2, o5 Sustaining - investing in 
known gaps to address 
ecosystem 'holes'  
22/01/16 NMD1: "So it went something like this. We 
started with a systematic search, but I’d downplay 
that, we aspired to it, but that’s not how it worked 
out over time. That initial search led to us accessing 
three key individuals who we collaborated with to 
write the Jump Start (Nature) paper. That provided a 
key to access more people. It was not so much that 
c4 Knowledge and 
technology 
gaps in 
ecosystem 
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 ECPO Analysis 
Case: NMD 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
they opened up their Rollerdex, as by working with 
them we had more credibility from those interactions 
and the paper in Nature, so we were perceived as 
serious and credible. That was key." 
c6 Researchers 
moving away 
from field due 
to lack of 
funding 
p3 Establishment 
of viable R&D 
community 
x2.3 Selection of 
areas requiring 
focused 
investment 
Daft Yes - sustaining 
action to 
ensure key 
academics 
remain 
o2, 
o3, o5 
Selection to ensure. 
Key researchers remain 
in the ecosystem (e.g. 
sustain) 
16/11/15 NMD4: "We know from discussions that 
researchers who were in this space moved away 
because of lack of funding." 
e3 Using media to 
put out firms 
interest and 
information about 
the field (F1) 
c2 Field not 
established or 
widely 
recognised.  
NMDs role in it 
not 
established.  
p4 Need Increased 
awareness & 
visibility.  Need 
to build NMD 
presence 
x3.1 Broadening the 
audience.  
Getting some of 
the ideas in to 
more 
mainstream 
media to help 
influence. 
Boundary 
Object - 
educating 
potential 
collaborators 
- Carlile 
Yes - need to 
increase 
awareness to 
attract interest 
and partners 
o2, o6 Sense-making via 
diverse stakeholder 
interactions - create 
visibility 
Various articles in Nature Medicine, New Scientist, 
Nature Biotech, Reuters, Financial Times in Q2/Q3 
2013 and Q2 2014 
e4 Organise 
collective 
meetings of 
researchers and 
other interested 
groups (F1, F2) 
c1 Nascent 
ecosystem, key 
actors not 
established, 
knowledge 
gaps in 
ecosystem 
p5 Need to 
develop wider 
and stronger 
ecosystem links 
x4.1 Interchange of 
ideas and 
challenges - to 
create 
known/unknown 
knowledge 
domains 
Gioia, Weick, 
Daft and 
Lengel 
Yes - need to 
identify where 
knowledge 
resides, but 
equally 
encourage 
more collective 
engagement to 
create viable 
ecosystem 
o2, 
o4, o5 
Shaping and Sustaining 
- investing in known 
gaps to address 
ecosystem 'holes'  
MS 09/01/14: [NMD] is taking a low-key stance as a 
facilitator of ideas rather than trying to dictate the 
terms of engagement.  “Our objective is to add value, 
and we do that in two ways: by encouraging more 
scientific diversity in the field, and helping prioritize a 
few practical outcomes thorough funding and 
partnerships that animate a spirit of co-ownership.” 
e5 Award of R&D 
projects to 
external partners 
(F10) 
c2 Lack of funds 
for 
researchers.  
Need to de-risk 
early on.  
p4 Need to build 
'presence' in 
field 
x5.1 A combination 
of risk reduction 
and early 
projects to 
demonstrate 
potential and 
capability.  Plus 
engagement of 
external 
community 
Schreiner; 
Kale & 
Corsten; 
Duane 
Ireland, Hitt 
Yes - Shape 
using Alliances 
via setting 
research 
agendas and 
providing 
funding.  Also 
increases 
'presence' in 
field 
o3, 
o4, o5 
Shaping (and 
sustaining) 
12/09/12 Internal Launch Paper: "In the first half of 
2013 we will activate the global research community 
by awarding up to 10 exploratory grants to research 
groups for proof-of-principle testing of attractive 
disease intervention hypotheses." 
26/01/16 NMD6: "They are like a catalyst and have 
open up new possibilities, provided a new purpose.  I 
was almost ready to retire….but this research 
provides a new perspective." 
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 ECPO Analysis 
Case: NMD 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
e6 Used ecosystem 
to map out and 
identify 
knowledge gaps 
c1 Nascent 
ecosystem, key 
actors not 
established, 
knowledge 
gaps in 
ecosystem 
p5 Need common 
understanding 
and areas to 
focus for 
investments 
x6.1 Sense-making 
(Wieck) - 
recognising need 
to plug the gap 
and engaging 
ecosystem to 
define it.  
Wieck - sense 
making 
Yes, reduces 
overall risk.  
Also 
significantly 
enhances 
NMDs position 
in the 
ecosystem.  
o2, o5 Sense-making and 
Sustaining 
16/11/15 NMD4 Interview: "We mapped out the 
challenges and opportunities. The consensus was that 
the community needed a device, a chronic implant 
that could be used to help in certain disease models 
and in normal physiological conditions" 
x6.2 Seeking to 
exploit gaps 
Doz No, not 
evidence of 
moving to 
exploitative 
action 
      
e7 Open Innovation 
Challenge to 
address 
ecosystem 
technology gaps 
(F1, F2) 
c5 Need 
technology 
solutions to 
fundamental 
measure, 
monitor, 
neural 
connections 
p1 Need to find 
potential 
solutions in 
ecosystem and 
beyond 
x7.1 Searching and 
engaging others 
to identify issues 
Wieck - sense 
making 
Yes - actively 
engaged other 
to help make 
sense of gap, 
solution and 
approach 
o2, 
o5, o6 
Sense-making and 
Sustaining, and raising 
visibility  
 16/11/15 NMD4: "We also consulted with a lot of 
academics and about it would need for them to 
participate (so we could be sure we’d have people 
competing for the prize).   We had originally 
considered a $1M prize, but it became clear it would 
need to be higher, so we set the prize pool at $5M, 
$2M for phase 1 (10 teams) and $3M for phase 2 (3 
teams)." 
x7.2 Identified need 
to modify 
approach as  
they developed 
it.  
Teece et al - 
dynamic 
capabilities - 
experiential 
learning 
Yes, partial, 
Incremental 
changes to 
process 
o5, o9 Sustaining, but 
evolving process 
16/11/15 NMD4: "So in summary, after the 
community identified the ‘problem’ we went out and 
consulted to confirm we had identified the right 
problem and decision criteria, we also got the funders 
to endorse and confirm this was critical and finally we 
checked that the community would be prepared to 
participate. So it was methodical, but it evolved. " 
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 ECPO Analysis 
Case: NMD 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
e8 Meeting to 
review OIC 
progress and 
share knowledge 
(F2) 
c6 Identified gap 
in technology. 
Impacts NIH 
funded 
projects, and 
NMD 
development 
plans.  
p6 Need 
Technology in 
place to enable 
innovation and 
NMD venture 
to develop. 
x8.1 Sharing 
knowledge 
across projects 
and then looking 
for best forward 
approach 
Wieck - 
sensemaking. 
Garud - 
creating 
events 
Yes - Sense-
making via diea 
and knowledge 
sharing plus 
Shaping via 
setting 
research 
agendas and 
providing 
funding.  
o4, o7 Shaping - balancing in 
near and long term 
aspirations 
03/12/15: NMD4 interview: "In May we are getting 
the 10 teams together in LA to present their work so 
far and share ideas and learning. We have also invited 
some major tech players (consumer electronics) who 
may be able to help or work across teams to provide 
solutions. We are hoping that from this we will have 
stronger proposals going into Phase 2." 
e9 Investing in 
ecosystem and 
shared IP (F9) 
c4 Ecosystem 
knowledge and 
capability gaps 
will inhibit 
innovation 
p7 Need to 
balance 
addressing 
ecosystem 
gaps and 
creating an 
increased 
credibility for 
NMD 
x9.1 Sense-making 
(Wieck) - 
recognising need 
to plug the gap.   
Sustaining - 
intent to address 
gap. 
Wieck - 
sensemaking 
Yes, reduces 
operall risk.  
Also 
signficantly 
enhances 
NMDs position 
in the 
ecosystem.  
o5, o8 Sustaining (and 
credibility-seeking) 
16/11/15 NMD4 Interview: "So we want to work in a 
truly open innovation way, to create opportunities 
but we recognize potential skepticism, our integrating 
role might be seen as undue influence. But its actually 
more about stimulating the ecosystem, in practice we 
cannot access that funding, only academics can. It 
might seem a little altruistic but its really about 
helping to catalyse the field. We know from 
discussions that researchers who were in this space 
moved away because of lack of funding. " 
c7 Researchers 
sceptical of 
intent?  And 
would 'take 
the IP' from 
researchers 
p8 Deliberate and 
open approach 
to open 
innovation and 
IP sharing 
x9.2 Sustaining - 
intent to address 
gap, but also 
provide support 
to ecosystem (by 
IP sharing) 
Wieck - 
sensemaking 
Yes, 
Signficantly 
enhances 
NMDs position 
in the 
ecosystem.  
o5, o8 Sustaining (and 
credibility-seeking) 
15/08/16 NMD4: "And if you look at P&G, when they 
do OI, they put it out, but then they take all the IP 
and they exploit it for own commercial reasons. But 
this was different. But when we put it out, everyone 
viewed it as like P&G. But actually it was very 
different." 
e10 Meetings with 
Government 
funding agencies 
(F1, F9) 
c9 Limited 
funding for 
field by US , EU 
and Asian 
agencies  
p2 Need to 
persuade 
funders to 
address 
funding gaps 
x10.1 Sense-making 
(Wieck) 
Wieck - 
sensemaking 
Yes, 
highlighting 
the potential 
and the lack of 
academic 
funding, can 
help influence 
policy. 
o5, o6 Sustaining - providing 
opportunities for 
others to support the 
ecosystem 
15/08/16 NMD4: "So we have been very careful that 
we are advocating for the future field, as opposed to 
trying to influence a particular pathway, that may be 
beneficial to [NMD]" 
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 ECPO Analysis 
Case: NMD 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
p9 Avoid being 
seen to unduly 
influence 
government 
spending 
x10.2 Sense-making 
(Wieck) 
Wieck - 
sensemaking 
Yes, NMD is UK 
based and 
main funding is 
US. Important 
to be seen to 
be 'neutral' 
and not unduly 
influencing.  
o4, 
o5, o6 
Shaping and Sustaining, 
increasing visibility and 
legitimacy 
15/08/15 NMD4: "...our engagements with NIH and 
DARPA have been constructive. That is not what has 
been difficult. What has been difficult is managing the 
external perception amongst the US community and 
established medical device companies that are 
predominantly US based. We are this ‘new kid on the 
block’, with no historical medical device ‘nouse’, who 
are now suddenly shaping this huge field. " 
e11 Meetings with 
Charities (F1, F9) 
c8 Limited 
funding for 
field research 
based Charities 
p2 Need to raise 
awareness of 
potential and 
address 
funding gaps 
x11.1 Meetings to 
advocate field 
and funding 
needs 
Wieck - sense 
making 
Yes, Important 
to be seen to 
be 'neutral' 
and not unduly 
influencing.  
o4, 
o5, o6 
Shaping and Sustaining See Above 
e12 Flexible approach 
to alliance and 
partner 
management 
(F10) 
c9 Different 
needs and 
capabilities of 
partners 
p10 Need differing 
approaches to 
reflect differing 
capabilities and 
risks 
x12.1 Partner 
Selection 
Schreiner; 
Kale & 
Corsten; 
Duane 
Ireland, Hitt 
Yes, Alliance 
management 
and 
relationship 
building is 
critical 
o9 Flexible management 
of alliances 
03/12/15 NMD4 Interview: "We have learned, that 
when investing in a company like [P1], with other 
investors, with a seasoned management, that we only 
need a low level of involvement. Compared to [P2] 
where we have daily interaction, helping guide their 
management."  
x12.2 Building partner 
relationships 
and trust 
24/03/15 NMD5: "All the formal contracts are 
essentially the same but each is managed differently.   
And as contracts have matured we’ve moved from 
formal to more informal management.  That 
interaction with the academics is really important." 
x12.3 Need to update 
and change 
processes 
Ambidexterity 
- Birkinshaw 
Partial - 
evidence of 
different 
capabilities 
across wider 
organisation, 
but no 
evidecne they 
are brought 
into play.  
Team is making 
small changes, 
by design and 
experiential 
feedback 
o9 Appear to make quite 
small changes.  Some 
are in response to 
previous experience (ie 
OIC), some are by 
design from the outset 
(ie VC fund) 
Pattern of changes across multiple interviews and 
activities - see examples in other rows (o9) 
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Case: NMD 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
Dynamic 
capabilities - 
Teece et al 
Partial - no 
evidence of 
systematic use 
of SST.  More 
about small 
changes and 
management 
agency? 
e13 Meet academic 
alliance partners 
every 6 months 
(F10) 
c10 Dispersed 
knowledge, 
academics do 
not know each 
other well. 
p11 Share 
information, to 
broaden 
understanding, 
build alliances 
and affirm 
NMD position 
x13.1 Regular 
meetings, curate 
and hosted by 
NMD.  
Schriener; 
Kale; Duane 
Ireland, Hitt 
Yes, Alliance 
management 
critical, regular 
meetings 
reinforce 
delivery of 
objectives, 
building 
relationships 
etc 
o9, o5 Flexible management 
of alliances.  Helps 
sustain and grow 
ecosystem connections 
20/02/15 NMD3: "...bring researchers together every 
6 months.  (we have done it 3 times so far).  Their are 
Funded PIs meetings, so they meet other PIs. 
Provides an opportunity to share results.  Enables 
some networking.  As a result some PIs now working 
together on other projects." 
e14 Early project 
commitments in 
the field (F8, F9) 
c11 Need to de-risk 
and show 
potential value 
p6 Need to find 
potential 
solutions in 
ecosystem and 
beyond 
x14.1 A combination 
of risk reduction 
and early 
projects to 
demonstrate 
potential and 
capability 
Sarasvathy - 
effectuation? 
Yes, looking to 
de-risk but also 
shape their 
offering and 
determine the 
field 
o5,o6 Shaping 19/06/15: Strategic Plan: These front-runner projects 
will collectively provide the biggest de-risking for the 
[NMD] endeavour over the next three years, so 
choosing the right approach, doing the work right the 
first time and driving forward the right projects with 
urgency is key. We want to drive through enough 
projects to ensure we have a balanced portfolio of 
risk, taking into account possible attrition yet quality 
comes first. 
e15 Creation of 
Internal Business 
Plan 
c12 Need for 
internal 
governance 
and 
investment 
p12 Use existing 
project 
approval and 
governance 
approach 
x15.1 Selection, 
Investment and 
internal selling 
of proposal 
Bettis & 
Prahalad, 
Tripsas & 
Gavetti, 
Danneels 
Yes, existing 
Governance 
and Selection 
processes 
require 
business plan 
o3 Selection NMD Business Plan document 
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E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
e16 Team that formed 
strategy is also 
executing it (F11) 
c13 Limited 
resources with 
skills internally 
p13 Ongoing 
Interest and 
commitment 
x16.1 Consistency and 
have Agency 
Garud  Yes, have 
strategy and 
ongoing 
commitment 
o8 Management Agency to 
incrementally change 
processes 
16/08/16 NMD4: "Because you have the same people 
shaping the strategy and then executing, we have 
stayed true, by and large, to that original ethos and 
direction. Because what normally happens with 
strategy is people formulate it, they hand it over, and 
once you hand it over…the next person wants to 
shape it in their own way and the original ethos and 
direction is lost." 
e17 Team built from 
diverse 
individuals with 
in-company 
knowledge, R&D 
expetise and 
external specialist 
technical 
expertise.  
c13 Lack of internal 
capability 
p14 Acquire 
adequate 
internal 
capability 
x17.1 Investment in 
capabilities and 
skills 
Teece, Winter 
et al 
Yes, need to 
build new 
capabilities, 
but build them 
on existing 
(dynamics 
capability?) 
o5, 
o8, 
o10 
Sustaining, balancing 
need for external and 
internal capabilities 
22/01/16 NMD1: "Towards the end of my time in the 
Strategy group, before I moved into a [...] role, I was 
asked to find a leader for BE. We spent months 
courting top academics in the field and eventually 
offered 3 candidates to [...].   He interviewed them, 
rejected all of them and over the summer, came back 
and said we wanted me to do it.  So, I think he was 
trading off two things here.  To make this venture a 
success we need to do two things – make the right 
scientific calls (and clearly the external candidates 
were better placed to do this), but we also needed to 
navigate the internal organisation.  And the view was 
that they would not be able to do that as well. " 
p14 Acquire 
adequate 
internal 
capacity 
x17.2 Investment in 
team, resources 
Teece, Winter 
et al 
Yes, need to 
build new 
capabilities 
o6 Sustaining - creates 
capability internally 
16/08/16 NMD4: "There are 30 of us now, managing 
over 50 academic collaborations.  That’s not including 
the funding agencies, OI challenge, Venture fund, plus 
philanthropic and management of upcoming JV." 
e18 Presenting 
updates to other 
related science 
and technology 
events 
c2 Increase 
awareness of 
field and NMD 
p15 Increase 
awareness and 
NMD's 
'innovator' role 
x18.1 Using repeated, 
ongoing 
communications 
to increase 
'voice' 
Sense-
making, 
Sense-giving 
(Wieck) and 
Shaping 
Yes, sharing 
information 
with 
ecosystem 
actors and 
potential 
ecosystem 
actors fosters 
knowledge 
exchange and 
the firms 
position. 
o2,o4, 
o6 
Sense-making and 
Shaping innovation 
"And we aren’t slowing down. We continue to look at 
new ways to innovate in the healthcare space. In fact 
last year at SXSW 2015, we presented our work on 
biosensors in partnership with McLaren. And this year 
for SXSW 2016, we’re presenting our work on 
bioelectronic medicine in a session called Inner 
Space: Bioelectronics and Medicine's Future." 
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Case: NMD 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
c2 Need to 
increase 
presence and 
credibility in 
field 
p16 Still not fully 
trusted in 
ecosystem, 
want to 
improve their 
position.  
x18.2 Undertake 
activities to 
underpin and 
provide tangible 
evidence that 
they will do 
what they said 
Shaping 
(Sitoh, 
Sarasvathy)  
Yes, clear case 
evidence want 
to shape 
destiny and 
back up words 
with deeds. 
Creating path.  
o2, 
o4, o7 
Sense-making and 
Shaping innovation to 
improve legitimacy and 
position for advantage 
15/08/16 NMD4 Interview: "So we were sticking to 
our whole OI ethos. We are not going to hide 
information. We want you to share your outputs, we 
will look for synergies. We will review your phase 2 
presentations in the light of you all knowing where 
everyone else is. So that is embracing that spirit." 
e19 Taking an 
increasing 
leasdership role in 
rhe field 
c2 Nascent 
ecosystem, 
with no natural 
lead company 
p17 Moved from a 
position to help 
create field to 
a leadership 
position.  
x19.1   Sustaining 
and Shaping 
Moved from 
Sustaining and 
credibility-
seeking 
position to a 
Shaping and 
advantage-
seeking 
position 
o5, o7 Advantage-seeking 
behaviours, to move to 
exploitative position 
15/08/16 NMD4: "I think our initial deliberate role 
was to integrate the community. To bring all those 
people in the community together. That then 
organically morphed into an expectation that [NMD] 
will evolve from playing an integrating role into a 
leadership position. So I wouldn’t say, that from the 
outset we said ‘we are going to be leaders’, this is 
what’s going to happen. We said, hey we are new to 
this field, let’s bring all those people together let’s 
work on what to do collectively to move this forward 
to bring treatments to patients. Along that journey 
we became the natural leader." 
e20 Changes to Open 
Innovation 
Challenge 
(funding and 
process) 
c1 Limited 
number of 
responses, lack 
of potential 
partners or 
knowledge of 
NMD 
p18 Need to get 
adequate 
competitors 
into  challenge 
to make it work 
x20.1 Engaged 
ecosystem to 
better 
understand the 
challenge and 
what was 
needed.  
Wieck - sense 
making 
Yes, engaged 
and then 
refined OIC 
o2, 
o5, o8 
Sense-making and 
Sustaining by using 
small changes 
16/11/15 NMD4: "We had originally considered a 
$1M prize, but it became clear it would need to be 
higher, so we set the prize pool at $5M, $2M for 
phase 1 (10 teams) and $3M for phase 2 (3 teams)." 
e21 Using ecosystem 
to help define 
criteria 
c13 Lack of internal 
knowledge and 
capability 
p19 Desire to get 
criteria right 
and build 
partnerships 
x21.1 Sense-making, 
Selecting 
Selection and 
Sense-making 
Yes- where 
defined criteria 
cannot be 
used, engaging 
others reduces 
risk of bias 
(Kahnemann 
Tversky) 
o2, 
o3, 
o6, 
o10 
Sense-making to re-risk 
decisions (selection) 
15/08/16 NMD4: "So in summary, after the 
community identified the ‘problem’ we went out and 
consulted to confirm we had identified the right 
problem and decision criteria, we also got the funders 
to endorse and confirm this was critical and finally we 
checked that the community would be prepared to 
participate. So it was methodical, but it evolved." 
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E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
e22 Setting up 
internal 
governance 
c14 Increasing R&D 
Investment 
p20 Need to be 
seen as on 
'similar' playing 
field to other 
R&D ventures 
x22.1 Sense-making, 
avoiding internal 
cognitive inertia 
or rejection 
Bettis & 
Prahalad, 
Tripsas & 
Gavetti, 
Danneels 
Yes- reduces 
risk of internal 
rejection  
o8 Internal acceptance, by 
creating sense of 
familiarity in how 
governed. 
22/01/16 NMD1: "A lot of our work is based on 
external collaborations.  So we modelled the R&D 
Unit on previous academic collaborations. ... So it 
made sense that the governance also followed." 
22/01/16 NMD1: "As our effort ramps up and our 
spend increases we inevitably end up in a trade off 
with other R&D areas.   There is a fixed R&D pot and 
we are competing for some of it.  So  it is crtical you 
have good governance, especially as our efforts have 
effects in other areas of R&D).  We need to have 
rigour in our capital allocation and ensure we have 
the right expert input.  Hence the new Investment 
Board." 
x22.2 Ensuring new 
practices look 
similar or 
familiar to 
exsiting 
organisation 
Lounsbury & 
Glynn 
Yes, skilled 
cultural 
entrepreneurs 
o8 Internal acceptance by 
making processes and 
structures look similar / 
familiar to others.  
Reducing perception of 
difference and 'risk'. 
NMD1: ‘I think there is also an element of familiarity.  
It’s partly about giving Exec management comfort. ...  
It also helps across the rest of the organisation.   We 
don’t want to be ‘seen’ as too different.   You should 
not underestimate the power of your peers.  They 
can challenge, especially in R&D and we are all trying 
to access the same funding pot.   So, there is a need 
for some familiarity, for people to be comfortable 
that the process, governance and arena is fair, it’s 
different but seen to be fair.  So, it isn’t easier for us 
to get money that someone else…. The structures 
looked similar or familiar, like … an Investment Board. 
So, we looked like we were on the same playing field 
as other R&D groups ... although clearly we were 
making different decisions and we used different 
criteria’." 
e23 Seeking a  Joint 
Venture (F10) 
c15 No major 
partnerships 
exist in 
ecosystem 
p21 Need to have 
capability to 
move into 
development 
in near term 
x23.1 Creating alliance 
with an 
organisation 
with 
complementary 
capabilities 
Schreiner; 
Kale & 
Corsten; 
Duane 
Ireland, Hitt 
Yes, Alliance 
management 
necessary to 
build capability 
quickly. 
o4, 
o7, o9 
Advantage-seeking 
behaviours, via alliance 
02/08/16: [NMD] is far from being the only corporate 
player in bioelectronics — several other biotech, 
medical devices and computer companies are 
involved — but no one else has made such an 
ambitious long-term commitment. {Financial Times) 
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E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
(F1-F12) 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize  
e24 Change in JV 
negotiations 
c16 IP negotiations 
protracted and 
difficult 
p22 Need for 
controlling 
position as 
moved into 
development 
x24.1 Creating alliance 
with sufficient 
control to 
exploit IP and 
create 
advantage 
Schreiner; 
Kale & 
Corsten; 
Duane 
Ireland, Hitt 
Yes, whilst an 
alliance was 
critical, the 
terms needed 
to enable 
advantage and 
value capture. 
o9, 
o10 
Advantage-seeking 
behaviours, to move to 
exploitative position 
13/10/16 NMD1: A quite fundamental concern from 
[NMD] side was…we didn’t want to invest together 
with a technology company to create a field and 
enable it and then that technology company has the 
right to form another partnership and build ... 
devices, because then we would not realize our 
investment. The benefit would flow elsewhere. We 
did not want an IP position where the other company 
would be able to take the IP and take all the value.   
e25 Forming Joint 
Venture 
c17 Revisited 
previous 
potential 
partner, they 
had progressed 
quickly and 
quickly found 
common 
ground  
p21 Ability to 
create a viable 
JV quickly 
x25.1 Creating alliance 
with an 
organisation 
with 
complementary 
capabilities 
Schreiner; 
Kale & 
Corsten; 
Duane 
Ireland, Hitt 
Yes, Alliance 
management 
necessary to 
build capability 
quickly. 
o7, o9 Advantage-seeking 
behaviours, to move to 
exploitative position 
13/10/16 NMD1: Now, the JV provides funding to do 
things differently.  And, yes, we are moving out of […] 
a little but it is still 55% [NMD] and we have control.  
And the ability to capture value. 
A5.3	Case	DH1	ECPO	analysis	
 ECPO Analysis 
Case: DH1 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
e1 Use of "Hack 
Days", mobile 
tools, twitter etc to 
engage with users, 
patients etc 
c1 Poor 
understanding 
of opportunity 
and that 
existing 'Apps' 
did not deliver 
user needs 
p1 Ensure DH1 
had access to 
patient / user 
needs 
x1.1 Crowdsourcing 
for inputs and 
solutions 
Chesbrough - 
open 
innovation 
Yes - well 
established 
mechanism 
o1 Strategic Search 
(crowdsourced) 
Multiple evidence on DH1 website, via Open Calls 
and on regular Twitter feed 
e2 Workshop 
Meetings and 
design sessions 
with patients, 
carers, 
practitioners (e.g. 
engagement days, 
discovery days) 
c1 Poor 
understanding 
of opportunity 
and that 
existing 'Apps' 
did not deliver 
user needs 
p2 Need to 
identify 
collaborators, 
sources of 
knowledge to 
ensure 
solutions 
were 
x2.1 Systematic search  Garud, 
Pandza - 
strategic 
search 
Yes - there is a 
need to 
identify where 
knowledge 
resides, it is 
new to the 
organization 
o1, 
o2 
Strategic Search (both 
local and distant - using 
structured and snowball 
approaches) and sense-
making via engagement 
We are well connected locally and continue to spend 
a lot of time networking. We are always making 
new connections. We are reasonably well known 
locally, so people come looking for us too. More 
broadly we are connected to NIB and some of their 
work streams; so that gives us an opportunity to 
influence at national level, particularly on Open 
Source software strategy. DH1-1.  
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E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
c2 Ecosystem of 
potential 
partners did 
not exist at the 
outset.  
Increase 
awareness 
across 
ecosystem 
appropriate 
and 
acceptable.  
x2.2 Use network to 
extend search 
(snowball) 
Goodman - 
snowballing 
Rosenkopf / 
Nerkar- 
distant 
knowledge 
Yes - it is a 
novel area, so 
need approach 
to scan 
'distant' 
knowledge and 
sources 
o1, 
o6 
Strategic Search (both 
local and distant - using 
structured and snowball 
approaches) 
Involving people who have lived experiences can 
really help. There is real opportunity, provided its 
done in the right way (not patronizing). The benefits 
of peer support can be realised, so there is a less 
paternal model (which can damage people’s self 
esteem, ‘telling them how to live’). It might give 
people more power and help with their digital skills 
too, to make them more employable. So lots of 
benefits or opportunities. DH1-4 
c3 Knowledge 
and 
technology 
gaps across 
ecosystem 
(especially in 
user groups) 
x2.3 Interchange of 
idea and 
challenges - 
sense-making 
Gioia, Weick, 
Daft and 
Lengel - 
sense-making 
Yes - as 
knowledge is 
new, there is a 
need to 
exchange and 
challenge to 
build 
understanding 
o2, 
o6 
Sense-making via diverse 
stakeholder interactions 
and an integrating role 
What we did in December was an open call, we were 
looking to incentivize interest. So we got several 
teams and questions. Many of the solutions people 
were looking for are website based (quite common) 
or something to do with workflow (which is IT 
related) - DH1-1 
e3 Open calls and 
'crowdsourcing' 
projects 
c4 Care and 
pathways 
problems were 
not well 
identified 
within the 
ecosystem 
p3 Need to 
engage users 
in identify 
(real) 
problems and 
potential 
solutions 
x3.1 Interchange of 
ideas and 
challenges - to 
create 
known/unknown 
knowledge 
domains 
Gioia, Weick, 
Daft and 
Lengel - 
sense-making 
Yes - as 
knowledge is 
new, there is a 
need to 
exchange and 
challenge to 
build 
understanding 
o2, 
o6 
Sense-making via diverse 
stakeholder interactions 
and an integrating role 
see above 
c1 Poor 
understanding 
of opportunity 
and that 
existing 'Apps' 
did not deliver 
user needs 
x3.2 Everyone else is 
doing, so need to 
do, to 'play the 
game' 
Need to 
follow 
No, DH1-1 very 
principled, and 
DH1 has 
limited 
resources so 
only does what 
is essential. 
    no evidence 
e4 Meetings with NHS 
Trusts, CCG and 
LCH 
c5 Limited 
sources of 
funding 
p4 Establish 
need for 
funds for 
venture 
development 
and 
technology 
platform 
creation 
x4.4 Raise awareness 
and 
understanding 
with funders 
Carlile, Leigh-
Starr - 
boundary 
object - 
educating 
potential 
collaborators 
Yes, reduces 
perceived risk 
o2, 
o6 
Sense-making via diverse 
stakeholder interactions, 
increases visibility. 
It’ s about education, marketing awareness, that will 
create market pull and accelerate changes…so it’s 
about PR, marketing. So, it will be about getting 
some examples of good practice out there…and not 
or limiting the number of counter examples… that 
create noise.  DH1-5 
c3 Knowledge 
and 
technology 
gaps across 
ecosystem 
(especially in 
user groups) 
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E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
c5 Prior digital 
solutions not 
delivering 
promise 
p5 Establishment 
of users’ 
needs and 
expectations 
in terms of 
functions and 
features 
x4.5 Simple response 
to bureaucratic 
governance, 
control of agency 
governance / 
agency 
Yes, partial o2, 
o3 
Selection - decision 
making criteria 
  
e5 Mapping 
stakeholders and 
ecosystem 
c6 Nascent 
ecosystem, key 
actors not 
established, 
knowledge 
gaps in 
ecosystem 
p6 Need to 
develop 
wider and 
stronger 
ecosystem 
links 
x5.1 identifying 
potential partners 
and blocks to 
progress 
Gioia, Weick, 
Daft and 
Lengel - 
sense-making 
Yes - as 
knowledge is 
new, there is a 
need to 
exchange and 
challenge to 
build 
understanding 
o2, 
o6 
Sense-making via diverse 
stakeholder interactions 
and an integrating role, 
also help create visible 
position in ecosystem 
We’ve also done some market research, or market 
intelligence work to understand our potential 
customers and if they would contract with us. That is 
not just the service groups or providers in the Trusts, 
we are aiming for a mixed income stream. DH1-1 
e6 Business model 
mapping exercises 
c7 Business 
models in 
ecosystem not 
generally 
established 
p7 Identify 
viable and 
sustainable 
model to 
deliver value 
and meet 
vision -  
x6.1 Need to develop a 
viable model for 
the venture, 
sources of 
funding / income 
not clear 
Gioia, Weick, 
Daft and 
Lengel - 
sense-making 
Yes, evidence 
that diversity 
of stakeholders 
and broader 
legal, IP issues 
make the 
decision 
challenging.   
o4, 
o5, 
o7 
Sustain- identify 
solutions that ensure 
venture is viable.  Shape - 
see opportunities to 
create and capture value. 
Business Model is to engage, identify problems and 
solutions, create IP and develop offerings that can 
then be delivered by others (for royalty) or license to 
other providers (source: draft business plan) 
e7 Mapping value 
from different 
stakeholder 
perspectives - 
'persona' 
c5 Prior digital 
solutions not 
delivering 
promise 
p5 Desire to add 
value and 
make a 
contribution 
to health 
outcomes 
x7.1 Want to ensure 
solutions are 
valuable to 
patients and 
providers and can 
deliver 
sustainable 
income to keep 
venture going 
Sarasvathy, 
Garud, Sydow 
- shape 
Yes - examples, 
of seeking to 
create value 
from several 
perspectives 
and where 
they can create 
future value 
o4, 
o6, 
o7 
Shape - credibility and 
advantage 
Explicitly look at ‘value’ from patient perspective in 
terms of outcome and experience.  Look at value 
from practitioners’ perspective in terms of 
effectiveness and efficiency.   Looks at wider impact 
to Trust/CCG in efficiency terms (cost). 
x7.2 Want to ensure 
they are sen as 
credible in a 
nascent 
ecosystem 
Yes - evidence 
of desire to be 
seen as 
credible in 
ecosystem, as 
important 
precursor to 
building 
relationships 
Above all its important to be seen to be ‘credible’. 
We need that to create legitimacy with patients and 
HCPs. So, as well as ideas, we have to bring ‘assets’ 
- examples of things we have made happen, and 
delivered. That lets people really understand what 
you are doing. DH1-1 
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 ECPO Analysis 
Case: DH1 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
e8 Development of 
own Catalyse, 
Incubate, Adopt 
and Embed 
process 
c6 NHS 
'bureaucracy' 
and inertia 
p8 Need agile 
process to 
deliver 
solutions in 
an efficient 
way 
x8.1 Need for simple 
processes, to fit 
organisation scale 
and culture.   
Existing 
incumbent 
models too 
complex 
Ries - 
efficiency / 
lean  
Yes - partial, 
aiming to 
deliver 'lean 
start-up' 
o8 Lean-start-up - Capability 
building 
Team aware of Lean Start-up principles, see as 
valuable approach.   Process is simple lifecycle 
approach 
x8.2 Desire to be 
creative and 
develop 'own' 
solutions 
Amabile - 
Creativity 
No, whilst 
there is 
evidence they 
are looking for 
creative 
solutions, they 
appear happy 
to use existing 
tools where 
suitable 
    no evidence 
e9 Developing simple 
Go/No go criteria 
in place.   
c7 There are no 
established 
processes, 
'rules' or 
criteria to 
go/no go.   
Existing one 
are 
bureaucratic 
and inefficient 
p9 Increase 
objectivity in 
decision 
making 
x9.1 Need for simple 
processes, to fit 
organisation scale 
and culture.   
Existing 
incumbent 
models too 
complex 
Ries - 
efficiency / 
lean  
Yes - partial, 
aiming to 
deliver 'lean 
start-up' 
o8 Lean-start-up  and agile 
ways of working  (see 
The Lean Start-up, Eric 
Ries) 
Team aware of Lean Start-up principles, see as 
valuable approach.   Process is simple lifecycle 
approach 
e10 Broadening 
activities to 
different 
geographical areas 
and national 
bodies 
c8 Network 
remains 
fragmented, 
with disperse 
and diffuse 
knowledge and 
resources 
p10 Increase 
credibility 
beyond local 
area and 
obtain some 
positional 
advantage to 
help 
deployment 
x10.1 Increase 
opportunities and 
position in field 
Sarasvathy, 
Garud, Sydow 
- shape 
Yes - evidence 
of desire to be 
seen as 
credible in 
ecosystem, as 
important 
precursor to 
building 
relationships 
o4, 
o7 
Shape - credibility and 
advantage-seeking 
We are well connected locally and continue to spend 
a lot of time networking. We are always making new 
connections. We are reasonably well known locally, 
so people come looking for us too. More broadly we 
are connected to NIB and some of their work 
streams; so that gives us an opportunity to influence 
at national level, particularly on Open Source 
software strategy. I have also been to meetings with 
Tim Kelsey (NHS National Director for Patients and 
Information) and other NHS England meetings. So 
we are building broader connections, particularly on 
digital participation, so informally we are good, but 
in other areas like HSCIC we are not so well 
connected.   DH1-1 
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 ECPO Analysis 
Case: DH1 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
e11 Managing ad-hoc 
Alliance partner 
formation 
c9 NHS 
bureaucracy 
and lack of 
Framework 
p11 Manage 
relationship 
with suppliers  
x11.1 Manage 
relationship with 
small number of 
suppliers in near 
term 
selection Yes, limited 
initial choices 
o3, 
o9 
Selection The other things we are trying to move on is to be 
able to make the decisions on our own pre-agreed 
criteria and not ‘standard NHS’ one. For example we 
recently went out for quotes and a Sheffield agency 
came in a lot cheaper, but it was clear they had really 
not got enough in their bid to do the job. DH1-2 
p2 ensure 
solutions 
were 
appropriate 
and 
acceptable 
x11.2 Need to identify 
collaborators, 
sources of 
knowledge  
selection Yes, selection 
processes are 
evolving 
o3, 
09 
Selection We still don’t have a framework. We have developed 
a draft, revised it , sent it back for comments and are 
still waiting. Over 2 months now. Its clear we need a 
little more rigor and structure, but some 
requirements are quite painful – for example - if we 
do not state in the advert that we intend to interview, 
we cannot, even if it makes sense to do so, so make 
the selection. DH1-2 
p12 Work to 
develop 
longer term 
solution via 
Framework 
x11.3 Need for 
sustainable model 
sustain Work to 
develop longer 
term solution 
via Framework 
o5, 
o8, 
o9 
Sustain - invest in longer 
term solutions, 
modifying process for 
longer term 
I’d describe the common interest as something more, 
there needs to be ‘congruence’ a real alignment, not 
just in terms of the outcome, but also cultural and 
how you are going to do it. Connections do not just 
happen. You need to ‘cultivate’ to create the right 
opportunities. That is where I see this spirit of 
generosity and being open, learning together as 
being important.   DH1-1 
e12 Continually 
refining internal 
processes 
c7 There are no 
established 
processes, 
'rules' or 
criteria to 
go/no go.   
Existing one 
are 
bureaucratic 
p8 Need agile 
and lean 
process to 
deliver 
solutions in 
an efficient 
way 
x12.1 Need to 
demonstrate 
early success 
Shape - 
Sarasvathy, 
Garud, Sydow 
Yes, need to 
justify funding 
provided and 
create real 
output with 
evidence of 
benefits 
o4, 
o6, 
o8 
Shape - legitimacy-
seeking 
I think that as we have evolved somethings have 
changed. But some things are core. Our approach is 
what you might call a ‘spirit of inquiry’ we want to 
foster ‘learning together’. That’s a very different 
approach to a Tech company coming along or even a 
HCP coming along with a ‘solution’. Our approach 
is about creating buy-in from all users. To do that 
you need to be prepared to ‘learn in public’. That 
means continually connecting via debates, 
workshops, meetings, ‘show and tell’.   DH1-1 
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 ECPO Analysis 
Case: DH1 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
and inefficient Selection - 
experiential 
learning 
Yes - need to 
refine criteria, 
experiential 
learning 
process 
o3, 
o8 
Selection, experiential We have introduced new decision points – Providers 
need to provide data at Discovery Day. We can pull 
out at DD phase if there is no real demand or data. If 
we progress, we build a prototype and seek further 
use/provider feedback. Again if demand, or 
prototype and spec are not right we can pull out and 
also we need commitment agreement (of providers 
time to enable development and adoption). Typically 
each project needs a Project Sponsor (specialty / 
department leader level) who secures funding, to 
move forwards. DH1-2 
Shape - 
Sarasvathy, 
Garud, Sydow 
Yes, need to 
justify funding 
provided and 
create real 
output with 
evidence of 
benefits 
o4, 
o6, 
o7 
Shape - legitimacy- and 
advantage -seeking 
Its also important that what we have done is visible, 
so people can see our track record. So another 
important part of our role is to curate and make 
public. So, you will find searchable content on our 
website, in our blogs etc.  DH1-1 
x12.2 Need to improve 
processes and 
performance 
Teece et al 
dynamic 
capabilities 
Partial - there 
is no pattern of 
continually SST 
actions. 
Changes are 
made  
o9 Broad small changes, 
shaped by management, 
rather than continual 
experimentation? 
Observations 
Ambidexterity 
- Birkinshaw 
et al 
No.  There is 
no evidence of 
range of 
capabilities 
across 
organisation - 
small new 
team 
o9 Broad small changes, 
shaped by management, 
rather than continual 
experimentation? 
Observations 
x12.3 Desire to be 
creative and 
develop 'own' 
solutions 
creativity No, whilst 
evidence 
looking for 
creative 
solutions, they 
appear happy 
to use existing 
tools where 
they exist 
    no evidence 
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 ECPO Analysis 
Case: DH1 
           
E Event - Interview, 
Observation or 
Document (e) - 
identified from 
Case Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
e13 Writing 
Conference and 
academic Papers 
c3 Knowledge 
and 
technology 
gaps across 
ecosystem 
(especially in 
user groups) 
p13 Increasing 
awareness 
across 
ecosystem 
x13.1 Need to grow 
network and 
position within it 
Shape - 
Sarasvathy, 
Garud, Sydow 
Yes, partial - 
there is belief 
solutions is 
good, so 
looking to 
'promote' it 
o4, 
o6 
Shape Legitimacy-seeking, advantage-seeking  
c2 Ecosystem of 
potential 
partners did 
not exist at the 
outset.  
Increase 
awareness 
across 
ecosystem 
x13.2 Need to identify 
other sources of 
knowledge and 
solutions 
search / 
shape 
Yes, partial - 
also provides 
opportunities 
to reach and 
engage others - 
as potential 
suppliers and 
customers 
o4,o6 Shape We are well connected locally and continue to spend 
a lot of time networking. We are always making 
new connections. We are reasonably well known 
locally, so people come looking for us too. More 
broadly we are connected to NIB and some of their 
work streams; so that gives us an opportunity to 
influence at national level, particularly on Open 
Source software strategy. DH1-1.  
e14 Internal Business 
Plan regularly 
refined 
c7 Business 
models in 
ecosystem not 
generally 
established 
p7 Identify 
viable and 
sustainable 
model to 
deliver value 
and meet 
vision  
x14.1 Business Model is 
to engage, 
identify problems 
and solutions, 
create IP and 
develop offerings 
that can then be 
delivered by 
others (for 
royalty) or license 
to other providers 
selection Yes, partial - 
the key 
elements of 
required model 
are understood 
o3, 
o8, 
o10 
Selection,  Sustain The plan though is still to form a company limited 
by guarantee, 100% owned by LYHFT, and run as a 
not for profit. So any surplus will be reinvested in 
the business and services. DH1-1 
p14 Lack of clarity 
in viable 
business 
models, DH1 
learning as it 
goes. 
x14.2 Unsure as to what 
is best option, so 
defer decision, 
but engage more 
widely to build 
learning and 
understanding 
Wieck - sense 
making 
Yes, partial, 
there is 
insufficient 
understanding 
to be confident 
in any one 
choice, so 
keeping 
options open 
and continually 
building 
network 
o2, 
o8, 
o10 
Sense-making - 
experiential learning 
process 
I’ve been paying more attention to National and 
local networks. We have run lots of Local show and 
tell events; we get good feedback, but its quite 
draining to run. We also run lunchtime learning – 
and peer consultations, and took on the National 
Event – People Driven Digital. I’ve also written a 
White Paper, which I’m presenting at the King’s 
Fund digital event and then ‘taking on tour’. I also 
took on running the Awards event on the 3 July, but 
that had the benefit of also providing Case Studies 
for the White Paper.  DH1-1 
c9 NHS 
'bureaucracy' 
and inertia 
p15 Need to 
address 
concerns of 
NHS Trust 
x14.3 Constraint in 
options available. 
Selection Yes, partial o8 Capability limiting? Note: no strong evidence of inertia 
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A5.4	Case	MLD	ECPO	analysis	
 ECPO Analysis 
Case: MLD 
           
E Event - 
Interview, 
Observation or 
Document (e) - 
identified from 
Case 
Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
e2 Regular 
Meetings with 
entrepreneurs, 
tech companies, 
developers, 
funders and 
opinion leaders 
c1 Limited 
understanding of 
ecosystem, 
innovation 
opportunity and 
stakeholders 
p2 Need to 
identify 
collaborators, 
sources of 
knowledge to 
ensure 
solutions 
were 
appropriate 
and 
acceptable.  
x2.1 Systematic 
search (initially) 
  Yes - there is a 
need to 
identify actors 
and knowledge 
holders 
o1, 
o2, 
o6 
Strategic Search (both 
local and distant - using 
structured and snowball 
approaches) 
MLD2: "So we’d contact 1 or 2 people, and it would 
take 1 or 2 weeks for them to reply, slow. ... There 
are a number of highly influential stakeholders, and 
to be honest without their buy-in its hard to 
connect." 
x2.2 Use network to 
extend search 
(snowball), 
continue to 
search and 
engage 
Goodman - 
snowballing 
Rosenkopf / 
Nerkar- 
distant 
knowledge 
Yes - it is a 
novel area, so 
need approach 
to scan 
'distant' 
knowledge and 
sources 
o1, 
o2, 
o6 
Strategic Search (both 
local and distant - using 
structured and snowball 
approaches) 
MLD4: "I think the technology is novel. I’ve had my 
own people do some basis due diligence, so I am 
aware of […] and […] and others, but this appears 
different. If it works it offers a different approach, 
and importantly an earlier diagnosis." 
Observed meetings with  Tech[P], VCs[F], VC [B] etc 
x2.3 Interchange of 
idea and 
challenges - 
sense-making 
Gioia, 
Weick, Daft 
and Lengel - 
sense-
making 
Yes - as 
knowledge is 
new, there is a 
need to 
exchange and 
challenge to 
build 
understanding 
o2, 
o6 
Sense-making via diverse 
stakeholder interactions 
and an integrating role 
MLD1: "To be honest, it’s a bit like Brownian 
motion. You are forever moving around, bumping 
into different people. And you cannot predict before 
hand whether they will add value or not, or even 
immediately after. Also its something about when 
you do business and have the meeting. so it's not 
pre-determined, it seems completely random. You 
might expect them to be interested based on your 
prior knowledge, but its not always like that, and it 
might just be timing or it doesn’t fit their exact 
interest." 
e3 Took part in 
Innovation 
competitions 
(multiple) 
c4 Opportunity to 
showcase 
innovation 
p3 Need to be 
visible and 
attract 
funding 
x3.1 Interchange of 
ideas to identify 
value 
Gioia, 
Weick, Daft 
and Lengel - 
sense-
making 
Yes - as 
knowledge is 
new, there is a 
need to 
exchange and 
challenge to 
build 
understanding 
o2, 
o6 
Sense-making via diverse 
stakeholder interactions 
and an integrating role 
MLD1: "Feedback from our bids was we need to 
make ‘more inventive’ or its not properly 
understood. What is the inventive or innovative 
step?" 
c5 Availability of 
competition 
funding 
e4 Meetings with 
investors, 
brokers, and 
conducting IPO 
c2 Access to funding x3.2 fuding to 
progress 
innovation 
    o6, 
o10 
Funding enables 
development and 
creation of value network 
Observed meetings at VC[F], VC [B], Broker [B] 
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 ECPO Analysis 
Case: MLD 
           
E Event - 
Interview, 
Observation or 
Document (e) - 
identified from 
Case 
Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
e5 Engaging GPs 
and other HCPs 
c6 Technology new to 
HCPs 
p4 Get feedback 
from 
potential 
users, 
customers 
x4.1 Meetings with 
prototypes or 
presentations to 
obtain feedback  
Gioia, 
Weick, Daft 
and Lengel - 
sense-
making. 
Carlile- 
boundary 
object 
Yes, use simple 
presentations 
to explain 
concept 
o2, 
o3, 
o4, 
o6, 
o7 
Engagement increase 
visibility, obtains 
feedback to help better 
position firm and 
innovation 
MLD1: "So we started to speak to Doctors, patients, 
providers, charities, specialists etc and use our 
personal contacts to talk to them and capture key 
points in a spreadsheet. We aimed to record the 
problems they had, why they would use our 
product, what problems it solved." 
e6 Meetings with 
potential 
collaborators 
(contractors) 
and technology 
companies 
c1 Technology 
companies 
interested in new 
technologies and 
potential 
partnerships 
p3, 
p5 
Potential to 
attract 
funding and 
partnership 
x5.1 Aim to attract 
major partners 
(long term) 
Shape - 
Sarasvathy, 
Garud, 
Sydow 
Yes,  o2,  
o6 
Shaping innovation and 
development path 
MLD1: "So, you have to invest in relationships, and 
it consumes your resources. But back to our 
network, we are building it, we have the first few 
critical ones in place and then we are working 
through them, to see more." 
c7 Software 
contractors 
available locally to 
do early 
development work 
p6 Potential to 
develop a 
testable 
prototype at 
low cost 
x5.2 Make near term 
progress on 
innovation and 
help de-risk 
Shape - 
Sarasvathy, 
Garud, 
Sydow 
Yes o6 Shaping and sustaining 
(reducing risk) 
MLD1: "We met Jean and Johannes through ... and a 
hack-athon. They are super developer’s They are 
young, but smart and very professional in 
developing software." 
e7 Mapping 
stakeholders 
and 
understanding 
the emerging 
ecosystem 
c1 Limited 
understanding of 
ecosystem, 
innovation 
opportunity and 
stakeholders 
p2, 
p7 
Need to 
develop 
wider 
understandin
g and 
stronger 
ecosystem 
links to 
support 
decision 
making and 
identify long 
term partners 
x6.1 identifying 
potential 
partners, future 
value network 
and blocks to 
progress 
Gioia, 
Weick, Daft 
and Lengel - 
sense-
making 
Yes - as 
knowledge is 
new, there is a 
need to 
exchange and 
challenge to 
build 
understanding 
o2, 
o9 
Sense-making via diverse 
stakeholder interactions 
and an integrating role 
MLD1: "We find people, we might make a little 
progress. But they don’t all work out. We are 
continually exploring new possibilities, in terms of 
partners, investors and people we could work with 
for trials etc. I think one of the challenges here is 
unless you have the finance in place and can buy 
services, you need to have several options in play, 
because one might not come off, and you don’t 
have any leverage. So they can just walk away. So 
building the network is critical." 
MLD1: "Have had discussions with Tech [P] about a 
European funded project. They want to form a 
consortium with us, and a large ... Health Insurance 
company. " 
MLD1: "When we first started we though that 
pharma might be sweet spot, as the test would 
support prescriptions. But after talking to J&J and 
Roche we realised we were not aligned.  Their focus 
is on biomarkers that specifically link to their drugs." 
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 ECPO Analysis 
Case: MLD 
           
E Event - 
Interview, 
Observation or 
Document (e) - 
identified from 
Case 
Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
e8 Mapping value 
from different 
stakeholder 
perspectives  
c8 Lack of 
understanding of 
'value' for new 
technologies  
p2, 
p4 
Desire to add 
value and 
identify key 
potential 
stakeholders 
x7.1 Want to ensure 
solutions are 
valuable to 
others  
Sarasvathy, 
Garud, 
Sydow - 
shape 
Yes - examples, 
of seeking to 
create value 
from several 
perspectives 
and where 
they can create 
future value 
o2, 
o4, 
o7 
Understanding and then 
trying to Shape - a viable 
model and advantage 
MLD1: "So our entry point is going to be the one 
that’s easiest and quickest to validate and the 
fastest to adopt. In terms of unmet need, we think 
screening is the biggest opportunity, with a high 
value. The current approaches are crude, paper 
based, time consuming, they are the bottleneck and 
result in under diagnosis." 
x7.2 Want to identify 
viable business 
models 
Yes - needed 
for investors 
MLD1: "Our business model is to offer the 
technology hardware/software free, but charge per 
test, so SaaS, a Service model." 
e9 Development 
Business Plans  
c2 Access to funding p3 Need to 
identify 
investors 
requirements 
and attract 
funding 
x8.1 Need for clear 
vision, business 
plan and funding 
needs 
Gioia, 
Weick, Daft 
and Lengel - 
sense-
making 
Yes, seeking to 
position as 
valuable 
innovation 
o2, 
o7 
  MLD4: "It was focussed on a particular injury / 
disease area and the [MLD] pitch was a little 
adjacent, but relevant. So, we got talking. Agreed to 
meet up. Which we have done a few times, 
informally." 
e10 Undertaking 
User Needs and 
exploratory 
studies 
(overseas) 
c6, 
c8 
Novel technology 
requiring data, but 
limited funding 
p3, 
p6 
Need to 
develop data 
to 
demonstrate 
credibility 
and potential, 
with minimal 
spend 
x9.1 Reduce risk and 
create value at 
least cost 
Shape - 
Sarasvathy, 
Garud, 
Sydow 
Yes,  o6, 
o7 
Shape innovation, but 
also sustain, as risks 
reduced.  
MLD1: "So, if we do planed trail we are essentially 
doing a head to head…. I spoke to the investigators 
this week. They are doing their own risk assessment. 
"  
e11 Engaging NHS 
Trusts and other 
R&D 
organisations 
c9 Viable locations for 
clinical studies. 
Desire in some 
Trusts to develop 
innovations  
p8 Need access 
to credible 
development 
partners for 
clinical 
studies 
x10.1   Shape - 
Sarasvathy, 
Garud, 
Sydow 
Yes, clinical 
studies critical 
to shaping 
innovation 
o6, 
o10 
  Observed meetings with NHS Trust 
e12 Establishing 
partnership 
with Gaming 
Technology 
company 
c10 Limited 
organisations who 
could develop rapid 
response software 
for testing 
p8 Need for 
technologicall
y capable 
firm as 
partner 
x11.1 Creates 
capability to 
develop test on 
iOS devices 
Shape - 
Sarasvathy, 
Garud, 
Sydow 
Yes, provides 
enabling 
capability and 
technological 
advantage 
o2, 
o3, 
o4, 
o7, 
o10 
Partnership enables 
technology to be 
developed on new 
platform with high 
performance 
Observed Meeting with developer Tech [O] and 
draft specification 
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 ECPO Analysis 
Case: MLD 
           
E Event - 
Interview, 
Observation or 
Document (e) - 
identified from 
Case 
Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
e13 Establish simple 
governance 
processes and 
meetings 
c11 Investors 
expectations for 
corporate 
governance 
p9 Need to meet 
investors 
expectations 
and manage 
key decisions 
x12.1 Regular 
management 
meetings 
(weekly) and 
infrequent 
Board meetings 
Ries - 
efficiency / 
lean  
Yes - partial o8, 
o11 
  Observed [MLD] Management Meetings  
e14 Undertaking 
formal risk 
reviews 
c12 Novel technology 
with wide range of 
risks 
p10 Need to 
identify and 
reduce risks 
to progress 
and increase 
valuation 
x13.1 Comprehensive 
and integrated 
review following 
ISO standards 
  Yes,  o5 Sustain, reduce risk Observed Risk Review (15/06/15) and access to Risk 
document  
e15 Developing 
internal 
processes and 
policies  
c13 Regulatory 
requirement to 
have ISO13485 
QMS and 
associated 
processes 
p11 Need to meet 
regulatory 
requirements 
to obtain EU 
and USA 
approval 
x14.1 Need agile 
process to 
deliver 
innovation 
Shape - 
Sarasvathy, 
Garud, 
Sydow 
Yes, need to 
justify funding 
provided and 
create real 
output with 
evidence of 
benefits 
o4, 
09 
Shape - legitimacy-
seeking 
Observed [MLD] Management Meetings.  Access to 
draft QMS document (21/10/16).   
x14.2 Need 
documented 
process to meet 
regulatory needs 
  Yes o9 Shape - legitimacy-
seeking 
e16 Changes in 
senior 
personnel 
c14 Limited 
experienced people 
available to team 
p12 Individuals 
unable or 
unwilling to 
work within 
start-up 
culture 
x15.1 Experienced 
individuals 
struggling with 
start-up culture 
and ambiguity of 
convergent 
innovation 
  Yes, partial - 
also a culture 
issue 
o3, 
o11 
Selection,  Sustain MLD1: "We then engaged another MBA student, he 
had been a senior director in [...].  He came across 
as very knowledgeable, but his interest wasn’t. 
there    I think he just wanted it on his CV. He 
provded no real input. In fact he wasted a lot of 
time. He always had excuses, so it ended up as a 
dead end.  Fortunately the disengagement was 
smotth.  Its just his mindset was different, not a 
start-up person." 
x15.2 Team diverse 
and difficult to 
work with 
Personality 
issues 
No, team 
diverse, but 
more about 
individuals’ 
willingness to 
work in 
ambiguous way 
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 ECPO Analysis 
Case: MLD 
           
E Event - 
Interview, 
Observation or 
Document (e) - 
identified from 
Case 
Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize - case evidence or quote 
p13 Evolving 
understandin
g of MLDs 
capability 
needs as 
innovation 
progresses 
x15.3 Unsure as to 
what is best 
skills mix in 
team.  Explore 
options and fit 
first before 
making 
commitment.  
Wieck - 
sense 
making.  
Cultural fit. 
Yes, team 
building, Belbin 
o2, 
o9, 
o11 
Sense-making - 
experiential learning 
process 
MLD1: "He’s continued to work with us, introduced 
us to other medics and is helping design the trials. 
So we’ve actually taken him on as Medical Director. 
As we need that now we are moving into some 
trials." 
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A5.5	Case	DH2	ECPO	analysis	
 ECPO Analysis 
Case: DH2 
           
E Event - 
Interview, 
Observation or 
Document (e) - 
identified from 
Case 
Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize 
e1 Engage with 
potential 
partners and 
funders at pitch 
days.  
c1 Poor 
understanding of 
opportunity and 
ecosystem 
p1 Ensure DH2 
had access 
to partners 
and funding 
x1.1 Need to be visible Search - 
Pandza et al 
Yes,  o1, o6 Strategic Search and 
visibility 
"...we won a Scottish Enterprise High Growth Start-
up award. " DH2-2 
e2 Obtained SE 
funding to 
develop 'pilot 
concept' 
c2 Open competition 
for early phase 
funding 
p2 Need to 
raise funding 
and profile 
x2.1 Open 
Competition  
Sustain - 
enables 
investment to 
support 
venture 
Yes, evidence 
from case, they 
are keen to do 
this.   Strong 
Alliance 
formation is 
recognised 
innovation path 
(Garud et al) 
o3 Sustain  "..Scottish Enterprise High Growth Start-up award.  
And we started their global programme, with access 
to potential investors.   Being part of SE high 
growth programme gave credibility.  In Central 
Belt, only 1% of start-ups meet the criteria, so it 
was good due diligence for investors. " DH2-2 
e3 Meetings with 
pharma and 
pharmacy 
c3 Variable and 
conflicting 
feedback 
p3 Looking to 
better 
understand 
opportunity 
x3.1   Sense-making 
(Wieck) 
Yes - taking in 
views of 
different 
stakeholders 
and modifying 
response 
o2, o6 Sense-making, 
credibility seeking 
"Our role is to make sense of that [feedback] and 
identify which feedback is going to help us move 
forwards." DH2-1 
e4 Pitched to US 
technology 
companies 
c2 Open competition 
for early phase 
venture funding 
p2 Need to 
raise funding 
x4.1 Identify Alliance 
partners that 
provide 
credibility and are 
attractive to 
investors 
Searching, 
Sense-
making, 
Selection 
Yes - exploring 
potential 
partners, 
looking at 
several options, 
using network 
to explore 
others 
o1,o2,o3 Searching, Sense-
making and Selection 
"… we were put in front of Walgreen, and got the 
nod.  They really liked it and put us in touch with 
Apple.  Apple gave great feedback, 'probably best 
user engagement they’d seen'.  They wanted to 
showcase internally, but we didn’t give 
permission." DH2-2 
p4 Need to 
raise profile 
with 
potential 
investors 
and 
collaborators 
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 ECPO Analysis 
Case: DH2 
           
E Event - 
Interview, 
Observation or 
Document (e) - 
identified from 
Case 
Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize 
e5 Engaging 
potential 
Alliance 
partners 
c4 Major pharma etc. 
want to link to 
start-up venture 
p5 Need 
partner as 
potential 
channel to 
market and 
revenue 
source.  
x5.1 Form long-term 
alliance 
partnership 
Alliances  Yes, evidence 
from case, they 
are keen to do 
this.   Strong 
Alliance 
formation is 
recognised 
innovation path 
(Garud et al) 
o4,o5 Sustain and Shape "But we want to engage big pharma before its too 
developed, to ensure it meets their needs and has 
value.   Ideally we are looking for one to partner 
with."  DH2-2 
e6 User 
engagement  
c5 Understanding 
value proposition 
p6 Need to 
understand 
value to aid 
design and 
value 
proposition 
x6.1 User engagement 
and involvement 
in design 
Sense-making 
(Weick) and 
User co-
creation (von 
Hippel) 
Yes - early 
evidence, but 
not evident later 
(?) 
o2, o6 Sense-making, 
creating credibility 
"Apple gave great feedback, 'probably best user 
engagement they’d seen.' "  DH2-2 
e7 Targeting 
Scottish 
investment 
community for 
investment 
c6 Local network p7 DH2 
focussed on 
using 
existing 
knowledge 
and network 
x7.1 Believe that their 
existing network 
is sufficiently 
broad/strong to 
provide solutions 
search Yes - had not 
engaged widely, 
so then subject 
to limitations of 
the small 
investment 
community. 
o1? Search -but note 
quote - search is 
narrow and 
predefined by existing 
knowledge or network 
"Once we are ready to engage, I will do mapping. 
Using my own network, as start. Which is based 
upon .. many I know personally, then I go to people 
who have introduced me, then finally people who 
know people I know."  DH2-1 
x7.2 Scottish 
Enterprise (SE) 
Policy? 
Policy 
restriction 
No, no evidence 
SE restrict 
investment 
although do 
expect firm to 
be Scotland 
based 
      
e8 Failure to 
secure follow 
on funding in 
Scotland 
c7 Scottish 
investment 
environment is 
limited (in terms of 
scale, scope and 
interest) 
p7 DH2 
focussed on 
using 
existing 
knowledge 
and network 
x8.1 Believe that their 
existing network 
is sufficiently 
broad/strong to 
provide solutions 
Search Yes - had not 
engaged widely, 
so then subject 
to limitations of 
the small 
investment 
community. 
o1, o6 Search - but is narrow "One of the big challenges is in the Investment 
community – in Scotland (it’s typically 
conservative, risk averse, poor investment funnel, 
only interested in SEIS/EIS tax efficiency, mainly 
65+ men, strong opinions, but no knowledge). 
Model is ... always looking for £250k, and to go for 
little and in tranches). DH2-2 
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 ECPO Analysis 
Case: DH2 
           
E Event - 
Interview, 
Observation or 
Document (e) - 
identified from 
Case 
Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize 
e9 Failure to 
obtain 
signficant 
engagement for 
funding in 
London 
c8 Bigger market for 
biotech funding, 
access to capital 
p8 Failure to 
raise 
investment 
locally drives 
need to 
engage with 
wider 
community 
x9.1 Lack of previous 
engagement 
means sense-
making and 
understanding 
remain poor, 
business model is 
still under-
developed and 
was challenged 
by investors 
Sense-making 
(Wieck) 
Yes - had not 
engaged widely, 
so then subject 
to challenging 
feedback  
o2, o6, 
o7? 
Sense-making, 
creating awareness, 
but not achieving 
position of value 
"[Investor] thought market was payers. ... She also 
struggles with the value proposition as we proposed 
it. She suggested we speak to payers." DH2-1 
9.2 London based 
investors not 
interested in SE 
funded venture 
selection No, no evidence 
to support this 
in London VC 
community 
      
e10 Internal 
Business Plan 
and business 
model changed  
c9 Business models in 
ecosystem not 
generally 
established 
p9 Identify 
viable and 
sustainable 
model to 
deliver value 
and meet 
vision  
x10.1 Belief in prior 
research results 
and previous 
experience 
selection Yes, partial - the 
key elements of 
required model 
are understood 
o3,o5, 
o11? 
Selection,  Sustain, 
clear on governance 
"I only work with people I know or have been 
introduced to by someone I trust.  ... For all my 
clients I have an approach or process where 7 
factors are tracked.  They cover everything from 
IPR, the value proposition, who the competition is , 
business model, etc , all ahead of fund raising." 
DH2-1 
p10 Lack of 
clarity in 
viable 
business 
models, DH2 
learning as it 
goes. 
x10.2 Believe they 
know best 
option, but then 
find that this is 
not supported by 
potential 
collaborators 
Wieck - 
sensemaking 
Yes, there is 
insufficient 
understanding 
to support their 
choice, but do 
not keep 
alternative open 
and do not build 
network 
o2 Sense-making  "We’ve done good research.  We have looked at 
strategic positioning. The software is specified, 
actually its about 60% done (as a favour).  We are 
close to having it fully specified. Then we had  
demo hardware.  If you remember we had someone 
from FoxConn Europe.  So we had a device and 
Bluetooth.   We had also worked out our Big Data 
app. But needed to confirm the algorithm." DH2-1  
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 ECPO Analysis 
Case: DH2 
           
E Event - 
Interview, 
Observation or 
Document (e) - 
identified from 
Case 
Summaries 
C Conditions or 
Context (in 
innovation 
ecosystem) (c) 
P Likely Causal 
Powers and 
Liabilities 
(tendencies) 
(p, l) 
x Possible 
Mechanisms 
(process, 
structure) (x) 
Theoretical 
foundation 
Plausible?  
Rationale 
O Suggested Object  - 
Mechanism, process, 
capability 
Contextualize 
Wieck - sense 
making 
Yes - had not 
engaged widely 
to ensure case 
was robust 
before pitching, 
so then subject 
to diverse 
feedback 
o2, o6 Sense-making and 
positioning for 
credibility 
"We’ve positioned it as ‘Olly’ a condition PA.  So 
its more than a piece of software, its there as your 
helper.   We’ve shown people the concept.    The 
concept is it tracks habits and uses these and 
informatics to help identify ways to improve and 
support adherence. Our primary objective is 
adherence.   We believe a 1% improvement in 
adherence is worth a lot to a big pharma company.   
So our focus is on pharma as a customer." DH2-2 
e11 Challenging or 
negative 
feedback in 
pitches 
c9 Feedback from 
potential partners, 
that model did not 
fit 
p11 Need to 
address 
pharma 
feedback, 
but have not 
developed 
alternatives 
x11.1 Constraint in 
options available. 
Sense-making 
and selection 
Yes, partial - 
evidence had 
not done 
sufficient sense-
making before 
making major 
commitments.  
o2, o3 Selection - processes 
narrow, tending to 
stick to initial plan.  
Failing to gain 
advantage or value 
position. 
"Biolauncher were quite stern about where would 
get investment, but gave them options.  [RG] 
rubbished our numbers, and others’.   Sees £250k as 
nonsense.   Asked to go away and start working on 
real numbers.  Biolauncher thought market was 
payers.  Seemed anti-pharma ..  Rubbished GSK as 
option too.  She also struggles with the value 
proposition as we proposed it.    She suggested we 
speak to payers". DH2-2 
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